6	AFINITOR.xml:S1:4:1	O
ADVERSE	AFINITOR.xml:S1:10:7	O
REACTIONS	AFINITOR.xml:S1:18:9	O

The	AFINITOR.xml:S1:31:3	O
following	AFINITOR.xml:S1:35:9	O
serious	AFINITOR.xml:S1:45:7	O
adverse	AFINITOR.xml:S1:53:7	O
reactions	AFINITOR.xml:S1:61:9	O
are	AFINITOR.xml:S1:71:3	O
discussed	AFINITOR.xml:S1:75:9	O
in	AFINITOR.xml:S1:85:2	O
greater	AFINITOR.xml:S1:88:7	O
detail	AFINITOR.xml:S1:96:6	O
in	AFINITOR.xml:S1:103:2	O
another	AFINITOR.xml:S1:106:7	O
section	AFINITOR.xml:S1:114:7	O
of	AFINITOR.xml:S1:122:2	O
the	AFINITOR.xml:S1:125:3	O
label	AFINITOR.xml:S1:129:5	O
[	AFINITOR.xml:S1:136:1	O
see	AFINITOR.xml:S1:137:3	O
Warnings	AFINITOR.xml:S1:141:8	O
and	AFINITOR.xml:S1:150:3	O
Precautions	AFINITOR.xml:S1:154:11	O
(	AFINITOR.xml:S1:166:1	O
5	AFINITOR.xml:S1:167:1	O
)]	AFINITOR.xml:S1:168:2	O
:	AFINITOR.xml:S1:172:1	O

Non	AFINITOR.xml:S1:181:3	B-AdverseReaction
-	AFINITOR.xml:S1:184:1	I-AdverseReaction
infectious	AFINITOR.xml:S1:185:10	I-AdverseReaction
pneumonitis	AFINITOR.xml:S1:196:11	I-AdverseReaction
[	AFINITOR.xml:S1:208:1	O
see	AFINITOR.xml:S1:209:3	O
Warnings	AFINITOR.xml:S1:213:8	O
and	AFINITOR.xml:S1:222:3	O
Precautions	AFINITOR.xml:S1:226:11	O
(	AFINITOR.xml:S1:238:1	O
5.1	AFINITOR.xml:S1:239:3	O
)]	AFINITOR.xml:S1:242:2	O
.	AFINITOR.xml:S1:245:1	O

Infections	AFINITOR.xml:S1:252:10	B-AdverseReaction
[	AFINITOR.xml:S1:263:1	O
see	AFINITOR.xml:S1:264:3	O
Warnings	AFINITOR.xml:S1:268:8	O
and	AFINITOR.xml:S1:277:3	O
Precautions	AFINITOR.xml:S1:281:11	O
(	AFINITOR.xml:S1:293:1	O
5.2	AFINITOR.xml:S1:294:3	O
)]	AFINITOR.xml:S1:297:2	O
.	AFINITOR.xml:S1:300:1	O

Angioedema	AFINITOR.xml:S1:307:10	B-AdverseReaction
with	AFINITOR.xml:S1:318:4	O
concomitant	AFINITOR.xml:S1:323:11	O
use	AFINITOR.xml:S1:335:3	O
of	AFINITOR.xml:S1:339:2	O
ACE	AFINITOR.xml:S1:342:3	O
inhibitors	AFINITOR.xml:S1:346:10	O
[	AFINITOR.xml:S1:357:1	O
see	AFINITOR.xml:S1:358:3	O
Warnings	AFINITOR.xml:S1:362:8	O
and	AFINITOR.xml:S1:371:3	O
Precautions	AFINITOR.xml:S1:375:11	O
(	AFINITOR.xml:S1:387:1	O
5.3	AFINITOR.xml:S1:388:3	O
)]	AFINITOR.xml:S1:391:2	O
.	AFINITOR.xml:S1:394:1	O

Oral	AFINITOR.xml:S1:401:4	B-AdverseReaction
ulceration	AFINITOR.xml:S1:406:10	I-AdverseReaction
[	AFINITOR.xml:S1:417:1	O
see	AFINITOR.xml:S1:418:3	O
Warnings	AFINITOR.xml:S1:422:8	O
and	AFINITOR.xml:S1:431:3	O
Precautions	AFINITOR.xml:S1:435:11	O
(	AFINITOR.xml:S1:447:1	O
5.4	AFINITOR.xml:S1:448:3	O
)]	AFINITOR.xml:S1:451:2	O
.	AFINITOR.xml:S1:454:1	O

Renal	AFINITOR.xml:S1:461:5	B-AdverseReaction
failure	AFINITOR.xml:S1:467:7	I-AdverseReaction
[	AFINITOR.xml:S1:475:1	O
see	AFINITOR.xml:S1:476:3	O
Warnings	AFINITOR.xml:S1:480:8	O
and	AFINITOR.xml:S1:489:3	O
Precautions	AFINITOR.xml:S1:493:11	O
(	AFINITOR.xml:S1:505:1	O
5.5	AFINITOR.xml:S1:506:3	O
)]	AFINITOR.xml:S1:509:2	O
.	AFINITOR.xml:S1:512:1	O

Impaired	AFINITOR.xml:S1:519:8	B-AdverseReaction
wound	AFINITOR.xml:S1:528:5	I-AdverseReaction
healing	AFINITOR.xml:S1:534:7	I-AdverseReaction
[	AFINITOR.xml:S1:542:1	O
see	AFINITOR.xml:S1:543:3	O
Warnings	AFINITOR.xml:S1:547:8	O
and	AFINITOR.xml:S1:556:3	O
Precautions	AFINITOR.xml:S1:560:11	O
(	AFINITOR.xml:S1:572:1	O
5.6	AFINITOR.xml:S1:573:3	O
)]	AFINITOR.xml:S1:576:2	O
.	AFINITOR.xml:S1:579:1	O

Because	AFINITOR.xml:S1:586:7	O
clinical	AFINITOR.xml:S1:594:8	O
trials	AFINITOR.xml:S1:603:6	O
are	AFINITOR.xml:S1:610:3	O
conducted	AFINITOR.xml:S1:614:9	O
under	AFINITOR.xml:S1:624:5	O
widely	AFINITOR.xml:S1:630:6	O
varying	AFINITOR.xml:S1:637:7	O
conditions	AFINITOR.xml:S1:645:10	O
,	AFINITOR.xml:S1:655:1	O
the	AFINITOR.xml:S1:657:3	O
adverse	AFINITOR.xml:S1:661:7	O
reaction	AFINITOR.xml:S1:669:8	O
rates	AFINITOR.xml:S1:678:5	O
observed	AFINITOR.xml:S1:684:8	O
cannot	AFINITOR.xml:S1:693:6	O
be	AFINITOR.xml:S1:700:2	O
directly	AFINITOR.xml:S1:703:8	O
compared	AFINITOR.xml:S1:712:8	O
to	AFINITOR.xml:S1:721:2	O
rates	AFINITOR.xml:S1:724:5	O
in	AFINITOR.xml:S1:730:2	O
other	AFINITOR.xml:S1:733:5	O
trials	AFINITOR.xml:S1:739:6	O
and	AFINITOR.xml:S1:746:3	O
may	AFINITOR.xml:S1:750:3	O
not	AFINITOR.xml:S1:754:3	O
reflect	AFINITOR.xml:S1:758:7	O
the	AFINITOR.xml:S1:766:3	O
rates	AFINITOR.xml:S1:770:5	O
observed	AFINITOR.xml:S1:776:8	O
in	AFINITOR.xml:S1:785:2	O
clinical	AFINITOR.xml:S1:788:8	O
practice	AFINITOR.xml:S1:797:8	O
.	AFINITOR.xml:S1:805:1	O

EXCERPT	AFINITOR.xml:S1:813:7	O

:	AFINITOR.xml:S1:820:1	O
Advanced	AFINITOR.xml:S1:824:8	O
HR	AFINITOR.xml:S1:833:2	O
BC	AFINITOR.xml:S1:837:2	O
,	AFINITOR.xml:S1:839:1	O
advanced	AFINITOR.xml:S1:841:8	O
PNET	AFINITOR.xml:S1:850:4	O
,	AFINITOR.xml:S1:854:1	O
advanced	AFINITOR.xml:S1:856:8	O
RCC	AFINITOR.xml:S1:865:3	O
:	AFINITOR.xml:S1:868:1	O
Most	AFINITOR.xml:S1:870:4	O
common	AFINITOR.xml:S1:875:6	O
adverse	AFINITOR.xml:S1:882:7	O
reactions	AFINITOR.xml:S1:890:9	O
(	AFINITOR.xml:S1:900:1	O
incidence	AFINITOR.xml:S1:901:9	O
30%	AFINITOR.xml:S1:913:3	O
)	AFINITOR.xml:S1:916:1	O
include	AFINITOR.xml:S1:918:7	O
stomatitis	AFINITOR.xml:S1:926:10	B-AdverseReaction
,	AFINITOR.xml:S1:936:1	O
infections	AFINITOR.xml:S1:938:10	B-AdverseReaction
,	AFINITOR.xml:S1:948:1	O
rash	AFINITOR.xml:S1:950:4	B-AdverseReaction
,	AFINITOR.xml:S1:954:1	O
fatigue	AFINITOR.xml:S1:956:7	B-AdverseReaction
,	AFINITOR.xml:S1:963:1	O
diarrhea	AFINITOR.xml:S1:965:8	B-AdverseReaction
,	AFINITOR.xml:S1:973:1	O
edema	AFINITOR.xml:S1:975:5	B-AdverseReaction
,	AFINITOR.xml:S1:980:1	O
abdominal	AFINITOR.xml:S1:982:9	B-AdverseReaction
pain	AFINITOR.xml:S1:992:4	I-AdverseReaction
,	AFINITOR.xml:S1:996:1	O
nausea	AFINITOR.xml:S1:998:6	B-AdverseReaction
,	AFINITOR.xml:S1:1004:1	O
fever	AFINITOR.xml:S1:1006:5	B-AdverseReaction
,	AFINITOR.xml:S1:1011:1	O
asthenia	AFINITOR.xml:S1:1013:8	B-AdverseReaction
,	AFINITOR.xml:S1:1021:1	O
cough	AFINITOR.xml:S1:1023:5	B-AdverseReaction
,	AFINITOR.xml:S1:1028:1	O
headache	AFINITOR.xml:S1:1030:8	B-AdverseReaction
and	AFINITOR.xml:S1:1039:3	O
decreased	AFINITOR.xml:S1:1043:9	B-AdverseReaction
appetite	AFINITOR.xml:S1:1053:8	I-AdverseReaction
.	AFINITOR.xml:S1:1061:1	O

(	AFINITOR.xml:S1:1063:1	O
6.1	AFINITOR.xml:S1:1066:3	O
,	AFINITOR.xml:S1:1071:1	O
6.2	AFINITOR.xml:S1:1074:3	O
,	AFINITOR.xml:S1:1079:1	O
6.3	AFINITOR.xml:S1:1082:3	O
)	AFINITOR.xml:S1:1087:1	O

Renal	AFINITOR.xml:S1:1093:5	O
angiomyolipoma	AFINITOR.xml:S1:1099:14	O
with	AFINITOR.xml:S1:1114:4	O
TSC	AFINITOR.xml:S1:1119:3	O
:	AFINITOR.xml:S1:1122:1	O
Most	AFINITOR.xml:S1:1124:4	O
common	AFINITOR.xml:S1:1129:6	O
adverse	AFINITOR.xml:S1:1136:7	O
reaction	AFINITOR.xml:S1:1144:8	O
(	AFINITOR.xml:S1:1153:1	O
incidence	AFINITOR.xml:S1:1154:9	O
30%	AFINITOR.xml:S1:1167:3	O
)	AFINITOR.xml:S1:1170:1	O
is	AFINITOR.xml:S1:1172:2	O
stomatitis	AFINITOR.xml:S1:1175:10	B-AdverseReaction
.	AFINITOR.xml:S1:1185:1	O

(	AFINITOR.xml:S1:1187:1	O
6.4	AFINITOR.xml:S1:1190:3	O
)	AFINITOR.xml:S1:1195:1	O

SEGA	AFINITOR.xml:S1:1201:4	O
with	AFINITOR.xml:S1:1206:4	O
TSC	AFINITOR.xml:S1:1211:3	O
:	AFINITOR.xml:S1:1214:1	O
Most	AFINITOR.xml:S1:1216:4	O
common	AFINITOR.xml:S1:1221:6	O
adverse	AFINITOR.xml:S1:1228:7	O
reactions	AFINITOR.xml:S1:1236:9	O
(	AFINITOR.xml:S1:1246:1	O
incidence	AFINITOR.xml:S1:1247:9	O
30%	AFINITOR.xml:S1:1260:3	O
)	AFINITOR.xml:S1:1263:1	O
are	AFINITOR.xml:S1:1265:3	O
stomatitis	AFINITOR.xml:S1:1269:10	B-AdverseReaction
and	AFINITOR.xml:S1:1280:3	O
respiratory	AFINITOR.xml:S1:1284:11	B-AdverseReaction
tract	AFINITOR.xml:S1:1296:5	I-AdverseReaction
infection	AFINITOR.xml:S1:1302:9	I-AdverseReaction
.	AFINITOR.xml:S1:1311:1	O

(	AFINITOR.xml:S1:1313:1	O
6.5	AFINITOR.xml:S1:1316:3	O
)	AFINITOR.xml:S1:1321:1	O

To	AFINITOR.xml:S1:1329:2	O
report	AFINITOR.xml:S1:1332:6	O
SUSPECTED	AFINITOR.xml:S1:1339:9	O
ADVERSE	AFINITOR.xml:S1:1349:7	O
REACTIONS	AFINITOR.xml:S1:1357:9	O
,	AFINITOR.xml:S1:1366:1	O
contact	AFINITOR.xml:S1:1368:7	O
Novartis	AFINITOR.xml:S1:1376:8	O
Pharmaceuticals	AFINITOR.xml:S1:1385:15	O
Corporation	AFINITOR.xml:S1:1401:11	O
at	AFINITOR.xml:S1:1413:2	O
1	AFINITOR.xml:S1:1416:1	O
-	AFINITOR.xml:S1:1417:1	O
888	AFINITOR.xml:S1:1418:3	O
-	AFINITOR.xml:S1:1421:1	O
669	AFINITOR.xml:S1:1422:3	O
-	AFINITOR.xml:S1:1425:1	O
6682	AFINITOR.xml:S1:1426:4	O
or	AFINITOR.xml:S1:1431:2	O
FDA	AFINITOR.xml:S1:1434:3	O
at	AFINITOR.xml:S1:1438:2	O
1	AFINITOR.xml:S1:1441:1	O
-	AFINITOR.xml:S1:1442:1	O
800	AFINITOR.xml:S1:1443:3	O
-	AFINITOR.xml:S1:1446:1	O
FDA	AFINITOR.xml:S1:1447:3	O
-	AFINITOR.xml:S1:1450:1	O
1088	AFINITOR.xml:S1:1451:4	O
or	AFINITOR.xml:S1:1456:2	O
www	AFINITOR.xml:S1:1459:3	O
.	AFINITOR.xml:S1:1462:1	O
fda	AFINITOR.xml:S1:1463:3	O
.	AFINITOR.xml:S1:1466:1	O
gov	AFINITOR.xml:S1:1467:3	O
medwatch	AFINITOR.xml:S1:1471:8	O
.	AFINITOR.xml:S1:1479:1	O

6.1	AFINITOR.xml:S1:1491:3	O

Clinical	AFINITOR.xml:S1:1499:8	O
Study	AFINITOR.xml:S1:1508:5	O
Experience	AFINITOR.xml:S1:1514:10	O
in	AFINITOR.xml:S1:1525:2	O
Advanced	AFINITOR.xml:S1:1528:8	O
Hormone	AFINITOR.xml:S1:1537:7	O
Receptor	AFINITOR.xml:S1:1545:8	O
-	AFINITOR.xml:S1:1553:1	O
Positive	AFINITOR.xml:S1:1554:8	O
,	AFINITOR.xml:S1:1562:1	O
HER2	AFINITOR.xml:S1:1564:4	O
-	AFINITOR.xml:S1:1568:1	O
Negative	AFINITOR.xml:S1:1569:8	O
Breast	AFINITOR.xml:S1:1578:6	O
Cancer	AFINITOR.xml:S1:1585:6	O

The	AFINITOR.xml:S1:1595:3	O
efficacy	AFINITOR.xml:S1:1599:8	O
and	AFINITOR.xml:S1:1608:3	O
safety	AFINITOR.xml:S1:1612:6	O
of	AFINITOR.xml:S1:1619:2	O
AFINITOR	AFINITOR.xml:S1:1622:8	O
(	AFINITOR.xml:S1:1631:1	O
10	AFINITOR.xml:S1:1632:2	O
mg	AFINITOR.xml:S1:1635:2	O
day	AFINITOR.xml:S1:1638:3	O
)	AFINITOR.xml:S1:1641:1	O
plus	AFINITOR.xml:S1:1643:4	O
exemestane	AFINITOR.xml:S1:1648:10	O
(	AFINITOR.xml:S1:1659:1	O
25	AFINITOR.xml:S1:1660:2	O
mg	AFINITOR.xml:S1:1663:2	O
day	AFINITOR.xml:S1:1666:3	O
)	AFINITOR.xml:S1:1669:1	O
(	AFINITOR.xml:S1:1671:1	O
n	AFINITOR.xml:S1:1672:1	O
485	AFINITOR.xml:S1:1674:3	O
)	AFINITOR.xml:S1:1677:1	O
versus	AFINITOR.xml:S1:1679:6	O
placebo	AFINITOR.xml:S1:1686:7	O
plus	AFINITOR.xml:S1:1694:4	O
exemestane	AFINITOR.xml:S1:1699:10	O
(	AFINITOR.xml:S1:1710:1	O
25	AFINITOR.xml:S1:1711:2	O
mg	AFINITOR.xml:S1:1714:2	O
day	AFINITOR.xml:S1:1717:3	O
)	AFINITOR.xml:S1:1720:1	O
(	AFINITOR.xml:S1:1722:1	O
n	AFINITOR.xml:S1:1723:1	O
239	AFINITOR.xml:S1:1725:3	O
)	AFINITOR.xml:S1:1728:1	O
was	AFINITOR.xml:S1:1730:3	O
evaluated	AFINITOR.xml:S1:1734:9	O
in	AFINITOR.xml:S1:1744:2	O
a	AFINITOR.xml:S1:1747:1	O
randomized	AFINITOR.xml:S1:1749:10	O
,	AFINITOR.xml:S1:1759:1	O
controlled	AFINITOR.xml:S1:1761:10	O
trial	AFINITOR.xml:S1:1772:5	O
in	AFINITOR.xml:S1:1778:2	O
patients	AFINITOR.xml:S1:1781:8	O
with	AFINITOR.xml:S1:1790:4	O
advanced	AFINITOR.xml:S1:1795:8	O
or	AFINITOR.xml:S1:1804:2	O
metastatic	AFINITOR.xml:S1:1807:10	O
hormone	AFINITOR.xml:S1:1818:7	O
receptor	AFINITOR.xml:S1:1826:8	O
-	AFINITOR.xml:S1:1834:1	O
positive	AFINITOR.xml:S1:1835:8	O
,	AFINITOR.xml:S1:1843:1	O
HER2	AFINITOR.xml:S1:1845:4	O
-	AFINITOR.xml:S1:1849:1	O
negative	AFINITOR.xml:S1:1850:8	O
breast	AFINITOR.xml:S1:1859:6	O
cancer	AFINITOR.xml:S1:1866:6	O
.	AFINITOR.xml:S1:1872:1	O

The	AFINITOR.xml:S1:1874:3	O
median	AFINITOR.xml:S1:1878:6	O
age	AFINITOR.xml:S1:1885:3	O
of	AFINITOR.xml:S1:1889:2	O
patients	AFINITOR.xml:S1:1892:8	O
was	AFINITOR.xml:S1:1901:3	O
61	AFINITOR.xml:S1:1905:2	O
years	AFINITOR.xml:S1:1908:5	O
(	AFINITOR.xml:S1:1914:1	O
range	AFINITOR.xml:S1:1915:5	O
28	AFINITOR.xml:S1:1921:2	O
-	AFINITOR.xml:S1:1923:1	O
93	AFINITOR.xml:S1:1924:2	O
years	AFINITOR.xml:S1:1927:5	O
)	AFINITOR.xml:S1:1932:1	O
,	AFINITOR.xml:S1:1933:1	O
and	AFINITOR.xml:S1:1935:3	O
75%	AFINITOR.xml:S1:1939:3	O
were	AFINITOR.xml:S1:1943:4	O
Caucasian	AFINITOR.xml:S1:1948:9	O
.	AFINITOR.xml:S1:1957:1	O

Safety	AFINITOR.xml:S1:1959:6	O
results	AFINITOR.xml:S1:1966:7	O
are	AFINITOR.xml:S1:1974:3	O
based	AFINITOR.xml:S1:1978:5	O
on	AFINITOR.xml:S1:1984:2	O
a	AFINITOR.xml:S1:1987:1	O
median	AFINITOR.xml:S1:1989:6	O
follow	AFINITOR.xml:S1:1996:6	O
-	AFINITOR.xml:S1:2002:1	O
up	AFINITOR.xml:S1:2003:2	O
of	AFINITOR.xml:S1:2006:2	O
approximately	AFINITOR.xml:S1:2009:13	O
13	AFINITOR.xml:S1:2023:2	O
months	AFINITOR.xml:S1:2026:6	O
.	AFINITOR.xml:S1:2032:1	O

The	AFINITOR.xml:S1:2038:3	O
most	AFINITOR.xml:S1:2042:4	O
common	AFINITOR.xml:S1:2047:6	O
adverse	AFINITOR.xml:S1:2054:7	O
reactions	AFINITOR.xml:S1:2062:9	O
(	AFINITOR.xml:S1:2072:1	O
incidence	AFINITOR.xml:S1:2073:9	O
30%	AFINITOR.xml:S1:2086:3	O
)	AFINITOR.xml:S1:2089:1	O
were	AFINITOR.xml:S1:2091:4	O
stomatitis	AFINITOR.xml:S1:2096:10	B-AdverseReaction
,	AFINITOR.xml:S1:2106:1	O
infections	AFINITOR.xml:S1:2108:10	B-AdverseReaction
,	AFINITOR.xml:S1:2118:1	O
rash	AFINITOR.xml:S1:2120:4	B-AdverseReaction
,	AFINITOR.xml:S1:2124:1	O
fatigue	AFINITOR.xml:S1:2126:7	B-AdverseReaction
,	AFINITOR.xml:S1:2133:1	O
diarrhea	AFINITOR.xml:S1:2135:8	B-AdverseReaction
,	AFINITOR.xml:S1:2143:1	O
and	AFINITOR.xml:S1:2145:3	O
decreased	AFINITOR.xml:S1:2149:9	B-AdverseReaction
appetite	AFINITOR.xml:S1:2159:8	I-AdverseReaction
.	AFINITOR.xml:S1:2167:1	O

The	AFINITOR.xml:S1:2169:3	O
most	AFINITOR.xml:S1:2173:4	O
common	AFINITOR.xml:S1:2178:6	O
Grade	AFINITOR.xml:S1:2185:5	B-Severity
3	AFINITOR.xml:S1:2191:1	I-Severity
4	AFINITOR.xml:S1:2193:1	I-Severity
adverse	AFINITOR.xml:S1:2195:7	O
reactions	AFINITOR.xml:S1:2203:9	O
(	AFINITOR.xml:S1:2213:1	O
incidence	AFINITOR.xml:S1:2214:9	O
2%	AFINITOR.xml:S1:2227:2	O
)	AFINITOR.xml:S1:2229:1	O
were	AFINITOR.xml:S1:2231:4	O
stomatitis	AFINITOR.xml:S1:2236:10	B-AdverseReaction
,	AFINITOR.xml:S1:2246:1	O
infections	AFINITOR.xml:S1:2248:10	B-AdverseReaction
,	AFINITOR.xml:S1:2258:1	O
hyperglycemia	AFINITOR.xml:S1:2260:13	B-AdverseReaction
,	AFINITOR.xml:S1:2273:1	O
fatigue	AFINITOR.xml:S1:2275:7	B-AdverseReaction
,	AFINITOR.xml:S1:2282:1	O
dyspnea	AFINITOR.xml:S1:2284:7	B-AdverseReaction
,	AFINITOR.xml:S1:2291:1	O
pneumonitis	AFINITOR.xml:S1:2293:11	B-AdverseReaction
,	AFINITOR.xml:S1:2304:1	O
and	AFINITOR.xml:S1:2306:3	O
diarrhea	AFINITOR.xml:S1:2310:8	B-AdverseReaction
.	AFINITOR.xml:S1:2318:1	O

The	AFINITOR.xml:S1:2320:3	O
most	AFINITOR.xml:S1:2324:4	O
common	AFINITOR.xml:S1:2329:6	O
laboratory	AFINITOR.xml:S1:2336:10	O
abnormalities	AFINITOR.xml:S1:2347:13	O
(	AFINITOR.xml:S1:2361:1	O
incidence	AFINITOR.xml:S1:2362:9	O
50%	AFINITOR.xml:S1:2375:3	O
)	AFINITOR.xml:S1:2378:1	O
were	AFINITOR.xml:S1:2380:4	O
hypercholesterolemia	AFINITOR.xml:S1:2385:20	B-AdverseReaction
,	AFINITOR.xml:S1:2405:1	O
hyperglycemia	AFINITOR.xml:S1:2407:13	B-AdverseReaction
,	AFINITOR.xml:S1:2420:1	O
increased	AFINITOR.xml:S1:2422:9	B-AdverseReaction
aspartate	AFINITOR.xml:S1:2432:9	I-AdverseReaction
transaminase	AFINITOR.xml:S1:2442:12	I-AdverseReaction
(	AFINITOR.xml:S1:2455:1	O
AST	AFINITOR.xml:S1:2456:3	I-AdverseReaction
)	AFINITOR.xml:S1:2459:1	O
,	AFINITOR.xml:S1:2460:1	O
anemia	AFINITOR.xml:S1:2462:6	B-AdverseReaction
,	AFINITOR.xml:S1:2468:1	O
leukopenia	AFINITOR.xml:S1:2470:10	B-AdverseReaction
,	AFINITOR.xml:S1:2480:1	O
thrombocytopenia	AFINITOR.xml:S1:2482:16	B-AdverseReaction
,	AFINITOR.xml:S1:2498:1	O
lymphopenia	AFINITOR.xml:S1:2500:11	B-AdverseReaction
,	AFINITOR.xml:S1:2511:1	O
increased	AFINITOR.xml:S1:2513:9	B-AdverseReaction
alanine	AFINITOR.xml:S1:2523:7	I-AdverseReaction
transaminase	AFINITOR.xml:S1:2531:12	I-AdverseReaction
(	AFINITOR.xml:S1:2544:1	O
ALT	AFINITOR.xml:S1:2545:3	I-AdverseReaction
)	AFINITOR.xml:S1:2548:1	O
,	AFINITOR.xml:S1:2549:1	O
and	AFINITOR.xml:S1:2551:3	O
hypertriglyceridemia	AFINITOR.xml:S1:2555:20	B-AdverseReaction
.	AFINITOR.xml:S1:2575:1	O

The	AFINITOR.xml:S1:2577:3	O
most	AFINITOR.xml:S1:2581:4	O
common	AFINITOR.xml:S1:2586:6	O
Grade	AFINITOR.xml:S1:2593:5	O
3	AFINITOR.xml:S1:2599:1	O
4	AFINITOR.xml:S1:2601:1	O
laboratory	AFINITOR.xml:S1:2603:10	O
abnormalities	AFINITOR.xml:S1:2614:13	O
(	AFINITOR.xml:S1:2628:1	O
incidence	AFINITOR.xml:S1:2629:9	O
3%	AFINITOR.xml:S1:2642:2	O
)	AFINITOR.xml:S1:2644:1	O
were	AFINITOR.xml:S1:2646:4	O
lymphopenia	AFINITOR.xml:S1:2651:11	B-AdverseReaction
,	AFINITOR.xml:S1:2662:1	O
hyperglycemia	AFINITOR.xml:S1:2664:13	B-AdverseReaction
,	AFINITOR.xml:S1:2677:1	O
anemia	AFINITOR.xml:S1:2679:6	B-AdverseReaction
,	AFINITOR.xml:S1:2685:1	O
decreased	AFINITOR.xml:S1:2687:9	B-AdverseReaction
potassium	AFINITOR.xml:S1:2697:9	I-AdverseReaction
,	AFINITOR.xml:S1:2706:1	O
increased	AFINITOR.xml:S1:2708:9	B-AdverseReaction
AST	AFINITOR.xml:S1:2718:3	I-AdverseReaction
,	AFINITOR.xml:S1:2721:1	O
increased	AFINITOR.xml:S1:2723:9	B-AdverseReaction
ALT	AFINITOR.xml:S1:2733:3	I-AdverseReaction
,	AFINITOR.xml:S1:2736:1	O
and	AFINITOR.xml:S1:2738:3	O
thrombocytopenia	AFINITOR.xml:S1:2742:16	B-AdverseReaction
.	AFINITOR.xml:S1:2758:1	O

Fatal	AFINITOR.xml:S1:2764:5	B-AdverseReaction
adverse	AFINITOR.xml:S1:2770:7	O
reactions	AFINITOR.xml:S1:2778:9	O
occurred	AFINITOR.xml:S1:2788:8	O
more	AFINITOR.xml:S1:2797:4	O
frequently	AFINITOR.xml:S1:2802:10	O
in	AFINITOR.xml:S1:2813:2	O
patients	AFINITOR.xml:S1:2816:8	O
who	AFINITOR.xml:S1:2825:3	O
received	AFINITOR.xml:S1:2829:8	O
AFINITOR	AFINITOR.xml:S1:2838:8	O
plus	AFINITOR.xml:S1:2847:4	O
exemestane	AFINITOR.xml:S1:2852:10	O
(	AFINITOR.xml:S1:2863:1	O
2%	AFINITOR.xml:S1:2864:2	O
)	AFINITOR.xml:S1:2866:1	O
compared	AFINITOR.xml:S1:2868:8	O
to	AFINITOR.xml:S1:2877:2	O
patients	AFINITOR.xml:S1:2880:8	O
on	AFINITOR.xml:S1:2889:2	O
the	AFINITOR.xml:S1:2892:3	O
placebo	AFINITOR.xml:S1:2896:7	O
plus	AFINITOR.xml:S1:2904:4	O
exemestane	AFINITOR.xml:S1:2909:10	O
arm	AFINITOR.xml:S1:2920:3	O
(	AFINITOR.xml:S1:2924:1	O
0.4%	AFINITOR.xml:S1:2925:4	O
)	AFINITOR.xml:S1:2929:1	O
.	AFINITOR.xml:S1:2930:1	O

The	AFINITOR.xml:S1:2932:3	O
rates	AFINITOR.xml:S1:2936:5	O
of	AFINITOR.xml:S1:2942:2	O
treatment	AFINITOR.xml:S1:2945:9	O
-	AFINITOR.xml:S1:2954:1	O
emergent	AFINITOR.xml:S1:2955:8	O
adverse	AFINITOR.xml:S1:2964:7	O
events	AFINITOR.xml:S1:2972:6	O
resulting	AFINITOR.xml:S1:2979:9	O
in	AFINITOR.xml:S1:2989:2	O
permanent	AFINITOR.xml:S1:2992:9	O
discontinuation	AFINITOR.xml:S1:3002:15	O
were	AFINITOR.xml:S1:3018:4	O
24%	AFINITOR.xml:S1:3023:3	O
and	AFINITOR.xml:S1:3027:3	O
5%	AFINITOR.xml:S1:3031:2	O
for	AFINITOR.xml:S1:3034:3	O
the	AFINITOR.xml:S1:3038:3	O
AFINITOR	AFINITOR.xml:S1:3042:8	O
plus	AFINITOR.xml:S1:3051:4	O
exemestane	AFINITOR.xml:S1:3056:10	O
and	AFINITOR.xml:S1:3067:3	O
placebo	AFINITOR.xml:S1:3071:7	O
plus	AFINITOR.xml:S1:3079:4	O
exemestane	AFINITOR.xml:S1:3084:10	O
treatment	AFINITOR.xml:S1:3095:9	O
groups	AFINITOR.xml:S1:3105:6	O
,	AFINITOR.xml:S1:3111:1	O
respectively	AFINITOR.xml:S1:3113:12	O
.	AFINITOR.xml:S1:3125:1	O

Dose	AFINITOR.xml:S1:3127:4	O
adjustments	AFINITOR.xml:S1:3132:11	O
(	AFINITOR.xml:S1:3144:1	O
interruptions	AFINITOR.xml:S1:3145:13	O
or	AFINITOR.xml:S1:3159:2	O
reductions	AFINITOR.xml:S1:3162:10	O
)	AFINITOR.xml:S1:3172:1	O
were	AFINITOR.xml:S1:3174:4	O
more	AFINITOR.xml:S1:3179:4	O
frequent	AFINITOR.xml:S1:3184:8	O
among	AFINITOR.xml:S1:3193:5	O
patients	AFINITOR.xml:S1:3199:8	O
in	AFINITOR.xml:S1:3208:2	O
the	AFINITOR.xml:S1:3211:3	O
AFINITOR	AFINITOR.xml:S1:3215:8	O
plus	AFINITOR.xml:S1:3224:4	O
exemestane	AFINITOR.xml:S1:3229:10	O
arm	AFINITOR.xml:S1:3240:3	O
than	AFINITOR.xml:S1:3244:4	O
in	AFINITOR.xml:S1:3249:2	O
the	AFINITOR.xml:S1:3252:3	O
placebo	AFINITOR.xml:S1:3256:7	O
plus	AFINITOR.xml:S1:3264:4	O
exemestane	AFINITOR.xml:S1:3269:10	O
arm	AFINITOR.xml:S1:3280:3	O
(	AFINITOR.xml:S1:3284:1	O
63%	AFINITOR.xml:S1:3285:3	O
versus	AFINITOR.xml:S1:3289:6	O
14%	AFINITOR.xml:S1:3296:3	O
)	AFINITOR.xml:S1:3299:1	O
.	AFINITOR.xml:S1:3300:1	O

Table	AFINITOR.xml:S1:3306:5	O
2	AFINITOR.xml:S1:3312:1	O
compares	AFINITOR.xml:S1:3314:8	O
the	AFINITOR.xml:S1:3323:3	O
incidence	AFINITOR.xml:S1:3327:9	O
of	AFINITOR.xml:S1:3337:2	O
treatment	AFINITOR.xml:S1:3340:9	O
-	AFINITOR.xml:S1:3349:1	O
emergent	AFINITOR.xml:S1:3350:8	O
adverse	AFINITOR.xml:S1:3359:7	O
reactions	AFINITOR.xml:S1:3367:9	O
reported	AFINITOR.xml:S1:3377:8	O
with	AFINITOR.xml:S1:3386:4	O
an	AFINITOR.xml:S1:3391:2	O
incidence	AFINITOR.xml:S1:3394:9	O
of	AFINITOR.xml:S1:3404:2	O
10%	AFINITOR.xml:S1:3409:3	O
for	AFINITOR.xml:S1:3413:3	O
patients	AFINITOR.xml:S1:3417:8	O
receiving	AFINITOR.xml:S1:3426:9	O
AFINITOR	AFINITOR.xml:S1:3436:8	O
10	AFINITOR.xml:S1:3445:2	O
mg	AFINITOR.xml:S1:3448:2	O
daily	AFINITOR.xml:S1:3451:5	O
versus	AFINITOR.xml:S1:3457:6	O
placebo	AFINITOR.xml:S1:3464:7	O
.	AFINITOR.xml:S1:3471:1	O

Table	AFINITOR.xml:S1:3477:5	O
2	AFINITOR.xml:S1:3483:1	O
:	AFINITOR.xml:S1:3484:1	O
Adverse	AFINITOR.xml:S1:3486:7	O
Reactions	AFINITOR.xml:S1:3494:9	O
Reported	AFINITOR.xml:S1:3504:8	O
10%	AFINITOR.xml:S1:3516:3	O
of	AFINITOR.xml:S1:3520:2	O
Patients	AFINITOR.xml:S1:3523:8	O
with	AFINITOR.xml:S1:3532:4	O
Advanced	AFINITOR.xml:S1:3537:8	O
HR	AFINITOR.xml:S1:3546:2	O
BC	AFINITOR.xml:S1:3550:2	O

Grading	AFINITOR.xml:S1:3556:7	O
according	AFINITOR.xml:S1:3564:9	O
to	AFINITOR.xml:S1:3574:2	O
CTCAE	AFINITOR.xml:S1:3577:5	O
Version	AFINITOR.xml:S1:3583:7	O
3.0	AFINITOR.xml:S1:3591:3	O
160	AFINITOR.xml:S1:3599:3	O
patients	AFINITOR.xml:S1:3603:8	O
(	AFINITOR.xml:S1:3612:1	O
33.2%	AFINITOR.xml:S1:3613:5	O
)	AFINITOR.xml:S1:3618:1	O
were	AFINITOR.xml:S1:3620:4	O
exposed	AFINITOR.xml:S1:3625:7	O
to	AFINITOR.xml:S1:3633:2	O
AFINITOR	AFINITOR.xml:S1:3636:8	O
therapy	AFINITOR.xml:S1:3645:7	O
for	AFINITOR.xml:S1:3653:3	O
a	AFINITOR.xml:S1:3657:1	O
period	AFINITOR.xml:S1:3659:6	O
of	AFINITOR.xml:S1:3666:2	O
32	AFINITOR.xml:S1:3672:2	O
weeks	AFINITOR.xml:S1:3675:5	O
a	AFINITOR.xml:S1:3682:1	O
Exemestane	AFINITOR.xml:S1:3685:10	O
(	AFINITOR.xml:S1:3696:1	O
25	AFINITOR.xml:S1:3697:2	O
mg	AFINITOR.xml:S1:3700:2	O
day	AFINITOR.xml:S1:3703:3	O
)	AFINITOR.xml:S1:3706:1	O
b	AFINITOR.xml:S1:3709:1	O
Includes	AFINITOR.xml:S1:3712:8	O
stomatitis	AFINITOR.xml:S1:3721:10	B-AdverseReaction
,	AFINITOR.xml:S1:3731:1	O
mouth	AFINITOR.xml:S1:3733:5	B-AdverseReaction
ulceration	AFINITOR.xml:S1:3739:10	I-AdverseReaction
,	AFINITOR.xml:S1:3749:1	O
aphthous	AFINITOR.xml:S1:3751:8	B-AdverseReaction
stomatitis	AFINITOR.xml:S1:3760:10	I-AdverseReaction
,	AFINITOR.xml:S1:3770:1	O
glossodynia	AFINITOR.xml:S1:3772:11	B-AdverseReaction
,	AFINITOR.xml:S1:3783:1	O
gingival	AFINITOR.xml:S1:3785:8	B-AdverseReaction
pain	AFINITOR.xml:S1:3794:4	I-AdverseReaction
,	AFINITOR.xml:S1:3798:1	O
glossitis	AFINITOR.xml:S1:3800:9	B-AdverseReaction
and	AFINITOR.xml:S1:3810:3	O
lip	AFINITOR.xml:S1:3814:3	B-AdverseReaction
ulceration	AFINITOR.xml:S1:3818:10	I-AdverseReaction
c	AFINITOR.xml:S1:3830:1	O
Includes	AFINITOR.xml:S1:3833:8	O
all	AFINITOR.xml:S1:3842:3	O
preferred	AFINITOR.xml:S1:3846:9	O
terms	AFINITOR.xml:S1:3856:5	O
within	AFINITOR.xml:S1:3862:6	O
the	AFINITOR.xml:S1:3869:3	O
infections	AFINITOR.xml:S1:3874:10	O
and	AFINITOR.xml:S1:3885:3	O
infestations	AFINITOR.xml:S1:3889:12	O
system	AFINITOR.xml:S1:3903:6	O
organ	AFINITOR.xml:S1:3910:5	O
class	AFINITOR.xml:S1:3916:5	O
,	AFINITOR.xml:S1:3921:1	O
the	AFINITOR.xml:S1:3923:3	O
most	AFINITOR.xml:S1:3927:4	O
common	AFINITOR.xml:S1:3932:6	O
being	AFINITOR.xml:S1:3939:5	O
nasopharyngitis	AFINITOR.xml:S1:3945:15	B-AdverseReaction
(	AFINITOR.xml:S1:3961:1	O
10%	AFINITOR.xml:S1:3962:3	O
)	AFINITOR.xml:S1:3965:1	O
,	AFINITOR.xml:S1:3966:1	O
urinary	AFINITOR.xml:S1:3968:7	B-AdverseReaction
tract	AFINITOR.xml:S1:3976:5	I-AdverseReaction
infection	AFINITOR.xml:S1:3982:9	I-AdverseReaction
(	AFINITOR.xml:S1:3992:1	O
10%	AFINITOR.xml:S1:3993:3	O
)	AFINITOR.xml:S1:3996:1	O
,	AFINITOR.xml:S1:3997:1	O
upper	AFINITOR.xml:S1:3999:5	B-AdverseReaction
respiratory	AFINITOR.xml:S1:4005:11	I-AdverseReaction
tract	AFINITOR.xml:S1:4017:5	I-AdverseReaction
infection	AFINITOR.xml:S1:4023:9	I-AdverseReaction
(	AFINITOR.xml:S1:4033:1	O
5%	AFINITOR.xml:S1:4034:2	O
)	AFINITOR.xml:S1:4036:1	O
,	AFINITOR.xml:S1:4037:1	O
pneumonia	AFINITOR.xml:S1:4039:9	B-AdverseReaction
(	AFINITOR.xml:S1:4049:1	O
4%	AFINITOR.xml:S1:4050:2	O
)	AFINITOR.xml:S1:4052:1	O
,	AFINITOR.xml:S1:4053:1	O
bronchitis	AFINITOR.xml:S1:4055:10	B-AdverseReaction
(	AFINITOR.xml:S1:4066:1	O
4%	AFINITOR.xml:S1:4067:2	O
)	AFINITOR.xml:S1:4069:1	O
,	AFINITOR.xml:S1:4070:1	O
cystitis	AFINITOR.xml:S1:4072:8	B-AdverseReaction
(	AFINITOR.xml:S1:4081:1	O
3%	AFINITOR.xml:S1:4082:2	O
)	AFINITOR.xml:S1:4084:1	O
,	AFINITOR.xml:S1:4085:1	O
sinusitis	AFINITOR.xml:S1:4087:9	B-AdverseReaction
(	AFINITOR.xml:S1:4097:1	O
3%	AFINITOR.xml:S1:4098:2	O
)	AFINITOR.xml:S1:4100:1	O
,	AFINITOR.xml:S1:4101:1	O
and	AFINITOR.xml:S1:4103:3	O
also	AFINITOR.xml:S1:4107:4	O
including	AFINITOR.xml:S1:4112:9	O
candidiasis	AFINITOR.xml:S1:4122:11	B-AdverseReaction
(	AFINITOR.xml:S1:4134:1	O
1%	AFINITOR.xml:S1:4136:2	O
)	AFINITOR.xml:S1:4138:1	O
,	AFINITOR.xml:S1:4139:1	O
and	AFINITOR.xml:S1:4141:3	O
sepsis	AFINITOR.xml:S1:4145:6	B-AdverseReaction
(	AFINITOR.xml:S1:4152:1	O
1%	AFINITOR.xml:S1:4154:2	O
)	AFINITOR.xml:S1:4156:1	O
,	AFINITOR.xml:S1:4157:1	O
and	AFINITOR.xml:S1:4159:3	O
hepatitis	AFINITOR.xml:S1:4163:9	B-AdverseReaction
C	AFINITOR.xml:S1:4173:1	I-AdverseReaction
(	AFINITOR.xml:S1:4175:1	O
1%	AFINITOR.xml:S1:4177:2	O
)	AFINITOR.xml:S1:4179:1	O
.	AFINITOR.xml:S1:4180:1	O

d	AFINITOR.xml:S1:4183:1	O
Includes	AFINITOR.xml:S1:4186:8	O
pneumonitis	AFINITOR.xml:S1:4195:11	B-AdverseReaction
,	AFINITOR.xml:S1:4206:1	O
interstitial	AFINITOR.xml:S1:4208:12	B-AdverseReaction
lung	AFINITOR.xml:S1:4221:4	I-AdverseReaction
disease	AFINITOR.xml:S1:4226:7	I-AdverseReaction
,	AFINITOR.xml:S1:4233:1	O
lung	AFINITOR.xml:S1:4235:4	B-AdverseReaction
infiltration	AFINITOR.xml:S1:4240:12	I-AdverseReaction
,	AFINITOR.xml:S1:4252:1	O
and	AFINITOR.xml:S1:4254:3	O
pulmonary	AFINITOR.xml:S1:4258:9	B-AdverseReaction
fibrosis	AFINITOR.xml:S1:4268:8	I-AdverseReaction
e	AFINITOR.xml:S1:4278:1	O
Exposure	AFINITOR.xml:S1:4281:8	O
to	AFINITOR.xml:S1:4290:2	O
AFINITOR	AFINITOR.xml:S1:4293:8	O
or	AFINITOR.xml:S1:4302:2	O
placebo	AFINITOR.xml:S1:4305:7	O

AFINITOR	AFINITOR.xml:S1:4339:8	O

(	AFINITOR.xml:S1:4348:1	O
10	AFINITOR.xml:S1:4349:2	O
mg	AFINITOR.xml:S1:4352:2	O
day	AFINITOR.xml:S1:4355:3	O
)	AFINITOR.xml:S1:4358:1	O
exemestane	AFINITOR.xml:S1:4365:10	O
a	AFINITOR.xml:S1:4377:1	O
N	AFINITOR.xml:S1:4384:1	O
482	AFINITOR.xml:S1:4386:3	O
Placebo	AFINITOR.xml:S1:4395:7	O
exemestane	AFINITOR.xml:S1:4408:10	O
a	AFINITOR.xml:S1:4420:1	O
N	AFINITOR.xml:S1:4427:1	O
238	AFINITOR.xml:S1:4429:3	O

All	AFINITOR.xml:S1:4458:3	O
grades	AFINITOR.xml:S1:4462:6	O
Grade	AFINITOR.xml:S1:4475:5	O
3	AFINITOR.xml:S1:4481:1	O
Grade	AFINITOR.xml:S1:4492:5	O
4	AFINITOR.xml:S1:4498:1	O
All	AFINITOR.xml:S1:4509:3	O
grades	AFINITOR.xml:S1:4513:6	O
Grade	AFINITOR.xml:S1:4526:5	O
3	AFINITOR.xml:S1:4532:1	O
Grade	AFINITOR.xml:S1:4543:5	O
4	AFINITOR.xml:S1:4549:1	O

Any	AFINITOR.xml:S1:4685:3	O

adverse	AFINITOR.xml:S1:4689:7	O
reaction	AFINITOR.xml:S1:4697:8	O
100	AFINITOR.xml:S1:4711:3	O
41	AFINITOR.xml:S1:4728:2	O
9	AFINITOR.xml:S1:4745:1	O
90	AFINITOR.xml:S1:4762:2	O
22	AFINITOR.xml:S1:4779:2	O
5	AFINITOR.xml:S1:4796:1	O

Gastrointestinal	AFINITOR.xml:S1:4816:16	O
disorders	AFINITOR.xml:S1:4833:9	O

Stomatitis	AFINITOR.xml:S1:4855:10	B-AdverseReaction
b	AFINITOR.xml:S1:4867:1	O
67	AFINITOR.xml:S1:4872:2	O
8	AFINITOR.xml:S1:4889:1	O
0	AFINITOR.xml:S1:4906:1	O
11	AFINITOR.xml:S1:4923:2	O
0.8	AFINITOR.xml:S1:4940:3	O
0	AFINITOR.xml:S1:4957:1	O

Diarrhea	AFINITOR.xml:S1:4983:8	B-AdverseReaction
33	AFINITOR.xml:S1:4994:2	O
2	AFINITOR.xml:S1:5011:1	O
0.2	AFINITOR.xml:S1:5028:3	O
18	AFINITOR.xml:S1:5045:2	O
0.8	AFINITOR.xml:S1:5062:3	O
0	AFINITOR.xml:S1:5079:1	O

Nausea	AFINITOR.xml:S1:5105:6	B-AdverseReaction
29	AFINITOR.xml:S1:5116:2	O
0.2	AFINITOR.xml:S1:5133:3	O
0.2	AFINITOR.xml:S1:5150:3	O
28	AFINITOR.xml:S1:5167:2	O
1	AFINITOR.xml:S1:5184:1	O
0	AFINITOR.xml:S1:5201:1	O

Vomiting	AFINITOR.xml:S1:5227:8	B-AdverseReaction
17	AFINITOR.xml:S1:5238:2	O
0.8	AFINITOR.xml:S1:5255:3	O
0.2	AFINITOR.xml:S1:5272:3	O
12	AFINITOR.xml:S1:5289:2	O
0.8	AFINITOR.xml:S1:5306:3	O
0	AFINITOR.xml:S1:5323:1	O

Constipation	AFINITOR.xml:S1:5349:12	B-AdverseReaction
14	AFINITOR.xml:S1:5363:2	O
0.4	AFINITOR.xml:S1:5380:3	O
0	AFINITOR.xml:S1:5397:1	O
13	AFINITOR.xml:S1:5414:2	O
0.4	AFINITOR.xml:S1:5431:3	O
0	AFINITOR.xml:S1:5448:1	O

Dry	AFINITOR.xml:S1:5474:3	B-AdverseReaction
mouth	AFINITOR.xml:S1:5478:5	I-AdverseReaction
11	AFINITOR.xml:S1:5485:2	O
0	AFINITOR.xml:S1:5502:1	O
0	AFINITOR.xml:S1:5519:1	O
7	AFINITOR.xml:S1:5536:1	O
0	AFINITOR.xml:S1:5553:1	O
0	AFINITOR.xml:S1:5570:1	O

General	AFINITOR.xml:S1:5592:7	O
disorders	AFINITOR.xml:S1:5600:9	O
and	AFINITOR.xml:S1:5610:3	O
administration	AFINITOR.xml:S1:5614:14	O
site	AFINITOR.xml:S1:5629:4	O
conditions	AFINITOR.xml:S1:5634:10	O

Fatigue	AFINITOR.xml:S1:5657:7	B-AdverseReaction
36	AFINITOR.xml:S1:5668:2	O
4	AFINITOR.xml:S1:5685:1	O
0.4	AFINITOR.xml:S1:5702:3	O
27	AFINITOR.xml:S1:5719:2	O
1	AFINITOR.xml:S1:5736:1	O
0	AFINITOR.xml:S1:5753:1	O

Edema	AFINITOR.xml:S1:5779:5	B-AdverseReaction
peripheral	AFINITOR.xml:S1:5785:10	I-AdverseReaction
19	AFINITOR.xml:S1:5797:2	O
1	AFINITOR.xml:S1:5814:1	O
0	AFINITOR.xml:S1:5831:1	O
6	AFINITOR.xml:S1:5848:1	O
0.4	AFINITOR.xml:S1:5865:3	O
0	AFINITOR.xml:S1:5882:1	O

Pyrexia	AFINITOR.xml:S1:5908:7	B-AdverseReaction
15	AFINITOR.xml:S1:5919:2	O
0.2	AFINITOR.xml:S1:5936:3	O
0	AFINITOR.xml:S1:5953:1	O
7	AFINITOR.xml:S1:5970:1	O
0.4	AFINITOR.xml:S1:5987:3	O
0	AFINITOR.xml:S1:6004:1	O

Asthenia	AFINITOR.xml:S1:6030:8	B-AdverseReaction
13	AFINITOR.xml:S1:6041:2	O
2	AFINITOR.xml:S1:6058:1	O
0.2	AFINITOR.xml:S1:6075:3	O
4	AFINITOR.xml:S1:6092:1	O
0	AFINITOR.xml:S1:6109:1	O
0	AFINITOR.xml:S1:6126:1	O

Infections	AFINITOR.xml:S1:6148:10	O
and	AFINITOR.xml:S1:6159:3	O
infestations	AFINITOR.xml:S1:6163:12	O

Infections	AFINITOR.xml:S1:6188:10	B-AdverseReaction
c	AFINITOR.xml:S1:6200:1	O
50	AFINITOR.xml:S1:6205:2	O
4	AFINITOR.xml:S1:6222:1	O
1	AFINITOR.xml:S1:6239:1	O
25	AFINITOR.xml:S1:6256:2	O
2	AFINITOR.xml:S1:6273:1	O
0	AFINITOR.xml:S1:6290:1	O

Investigations	AFINITOR.xml:S1:6312:14	O

Weight	AFINITOR.xml:S1:6339:6	B-AdverseReaction
decreased	AFINITOR.xml:S1:6346:9	I-AdverseReaction
25	AFINITOR.xml:S1:6357:2	O
1	AFINITOR.xml:S1:6374:1	O
0	AFINITOR.xml:S1:6391:1	O
6	AFINITOR.xml:S1:6408:1	O
0	AFINITOR.xml:S1:6425:1	O
0	AFINITOR.xml:S1:6442:1	O

Metabolism	AFINITOR.xml:S1:6464:10	O
and	AFINITOR.xml:S1:6475:3	O
nutrition	AFINITOR.xml:S1:6479:9	O
disorders	AFINITOR.xml:S1:6489:9	O

Decreased	AFINITOR.xml:S1:6511:9	B-AdverseReaction
appetite	AFINITOR.xml:S1:6521:8	I-AdverseReaction
30	AFINITOR.xml:S1:6531:2	O
1	AFINITOR.xml:S1:6548:1	O
0	AFINITOR.xml:S1:6565:1	O
12	AFINITOR.xml:S1:6582:2	O
0.4	AFINITOR.xml:S1:6599:3	O
0	AFINITOR.xml:S1:6616:1	O

Hyperglycemia	AFINITOR.xml:S1:6642:13	B-AdverseReaction
14	AFINITOR.xml:S1:6657:2	O
5	AFINITOR.xml:S1:6674:1	O
0.4	AFINITOR.xml:S1:6691:3	O
2	AFINITOR.xml:S1:6708:1	O
0.4	AFINITOR.xml:S1:6725:3	O
0	AFINITOR.xml:S1:6742:1	O

Musculoskeletal	AFINITOR.xml:S1:6764:15	O
and	AFINITOR.xml:S1:6780:3	O
connective	AFINITOR.xml:S1:6784:10	O
tissue	AFINITOR.xml:S1:6795:6	O
disorders	AFINITOR.xml:S1:6802:9	O

Arthralgia	AFINITOR.xml:S1:6824:10	B-AdverseReaction
20	AFINITOR.xml:S1:6836:2	O
0.8	AFINITOR.xml:S1:6853:3	O
0	AFINITOR.xml:S1:6870:1	O
17	AFINITOR.xml:S1:6887:2	O
0	AFINITOR.xml:S1:6904:1	O
0	AFINITOR.xml:S1:6921:1	O

Back	AFINITOR.xml:S1:6947:4	B-AdverseReaction
pain	AFINITOR.xml:S1:6952:4	I-AdverseReaction
14	AFINITOR.xml:S1:6958:2	O
0.2	AFINITOR.xml:S1:6975:3	O
0	AFINITOR.xml:S1:6992:1	O
10	AFINITOR.xml:S1:7009:2	O
0.8	AFINITOR.xml:S1:7026:3	O
0	AFINITOR.xml:S1:7043:1	O

Pain	AFINITOR.xml:S1:7069:4	B-AdverseReaction
in	AFINITOR.xml:S1:7074:2	I-AdverseReaction
extremity	AFINITOR.xml:S1:7077:9	I-AdverseReaction
9	AFINITOR.xml:S1:7088:1	O
0.4	AFINITOR.xml:S1:7105:3	O
0	AFINITOR.xml:S1:7122:1	O
11	AFINITOR.xml:S1:7139:2	O
2	AFINITOR.xml:S1:7156:1	O
0	AFINITOR.xml:S1:7173:1	O

Nervous	AFINITOR.xml:S1:7195:7	O
system	AFINITOR.xml:S1:7203:6	O
disorders	AFINITOR.xml:S1:7210:9	O

Dysgeusia	AFINITOR.xml:S1:7232:9	B-AdverseReaction
22	AFINITOR.xml:S1:7243:2	O
0.2	AFINITOR.xml:S1:7260:3	O
0	AFINITOR.xml:S1:7277:1	O
6	AFINITOR.xml:S1:7294:1	O
0	AFINITOR.xml:S1:7311:1	O
0	AFINITOR.xml:S1:7328:1	O

Headache	AFINITOR.xml:S1:7354:8	B-AdverseReaction
21	AFINITOR.xml:S1:7365:2	O
0.4	AFINITOR.xml:S1:7382:3	O
0	AFINITOR.xml:S1:7399:1	O
14	AFINITOR.xml:S1:7416:2	O
0	AFINITOR.xml:S1:7433:1	O
0	AFINITOR.xml:S1:7450:1	O

Psychiatric	AFINITOR.xml:S1:7472:11	O
disorders	AFINITOR.xml:S1:7484:9	O

Insomnia	AFINITOR.xml:S1:7506:8	B-AdverseReaction
13	AFINITOR.xml:S1:7517:2	O
0.2	AFINITOR.xml:S1:7534:3	O
0	AFINITOR.xml:S1:7551:1	O
8	AFINITOR.xml:S1:7568:1	O
0	AFINITOR.xml:S1:7585:1	O
0	AFINITOR.xml:S1:7602:1	O

Respiratory	AFINITOR.xml:S1:7624:11	O
,	AFINITOR.xml:S1:7635:1	O
thoracic	AFINITOR.xml:S1:7637:8	O
and	AFINITOR.xml:S1:7646:3	O
mediastinal	AFINITOR.xml:S1:7650:11	O
disorders	AFINITOR.xml:S1:7662:9	O

Cough	AFINITOR.xml:S1:7684:5	B-AdverseReaction
24	AFINITOR.xml:S1:7695:2	O
0.6	AFINITOR.xml:S1:7712:3	O
0	AFINITOR.xml:S1:7729:1	O
12	AFINITOR.xml:S1:7746:2	O
0	AFINITOR.xml:S1:7763:1	O
0	AFINITOR.xml:S1:7780:1	O

Dyspnea	AFINITOR.xml:S1:7806:7	B-AdverseReaction
21	AFINITOR.xml:S1:7817:2	O
4	AFINITOR.xml:S1:7834:1	O
0.2	AFINITOR.xml:S1:7851:3	O
11	AFINITOR.xml:S1:7868:2	O
0.8	AFINITOR.xml:S1:7885:3	O
0.4	AFINITOR.xml:S1:7902:3	O

Epistaxis	AFINITOR.xml:S1:7928:9	B-AdverseReaction
17	AFINITOR.xml:S1:7939:2	O
0	AFINITOR.xml:S1:7956:1	O
0	AFINITOR.xml:S1:7973:1	O
1	AFINITOR.xml:S1:7990:1	O
0	AFINITOR.xml:S1:8007:1	O
0	AFINITOR.xml:S1:8024:1	O

Pneumonitis	AFINITOR.xml:S1:8050:11	B-AdverseReaction
d	AFINITOR.xml:S1:8063:1	O
19	AFINITOR.xml:S1:8068:2	O
4	AFINITOR.xml:S1:8085:1	O
0.2	AFINITOR.xml:S1:8102:3	O
0.4	AFINITOR.xml:S1:8119:3	O
0	AFINITOR.xml:S1:8136:1	O
0	AFINITOR.xml:S1:8153:1	O

Skin	AFINITOR.xml:S1:8175:4	O
and	AFINITOR.xml:S1:8180:3	O
subcutaneous	AFINITOR.xml:S1:8184:12	O
tissue	AFINITOR.xml:S1:8197:6	O
disorders	AFINITOR.xml:S1:8204:9	O

Rash	AFINITOR.xml:S1:8226:4	B-AdverseReaction
39	AFINITOR.xml:S1:8237:2	O
1	AFINITOR.xml:S1:8254:1	O
0	AFINITOR.xml:S1:8271:1	O
6	AFINITOR.xml:S1:8288:1	O
0	AFINITOR.xml:S1:8305:1	O
0	AFINITOR.xml:S1:8322:1	O

Pruritus	AFINITOR.xml:S1:8348:8	B-AdverseReaction
13	AFINITOR.xml:S1:8359:2	O
0.2	AFINITOR.xml:S1:8376:3	O
0	AFINITOR.xml:S1:8393:1	O
5	AFINITOR.xml:S1:8410:1	O
0	AFINITOR.xml:S1:8427:1	O
0	AFINITOR.xml:S1:8444:1	O

Alopecia	AFINITOR.xml:S1:8470:8	B-AdverseReaction
10	AFINITOR.xml:S1:8481:2	O
0	AFINITOR.xml:S1:8498:1	O
0	AFINITOR.xml:S1:8515:1	O
5	AFINITOR.xml:S1:8532:1	O
0	AFINITOR.xml:S1:8549:1	O
0	AFINITOR.xml:S1:8566:1	O

Vascular	AFINITOR.xml:S1:8588:8	O
disorders	AFINITOR.xml:S1:8597:9	O

Hot	AFINITOR.xml:S1:8619:3	B-AdverseReaction
flush	AFINITOR.xml:S1:8623:5	I-AdverseReaction
6	AFINITOR.xml:S1:8630:1	O
0	AFINITOR.xml:S1:8647:1	O
0	AFINITOR.xml:S1:8664:1	O
14	AFINITOR.xml:S1:8681:2	O
0	AFINITOR.xml:S1:8698:1	O
0	AFINITOR.xml:S1:8715:1	O

Median	AFINITOR.xml:S1:8737:6	O
duration	AFINITOR.xml:S1:8744:8	O
of	AFINITOR.xml:S1:8753:2	O
treatment	AFINITOR.xml:S1:8756:9	O
e	AFINITOR.xml:S1:8767:1	O
23.9	AFINITOR.xml:S1:8776:4	O
weeks	AFINITOR.xml:S1:8781:5	O
13.4	AFINITOR.xml:S1:8793:4	O
weeks	AFINITOR.xml:S1:8798:5	O

Key	AFINITOR.xml:S1:8823:3	O
observed	AFINITOR.xml:S1:8827:8	O
laboratory	AFINITOR.xml:S1:8836:10	O
abnormalities	AFINITOR.xml:S1:8847:13	O
are	AFINITOR.xml:S1:8861:3	O
presented	AFINITOR.xml:S1:8865:9	O
in	AFINITOR.xml:S1:8875:2	O
Table	AFINITOR.xml:S1:8878:5	O
3	AFINITOR.xml:S1:8884:1	O
.	AFINITOR.xml:S1:8885:1	O

Table	AFINITOR.xml:S1:8891:5	O

3	AFINITOR.xml:S1:8897:1	O
:	AFINITOR.xml:S1:8898:1	O
Key	AFINITOR.xml:S1:8900:3	O
Laboratory	AFINITOR.xml:S1:8904:10	O
Abnormalities	AFINITOR.xml:S1:8915:13	O
Reported	AFINITOR.xml:S1:8929:8	O
in	AFINITOR.xml:S1:8938:2	O
10%	AFINITOR.xml:S1:8944:3	O
of	AFINITOR.xml:S1:8948:2	O
Patients	AFINITOR.xml:S1:8951:8	O
with	AFINITOR.xml:S1:8960:4	O
Advanced	AFINITOR.xml:S1:8965:8	O
HR	AFINITOR.xml:S1:8974:2	O
BC	AFINITOR.xml:S1:8978:2	O

Grading	AFINITOR.xml:S1:8983:7	O
according	AFINITOR.xml:S1:8991:9	O
to	AFINITOR.xml:S1:9001:2	O
CTCAE	AFINITOR.xml:S1:9004:5	O
Version	AFINITOR.xml:S1:9010:7	O
3.0	AFINITOR.xml:S1:9018:3	O
a	AFINITOR.xml:S1:9023:1	O
Exemestane	AFINITOR.xml:S1:9026:10	O
(	AFINITOR.xml:S1:9037:1	O
25	AFINITOR.xml:S1:9038:2	O
mg	AFINITOR.xml:S1:9041:2	O
day	AFINITOR.xml:S1:9044:3	O
)	AFINITOR.xml:S1:9047:1	O
b	AFINITOR.xml:S1:9050:1	O
Reflects	AFINITOR.xml:S1:9053:8	O
corresponding	AFINITOR.xml:S1:9062:13	O
adverse	AFINITOR.xml:S1:9076:7	O
drug	AFINITOR.xml:S1:9084:4	O
reaction	AFINITOR.xml:S1:9089:8	O
reports	AFINITOR.xml:S1:9098:7	O
of	AFINITOR.xml:S1:9106:2	O
anemia	AFINITOR.xml:S1:9109:6	B-AdverseReaction
,	AFINITOR.xml:S1:9115:1	O
leukopenia	AFINITOR.xml:S1:9117:10	B-AdverseReaction
,	AFINITOR.xml:S1:9127:1	O
lymphopenia	AFINITOR.xml:S1:9129:11	B-AdverseReaction
,	AFINITOR.xml:S1:9140:1	O
neutropenia	AFINITOR.xml:S1:9142:11	B-AdverseReaction
,	AFINITOR.xml:S1:9153:1	O
and	AFINITOR.xml:S1:9155:3	O
thrombocytopenia	AFINITOR.xml:S1:9159:16	B-AdverseReaction
(	AFINITOR.xml:S1:9176:1	O
collectively	AFINITOR.xml:S1:9177:12	O
as	AFINITOR.xml:S1:9190:2	O
pancytopenia	AFINITOR.xml:S1:9193:12	B-AdverseReaction
)	AFINITOR.xml:S1:9205:1	O
,	AFINITOR.xml:S1:9206:1	O
which	AFINITOR.xml:S1:9208:5	O
occurred	AFINITOR.xml:S1:9214:8	O
at	AFINITOR.xml:S1:9223:2	O
lower	AFINITOR.xml:S1:9226:5	O
frequency	AFINITOR.xml:S1:9232:9	O
.	AFINITOR.xml:S1:9241:1	O

Laboratory	AFINITOR.xml:S1:9252:10	O

parameter	AFINITOR.xml:S1:9263:9	O
AFINITOR	AFINITOR.xml:S1:9278:8	O
(	AFINITOR.xml:S1:9287:1	O
10	AFINITOR.xml:S1:9288:2	O
mg	AFINITOR.xml:S1:9291:2	O
day	AFINITOR.xml:S1:9294:3	O
)	AFINITOR.xml:S1:9297:1	O
exemestane	AFINITOR.xml:S1:9304:10	O
a	AFINITOR.xml:S1:9316:1	O
N	AFINITOR.xml:S1:9323:1	O
482	AFINITOR.xml:S1:9325:3	O
Placebo	AFINITOR.xml:S1:9334:7	O
exemestane	AFINITOR.xml:S1:9347:10	O
a	AFINITOR.xml:S1:9359:1	O
N	AFINITOR.xml:S1:9366:1	O
238	AFINITOR.xml:S1:9368:3	O

All	AFINITOR.xml:S1:9397:3	O
grades	AFINITOR.xml:S1:9401:6	O
Grade	AFINITOR.xml:S1:9414:5	O
3	AFINITOR.xml:S1:9420:1	O
Grade	AFINITOR.xml:S1:9431:5	O
4	AFINITOR.xml:S1:9437:1	O
All	AFINITOR.xml:S1:9448:3	O
grades	AFINITOR.xml:S1:9452:6	O
Grade	AFINITOR.xml:S1:9465:5	O
3	AFINITOR.xml:S1:9471:1	O
Grade	AFINITOR.xml:S1:9482:5	O
4	AFINITOR.xml:S1:9488:1	O

Hematology	AFINITOR.xml:S1:9624:10	O

b	AFINITOR.xml:S1:9636:1	O

Hemoglobin	AFINITOR.xml:S1:9646:10	B-AdverseReaction
decreased	AFINITOR.xml:S1:9657:9	I-AdverseReaction
68	AFINITOR.xml:S1:9668:2	O
6	AFINITOR.xml:S1:9685:1	O
0.6	AFINITOR.xml:S1:9702:3	O
40	AFINITOR.xml:S1:9719:2	O
0.8	AFINITOR.xml:S1:9736:3	O
0.4	AFINITOR.xml:S1:9753:3	O

WBC	AFINITOR.xml:S1:9773:3	B-AdverseReaction
decreased	AFINITOR.xml:S1:9777:9	I-AdverseReaction
58	AFINITOR.xml:S1:9790:2	O
1	AFINITOR.xml:S1:9807:1	O
0	AFINITOR.xml:S1:9824:1	O
28	AFINITOR.xml:S1:9841:2	O
5	AFINITOR.xml:S1:9858:1	O
0.8	AFINITOR.xml:S1:9875:3	O

Platelets	AFINITOR.xml:S1:9895:9	B-AdverseReaction
decreased	AFINITOR.xml:S1:9905:9	I-AdverseReaction
54	AFINITOR.xml:S1:9916:2	O
3	AFINITOR.xml:S1:9933:1	O
0.2	AFINITOR.xml:S1:9950:3	O
5	AFINITOR.xml:S1:9967:1	O
0	AFINITOR.xml:S1:9984:1	O
0.4	AFINITOR.xml:S1:10001:3	O

Lymphocytes	AFINITOR.xml:S1:10021:11	B-AdverseReaction
decreased	AFINITOR.xml:S1:10033:9	I-AdverseReaction
54	AFINITOR.xml:S1:10044:2	O
11	AFINITOR.xml:S1:10061:2	O
0.6	AFINITOR.xml:S1:10078:3	O
37	AFINITOR.xml:S1:10095:2	O
5	AFINITOR.xml:S1:10112:1	O
0.8	AFINITOR.xml:S1:10129:3	O

Neutrophils	AFINITOR.xml:S1:10149:11	B-AdverseReaction
decreased	AFINITOR.xml:S1:10161:9	I-AdverseReaction
31	AFINITOR.xml:S1:10172:2	O
2	AFINITOR.xml:S1:10189:1	O
0	AFINITOR.xml:S1:10206:1	O
11	AFINITOR.xml:S1:10223:2	O
0.8	AFINITOR.xml:S1:10240:3	O
0.8	AFINITOR.xml:S1:10257:3	O

Clinical	AFINITOR.xml:S1:10279:8	O
chemistry	AFINITOR.xml:S1:10288:9	O

Glucose	AFINITOR.xml:S1:10304:7	B-AdverseReaction
increased	AFINITOR.xml:S1:10312:9	I-AdverseReaction
69	AFINITOR.xml:S1:10323:2	O
9	AFINITOR.xml:S1:10340:1	O
0.4	AFINITOR.xml:S1:10357:3	O
44	AFINITOR.xml:S1:10374:2	O
0.8	AFINITOR.xml:S1:10391:3	O
0.4	AFINITOR.xml:S1:10408:3	O

Cholesterol	AFINITOR.xml:S1:10428:11	B-AdverseReaction
increased	AFINITOR.xml:S1:10440:9	I-AdverseReaction
70	AFINITOR.xml:S1:10451:2	O
0.6	AFINITOR.xml:S1:10468:3	O
0.2	AFINITOR.xml:S1:10485:3	O
38	AFINITOR.xml:S1:10502:2	O
0.8	AFINITOR.xml:S1:10519:3	O
0.8	AFINITOR.xml:S1:10536:3	O

Aspartate	AFINITOR.xml:S1:10556:9	B-AdverseReaction
transaminase	AFINITOR.xml:S1:10566:12	I-AdverseReaction
(	AFINITOR.xml:S1:10579:1	O
AST	AFINITOR.xml:S1:10580:3	B-AdverseReaction
)	AFINITOR.xml:S1:10583:1	O
increased	AFINITOR.xml:S1:10585:9	I-AdverseReaction
69	AFINITOR.xml:S1:10596:2	O
4	AFINITOR.xml:S1:10613:1	O
0.2	AFINITOR.xml:S1:10630:3	O
45	AFINITOR.xml:S1:10647:2	O
3	AFINITOR.xml:S1:10664:1	O
0.4	AFINITOR.xml:S1:10681:3	O

Alanine	AFINITOR.xml:S1:10701:7	B-AdverseReaction
transaminase	AFINITOR.xml:S1:10709:12	I-AdverseReaction
(	AFINITOR.xml:S1:10722:1	O
ALT	AFINITOR.xml:S1:10723:3	B-AdverseReaction
)	AFINITOR.xml:S1:10726:1	O
increased	AFINITOR.xml:S1:10728:9	I-AdverseReaction
51	AFINITOR.xml:S1:10739:2	O
4	AFINITOR.xml:S1:10756:1	O
0.2	AFINITOR.xml:S1:10773:3	O
29	AFINITOR.xml:S1:10790:2	O
5	AFINITOR.xml:S1:10807:1	O
0	AFINITOR.xml:S1:10824:1	O

Triglycerides	AFINITOR.xml:S1:10844:13	B-AdverseReaction
increased	AFINITOR.xml:S1:10858:9	I-AdverseReaction
50	AFINITOR.xml:S1:10869:2	O
0.8	AFINITOR.xml:S1:10886:3	O
0	AFINITOR.xml:S1:10903:1	O
26	AFINITOR.xml:S1:10920:2	O
0	AFINITOR.xml:S1:10937:1	O
0	AFINITOR.xml:S1:10954:1	O

Albumin	AFINITOR.xml:S1:10974:7	B-AdverseReaction
decreased	AFINITOR.xml:S1:10982:9	I-AdverseReaction
33	AFINITOR.xml:S1:10993:2	O
0.8	AFINITOR.xml:S1:11010:3	O
0	AFINITOR.xml:S1:11027:1	O
16	AFINITOR.xml:S1:11044:2	O
0.8	AFINITOR.xml:S1:11061:3	O
0	AFINITOR.xml:S1:11078:1	O

Potassium	AFINITOR.xml:S1:11098:9	B-AdverseReaction
decreased	AFINITOR.xml:S1:11108:9	I-AdverseReaction
29	AFINITOR.xml:S1:11119:2	O
4	AFINITOR.xml:S1:11136:1	O
0.2	AFINITOR.xml:S1:11153:3	O
7	AFINITOR.xml:S1:11170:1	O
1	AFINITOR.xml:S1:11187:1	O
0	AFINITOR.xml:S1:11204:1	O

Creatinine	AFINITOR.xml:S1:11224:10	B-AdverseReaction
increased	AFINITOR.xml:S1:11235:9	I-AdverseReaction
24	AFINITOR.xml:S1:11246:2	O
2	AFINITOR.xml:S1:11263:1	O
0.2	AFINITOR.xml:S1:11280:3	O
13	AFINITOR.xml:S1:11297:2	O
0	AFINITOR.xml:S1:11314:1	O
0	AFINITOR.xml:S1:11331:1	O

6.2	AFINITOR.xml:S1:11365:3	O
Clinical	AFINITOR.xml:S1:11373:8	O
Study	AFINITOR.xml:S1:11382:5	O
Experience	AFINITOR.xml:S1:11388:10	O
in	AFINITOR.xml:S1:11399:2	O
Advanced	AFINITOR.xml:S1:11402:8	O
Pancreatic	AFINITOR.xml:S1:11411:10	O
Neuroendocrine	AFINITOR.xml:S1:11422:14	O
Tumors	AFINITOR.xml:S1:11437:6	O

In	AFINITOR.xml:S1:11447:2	O
a	AFINITOR.xml:S1:11450:1	O
randomized	AFINITOR.xml:S1:11452:10	O
,	AFINITOR.xml:S1:11462:1	O
controlled	AFINITOR.xml:S1:11464:10	O
trial	AFINITOR.xml:S1:11475:5	O
of	AFINITOR.xml:S1:11481:2	O
AFINITOR	AFINITOR.xml:S1:11484:8	O
(	AFINITOR.xml:S1:11493:1	O
n	AFINITOR.xml:S1:11494:1	O
204	AFINITOR.xml:S1:11496:3	O
)	AFINITOR.xml:S1:11499:1	O
versus	AFINITOR.xml:S1:11501:6	O
placebo	AFINITOR.xml:S1:11508:7	O
(	AFINITOR.xml:S1:11516:1	O
n	AFINITOR.xml:S1:11517:1	O
203	AFINITOR.xml:S1:11519:3	O
)	AFINITOR.xml:S1:11522:1	O
in	AFINITOR.xml:S1:11524:2	O
patients	AFINITOR.xml:S1:11527:8	O
with	AFINITOR.xml:S1:11536:4	O
advanced	AFINITOR.xml:S1:11541:8	O
PNET	AFINITOR.xml:S1:11550:4	O
the	AFINITOR.xml:S1:11555:3	O
median	AFINITOR.xml:S1:11559:6	O
age	AFINITOR.xml:S1:11566:3	O
of	AFINITOR.xml:S1:11570:2	O
patients	AFINITOR.xml:S1:11573:8	O
was	AFINITOR.xml:S1:11582:3	O
58	AFINITOR.xml:S1:11586:2	O
years	AFINITOR.xml:S1:11589:5	O
(	AFINITOR.xml:S1:11595:1	O
range	AFINITOR.xml:S1:11596:5	O
20	AFINITOR.xml:S1:11602:2	O
-	AFINITOR.xml:S1:11604:1	O
87	AFINITOR.xml:S1:11605:2	O
)	AFINITOR.xml:S1:11607:1	O
,	AFINITOR.xml:S1:11608:1	O
79%	AFINITOR.xml:S1:11610:3	O
were	AFINITOR.xml:S1:11614:4	O
Caucasian	AFINITOR.xml:S1:11619:9	O
,	AFINITOR.xml:S1:11628:1	O
and	AFINITOR.xml:S1:11630:3	O
55%	AFINITOR.xml:S1:11634:3	O
were	AFINITOR.xml:S1:11638:4	O
male	AFINITOR.xml:S1:11643:4	O
.	AFINITOR.xml:S1:11647:1	O

Patients	AFINITOR.xml:S1:11649:8	O
on	AFINITOR.xml:S1:11658:2	O
the	AFINITOR.xml:S1:11661:3	O
placebo	AFINITOR.xml:S1:11665:7	O
arm	AFINITOR.xml:S1:11673:3	O
could	AFINITOR.xml:S1:11677:5	O
cross	AFINITOR.xml:S1:11683:5	O
over	AFINITOR.xml:S1:11689:4	O
to	AFINITOR.xml:S1:11694:2	O
open	AFINITOR.xml:S1:11697:4	O
-	AFINITOR.xml:S1:11701:1	O
label	AFINITOR.xml:S1:11702:5	O
AFINITOR	AFINITOR.xml:S1:11708:8	O
upon	AFINITOR.xml:S1:11717:4	O
disease	AFINITOR.xml:S1:11722:7	O
progression	AFINITOR.xml:S1:11730:11	O
.	AFINITOR.xml:S1:11741:1	O

The	AFINITOR.xml:S1:11748:3	O
most	AFINITOR.xml:S1:11752:4	O
common	AFINITOR.xml:S1:11757:6	O
adverse	AFINITOR.xml:S1:11764:7	O
reactions	AFINITOR.xml:S1:11772:9	O
(	AFINITOR.xml:S1:11782:1	O
incidence	AFINITOR.xml:S1:11783:9	O
30%	AFINITOR.xml:S1:11796:3	O
)	AFINITOR.xml:S1:11799:1	O
were	AFINITOR.xml:S1:11801:4	O
stomatitis	AFINITOR.xml:S1:11806:10	B-AdverseReaction
,	AFINITOR.xml:S1:11816:1	O
rash	AFINITOR.xml:S1:11818:4	B-AdverseReaction
,	AFINITOR.xml:S1:11822:1	O
diarrhea	AFINITOR.xml:S1:11824:8	B-AdverseReaction
,	AFINITOR.xml:S1:11832:1	O
fatigue	AFINITOR.xml:S1:11834:7	B-AdverseReaction
,	AFINITOR.xml:S1:11841:1	O
edema	AFINITOR.xml:S1:11843:5	B-AdverseReaction
,	AFINITOR.xml:S1:11848:1	O
abdominal	AFINITOR.xml:S1:11850:9	B-AdverseReaction
pain	AFINITOR.xml:S1:11860:4	I-AdverseReaction
,	AFINITOR.xml:S1:11864:1	O
nausea	AFINITOR.xml:S1:11866:6	B-AdverseReaction
,	AFINITOR.xml:S1:11872:1	O
fever	AFINITOR.xml:S1:11874:5	B-AdverseReaction
,	AFINITOR.xml:S1:11879:1	O
and	AFINITOR.xml:S1:11881:3	O
headache	AFINITOR.xml:S1:11885:8	B-AdverseReaction
.	AFINITOR.xml:S1:11893:1	O

The	AFINITOR.xml:S1:11895:3	O
most	AFINITOR.xml:S1:11899:4	O
common	AFINITOR.xml:S1:11904:6	O
Grade	AFINITOR.xml:S1:11911:5	B-Severity
3	AFINITOR.xml:S1:11917:1	I-Severity
-	AFINITOR.xml:S1:11918:1	I-Severity
4	AFINITOR.xml:S1:11919:1	I-Severity
adverse	AFINITOR.xml:S1:11921:7	O
reactions	AFINITOR.xml:S1:11929:9	O
(	AFINITOR.xml:S1:11939:1	O
incidence	AFINITOR.xml:S1:11940:9	O
5%	AFINITOR.xml:S1:11953:2	O
)	AFINITOR.xml:S1:11955:1	O
were	AFINITOR.xml:S1:11957:4	O
stomatitis	AFINITOR.xml:S1:11962:10	B-AdverseReaction
and	AFINITOR.xml:S1:11973:3	O
diarrhea	AFINITOR.xml:S1:11977:8	B-AdverseReaction
.	AFINITOR.xml:S1:11985:1	O

The	AFINITOR.xml:S1:11987:3	O
most	AFINITOR.xml:S1:11991:4	O
common	AFINITOR.xml:S1:11996:6	O
laboratory	AFINITOR.xml:S1:12003:10	O
abnormalities	AFINITOR.xml:S1:12014:13	O
(	AFINITOR.xml:S1:12028:1	O
incidence	AFINITOR.xml:S1:12029:9	O
50%	AFINITOR.xml:S1:12042:3	O
)	AFINITOR.xml:S1:12045:1	O
were	AFINITOR.xml:S1:12047:4	O
decreased	AFINITOR.xml:S1:12052:9	B-AdverseReaction
hemoglobin	AFINITOR.xml:S1:12062:10	I-AdverseReaction
,	AFINITOR.xml:S1:12072:1	O
hyperglycemia	AFINITOR.xml:S1:12074:13	B-AdverseReaction
,	AFINITOR.xml:S1:12087:1	O
alkaline	AFINITOR.xml:S1:12089:8	B-AdverseReaction
phosphatase	AFINITOR.xml:S1:12098:11	I-AdverseReaction
increased	AFINITOR.xml:S1:12110:9	I-AdverseReaction
,	AFINITOR.xml:S1:12119:1	O
hypercholesterolemia	AFINITOR.xml:S1:12121:20	B-AdverseReaction
,	AFINITOR.xml:S1:12141:1	O
bicarbonate	AFINITOR.xml:S1:12143:11	B-AdverseReaction
decreased	AFINITOR.xml:S1:12155:9	I-AdverseReaction
,	AFINITOR.xml:S1:12164:1	O
and	AFINITOR.xml:S1:12166:3	O
increased	AFINITOR.xml:S1:12170:9	B-AdverseReaction
aspartate	AFINITOR.xml:S1:12180:9	I-AdverseReaction
transaminase	AFINITOR.xml:S1:12190:12	I-AdverseReaction
(	AFINITOR.xml:S1:12203:1	O
AST	AFINITOR.xml:S1:12204:3	I-AdverseReaction
)	AFINITOR.xml:S1:12207:1	O
.	AFINITOR.xml:S1:12208:1	O

The	AFINITOR.xml:S1:12210:3	O
most	AFINITOR.xml:S1:12214:4	O
common	AFINITOR.xml:S1:12219:6	O
Grade	AFINITOR.xml:S1:12226:5	B-Severity
3	AFINITOR.xml:S1:12232:1	I-Severity
-	AFINITOR.xml:S1:12233:1	I-Severity
4	AFINITOR.xml:S1:12234:1	I-Severity
laboratory	AFINITOR.xml:S1:12236:10	O
abnormalities	AFINITOR.xml:S1:12247:13	O
(	AFINITOR.xml:S1:12261:1	O
incidence	AFINITOR.xml:S1:12262:9	O
3%	AFINITOR.xml:S1:12275:2	O
)	AFINITOR.xml:S1:12277:1	O
were	AFINITOR.xml:S1:12279:4	O
hyperglycemia	AFINITOR.xml:S1:12284:13	B-AdverseReaction
,	AFINITOR.xml:S1:12297:1	O
lymphopenia	AFINITOR.xml:S1:12299:11	B-AdverseReaction
,	AFINITOR.xml:S1:12310:1	O
decreased	AFINITOR.xml:S1:12312:9	B-AdverseReaction
hemoglobin	AFINITOR.xml:S1:12322:10	I-AdverseReaction
,	AFINITOR.xml:S1:12332:1	O
hypophosphatemia	AFINITOR.xml:S1:12334:16	B-AdverseReaction
,	AFINITOR.xml:S1:12350:1	O
increased	AFINITOR.xml:S1:12352:9	B-AdverseReaction
alkaline	AFINITOR.xml:S1:12362:8	I-AdverseReaction
phosphatase	AFINITOR.xml:S1:12371:11	I-AdverseReaction
,	AFINITOR.xml:S1:12382:1	O
neutropenia	AFINITOR.xml:S1:12384:11	B-AdverseReaction
,	AFINITOR.xml:S1:12395:1	O
increased	AFINITOR.xml:S1:12397:9	B-AdverseReaction
aspartate	AFINITOR.xml:S1:12407:9	I-AdverseReaction
transaminase	AFINITOR.xml:S1:12417:12	I-AdverseReaction
(	AFINITOR.xml:S1:12430:1	O
AST	AFINITOR.xml:S1:12431:3	I-AdverseReaction
)	AFINITOR.xml:S1:12434:1	O
,	AFINITOR.xml:S1:12435:1	O
potassium	AFINITOR.xml:S1:12437:9	B-AdverseReaction
decreased	AFINITOR.xml:S1:12447:9	I-AdverseReaction
,	AFINITOR.xml:S1:12456:1	O
and	AFINITOR.xml:S1:12458:3	O
thrombocytopenia	AFINITOR.xml:S1:12462:16	B-AdverseReaction
.	AFINITOR.xml:S1:12478:1	O

Deaths	AFINITOR.xml:S1:12481:6	B-AdverseReaction
during	AFINITOR.xml:S1:12488:6	O
double	AFINITOR.xml:S1:12495:6	O
-	AFINITOR.xml:S1:12501:1	O
blind	AFINITOR.xml:S1:12502:5	O
treatment	AFINITOR.xml:S1:12508:9	O
where	AFINITOR.xml:S1:12518:5	O
an	AFINITOR.xml:S1:12524:2	O
adverse	AFINITOR.xml:S1:12527:7	O
event	AFINITOR.xml:S1:12535:5	O
was	AFINITOR.xml:S1:12541:3	O
the	AFINITOR.xml:S1:12545:3	O
primary	AFINITOR.xml:S1:12549:7	O
cause	AFINITOR.xml:S1:12557:5	O
occurred	AFINITOR.xml:S1:12563:8	O
in	AFINITOR.xml:S1:12572:2	O
seven	AFINITOR.xml:S1:12575:5	O
patients	AFINITOR.xml:S1:12581:8	O
on	AFINITOR.xml:S1:12590:2	O
AFINITOR	AFINITOR.xml:S1:12593:8	O
and	AFINITOR.xml:S1:12602:3	O
one	AFINITOR.xml:S1:12606:3	O
patient	AFINITOR.xml:S1:12610:7	O
on	AFINITOR.xml:S1:12618:2	O
placebo	AFINITOR.xml:S1:12621:7	O
.	AFINITOR.xml:S1:12628:1	O

Causes	AFINITOR.xml:S1:12630:6	O
of	AFINITOR.xml:S1:12637:2	O
death	AFINITOR.xml:S1:12640:5	B-AdverseReaction
on	AFINITOR.xml:S1:12646:2	O
the	AFINITOR.xml:S1:12649:3	O
AFINITOR	AFINITOR.xml:S1:12653:8	O
arm	AFINITOR.xml:S1:12662:3	O
included	AFINITOR.xml:S1:12666:8	O
one	AFINITOR.xml:S1:12675:3	O
case	AFINITOR.xml:S1:12679:4	O
of	AFINITOR.xml:S1:12684:2	O
each	AFINITOR.xml:S1:12687:4	O
of	AFINITOR.xml:S1:12692:2	O
the	AFINITOR.xml:S1:12695:3	O
following	AFINITOR.xml:S1:12699:9	O
:	AFINITOR.xml:S1:12708:1	O
acute	AFINITOR.xml:S1:12710:5	B-AdverseReaction
renal	AFINITOR.xml:S1:12716:5	I-AdverseReaction
failure	AFINITOR.xml:S1:12722:7	I-AdverseReaction
,	AFINITOR.xml:S1:12729:1	O
acute	AFINITOR.xml:S1:12731:5	B-AdverseReaction
respiratory	AFINITOR.xml:S1:12737:11	I-AdverseReaction
distress	AFINITOR.xml:S1:12749:8	I-AdverseReaction
,	AFINITOR.xml:S1:12757:1	O
cardiac	AFINITOR.xml:S1:12759:7	B-AdverseReaction
arrest	AFINITOR.xml:S1:12767:6	I-AdverseReaction
,	AFINITOR.xml:S1:12773:1	O
death	AFINITOR.xml:S1:12775:5	B-AdverseReaction
(	AFINITOR.xml:S1:12781:1	O
cause	AFINITOR.xml:S1:12782:5	O
unknown	AFINITOR.xml:S1:12788:7	O
)	AFINITOR.xml:S1:12795:1	O
,	AFINITOR.xml:S1:12796:1	O
hepatic	AFINITOR.xml:S1:12798:7	B-AdverseReaction
failure	AFINITOR.xml:S1:12806:7	I-AdverseReaction
,	AFINITOR.xml:S1:12813:1	O
pneumonia	AFINITOR.xml:S1:12815:9	B-AdverseReaction
,	AFINITOR.xml:S1:12824:1	O
and	AFINITOR.xml:S1:12826:3	O
sepsis	AFINITOR.xml:S1:12830:6	B-AdverseReaction
.	AFINITOR.xml:S1:12836:1	O

There	AFINITOR.xml:S1:12838:5	O
was	AFINITOR.xml:S1:12844:3	O
one	AFINITOR.xml:S1:12848:3	O
death	AFINITOR.xml:S1:12852:5	B-AdverseReaction
due	AFINITOR.xml:S1:12858:3	O
to	AFINITOR.xml:S1:12862:2	O
pulmonary	AFINITOR.xml:S1:12865:9	B-AdverseReaction
embolism	AFINITOR.xml:S1:12875:8	I-AdverseReaction
on	AFINITOR.xml:S1:12884:2	O
the	AFINITOR.xml:S1:12887:3	O
placebo	AFINITOR.xml:S1:12891:7	B-Factor
arm	AFINITOR.xml:S1:12899:3	O
.	AFINITOR.xml:S1:12902:1	O

After	AFINITOR.xml:S1:12904:5	O
cross	AFINITOR.xml:S1:12910:5	O
-	AFINITOR.xml:S1:12915:1	O
over	AFINITOR.xml:S1:12916:4	O
to	AFINITOR.xml:S1:12921:2	O
open	AFINITOR.xml:S1:12924:4	O
-	AFINITOR.xml:S1:12928:1	O
label	AFINITOR.xml:S1:12929:5	O
AFINITOR	AFINITOR.xml:S1:12935:8	O
,	AFINITOR.xml:S1:12943:1	O
there	AFINITOR.xml:S1:12945:5	O
were	AFINITOR.xml:S1:12951:4	O
three	AFINITOR.xml:S1:12956:5	O
additional	AFINITOR.xml:S1:12962:10	O
deaths	AFINITOR.xml:S1:12973:6	B-AdverseReaction
,	AFINITOR.xml:S1:12979:1	O
one	AFINITOR.xml:S1:12981:3	O
due	AFINITOR.xml:S1:12985:3	O
to	AFINITOR.xml:S1:12989:2	O
hypoglycemia	AFINITOR.xml:S1:12992:12	B-AdverseReaction
and	AFINITOR.xml:S1:13005:3	O
cardiac	AFINITOR.xml:S1:13009:7	B-AdverseReaction
arrest	AFINITOR.xml:S1:13017:6	I-AdverseReaction
in	AFINITOR.xml:S1:13024:2	O
a	AFINITOR.xml:S1:13027:1	O
patient	AFINITOR.xml:S1:13029:7	O
with	AFINITOR.xml:S1:13037:4	O
insulinoma	AFINITOR.xml:S1:13042:10	O
,	AFINITOR.xml:S1:13052:1	O
one	AFINITOR.xml:S1:13054:3	O
due	AFINITOR.xml:S1:13058:3	O
to	AFINITOR.xml:S1:13062:2	O
myocardial	AFINITOR.xml:S1:13065:10	B-AdverseReaction
infarction	AFINITOR.xml:S1:13076:10	I-AdverseReaction
with	AFINITOR.xml:S1:13087:4	O
congestive	AFINITOR.xml:S1:13092:10	B-AdverseReaction
heart	AFINITOR.xml:S1:13103:5	I-AdverseReaction
failure	AFINITOR.xml:S1:13109:7	I-AdverseReaction
,	AFINITOR.xml:S1:13116:1	O
and	AFINITOR.xml:S1:13118:3	O
the	AFINITOR.xml:S1:13122:3	O
other	AFINITOR.xml:S1:13126:5	O
due	AFINITOR.xml:S1:13132:3	O
to	AFINITOR.xml:S1:13136:2	O
sudden	AFINITOR.xml:S1:13139:6	B-AdverseReaction
death	AFINITOR.xml:S1:13146:5	I-AdverseReaction
.	AFINITOR.xml:S1:13151:1	O

The	AFINITOR.xml:S1:13153:3	O
rates	AFINITOR.xml:S1:13157:5	O
of	AFINITOR.xml:S1:13163:2	O
treatment	AFINITOR.xml:S1:13166:9	O
-	AFINITOR.xml:S1:13175:1	O
emergent	AFINITOR.xml:S1:13176:8	O
adverse	AFINITOR.xml:S1:13185:7	O
events	AFINITOR.xml:S1:13193:6	O
resulting	AFINITOR.xml:S1:13200:9	O
in	AFINITOR.xml:S1:13210:2	O
permanent	AFINITOR.xml:S1:13213:9	O
discontinuation	AFINITOR.xml:S1:13223:15	O
were	AFINITOR.xml:S1:13239:4	O
20%	AFINITOR.xml:S1:13244:3	O
and	AFINITOR.xml:S1:13248:3	O
6%	AFINITOR.xml:S1:13252:2	O
for	AFINITOR.xml:S1:13255:3	O
the	AFINITOR.xml:S1:13259:3	O
AFINITOR	AFINITOR.xml:S1:13263:8	O
and	AFINITOR.xml:S1:13272:3	O
placebo	AFINITOR.xml:S1:13276:7	O
treatment	AFINITOR.xml:S1:13284:9	O
groups	AFINITOR.xml:S1:13294:6	O
,	AFINITOR.xml:S1:13300:1	O
respectively	AFINITOR.xml:S1:13302:12	O
.	AFINITOR.xml:S1:13314:1	O

Dose	AFINITOR.xml:S1:13316:4	O
delay	AFINITOR.xml:S1:13321:5	O
or	AFINITOR.xml:S1:13327:2	O
reduction	AFINITOR.xml:S1:13330:9	O
was	AFINITOR.xml:S1:13340:3	O
necessary	AFINITOR.xml:S1:13344:9	O
in	AFINITOR.xml:S1:13354:2	O
61%	AFINITOR.xml:S1:13357:3	O
of	AFINITOR.xml:S1:13361:2	O
everolimus	AFINITOR.xml:S1:13364:10	O
patients	AFINITOR.xml:S1:13375:8	O
and	AFINITOR.xml:S1:13384:3	O
29%	AFINITOR.xml:S1:13388:3	O
of	AFINITOR.xml:S1:13392:2	O
placebo	AFINITOR.xml:S1:13395:7	O
patients	AFINITOR.xml:S1:13403:8	O
.	AFINITOR.xml:S1:13411:1	O

Grade	AFINITOR.xml:S1:13413:5	B-Severity
3	AFINITOR.xml:S1:13419:1	I-Severity
-	AFINITOR.xml:S1:13420:1	O
4	AFINITOR.xml:S1:13421:1	I-Severity
renal	AFINITOR.xml:S1:13423:5	B-AdverseReaction
failure	AFINITOR.xml:S1:13429:7	I-AdverseReaction
occurred	AFINITOR.xml:S1:13437:8	O
in	AFINITOR.xml:S1:13446:2	O
six	AFINITOR.xml:S1:13449:3	O
patients	AFINITOR.xml:S1:13453:8	O
in	AFINITOR.xml:S1:13462:2	O
the	AFINITOR.xml:S1:13465:3	O
everolimus	AFINITOR.xml:S1:13469:10	O
arm	AFINITOR.xml:S1:13480:3	O
and	AFINITOR.xml:S1:13484:3	O
three	AFINITOR.xml:S1:13488:5	O
patients	AFINITOR.xml:S1:13494:8	O
in	AFINITOR.xml:S1:13503:2	O
the	AFINITOR.xml:S1:13506:3	O
placebo	AFINITOR.xml:S1:13510:7	O
arm	AFINITOR.xml:S1:13518:3	O
.	AFINITOR.xml:S1:13521:1	O

Thrombotic	AFINITOR.xml:S1:13523:10	B-AdverseReaction
events	AFINITOR.xml:S1:13534:6	I-AdverseReaction
included	AFINITOR.xml:S1:13541:8	O
five	AFINITOR.xml:S1:13550:4	O
patients	AFINITOR.xml:S1:13555:8	O
with	AFINITOR.xml:S1:13564:4	O
pulmonary	AFINITOR.xml:S1:13569:9	B-AdverseReaction
embolus	AFINITOR.xml:S1:13579:7	I-AdverseReaction
in	AFINITOR.xml:S1:13587:2	O
the	AFINITOR.xml:S1:13590:3	O
everolimus	AFINITOR.xml:S1:13594:10	O
arm	AFINITOR.xml:S1:13605:3	O
and	AFINITOR.xml:S1:13609:3	O
one	AFINITOR.xml:S1:13613:3	O
in	AFINITOR.xml:S1:13617:2	O
the	AFINITOR.xml:S1:13620:3	O
placebo	AFINITOR.xml:S1:13624:7	O
arm	AFINITOR.xml:S1:13632:3	O
as	AFINITOR.xml:S1:13636:2	O
well	AFINITOR.xml:S1:13639:4	O
as	AFINITOR.xml:S1:13644:2	O
three	AFINITOR.xml:S1:13647:5	O
patients	AFINITOR.xml:S1:13653:8	O
with	AFINITOR.xml:S1:13662:4	O
thrombosis	AFINITOR.xml:S1:13667:10	B-AdverseReaction
in	AFINITOR.xml:S1:13678:2	O
the	AFINITOR.xml:S1:13681:3	O
everolimus	AFINITOR.xml:S1:13685:10	O
arm	AFINITOR.xml:S1:13696:3	O
and	AFINITOR.xml:S1:13700:3	O
two	AFINITOR.xml:S1:13704:3	O
in	AFINITOR.xml:S1:13708:2	O
the	AFINITOR.xml:S1:13711:3	O
placebo	AFINITOR.xml:S1:13715:7	O
arm	AFINITOR.xml:S1:13723:3	O
.	AFINITOR.xml:S1:13726:1	O

Table	AFINITOR.xml:S1:13732:5	O
4	AFINITOR.xml:S1:13738:1	O
compares	AFINITOR.xml:S1:13740:8	O
the	AFINITOR.xml:S1:13749:3	O
incidence	AFINITOR.xml:S1:13753:9	O
of	AFINITOR.xml:S1:13763:2	O
treatment	AFINITOR.xml:S1:13766:9	O
-	AFINITOR.xml:S1:13775:1	O
emergent	AFINITOR.xml:S1:13776:8	O
adverse	AFINITOR.xml:S1:13785:7	O
reactions	AFINITOR.xml:S1:13793:9	O
reported	AFINITOR.xml:S1:13803:8	O
with	AFINITOR.xml:S1:13812:4	O
an	AFINITOR.xml:S1:13817:2	O
incidence	AFINITOR.xml:S1:13820:9	O
of	AFINITOR.xml:S1:13830:2	O
10%	AFINITOR.xml:S1:13836:3	O
for	AFINITOR.xml:S1:13840:3	O
patients	AFINITOR.xml:S1:13844:8	O
receiving	AFINITOR.xml:S1:13853:9	O
AFINITOR	AFINITOR.xml:S1:13863:8	O
10	AFINITOR.xml:S1:13872:2	O
mg	AFINITOR.xml:S1:13875:2	O
daily	AFINITOR.xml:S1:13878:5	O
versus	AFINITOR.xml:S1:13884:6	O
placebo	AFINITOR.xml:S1:13891:7	O
.	AFINITOR.xml:S1:13898:1	O

Table	AFINITOR.xml:S1:13905:5	O
4	AFINITOR.xml:S1:13911:1	O
:	AFINITOR.xml:S1:13912:1	O
Adverse	AFINITOR.xml:S1:13915:7	O
Reactions	AFINITOR.xml:S1:13923:9	O
Reported	AFINITOR.xml:S1:13933:8	O
10%	AFINITOR.xml:S1:13945:3	O
of	AFINITOR.xml:S1:13949:2	O
Patients	AFINITOR.xml:S1:13952:8	O
with	AFINITOR.xml:S1:13961:4	O
Advanced	AFINITOR.xml:S1:13966:8	O
PNET	AFINITOR.xml:S1:13975:4	O

Grading	AFINITOR.xml:S1:13983:7	O
according	AFINITOR.xml:S1:13991:9	O
to	AFINITOR.xml:S1:14001:2	O
CTCAE	AFINITOR.xml:S1:14004:5	O
Version	AFINITOR.xml:S1:14010:7	O
3.0	AFINITOR.xml:S1:14018:3	O
a	AFINITOR.xml:S1:14023:1	O
Includes	AFINITOR.xml:S1:14027:8	O
stomatitis	AFINITOR.xml:S1:14036:10	B-AdverseReaction
,	AFINITOR.xml:S1:14046:1	O
aphthous	AFINITOR.xml:S1:14048:8	B-AdverseReaction
stomatitis	AFINITOR.xml:S1:14057:10	I-AdverseReaction
,	AFINITOR.xml:S1:14067:1	O
gingival	AFINITOR.xml:S1:14069:8	B-AdverseReaction
pain	AFINITOR.xml:S1:14078:4	I-AdverseReaction
swelling	AFINITOR.xml:S1:14083:8	I-AdverseReaction
ulceration	AFINITOR.xml:S1:14092:10	I-AdverseReaction
,	AFINITOR.xml:S1:14102:1	O
glossitis	AFINITOR.xml:S1:14104:9	B-AdverseReaction
,	AFINITOR.xml:S1:14113:1	O
glossodynia	AFINITOR.xml:S1:14115:11	B-AdverseReaction
,	AFINITOR.xml:S1:14126:1	O
lip	AFINITOR.xml:S1:14128:3	B-AdverseReaction
ulceration	AFINITOR.xml:S1:14132:10	I-AdverseReaction
,	AFINITOR.xml:S1:14142:1	O
mouth	AFINITOR.xml:S1:14144:5	B-AdverseReaction
ulceration	AFINITOR.xml:S1:14150:10	I-AdverseReaction
,	AFINITOR.xml:S1:14160:1	O
tongue	AFINITOR.xml:S1:14162:6	B-AdverseReaction
ulceration	AFINITOR.xml:S1:14169:10	I-AdverseReaction
,	AFINITOR.xml:S1:14179:1	O
and	AFINITOR.xml:S1:14181:3	O
mucosal	AFINITOR.xml:S1:14185:7	B-AdverseReaction
inflammation	AFINITOR.xml:S1:14193:12	I-AdverseReaction
.	AFINITOR.xml:S1:14205:1	O

b	AFINITOR.xml:S1:14208:1	O
Includes	AFINITOR.xml:S1:14212:8	O
diarrhea	AFINITOR.xml:S1:14221:8	B-AdverseReaction
,	AFINITOR.xml:S1:14229:1	O
enteritis	AFINITOR.xml:S1:14231:9	B-AdverseReaction
,	AFINITOR.xml:S1:14240:1	O
enterocolitis	AFINITOR.xml:S1:14242:13	B-AdverseReaction
,	AFINITOR.xml:S1:14255:1	O
colitis	AFINITOR.xml:S1:14257:7	B-AdverseReaction
,	AFINITOR.xml:S1:14264:1	O
defecation	AFINITOR.xml:S1:14266:10	B-AdverseReaction
urgency	AFINITOR.xml:S1:14277:7	I-AdverseReaction
,	AFINITOR.xml:S1:14284:1	O
and	AFINITOR.xml:S1:14286:3	O
steatorrhea	AFINITOR.xml:S1:14290:11	B-AdverseReaction
.	AFINITOR.xml:S1:14301:1	O

c	AFINITOR.xml:S1:14304:1	O
Includes	AFINITOR.xml:S1:14307:8	O
pneumonitis	AFINITOR.xml:S1:14316:11	B-AdverseReaction
,	AFINITOR.xml:S1:14327:1	O
interstitial	AFINITOR.xml:S1:14329:12	B-AdverseReaction
lung	AFINITOR.xml:S1:14342:4	I-AdverseReaction
disease	AFINITOR.xml:S1:14347:7	I-AdverseReaction
,	AFINITOR.xml:S1:14354:1	O
pulmonary	AFINITOR.xml:S1:14356:9	B-AdverseReaction
fibrosis	AFINITOR.xml:S1:14366:8	I-AdverseReaction
and	AFINITOR.xml:S1:14375:3	O
restrictive	AFINITOR.xml:S1:14379:11	B-AdverseReaction
pulmonary	AFINITOR.xml:S1:14391:9	I-AdverseReaction
disease	AFINITOR.xml:S1:14401:7	I-AdverseReaction
.	AFINITOR.xml:S1:14408:1	O

AFINITOR	AFINITOR.xml:S1:14436:8	O

N	AFINITOR.xml:S1:14448:1	O
204	AFINITOR.xml:S1:14450:3	O
Placebo	AFINITOR.xml:S1:14459:7	O
N	AFINITOR.xml:S1:14470:1	O
203	AFINITOR.xml:S1:14472:3	O

All	AFINITOR.xml:S1:14501:3	O
grades	AFINITOR.xml:S1:14505:6	O
Grade	AFINITOR.xml:S1:14518:5	O
3	AFINITOR.xml:S1:14524:1	O
Grade	AFINITOR.xml:S1:14535:5	O
4	AFINITOR.xml:S1:14541:1	O
All	AFINITOR.xml:S1:14552:3	O
grades	AFINITOR.xml:S1:14556:6	O
Grade	AFINITOR.xml:S1:14569:5	O
3	AFINITOR.xml:S1:14575:1	O
Grade	AFINITOR.xml:S1:14586:5	O
4	AFINITOR.xml:S1:14592:1	O

Any	AFINITOR.xml:S1:14728:3	O

adverse	AFINITOR.xml:S1:14732:7	O
reaction	AFINITOR.xml:S1:14740:8	O
100	AFINITOR.xml:S1:14754:3	O
49	AFINITOR.xml:S1:14771:2	O
13	AFINITOR.xml:S1:14788:2	O
98	AFINITOR.xml:S1:14805:2	O
32	AFINITOR.xml:S1:14822:2	O
8	AFINITOR.xml:S1:14839:1	O

Gastrointestinal	AFINITOR.xml:S1:14859:16	O
disorders	AFINITOR.xml:S1:14876:9	O

Stomatitis	AFINITOR.xml:S1:14898:10	B-AdverseReaction
a	AFINITOR.xml:S1:14910:1	O
70	AFINITOR.xml:S1:14915:2	O
7	AFINITOR.xml:S1:14932:1	O
0	AFINITOR.xml:S1:14949:1	O
20	AFINITOR.xml:S1:14966:2	O
0	AFINITOR.xml:S1:14983:1	O
0	AFINITOR.xml:S1:15000:1	O

Diarrhea	AFINITOR.xml:S1:15026:8	B-AdverseReaction
b	AFINITOR.xml:S1:15036:1	O
50	AFINITOR.xml:S1:15041:2	O
5	AFINITOR.xml:S1:15058:1	O
0.5	AFINITOR.xml:S1:15075:3	O
25	AFINITOR.xml:S1:15092:2	O
3	AFINITOR.xml:S1:15109:1	O
0	AFINITOR.xml:S1:15126:1	O

Abdominal	AFINITOR.xml:S1:15152:9	B-AdverseReaction
pain	AFINITOR.xml:S1:15162:4	I-AdverseReaction
36	AFINITOR.xml:S1:15168:2	O
4	AFINITOR.xml:S1:15185:1	O
0	AFINITOR.xml:S1:15202:1	O
32	AFINITOR.xml:S1:15219:2	O
6	AFINITOR.xml:S1:15236:1	O
1	AFINITOR.xml:S1:15253:1	O

Nausea	AFINITOR.xml:S1:15279:6	B-AdverseReaction
32	AFINITOR.xml:S1:15290:2	O
2	AFINITOR.xml:S1:15307:1	O
0	AFINITOR.xml:S1:15324:1	O
33	AFINITOR.xml:S1:15341:2	O
2	AFINITOR.xml:S1:15358:1	O
0	AFINITOR.xml:S1:15375:1	O

Vomiting	AFINITOR.xml:S1:15401:8	B-AdverseReaction
29	AFINITOR.xml:S1:15412:2	O
1	AFINITOR.xml:S1:15429:1	O
0	AFINITOR.xml:S1:15446:1	O
21	AFINITOR.xml:S1:15463:2	O
2	AFINITOR.xml:S1:15480:1	O
0	AFINITOR.xml:S1:15497:1	O

Constipation	AFINITOR.xml:S1:15523:12	B-AdverseReaction
14	AFINITOR.xml:S1:15537:2	O
0	AFINITOR.xml:S1:15554:1	O
0	AFINITOR.xml:S1:15571:1	O
13	AFINITOR.xml:S1:15588:2	O
0.5	AFINITOR.xml:S1:15605:3	O
0	AFINITOR.xml:S1:15622:1	O

Dry	AFINITOR.xml:S1:15648:3	B-AdverseReaction
mouth	AFINITOR.xml:S1:15652:5	I-AdverseReaction
11	AFINITOR.xml:S1:15659:2	O
0	AFINITOR.xml:S1:15676:1	O
0	AFINITOR.xml:S1:15693:1	O
4	AFINITOR.xml:S1:15710:1	O
0	AFINITOR.xml:S1:15727:1	O
0	AFINITOR.xml:S1:15744:1	O

General	AFINITOR.xml:S1:15766:7	O
disorders	AFINITOR.xml:S1:15774:9	O
and	AFINITOR.xml:S1:15784:3	O
administration	AFINITOR.xml:S1:15788:14	O
site	AFINITOR.xml:S1:15803:4	O
conditions	AFINITOR.xml:S1:15808:10	O

Fatigue	AFINITOR.xml:S1:15831:7	B-AdverseReaction
malaise	AFINITOR.xml:S1:15839:7	B-AdverseReaction
45	AFINITOR.xml:S1:15848:2	O
3	AFINITOR.xml:S1:15865:1	O
0.5	AFINITOR.xml:S1:15882:3	O
27	AFINITOR.xml:S1:15899:2	O
2	AFINITOR.xml:S1:15916:1	O
0.5	AFINITOR.xml:S1:15933:3	O

Edema	AFINITOR.xml:S1:15959:5	B-AdverseReaction
(	AFINITOR.xml:S1:15965:1	O
general	AFINITOR.xml:S1:15966:7	I-AdverseReaction
and	AFINITOR.xml:S1:15974:3	O
peripheral	AFINITOR.xml:S1:15978:10	I-AdverseReaction
)	AFINITOR.xml:S1:15988:1	O
39	AFINITOR.xml:S1:15991:2	O
1	AFINITOR.xml:S1:16008:1	O
0.5	AFINITOR.xml:S1:16025:3	O
12	AFINITOR.xml:S1:16042:2	O
1	AFINITOR.xml:S1:16059:1	O
0	AFINITOR.xml:S1:16076:1	O

Fever	AFINITOR.xml:S1:16102:5	B-AdverseReaction
31	AFINITOR.xml:S1:16113:2	O
0.5	AFINITOR.xml:S1:16130:3	O
0.5	AFINITOR.xml:S1:16147:3	O
13	AFINITOR.xml:S1:16164:2	O
0.5	AFINITOR.xml:S1:16181:3	O
0	AFINITOR.xml:S1:16198:1	O

Asthenia	AFINITOR.xml:S1:16224:8	B-AdverseReaction
19	AFINITOR.xml:S1:16235:2	O
3	AFINITOR.xml:S1:16252:1	O
0	AFINITOR.xml:S1:16269:1	O
20	AFINITOR.xml:S1:16286:2	O
3	AFINITOR.xml:S1:16303:1	O
0	AFINITOR.xml:S1:16320:1	O

Infections	AFINITOR.xml:S1:16342:10	O
and	AFINITOR.xml:S1:16353:3	O
infestations	AFINITOR.xml:S1:16357:12	O

Nasopharyngitis	AFINITOR.xml:S1:16383:15	B-AdverseReaction
rhinitis	AFINITOR.xml:S1:16399:8	B-AdverseReaction
URI	AFINITOR.xml:S1:16408:3	B-AdverseReaction
25	AFINITOR.xml:S1:16413:2	O
0	AFINITOR.xml:S1:16430:1	O
0	AFINITOR.xml:S1:16447:1	O
13	AFINITOR.xml:S1:16464:2	O
0	AFINITOR.xml:S1:16481:1	O
0	AFINITOR.xml:S1:16498:1	O

Urinary	AFINITOR.xml:S1:16524:7	B-AdverseReaction
tract	AFINITOR.xml:S1:16532:5	I-AdverseReaction
infection	AFINITOR.xml:S1:16538:9	I-AdverseReaction
16	AFINITOR.xml:S1:16549:2	O
0	AFINITOR.xml:S1:16566:1	O
0	AFINITOR.xml:S1:16583:1	O
6	AFINITOR.xml:S1:16600:1	O
0.5	AFINITOR.xml:S1:16617:3	O
0	AFINITOR.xml:S1:16634:1	O

Investigations	AFINITOR.xml:S1:16656:14	O

Weight	AFINITOR.xml:S1:16683:6	B-AdverseReaction
decreased	AFINITOR.xml:S1:16690:9	I-AdverseReaction
28	AFINITOR.xml:S1:16701:2	O
0.5	AFINITOR.xml:S1:16718:3	O
0	AFINITOR.xml:S1:16735:1	O
11	AFINITOR.xml:S1:16752:2	O
0	AFINITOR.xml:S1:16769:1	O
0	AFINITOR.xml:S1:16786:1	O

Metabolism	AFINITOR.xml:S1:16808:10	O
and	AFINITOR.xml:S1:16819:3	O
nutrition	AFINITOR.xml:S1:16823:9	O
disorders	AFINITOR.xml:S1:16833:9	O

Decreased	AFINITOR.xml:S1:16855:9	B-AdverseReaction
appetite	AFINITOR.xml:S1:16865:8	I-AdverseReaction
30	AFINITOR.xml:S1:16875:2	O
1	AFINITOR.xml:S1:16892:1	O
0	AFINITOR.xml:S1:16909:1	O
18	AFINITOR.xml:S1:16926:2	O
1	AFINITOR.xml:S1:16943:1	O
0	AFINITOR.xml:S1:16960:1	O

Diabetes	AFINITOR.xml:S1:16986:8	B-AdverseReaction
mellitus	AFINITOR.xml:S1:16995:8	I-AdverseReaction
10	AFINITOR.xml:S1:17005:2	O
2	AFINITOR.xml:S1:17022:1	O
0	AFINITOR.xml:S1:17039:1	O
0.5	AFINITOR.xml:S1:17056:3	O
0	AFINITOR.xml:S1:17073:1	O
0	AFINITOR.xml:S1:17090:1	O

Musculoskeletal	AFINITOR.xml:S1:17112:15	O
and	AFINITOR.xml:S1:17128:3	O
connective	AFINITOR.xml:S1:17132:10	O
tissue	AFINITOR.xml:S1:17143:6	O
disorders	AFINITOR.xml:S1:17150:9	O

Arthralgia	AFINITOR.xml:S1:17172:10	B-AdverseReaction
15	AFINITOR.xml:S1:17184:2	O
1	AFINITOR.xml:S1:17201:1	O
0.5	AFINITOR.xml:S1:17218:3	O
7	AFINITOR.xml:S1:17235:1	O
0.5	AFINITOR.xml:S1:17252:3	O
0	AFINITOR.xml:S1:17269:1	O

Back	AFINITOR.xml:S1:17295:4	B-AdverseReaction
pain	AFINITOR.xml:S1:17300:4	I-AdverseReaction
15	AFINITOR.xml:S1:17306:2	O
1	AFINITOR.xml:S1:17323:1	O
0	AFINITOR.xml:S1:17340:1	O
11	AFINITOR.xml:S1:17357:2	O
1	AFINITOR.xml:S1:17374:1	O
0	AFINITOR.xml:S1:17391:1	O

Pain	AFINITOR.xml:S1:17417:4	B-AdverseReaction
in	AFINITOR.xml:S1:17422:2	I-AdverseReaction
extremity	AFINITOR.xml:S1:17425:9	I-AdverseReaction
14	AFINITOR.xml:S1:17436:2	O
0.5	AFINITOR.xml:S1:17453:3	O
0	AFINITOR.xml:S1:17470:1	O
6	AFINITOR.xml:S1:17487:1	O
1	AFINITOR.xml:S1:17504:1	O
0	AFINITOR.xml:S1:17521:1	O

Muscle	AFINITOR.xml:S1:17547:6	B-AdverseReaction
spasms	AFINITOR.xml:S1:17554:6	I-AdverseReaction
10	AFINITOR.xml:S1:17562:2	O
0	AFINITOR.xml:S1:17579:1	O
0	AFINITOR.xml:S1:17596:1	O
4	AFINITOR.xml:S1:17613:1	O
0	AFINITOR.xml:S1:17630:1	O
0	AFINITOR.xml:S1:17647:1	O

Nervous	AFINITOR.xml:S1:17669:7	O
system	AFINITOR.xml:S1:17677:6	O
disorders	AFINITOR.xml:S1:17684:9	O

Headache	AFINITOR.xml:S1:17706:8	B-AdverseReaction
migraine	AFINITOR.xml:S1:17715:8	B-AdverseReaction
30	AFINITOR.xml:S1:17725:2	O
0.5	AFINITOR.xml:S1:17742:3	O
0	AFINITOR.xml:S1:17759:1	O
15	AFINITOR.xml:S1:17776:2	O
1	AFINITOR.xml:S1:17793:1	O
0	AFINITOR.xml:S1:17810:1	O

Dysgeusia	AFINITOR.xml:S1:17836:9	B-AdverseReaction
19	AFINITOR.xml:S1:17847:2	O
0	AFINITOR.xml:S1:17864:1	O
0	AFINITOR.xml:S1:17881:1	O
5	AFINITOR.xml:S1:17898:1	O
0	AFINITOR.xml:S1:17915:1	O
0	AFINITOR.xml:S1:17932:1	O

Dizziness	AFINITOR.xml:S1:17958:9	B-AdverseReaction
12	AFINITOR.xml:S1:17969:2	O
0.5	AFINITOR.xml:S1:17986:3	O
0	AFINITOR.xml:S1:18003:1	O
7	AFINITOR.xml:S1:18020:1	O
0	AFINITOR.xml:S1:18037:1	O
0	AFINITOR.xml:S1:18054:1	O

Psychiatric	AFINITOR.xml:S1:18076:11	O
disorders	AFINITOR.xml:S1:18088:9	O

Insomnia	AFINITOR.xml:S1:18110:8	B-AdverseReaction
14	AFINITOR.xml:S1:18121:2	O
0	AFINITOR.xml:S1:18138:1	O
0	AFINITOR.xml:S1:18155:1	O
8	AFINITOR.xml:S1:18172:1	O
0	AFINITOR.xml:S1:18189:1	O
0	AFINITOR.xml:S1:18206:1	O

Respiratory	AFINITOR.xml:S1:18228:11	O
,	AFINITOR.xml:S1:18239:1	O
thoracic	AFINITOR.xml:S1:18241:8	O
and	AFINITOR.xml:S1:18250:3	O
mediastinal	AFINITOR.xml:S1:18254:11	O
disorders	AFINITOR.xml:S1:18266:9	O

Cough	AFINITOR.xml:S1:18288:5	B-AdverseReaction
productive	AFINITOR.xml:S1:18294:10	B-AdverseReaction
cough	AFINITOR.xml:S1:18305:5	I-AdverseReaction
25	AFINITOR.xml:S1:18312:2	O
0.5	AFINITOR.xml:S1:18329:3	O
0	AFINITOR.xml:S1:18346:1	O
13	AFINITOR.xml:S1:18363:2	O
0	AFINITOR.xml:S1:18380:1	O
0	AFINITOR.xml:S1:18397:1	O

Epistaxis	AFINITOR.xml:S1:18423:9	B-AdverseReaction
22	AFINITOR.xml:S1:18434:2	O
0	AFINITOR.xml:S1:18451:1	O
0	AFINITOR.xml:S1:18468:1	O
1	AFINITOR.xml:S1:18485:1	O
0	AFINITOR.xml:S1:18502:1	O
0	AFINITOR.xml:S1:18519:1	O

Dyspnea	AFINITOR.xml:S1:18545:7	B-AdverseReaction
dyspnea	AFINITOR.xml:S1:18553:7	B-AdverseReaction
exertional	AFINITOR.xml:S1:18561:10	I-AdverseReaction
20	AFINITOR.xml:S1:18573:2	O
2	AFINITOR.xml:S1:18590:1	O
0.5	AFINITOR.xml:S1:18607:3	O
7	AFINITOR.xml:S1:18624:1	O
0.5	AFINITOR.xml:S1:18641:3	O
0	AFINITOR.xml:S1:18658:1	O

Pneumonitis	AFINITOR.xml:S1:18684:11	B-AdverseReaction
c	AFINITOR.xml:S1:18697:1	O
17	AFINITOR.xml:S1:18702:2	O
3	AFINITOR.xml:S1:18719:1	O
0.5	AFINITOR.xml:S1:18736:3	O
0	AFINITOR.xml:S1:18753:1	O
0	AFINITOR.xml:S1:18770:1	O
0	AFINITOR.xml:S1:18787:1	O

Oropharyngeal	AFINITOR.xml:S1:18813:13	B-AdverseReaction
pain	AFINITOR.xml:S1:18827:4	I-AdverseReaction
11	AFINITOR.xml:S1:18833:2	O
0	AFINITOR.xml:S1:18850:1	O
0	AFINITOR.xml:S1:18867:1	O
6	AFINITOR.xml:S1:18884:1	O
0	AFINITOR.xml:S1:18901:1	O
0	AFINITOR.xml:S1:18918:1	O

Skin	AFINITOR.xml:S1:18940:4	O
and	AFINITOR.xml:S1:18945:3	O
subcutaneous	AFINITOR.xml:S1:18949:12	O
disorders	AFINITOR.xml:S1:18962:9	O

Rash	AFINITOR.xml:S1:18984:4	B-AdverseReaction
59	AFINITOR.xml:S1:18995:2	O
0.5	AFINITOR.xml:S1:19012:3	O
0	AFINITOR.xml:S1:19029:1	O
19	AFINITOR.xml:S1:19046:2	O
0	AFINITOR.xml:S1:19063:1	O
0	AFINITOR.xml:S1:19080:1	O

Nail	AFINITOR.xml:S1:19106:4	B-AdverseReaction
disorders	AFINITOR.xml:S1:19111:9	I-AdverseReaction
22	AFINITOR.xml:S1:19122:2	O
0.5	AFINITOR.xml:S1:19139:3	O
0	AFINITOR.xml:S1:19156:1	O
2	AFINITOR.xml:S1:19173:1	O
0	AFINITOR.xml:S1:19190:1	O
0	AFINITOR.xml:S1:19207:1	O

Pruritus	AFINITOR.xml:S1:19233:8	B-AdverseReaction
pruritus	AFINITOR.xml:S1:19242:8	B-AdverseReaction
generalized	AFINITOR.xml:S1:19251:11	I-AdverseReaction
21	AFINITOR.xml:S1:19264:2	O
0	AFINITOR.xml:S1:19281:1	O
0	AFINITOR.xml:S1:19298:1	O
13	AFINITOR.xml:S1:19315:2	O
0	AFINITOR.xml:S1:19332:1	O
0	AFINITOR.xml:S1:19349:1	O

Dry	AFINITOR.xml:S1:19375:3	B-AdverseReaction
skin	AFINITOR.xml:S1:19379:4	I-AdverseReaction
xeroderma	AFINITOR.xml:S1:19384:9	B-AdverseReaction
13	AFINITOR.xml:S1:19395:2	O
0	AFINITOR.xml:S1:19412:1	O
0	AFINITOR.xml:S1:19429:1	O
6	AFINITOR.xml:S1:19446:1	O
0	AFINITOR.xml:S1:19463:1	O
0	AFINITOR.xml:S1:19480:1	O

Vascular	AFINITOR.xml:S1:19502:8	O
disorders	AFINITOR.xml:S1:19511:9	O

Hypertension	AFINITOR.xml:S1:19533:12	B-AdverseReaction
13	AFINITOR.xml:S1:19547:2	O
1	AFINITOR.xml:S1:19564:1	O
0	AFINITOR.xml:S1:19581:1	O
6	AFINITOR.xml:S1:19598:1	O
1	AFINITOR.xml:S1:19615:1	O
0	AFINITOR.xml:S1:19632:1	O

Median	AFINITOR.xml:S1:19654:6	O
duration	AFINITOR.xml:S1:19661:8	O
of	AFINITOR.xml:S1:19670:2	O
treatment	AFINITOR.xml:S1:19673:9	O
(	AFINITOR.xml:S1:19683:1	O
wks	AFINITOR.xml:S1:19684:3	O
)	AFINITOR.xml:S1:19687:1	O
37	AFINITOR.xml:S1:19694:2	O
16	AFINITOR.xml:S1:19711:2	O

In	AFINITOR.xml:S1:19741:2	O
female	AFINITOR.xml:S1:19744:6	O
patients	AFINITOR.xml:S1:19751:8	O
aged	AFINITOR.xml:S1:19760:4	O
18	AFINITOR.xml:S1:19765:2	O
to	AFINITOR.xml:S1:19768:2	O
55	AFINITOR.xml:S1:19771:2	O
years	AFINITOR.xml:S1:19774:5	O
,	AFINITOR.xml:S1:19779:1	O
irregular	AFINITOR.xml:S1:19781:9	B-AdverseReaction
menstruation	AFINITOR.xml:S1:19791:12	I-AdverseReaction
occurred	AFINITOR.xml:S1:19804:8	O
in	AFINITOR.xml:S1:19813:2	O
5	AFINITOR.xml:S1:19816:1	O
of	AFINITOR.xml:S1:19818:2	O
46	AFINITOR.xml:S1:19821:2	O
(	AFINITOR.xml:S1:19824:1	O
11%	AFINITOR.xml:S1:19825:3	O
)	AFINITOR.xml:S1:19828:1	O
AFINITOR	AFINITOR.xml:S1:19830:8	O
-	AFINITOR.xml:S1:19838:1	O
treated	AFINITOR.xml:S1:19839:7	O
females	AFINITOR.xml:S1:19847:7	O
and	AFINITOR.xml:S1:19855:3	O
none	AFINITOR.xml:S1:19859:4	O
of	AFINITOR.xml:S1:19864:2	O
the	AFINITOR.xml:S1:19867:3	O
33	AFINITOR.xml:S1:19871:2	O
females	AFINITOR.xml:S1:19874:7	O
in	AFINITOR.xml:S1:19882:2	O
the	AFINITOR.xml:S1:19885:3	O
placebo	AFINITOR.xml:S1:19889:7	O
group	AFINITOR.xml:S1:19897:5	O
.	AFINITOR.xml:S1:19902:1	O

Key	AFINITOR.xml:S1:19908:3	O

observed	AFINITOR.xml:S1:19912:8	O
laboratory	AFINITOR.xml:S1:19921:10	O
abnormalities	AFINITOR.xml:S1:19932:13	O
are	AFINITOR.xml:S1:19946:3	O
presented	AFINITOR.xml:S1:19950:9	O
in	AFINITOR.xml:S1:19960:2	O
Table	AFINITOR.xml:S1:19963:5	O
5	AFINITOR.xml:S1:19969:1	O
.	AFINITOR.xml:S1:19970:1	O

Table	AFINITOR.xml:S1:19977:5	O
5	AFINITOR.xml:S1:19983:1	O
:	AFINITOR.xml:S1:19984:1	O
Key	AFINITOR.xml:S1:19987:3	O
Laboratory	AFINITOR.xml:S1:19991:10	O
Abnormalities	AFINITOR.xml:S1:20002:13	O
Reported	AFINITOR.xml:S1:20016:8	O
in	AFINITOR.xml:S1:20025:2	O
10%	AFINITOR.xml:S1:20031:3	O
of	AFINITOR.xml:S1:20035:2	O
Patients	AFINITOR.xml:S1:20038:8	O
with	AFINITOR.xml:S1:20047:4	O
Advanced	AFINITOR.xml:S1:20052:8	O
PNET	AFINITOR.xml:S1:20061:4	O

Grading	AFINITOR.xml:S1:20069:7	O
according	AFINITOR.xml:S1:20077:9	O
to	AFINITOR.xml:S1:20087:2	O
CTCAE	AFINITOR.xml:S1:20090:5	O
Version	AFINITOR.xml:S1:20096:7	O
3.0	AFINITOR.xml:S1:20104:3	O

Laboratory	AFINITOR.xml:S1:20117:10	O

parameter	AFINITOR.xml:S1:20128:9	O
AFINITOR	AFINITOR.xml:S1:20143:8	O
N	AFINITOR.xml:S1:20155:1	O
204	AFINITOR.xml:S1:20157:3	O
Placebo	AFINITOR.xml:S1:20166:7	O
N	AFINITOR.xml:S1:20177:1	O
203	AFINITOR.xml:S1:20179:3	O

All	AFINITOR.xml:S1:20208:3	O
grades	AFINITOR.xml:S1:20212:6	O
Grade	AFINITOR.xml:S1:20225:5	O
3	AFINITOR.xml:S1:20231:1	O
-	AFINITOR.xml:S1:20232:1	O
4	AFINITOR.xml:S1:20233:1	O
All	AFINITOR.xml:S1:20242:3	O
grades	AFINITOR.xml:S1:20246:6	O
Grade	AFINITOR.xml:S1:20259:5	O
3	AFINITOR.xml:S1:20265:1	O
-	AFINITOR.xml:S1:20266:1	O
4	AFINITOR.xml:S1:20267:1	O

Hematology	AFINITOR.xml:S1:20367:10	O

Hemoglobin	AFINITOR.xml:S1:20459:10	B-AdverseReaction

decreased	AFINITOR.xml:S1:20470:9	I-AdverseReaction
86	AFINITOR.xml:S1:20481:2	O
15	AFINITOR.xml:S1:20498:2	O
63	AFINITOR.xml:S1:20515:2	O
1	AFINITOR.xml:S1:20532:1	O

Lymphocytes	AFINITOR.xml:S1:20558:11	B-AdverseReaction
decreased	AFINITOR.xml:S1:20570:9	I-AdverseReaction
45	AFINITOR.xml:S1:20581:2	O
16	AFINITOR.xml:S1:20598:2	O
22	AFINITOR.xml:S1:20615:2	O
4	AFINITOR.xml:S1:20632:1	O

Platelets	AFINITOR.xml:S1:20658:9	B-AdverseReaction
decreased	AFINITOR.xml:S1:20668:9	I-AdverseReaction
45	AFINITOR.xml:S1:20679:2	O
3	AFINITOR.xml:S1:20696:1	O
11	AFINITOR.xml:S1:20713:2	O
0	AFINITOR.xml:S1:20730:1	O

WBC	AFINITOR.xml:S1:20756:3	B-AdverseReaction
decreased	AFINITOR.xml:S1:20760:9	I-AdverseReaction
43	AFINITOR.xml:S1:20771:2	O
2	AFINITOR.xml:S1:20788:1	O
13	AFINITOR.xml:S1:20805:2	O
0	AFINITOR.xml:S1:20822:1	O

Neutrophils	AFINITOR.xml:S1:20848:11	B-AdverseReaction
decreased	AFINITOR.xml:S1:20860:9	I-AdverseReaction
30	AFINITOR.xml:S1:20871:2	O
4	AFINITOR.xml:S1:20888:1	O
17	AFINITOR.xml:S1:20905:2	O
2	AFINITOR.xml:S1:20922:1	O

Clinical	AFINITOR.xml:S1:21032:8	O

chemistry	AFINITOR.xml:S1:21044:9	O

Alkaline	AFINITOR.xml:S1:21135:8	B-AdverseReaction
phosphatase	AFINITOR.xml:S1:21144:11	I-AdverseReaction
increased	AFINITOR.xml:S1:21156:9	I-AdverseReaction
74	AFINITOR.xml:S1:21167:2	O
8	AFINITOR.xml:S1:21184:1	O
66	AFINITOR.xml:S1:21201:2	O
8	AFINITOR.xml:S1:21218:1	O

Glucose	AFINITOR.xml:S1:21244:7	B-AdverseReaction
(	AFINITOR.xml:S1:21252:1	I-AdverseReaction
fasting	AFINITOR.xml:S1:21253:7	I-AdverseReaction
)	AFINITOR.xml:S1:21260:1	I-AdverseReaction
increased	AFINITOR.xml:S1:21262:9	I-AdverseReaction
75	AFINITOR.xml:S1:21273:2	O
17	AFINITOR.xml:S1:21290:2	O
53	AFINITOR.xml:S1:21307:2	O
6	AFINITOR.xml:S1:21324:1	O

Cholesterol	AFINITOR.xml:S1:21350:11	B-AdverseReaction
increased	AFINITOR.xml:S1:21362:9	I-AdverseReaction
66	AFINITOR.xml:S1:21373:2	O
0.5	AFINITOR.xml:S1:21390:3	O
22	AFINITOR.xml:S1:21407:2	O
0	AFINITOR.xml:S1:21424:1	O

Bicarbonate	AFINITOR.xml:S1:21450:11	B-AdverseReaction
decreased	AFINITOR.xml:S1:21462:9	I-AdverseReaction
56	AFINITOR.xml:S1:21473:2	O
0	AFINITOR.xml:S1:21490:1	O
40	AFINITOR.xml:S1:21507:2	O
0	AFINITOR.xml:S1:21524:1	O

Aspartate	AFINITOR.xml:S1:21550:9	B-AdverseReaction
transaminase	AFINITOR.xml:S1:21560:12	I-AdverseReaction
(	AFINITOR.xml:S1:21573:1	O
AST	AFINITOR.xml:S1:21574:3	B-AdverseReaction
)	AFINITOR.xml:S1:21577:1	O
increased	AFINITOR.xml:S1:21579:9	I-AdverseReaction
56	AFINITOR.xml:S1:21590:2	O
4	AFINITOR.xml:S1:21607:1	O
41	AFINITOR.xml:S1:21624:2	O
4	AFINITOR.xml:S1:21641:1	O

Alanine	AFINITOR.xml:S1:21667:7	B-AdverseReaction
transaminase	AFINITOR.xml:S1:21675:12	I-AdverseReaction
(	AFINITOR.xml:S1:21688:1	O
ALT	AFINITOR.xml:S1:21689:3	B-AdverseReaction
)	AFINITOR.xml:S1:21692:1	O
increased	AFINITOR.xml:S1:21694:9	I-AdverseReaction
48	AFINITOR.xml:S1:21705:2	O
2	AFINITOR.xml:S1:21722:1	O
35	AFINITOR.xml:S1:21739:2	O
2	AFINITOR.xml:S1:21756:1	O

Phosphate	AFINITOR.xml:S1:21782:9	B-AdverseReaction
decreased	AFINITOR.xml:S1:21792:9	I-AdverseReaction
40	AFINITOR.xml:S1:21803:2	O
10	AFINITOR.xml:S1:21820:2	O
14	AFINITOR.xml:S1:21837:2	O
3	AFINITOR.xml:S1:21854:1	O

Triglycerides	AFINITOR.xml:S1:21880:13	B-AdverseReaction
increased	AFINITOR.xml:S1:21894:9	I-AdverseReaction
39	AFINITOR.xml:S1:21905:2	O
0	AFINITOR.xml:S1:21922:1	O
10	AFINITOR.xml:S1:21939:2	O
0	AFINITOR.xml:S1:21956:1	O

Calcium	AFINITOR.xml:S1:21982:7	B-AdverseReaction
decreased	AFINITOR.xml:S1:21990:9	I-AdverseReaction
37	AFINITOR.xml:S1:22001:2	O
0.5	AFINITOR.xml:S1:22018:3	O
12	AFINITOR.xml:S1:22035:2	O
0	AFINITOR.xml:S1:22052:1	O

Potassium	AFINITOR.xml:S1:22078:9	B-AdverseReaction
decreased	AFINITOR.xml:S1:22088:9	I-AdverseReaction
23	AFINITOR.xml:S1:22099:2	O
4	AFINITOR.xml:S1:22116:1	O
5	AFINITOR.xml:S1:22133:1	O
0	AFINITOR.xml:S1:22150:1	O

Creatinine	AFINITOR.xml:S1:22176:10	B-AdverseReaction
increased	AFINITOR.xml:S1:22187:9	I-AdverseReaction
19	AFINITOR.xml:S1:22198:2	O
2	AFINITOR.xml:S1:22215:1	O
14	AFINITOR.xml:S1:22232:2	O
0	AFINITOR.xml:S1:22249:1	O

Sodium	AFINITOR.xml:S1:22275:6	B-AdverseReaction
decreased	AFINITOR.xml:S1:22282:9	I-AdverseReaction
16	AFINITOR.xml:S1:22293:2	O
1	AFINITOR.xml:S1:22310:1	O
16	AFINITOR.xml:S1:22327:2	O
1	AFINITOR.xml:S1:22344:1	O

Albumin	AFINITOR.xml:S1:22370:7	B-AdverseReaction
decreased	AFINITOR.xml:S1:22378:9	I-AdverseReaction
13	AFINITOR.xml:S1:22389:2	O
1	AFINITOR.xml:S1:22406:1	O
8	AFINITOR.xml:S1:22423:1	O
0	AFINITOR.xml:S1:22440:1	O

Bilirubin	AFINITOR.xml:S1:22466:9	B-AdverseReaction
increased	AFINITOR.xml:S1:22476:9	I-AdverseReaction
10	AFINITOR.xml:S1:22487:2	O
1	AFINITOR.xml:S1:22504:1	O
14	AFINITOR.xml:S1:22521:2	O
2	AFINITOR.xml:S1:22538:1	O

Potassium	AFINITOR.xml:S1:22564:9	B-AdverseReaction
increased	AFINITOR.xml:S1:22574:9	I-AdverseReaction
7	AFINITOR.xml:S1:22585:1	O
0	AFINITOR.xml:S1:22602:1	O
10	AFINITOR.xml:S1:22619:2	O
0.5	AFINITOR.xml:S1:22636:3	O

6.3	AFINITOR.xml:S1:22668:3	O
Clinical	AFINITOR.xml:S1:22676:8	O
Study	AFINITOR.xml:S1:22685:5	O
Experience	AFINITOR.xml:S1:22691:10	O
in	AFINITOR.xml:S1:22702:2	O
Advanced	AFINITOR.xml:S1:22705:8	O
Renal	AFINITOR.xml:S1:22714:5	O
Cell	AFINITOR.xml:S1:22720:4	O
Carcinoma	AFINITOR.xml:S1:22725:9	O

The	AFINITOR.xml:S1:22738:3	O
data	AFINITOR.xml:S1:22742:4	O
described	AFINITOR.xml:S1:22747:9	O
below	AFINITOR.xml:S1:22757:5	O
reflect	AFINITOR.xml:S1:22763:7	O
exposure	AFINITOR.xml:S1:22771:8	O
to	AFINITOR.xml:S1:22780:2	O
AFINITOR	AFINITOR.xml:S1:22783:8	O
(	AFINITOR.xml:S1:22792:1	O
n	AFINITOR.xml:S1:22793:1	O
274	AFINITOR.xml:S1:22795:3	O
)	AFINITOR.xml:S1:22798:1	O
and	AFINITOR.xml:S1:22800:3	O
placebo	AFINITOR.xml:S1:22804:7	O
(	AFINITOR.xml:S1:22812:1	O
n	AFINITOR.xml:S1:22813:1	O
137	AFINITOR.xml:S1:22815:3	O
)	AFINITOR.xml:S1:22818:1	O
in	AFINITOR.xml:S1:22820:2	O
a	AFINITOR.xml:S1:22823:1	O
randomized	AFINITOR.xml:S1:22825:10	O
,	AFINITOR.xml:S1:22835:1	O
controlled	AFINITOR.xml:S1:22837:10	O
trial	AFINITOR.xml:S1:22848:5	O
in	AFINITOR.xml:S1:22854:2	O
patients	AFINITOR.xml:S1:22857:8	O
with	AFINITOR.xml:S1:22866:4	O
metastatic	AFINITOR.xml:S1:22871:10	O
renal	AFINITOR.xml:S1:22882:5	O
cell	AFINITOR.xml:S1:22888:4	O
carcinoma	AFINITOR.xml:S1:22893:9	O
who	AFINITOR.xml:S1:22903:3	O
received	AFINITOR.xml:S1:22907:8	O
prior	AFINITOR.xml:S1:22916:5	O
treatment	AFINITOR.xml:S1:22922:9	O
with	AFINITOR.xml:S1:22932:4	O
sunitinib	AFINITOR.xml:S1:22937:9	O
and	AFINITOR.xml:S1:22947:3	O
or	AFINITOR.xml:S1:22951:2	O
sorafenib	AFINITOR.xml:S1:22954:9	O
.	AFINITOR.xml:S1:22963:1	O

The	AFINITOR.xml:S1:22965:3	O
median	AFINITOR.xml:S1:22969:6	O
age	AFINITOR.xml:S1:22976:3	O
of	AFINITOR.xml:S1:22980:2	O
patients	AFINITOR.xml:S1:22983:8	O
was	AFINITOR.xml:S1:22992:3	O
61	AFINITOR.xml:S1:22996:2	O
years	AFINITOR.xml:S1:22999:5	O
(	AFINITOR.xml:S1:23005:1	O
range	AFINITOR.xml:S1:23006:5	O
27	AFINITOR.xml:S1:23012:2	O
-	AFINITOR.xml:S1:23014:1	O
85	AFINITOR.xml:S1:23015:2	O
)	AFINITOR.xml:S1:23017:1	O
,	AFINITOR.xml:S1:23018:1	O
88%	AFINITOR.xml:S1:23020:3	O
were	AFINITOR.xml:S1:23024:4	O
Caucasian	AFINITOR.xml:S1:23029:9	O
,	AFINITOR.xml:S1:23038:1	O
and	AFINITOR.xml:S1:23040:3	O
78%	AFINITOR.xml:S1:23044:3	O
were	AFINITOR.xml:S1:23048:4	O
male	AFINITOR.xml:S1:23053:4	O
.	AFINITOR.xml:S1:23057:1	O

The	AFINITOR.xml:S1:23059:3	O
median	AFINITOR.xml:S1:23063:6	O
duration	AFINITOR.xml:S1:23070:8	O
of	AFINITOR.xml:S1:23079:2	O
blinded	AFINITOR.xml:S1:23082:7	O
study	AFINITOR.xml:S1:23090:5	O
treatment	AFINITOR.xml:S1:23096:9	O
was	AFINITOR.xml:S1:23106:3	O
141	AFINITOR.xml:S1:23110:3	O
days	AFINITOR.xml:S1:23114:4	O
(	AFINITOR.xml:S1:23119:1	O
range	AFINITOR.xml:S1:23120:5	O
19	AFINITOR.xml:S1:23126:2	O
-	AFINITOR.xml:S1:23128:1	O
451	AFINITOR.xml:S1:23129:3	O
days	AFINITOR.xml:S1:23133:4	O
)	AFINITOR.xml:S1:23137:1	O
for	AFINITOR.xml:S1:23139:3	O
patients	AFINITOR.xml:S1:23143:8	O
receiving	AFINITOR.xml:S1:23152:9	O
AFINITOR	AFINITOR.xml:S1:23162:8	O
and	AFINITOR.xml:S1:23171:3	O
60	AFINITOR.xml:S1:23175:2	O
days	AFINITOR.xml:S1:23178:4	O
(	AFINITOR.xml:S1:23183:1	O
range	AFINITOR.xml:S1:23184:5	O
21	AFINITOR.xml:S1:23190:2	O
-	AFINITOR.xml:S1:23192:1	O
295	AFINITOR.xml:S1:23193:3	O
days	AFINITOR.xml:S1:23197:4	O
)	AFINITOR.xml:S1:23201:1	O
for	AFINITOR.xml:S1:23203:3	O
those	AFINITOR.xml:S1:23207:5	O
receiving	AFINITOR.xml:S1:23213:9	O
placebo	AFINITOR.xml:S1:23223:7	O
.	AFINITOR.xml:S1:23230:1	O

The	AFINITOR.xml:S1:23236:3	O
most	AFINITOR.xml:S1:23240:4	O
common	AFINITOR.xml:S1:23245:6	O
adverse	AFINITOR.xml:S1:23252:7	O
reactions	AFINITOR.xml:S1:23260:9	O
(	AFINITOR.xml:S1:23270:1	O
incidence	AFINITOR.xml:S1:23271:9	O
30%	AFINITOR.xml:S1:23284:3	O
)	AFINITOR.xml:S1:23287:1	O
were	AFINITOR.xml:S1:23289:4	O
stomatitis	AFINITOR.xml:S1:23294:10	B-AdverseReaction
,	AFINITOR.xml:S1:23304:1	O
infections	AFINITOR.xml:S1:23306:10	B-AdverseReaction
,	AFINITOR.xml:S1:23316:1	O
asthenia	AFINITOR.xml:S1:23318:8	B-AdverseReaction
,	AFINITOR.xml:S1:23326:1	O
fatigue	AFINITOR.xml:S1:23328:7	B-AdverseReaction
,	AFINITOR.xml:S1:23335:1	O
cough	AFINITOR.xml:S1:23337:5	B-AdverseReaction
,	AFINITOR.xml:S1:23342:1	O
and	AFINITOR.xml:S1:23344:3	O
diarrhea	AFINITOR.xml:S1:23348:8	B-AdverseReaction
.	AFINITOR.xml:S1:23356:1	O

The	AFINITOR.xml:S1:23358:3	O
most	AFINITOR.xml:S1:23362:4	O
common	AFINITOR.xml:S1:23367:6	O
Grade	AFINITOR.xml:S1:23374:5	B-Severity
3	AFINITOR.xml:S1:23380:1	I-Severity
-	AFINITOR.xml:S1:23381:1	I-Severity
4	AFINITOR.xml:S1:23382:1	I-Severity
adverse	AFINITOR.xml:S1:23384:7	O
reactions	AFINITOR.xml:S1:23392:9	O
(	AFINITOR.xml:S1:23402:1	O
incidence	AFINITOR.xml:S1:23403:9	O
3%	AFINITOR.xml:S1:23416:2	O
)	AFINITOR.xml:S1:23418:1	O
were	AFINITOR.xml:S1:23420:4	O
infections	AFINITOR.xml:S1:23425:10	B-AdverseReaction
,	AFINITOR.xml:S1:23435:1	O
dyspnea	AFINITOR.xml:S1:23437:7	B-AdverseReaction
,	AFINITOR.xml:S1:23444:1	O
fatigue	AFINITOR.xml:S1:23446:7	B-AdverseReaction
,	AFINITOR.xml:S1:23453:1	O
stomatitis	AFINITOR.xml:S1:23455:10	B-AdverseReaction
,	AFINITOR.xml:S1:23465:1	O
dehydration	AFINITOR.xml:S1:23467:11	B-AdverseReaction
,	AFINITOR.xml:S1:23478:1	O
pneumonitis	AFINITOR.xml:S1:23480:11	B-AdverseReaction
,	AFINITOR.xml:S1:23491:1	O
abdominal	AFINITOR.xml:S1:23493:9	B-AdverseReaction
pain	AFINITOR.xml:S1:23503:4	I-AdverseReaction
,	AFINITOR.xml:S1:23507:1	O
and	AFINITOR.xml:S1:23509:3	O
asthenia	AFINITOR.xml:S1:23513:8	B-AdverseReaction
.	AFINITOR.xml:S1:23521:1	O

The	AFINITOR.xml:S1:23523:3	O
most	AFINITOR.xml:S1:23527:4	O
common	AFINITOR.xml:S1:23532:6	O
laboratory	AFINITOR.xml:S1:23539:10	O
abnormalities	AFINITOR.xml:S1:23550:13	O
(	AFINITOR.xml:S1:23564:1	O
incidence	AFINITOR.xml:S1:23565:9	O
50%	AFINITOR.xml:S1:23578:3	O
)	AFINITOR.xml:S1:23581:1	O
were	AFINITOR.xml:S1:23583:4	O
anemia	AFINITOR.xml:S1:23588:6	B-AdverseReaction
,	AFINITOR.xml:S1:23594:1	O
hypercholesterolemia	AFINITOR.xml:S1:23596:20	B-AdverseReaction
,	AFINITOR.xml:S1:23616:1	O
hypertriglyceridemia	AFINITOR.xml:S1:23618:20	O
,	AFINITOR.xml:S1:23638:1	O
hyperglycemia	AFINITOR.xml:S1:23640:13	B-AdverseReaction
,	AFINITOR.xml:S1:23653:1	O
lymphopenia	AFINITOR.xml:S1:23655:11	B-AdverseReaction
,	AFINITOR.xml:S1:23666:1	O
and	AFINITOR.xml:S1:23668:3	O
increased	AFINITOR.xml:S1:23672:9	B-AdverseReaction
creatinine	AFINITOR.xml:S1:23682:10	I-AdverseReaction
.	AFINITOR.xml:S1:23692:1	O

The	AFINITOR.xml:S1:23694:3	O
most	AFINITOR.xml:S1:23698:4	O
common	AFINITOR.xml:S1:23703:6	O
Grade	AFINITOR.xml:S1:23710:5	B-Severity
3	AFINITOR.xml:S1:23716:1	I-Severity
-	AFINITOR.xml:S1:23717:1	I-Severity
4	AFINITOR.xml:S1:23718:1	I-Severity
laboratory	AFINITOR.xml:S1:23720:10	O
abnormalities	AFINITOR.xml:S1:23731:13	O
(	AFINITOR.xml:S1:23745:1	O
incidence	AFINITOR.xml:S1:23746:9	O
3%	AFINITOR.xml:S1:23759:2	O
)	AFINITOR.xml:S1:23761:1	O
were	AFINITOR.xml:S1:23763:4	O
lymphopenia	AFINITOR.xml:S1:23768:11	B-AdverseReaction
,	AFINITOR.xml:S1:23779:1	O
hyperglycemia	AFINITOR.xml:S1:23781:13	B-AdverseReaction
,	AFINITOR.xml:S1:23794:1	O
anemia	AFINITOR.xml:S1:23796:6	B-AdverseReaction
,	AFINITOR.xml:S1:23802:1	O
hypophosphatemia	AFINITOR.xml:S1:23804:16	B-AdverseReaction
,	AFINITOR.xml:S1:23820:1	O
and	AFINITOR.xml:S1:23822:3	O
hypercholesterolemia	AFINITOR.xml:S1:23826:20	B-AdverseReaction
.	AFINITOR.xml:S1:23846:1	O

Deaths	AFINITOR.xml:S1:23848:6	B-AdverseReaction
due	AFINITOR.xml:S1:23855:3	O
to	AFINITOR.xml:S1:23859:2	O
acute	AFINITOR.xml:S1:23862:5	B-AdverseReaction
respiratory	AFINITOR.xml:S1:23868:11	I-AdverseReaction
failure	AFINITOR.xml:S1:23880:7	I-AdverseReaction
(	AFINITOR.xml:S1:23888:1	O
0.7%	AFINITOR.xml:S1:23889:4	O
)	AFINITOR.xml:S1:23893:1	O
,	AFINITOR.xml:S1:23894:1	O
infection	AFINITOR.xml:S1:23896:9	B-AdverseReaction
(	AFINITOR.xml:S1:23906:1	O
0.7%	AFINITOR.xml:S1:23907:4	O
)	AFINITOR.xml:S1:23911:1	O
,	AFINITOR.xml:S1:23912:1	O
and	AFINITOR.xml:S1:23914:3	O
acute	AFINITOR.xml:S1:23918:5	B-AdverseReaction
renal	AFINITOR.xml:S1:23924:5	I-AdverseReaction
failure	AFINITOR.xml:S1:23930:7	I-AdverseReaction
(	AFINITOR.xml:S1:23938:1	O
0.4%	AFINITOR.xml:S1:23939:4	O
)	AFINITOR.xml:S1:23943:1	O
were	AFINITOR.xml:S1:23945:4	O
observed	AFINITOR.xml:S1:23950:8	O
on	AFINITOR.xml:S1:23959:2	O
the	AFINITOR.xml:S1:23962:3	O
AFINITOR	AFINITOR.xml:S1:23966:8	O
arm	AFINITOR.xml:S1:23975:3	O
but	AFINITOR.xml:S1:23979:3	O
none	AFINITOR.xml:S1:23983:4	O
on	AFINITOR.xml:S1:23988:2	O
the	AFINITOR.xml:S1:23991:3	O
placebo	AFINITOR.xml:S1:23995:7	O
arm	AFINITOR.xml:S1:24003:3	O
.	AFINITOR.xml:S1:24006:1	O

The	AFINITOR.xml:S1:24008:3	O
rates	AFINITOR.xml:S1:24012:5	O
of	AFINITOR.xml:S1:24018:2	O
treatment	AFINITOR.xml:S1:24021:9	O
-	AFINITOR.xml:S1:24030:1	O
emergent	AFINITOR.xml:S1:24031:8	O
adverse	AFINITOR.xml:S1:24040:7	O
events	AFINITOR.xml:S1:24048:6	O
(	AFINITOR.xml:S1:24055:1	O
irrespective	AFINITOR.xml:S1:24056:12	O
of	AFINITOR.xml:S1:24069:2	O
causality	AFINITOR.xml:S1:24072:9	O
)	AFINITOR.xml:S1:24081:1	O
resulting	AFINITOR.xml:S1:24083:9	O
in	AFINITOR.xml:S1:24093:2	O
permanent	AFINITOR.xml:S1:24096:9	O
discontinuation	AFINITOR.xml:S1:24106:15	O
were	AFINITOR.xml:S1:24122:4	O
14%	AFINITOR.xml:S1:24127:3	O
and	AFINITOR.xml:S1:24131:3	O
3%	AFINITOR.xml:S1:24135:2	O
for	AFINITOR.xml:S1:24138:3	O
the	AFINITOR.xml:S1:24142:3	O
AFINITOR	AFINITOR.xml:S1:24146:8	O
and	AFINITOR.xml:S1:24155:3	O
placebo	AFINITOR.xml:S1:24159:7	O
treatment	AFINITOR.xml:S1:24167:9	O
groups	AFINITOR.xml:S1:24177:6	O
,	AFINITOR.xml:S1:24183:1	O
respectively	AFINITOR.xml:S1:24185:12	O
.	AFINITOR.xml:S1:24197:1	O

The	AFINITOR.xml:S1:24199:3	O
most	AFINITOR.xml:S1:24203:4	O
common	AFINITOR.xml:S1:24208:6	O
adverse	AFINITOR.xml:S1:24215:7	O
reactions	AFINITOR.xml:S1:24223:9	O
(	AFINITOR.xml:S1:24233:1	O
irrespective	AFINITOR.xml:S1:24234:12	O
of	AFINITOR.xml:S1:24247:2	O
causality	AFINITOR.xml:S1:24250:9	O
)	AFINITOR.xml:S1:24259:1	O
leading	AFINITOR.xml:S1:24261:7	O
to	AFINITOR.xml:S1:24269:2	O
treatment	AFINITOR.xml:S1:24272:9	O
discontinuation	AFINITOR.xml:S1:24282:15	O
were	AFINITOR.xml:S1:24298:4	O
pneumonitis	AFINITOR.xml:S1:24303:11	B-AdverseReaction
and	AFINITOR.xml:S1:24315:3	O
dyspnea	AFINITOR.xml:S1:24319:7	B-AdverseReaction
.	AFINITOR.xml:S1:24326:1	O

Infections	AFINITOR.xml:S1:24328:10	B-AdverseReaction
,	AFINITOR.xml:S1:24338:1	O
stomatitis	AFINITOR.xml:S1:24340:10	B-AdverseReaction
,	AFINITOR.xml:S1:24350:1	O
and	AFINITOR.xml:S1:24352:3	O
pneumonitis	AFINITOR.xml:S1:24356:11	B-AdverseReaction
were	AFINITOR.xml:S1:24368:4	O
the	AFINITOR.xml:S1:24373:3	O
most	AFINITOR.xml:S1:24377:4	O
common	AFINITOR.xml:S1:24382:6	O
reasons	AFINITOR.xml:S1:24389:7	O
for	AFINITOR.xml:S1:24397:3	O
treatment	AFINITOR.xml:S1:24401:9	O
delay	AFINITOR.xml:S1:24411:5	O
or	AFINITOR.xml:S1:24417:2	O
dose	AFINITOR.xml:S1:24420:4	O
reduction	AFINITOR.xml:S1:24425:9	O
.	AFINITOR.xml:S1:24434:1	O

The	AFINITOR.xml:S1:24436:3	O
most	AFINITOR.xml:S1:24440:4	O
common	AFINITOR.xml:S1:24445:6	O
medical	AFINITOR.xml:S1:24452:7	O
interventions	AFINITOR.xml:S1:24460:13	O
required	AFINITOR.xml:S1:24474:8	O
during	AFINITOR.xml:S1:24483:6	O
AFINITOR	AFINITOR.xml:S1:24490:8	O
treatment	AFINITOR.xml:S1:24499:9	O
were	AFINITOR.xml:S1:24509:4	O
for	AFINITOR.xml:S1:24514:3	O
infections	AFINITOR.xml:S1:24518:10	B-AdverseReaction
,	AFINITOR.xml:S1:24528:1	O
anemia	AFINITOR.xml:S1:24530:6	B-AdverseReaction
,	AFINITOR.xml:S1:24536:1	O
and	AFINITOR.xml:S1:24538:3	O
stomatitis	AFINITOR.xml:S1:24542:10	B-AdverseReaction
.	AFINITOR.xml:S1:24552:1	O

Table	AFINITOR.xml:S1:24558:5	O
6	AFINITOR.xml:S1:24564:1	O
compares	AFINITOR.xml:S1:24566:8	O
the	AFINITOR.xml:S1:24575:3	O
incidence	AFINITOR.xml:S1:24579:9	O
of	AFINITOR.xml:S1:24589:2	O
treatment	AFINITOR.xml:S1:24592:9	O
-	AFINITOR.xml:S1:24601:1	O
emergent	AFINITOR.xml:S1:24602:8	O
adverse	AFINITOR.xml:S1:24611:7	O
reactions	AFINITOR.xml:S1:24619:9	O
reported	AFINITOR.xml:S1:24629:8	O
with	AFINITOR.xml:S1:24638:4	O
an	AFINITOR.xml:S1:24643:2	O
incidence	AFINITOR.xml:S1:24646:9	O
of	AFINITOR.xml:S1:24656:2	O
10%	AFINITOR.xml:S1:24662:3	O
for	AFINITOR.xml:S1:24666:3	O
patients	AFINITOR.xml:S1:24670:8	O
receiving	AFINITOR.xml:S1:24679:9	O
AFINITOR	AFINITOR.xml:S1:24689:8	O
10	AFINITOR.xml:S1:24698:2	O
mg	AFINITOR.xml:S1:24701:2	O
daily	AFINITOR.xml:S1:24704:5	O
versus	AFINITOR.xml:S1:24710:6	O
placebo	AFINITOR.xml:S1:24717:7	O
.	AFINITOR.xml:S1:24724:1	O

Within	AFINITOR.xml:S1:24726:6	O
each	AFINITOR.xml:S1:24733:4	O
MedDRA	AFINITOR.xml:S1:24738:6	O
system	AFINITOR.xml:S1:24745:6	O
organ	AFINITOR.xml:S1:24752:5	O
class	AFINITOR.xml:S1:24758:5	O
,	AFINITOR.xml:S1:24763:1	O
the	AFINITOR.xml:S1:24765:3	O
adverse	AFINITOR.xml:S1:24769:7	O
reactions	AFINITOR.xml:S1:24777:9	O
are	AFINITOR.xml:S1:24787:3	O
presented	AFINITOR.xml:S1:24791:9	O
in	AFINITOR.xml:S1:24801:2	O
order	AFINITOR.xml:S1:24804:5	O
of	AFINITOR.xml:S1:24810:2	O
decreasing	AFINITOR.xml:S1:24813:10	O
frequency	AFINITOR.xml:S1:24824:9	O
.	AFINITOR.xml:S1:24833:1	O

Table	AFINITOR.xml:S1:24839:5	O
6	AFINITOR.xml:S1:24845:1	O
:	AFINITOR.xml:S1:24846:1	O
Adverse	AFINITOR.xml:S1:24848:7	O
Reactions	AFINITOR.xml:S1:24856:9	O
Reported	AFINITOR.xml:S1:24866:8	O
in	AFINITOR.xml:S1:24875:2	O
at	AFINITOR.xml:S1:24878:2	O
Least	AFINITOR.xml:S1:24881:5	O
10%	AFINITOR.xml:S1:24887:3	O
of	AFINITOR.xml:S1:24891:2	O
Patients	AFINITOR.xml:S1:24894:8	O
with	AFINITOR.xml:S1:24903:4	O
RCC	AFINITOR.xml:S1:24908:3	O
and	AFINITOR.xml:S1:24912:3	O
at	AFINITOR.xml:S1:24916:2	O
a	AFINITOR.xml:S1:24919:1	O
Higher	AFINITOR.xml:S1:24921:6	O
Rate	AFINITOR.xml:S1:24928:4	O
in	AFINITOR.xml:S1:24933:2	O
the	AFINITOR.xml:S1:24936:3	O
AFINITOR	AFINITOR.xml:S1:24940:8	O
Arm	AFINITOR.xml:S1:24949:3	O
than	AFINITOR.xml:S1:24953:4	O
in	AFINITOR.xml:S1:24958:2	O
the	AFINITOR.xml:S1:24961:3	O
Placebo	AFINITOR.xml:S1:24965:7	O
Arm	AFINITOR.xml:S1:24973:3	O

Grading	AFINITOR.xml:S1:24979:7	O
according	AFINITOR.xml:S1:24987:9	O
to	AFINITOR.xml:S1:24997:2	O
CTCAE	AFINITOR.xml:S1:25000:5	O
Version	AFINITOR.xml:S1:25006:7	O
3.0	AFINITOR.xml:S1:25014:3	O
a	AFINITOR.xml:S1:25019:1	O
Stomatitis	AFINITOR.xml:S1:25022:10	B-AdverseReaction
(	AFINITOR.xml:S1:25033:1	O
including	AFINITOR.xml:S1:25034:9	O
aphthous	AFINITOR.xml:S1:25044:8	B-AdverseReaction
stomatitis	AFINITOR.xml:S1:25053:10	I-AdverseReaction
)	AFINITOR.xml:S1:25063:1	O
,	AFINITOR.xml:S1:25064:1	O
and	AFINITOR.xml:S1:25066:3	O
mouth	AFINITOR.xml:S1:25070:5	B-AdverseReaction
and	AFINITOR.xml:S1:25076:3	O
tongue	AFINITOR.xml:S1:25080:6	B-AdverseReaction
ulceration	AFINITOR.xml:S1:25087:10	I-AdverseReaction
.	AFINITOR.xml:S1:25097:1	O

b	AFINITOR.xml:S1:25100:1	O
Includes	AFINITOR.xml:S1:25103:8	O
all	AFINITOR.xml:S1:25112:3	O
preferred	AFINITOR.xml:S1:25116:9	O
terms	AFINITOR.xml:S1:25126:5	O
within	AFINITOR.xml:S1:25132:6	O
the	AFINITOR.xml:S1:25139:3	O
infections	AFINITOR.xml:S1:25144:10	O
and	AFINITOR.xml:S1:25155:3	O
infestations	AFINITOR.xml:S1:25159:12	O
system	AFINITOR.xml:S1:25173:6	O
organ	AFINITOR.xml:S1:25180:5	O
class	AFINITOR.xml:S1:25186:5	O
,	AFINITOR.xml:S1:25191:1	O
the	AFINITOR.xml:S1:25193:3	O
most	AFINITOR.xml:S1:25197:4	O
common	AFINITOR.xml:S1:25202:6	O
being	AFINITOR.xml:S1:25209:5	O
nasopharyngitis	AFINITOR.xml:S1:25215:15	B-AdverseReaction
(	AFINITOR.xml:S1:25231:1	O
6%	AFINITOR.xml:S1:25232:2	O
)	AFINITOR.xml:S1:25234:1	O
,	AFINITOR.xml:S1:25235:1	O
pneumonia	AFINITOR.xml:S1:25237:9	B-AdverseReaction
(	AFINITOR.xml:S1:25247:1	O
6%	AFINITOR.xml:S1:25248:2	O
)	AFINITOR.xml:S1:25250:1	O
,	AFINITOR.xml:S1:25251:1	O
urinary	AFINITOR.xml:S1:25253:7	B-AdverseReaction
tract	AFINITOR.xml:S1:25261:5	I-AdverseReaction
infection	AFINITOR.xml:S1:25267:9	I-AdverseReaction
(	AFINITOR.xml:S1:25277:1	O
5%	AFINITOR.xml:S1:25278:2	O
)	AFINITOR.xml:S1:25280:1	O
,	AFINITOR.xml:S1:25281:1	O
bronchitis	AFINITOR.xml:S1:25283:10	B-AdverseReaction
(	AFINITOR.xml:S1:25294:1	O
4%	AFINITOR.xml:S1:25295:2	O
)	AFINITOR.xml:S1:25297:1	O
,	AFINITOR.xml:S1:25298:1	O
and	AFINITOR.xml:S1:25300:3	O
sinusitis	AFINITOR.xml:S1:25304:9	B-AdverseReaction
(	AFINITOR.xml:S1:25314:1	O
3%	AFINITOR.xml:S1:25315:2	O
)	AFINITOR.xml:S1:25317:1	O
,	AFINITOR.xml:S1:25318:1	O
and	AFINITOR.xml:S1:25320:3	O
also	AFINITOR.xml:S1:25324:4	O
including	AFINITOR.xml:S1:25329:9	O
aspergillosis	AFINITOR.xml:S1:25339:13	B-AdverseReaction
(	AFINITOR.xml:S1:25353:1	O
1%	AFINITOR.xml:S1:25355:2	O
)	AFINITOR.xml:S1:25357:1	O
,	AFINITOR.xml:S1:25358:1	O
candidiasis	AFINITOR.xml:S1:25360:11	B-AdverseReaction
(	AFINITOR.xml:S1:25372:1	O
1%	AFINITOR.xml:S1:25374:2	O
)	AFINITOR.xml:S1:25376:1	O
,	AFINITOR.xml:S1:25377:1	O
and	AFINITOR.xml:S1:25379:3	O
sepsis	AFINITOR.xml:S1:25383:6	B-AdverseReaction
(	AFINITOR.xml:S1:25390:1	O
1%	AFINITOR.xml:S1:25392:2	O
)	AFINITOR.xml:S1:25394:1	O
.	AFINITOR.xml:S1:25395:1	O

c	AFINITOR.xml:S1:25398:1	O
Includes	AFINITOR.xml:S1:25401:8	O
pneumonitis	AFINITOR.xml:S1:25410:11	B-AdverseReaction
,	AFINITOR.xml:S1:25421:1	O
interstitial	AFINITOR.xml:S1:25423:12	B-AdverseReaction
lung	AFINITOR.xml:S1:25436:4	I-AdverseReaction
disease	AFINITOR.xml:S1:25441:7	I-AdverseReaction
,	AFINITOR.xml:S1:25448:1	O
lung	AFINITOR.xml:S1:25450:4	B-AdverseReaction
infiltration	AFINITOR.xml:S1:25455:12	I-AdverseReaction
,	AFINITOR.xml:S1:25467:1	O
pulmonary	AFINITOR.xml:S1:25469:9	B-AdverseReaction
alveolar	AFINITOR.xml:S1:25479:8	I-AdverseReaction
hemorrhage	AFINITOR.xml:S1:25488:10	I-AdverseReaction
,	AFINITOR.xml:S1:25498:1	O
pulmonary	AFINITOR.xml:S1:25500:9	B-AdverseReaction
toxicity	AFINITOR.xml:S1:25510:8	I-AdverseReaction
,	AFINITOR.xml:S1:25518:1	O
and	AFINITOR.xml:S1:25520:3	O
alveolitis	AFINITOR.xml:S1:25524:10	B-AdverseReaction
.	AFINITOR.xml:S1:25534:1	O

AFINITOR	AFINITOR.xml:S1:25562:8	O

10	AFINITOR.xml:S1:25574:2	O
mg	AFINITOR.xml:S1:25577:2	O
day	AFINITOR.xml:S1:25580:3	O
N	AFINITOR.xml:S1:25587:1	O
274	AFINITOR.xml:S1:25589:3	O
Placebo	AFINITOR.xml:S1:25598:7	O
N	AFINITOR.xml:S1:25609:1	O
137	AFINITOR.xml:S1:25611:3	O

All	AFINITOR.xml:S1:25640:3	O
grades	AFINITOR.xml:S1:25644:6	O
Grade	AFINITOR.xml:S1:25657:5	O
3	AFINITOR.xml:S1:25663:1	O
Grade	AFINITOR.xml:S1:25674:5	O
4	AFINITOR.xml:S1:25680:1	O
All	AFINITOR.xml:S1:25691:3	O
grades	AFINITOR.xml:S1:25695:6	O
Grade	AFINITOR.xml:S1:25708:5	O
3	AFINITOR.xml:S1:25714:1	O
Grade	AFINITOR.xml:S1:25725:5	O
4	AFINITOR.xml:S1:25731:1	O

Any	AFINITOR.xml:S1:25867:3	O

a	AFINITOR.xml:S1:25874:1	O
dverse	AFINITOR.xml:S1:25879:6	O
r	AFINITOR.xml:S1:25889:1	O
eaction	AFINITOR.xml:S1:25894:7	O
97	AFINITOR.xml:S1:25905:2	O
52	AFINITOR.xml:S1:25922:2	O
13	AFINITOR.xml:S1:25939:2	O
93	AFINITOR.xml:S1:25956:2	O
23	AFINITOR.xml:S1:25973:2	O
5	AFINITOR.xml:S1:25990:1	O

Gastrointestinal	AFINITOR.xml:S1:26012:16	O
d	AFINITOR.xml:S1:26032:1	O
isorders	AFINITOR.xml:S1:26037:8	O

Stomatitis	AFINITOR.xml:S1:26058:10	B-AdverseReaction
a	AFINITOR.xml:S1:26070:1	O
44	AFINITOR.xml:S1:26075:2	O
4	AFINITOR.xml:S1:26092:1	O
1	AFINITOR.xml:S1:26110:1	O
8	AFINITOR.xml:S1:26126:1	O
0	AFINITOR.xml:S1:26143:1	O
0	AFINITOR.xml:S1:26160:1	O

Diarrhea	AFINITOR.xml:S1:26186:8	B-AdverseReaction
30	AFINITOR.xml:S1:26197:2	O
1	AFINITOR.xml:S1:26214:1	O
0	AFINITOR.xml:S1:26231:1	O
7	AFINITOR.xml:S1:26248:1	O
0	AFINITOR.xml:S1:26265:1	O
0	AFINITOR.xml:S1:26282:1	O

Nausea	AFINITOR.xml:S1:26308:6	B-AdverseReaction
26	AFINITOR.xml:S1:26319:2	O
1	AFINITOR.xml:S1:26336:1	O
0	AFINITOR.xml:S1:26353:1	O
19	AFINITOR.xml:S1:26370:2	O
0	AFINITOR.xml:S1:26387:1	O
0	AFINITOR.xml:S1:26404:1	O

Vomiting	AFINITOR.xml:S1:26430:8	B-AdverseReaction
20	AFINITOR.xml:S1:26441:2	O
2	AFINITOR.xml:S1:26458:1	O
0	AFINITOR.xml:S1:26475:1	O
12	AFINITOR.xml:S1:26492:2	O
0	AFINITOR.xml:S1:26509:1	O
0	AFINITOR.xml:S1:26526:1	O

Infections	AFINITOR.xml:S1:26548:10	O
and	AFINITOR.xml:S1:26559:3	O
i	AFINITOR.xml:S1:26566:1	O
nfestations	AFINITOR.xml:S1:26571:11	O
b	AFINITOR.xml:S1:26588:1	O
37	AFINITOR.xml:S1:26595:2	O
7	AFINITOR.xml:S1:26612:1	O
3	AFINITOR.xml:S1:26629:1	O
18	AFINITOR.xml:S1:26646:2	O
1	AFINITOR.xml:S1:26663:1	O
0	AFINITOR.xml:S1:26680:1	O

General	AFINITOR.xml:S1:26702:7	O
d	AFINITOR.xml:S1:26713:1	O
isorders	AFINITOR.xml:S1:26718:8	O
and	AFINITOR.xml:S1:26727:3	O
a	AFINITOR.xml:S1:26734:1	O
dministration	AFINITOR.xml:S1:26739:13	O
s	AFINITOR.xml:S1:26756:1	O
ite	AFINITOR.xml:S1:26761:3	O
c	AFINITOR.xml:S1:26768:1	O
onditions	AFINITOR.xml:S1:26773:9	O

Asthenia	AFINITOR.xml:S1:26795:8	B-AdverseReaction
33	AFINITOR.xml:S1:26806:2	O
3	AFINITOR.xml:S1:26823:1	O
1	AFINITOR.xml:S1:26841:1	O
23	AFINITOR.xml:S1:26857:2	O
4	AFINITOR.xml:S1:26874:1	O
0	AFINITOR.xml:S1:26891:1	O

Fatigue	AFINITOR.xml:S1:26917:7	B-AdverseReaction
31	AFINITOR.xml:S1:26928:2	O
5	AFINITOR.xml:S1:26945:1	O
0	AFINITOR.xml:S1:26962:1	O
27	AFINITOR.xml:S1:26979:2	O
3	AFINITOR.xml:S1:26996:1	O
1	AFINITOR.xml:S1:27014:1	O

Edema	AFINITOR.xml:S1:27039:5	B-AdverseReaction
peripheral	AFINITOR.xml:S1:27045:10	I-AdverseReaction
25	AFINITOR.xml:S1:27057:2	O
1	AFINITOR.xml:S1:27075:1	O
0	AFINITOR.xml:S1:27091:1	O
8	AFINITOR.xml:S1:27108:1	O
1	AFINITOR.xml:S1:27126:1	O
0	AFINITOR.xml:S1:27142:1	O

Pyrexia	AFINITOR.xml:S1:27168:7	B-AdverseReaction
20	AFINITOR.xml:S1:27179:2	O
1	AFINITOR.xml:S1:27197:1	O
0	AFINITOR.xml:S1:27213:1	O
9	AFINITOR.xml:S1:27230:1	O
0	AFINITOR.xml:S1:27247:1	O
0	AFINITOR.xml:S1:27264:1	O

Mucosal	AFINITOR.xml:S1:27290:7	B-AdverseReaction
inflammation	AFINITOR.xml:S1:27298:12	I-AdverseReaction
19	AFINITOR.xml:S1:27312:2	O
1	AFINITOR.xml:S1:27329:1	O
0	AFINITOR.xml:S1:27346:1	O
1	AFINITOR.xml:S1:27363:1	O
0	AFINITOR.xml:S1:27380:1	O
0	AFINITOR.xml:S1:27397:1	O

Respiratory	AFINITOR.xml:S1:27419:11	O
,	AFINITOR.xml:S1:27430:1	O
t	AFINITOR.xml:S1:27435:1	O
horacic	AFINITOR.xml:S1:27440:7	O
and	AFINITOR.xml:S1:27448:3	O
m	AFINITOR.xml:S1:27455:1	O
ediastinal	AFINITOR.xml:S1:27460:10	O
d	AFINITOR.xml:S1:27474:1	O
isorders	AFINITOR.xml:S1:27479:8	O

Cough	AFINITOR.xml:S1:27500:5	B-AdverseReaction
30	AFINITOR.xml:S1:27511:2	O
1	AFINITOR.xml:S1:27529:1	O
0	AFINITOR.xml:S1:27545:1	O
16	AFINITOR.xml:S1:27562:2	O
0	AFINITOR.xml:S1:27579:1	O
0	AFINITOR.xml:S1:27596:1	O

Dyspnea	AFINITOR.xml:S1:27622:7	B-AdverseReaction
24	AFINITOR.xml:S1:27633:2	O
6	AFINITOR.xml:S1:27650:1	O
1	AFINITOR.xml:S1:27667:1	O
15	AFINITOR.xml:S1:27684:2	O
3	AFINITOR.xml:S1:27701:1	O
0	AFINITOR.xml:S1:27718:1	O

Epistaxis	AFINITOR.xml:S1:27744:9	B-AdverseReaction
18	AFINITOR.xml:S1:27755:2	O
0	AFINITOR.xml:S1:27772:1	O
0	AFINITOR.xml:S1:27789:1	O
0	AFINITOR.xml:S1:27806:1	O
0	AFINITOR.xml:S1:27823:1	O
0	AFINITOR.xml:S1:27840:1	O

Pneumonitis	AFINITOR.xml:S1:27866:11	B-AdverseReaction
c	AFINITOR.xml:S1:27879:1	O
14	AFINITOR.xml:S1:27884:2	O
4	AFINITOR.xml:S1:27901:1	O
0	AFINITOR.xml:S1:27918:1	O
0	AFINITOR.xml:S1:27935:1	O
0	AFINITOR.xml:S1:27952:1	O
0	AFINITOR.xml:S1:27969:1	O

Skin	AFINITOR.xml:S1:27991:4	O
and	AFINITOR.xml:S1:27996:3	O
s	AFINITOR.xml:S1:28003:1	O
ubcutaneous	AFINITOR.xml:S1:28008:11	O
t	AFINITOR.xml:S1:28023:1	O
issue	AFINITOR.xml:S1:28028:5	O
d	AFINITOR.xml:S1:28037:1	O
isorders	AFINITOR.xml:S1:28042:8	O

Rash	AFINITOR.xml:S1:28063:4	B-AdverseReaction
29	AFINITOR.xml:S1:28074:2	O
1	AFINITOR.xml:S1:28091:1	O
0	AFINITOR.xml:S1:28108:1	O
7	AFINITOR.xml:S1:28125:1	O
0	AFINITOR.xml:S1:28142:1	O
0	AFINITOR.xml:S1:28159:1	O

Pruritus	AFINITOR.xml:S1:28185:8	B-AdverseReaction
14	AFINITOR.xml:S1:28196:2	O
1	AFINITOR.xml:S1:28214:1	O
0	AFINITOR.xml:S1:28230:1	O
7	AFINITOR.xml:S1:28247:1	O
0	AFINITOR.xml:S1:28264:1	O
0	AFINITOR.xml:S1:28281:1	O

Dry	AFINITOR.xml:S1:28307:3	B-AdverseReaction
skin	AFINITOR.xml:S1:28311:4	I-AdverseReaction
13	AFINITOR.xml:S1:28318:2	O
1	AFINITOR.xml:S1:28336:1	O
0	AFINITOR.xml:S1:28352:1	O
5	AFINITOR.xml:S1:28369:1	O
0	AFINITOR.xml:S1:28386:1	O
0	AFINITOR.xml:S1:28403:1	O

Metabolism	AFINITOR.xml:S1:28425:10	O
and	AFINITOR.xml:S1:28436:3	O
n	AFINITOR.xml:S1:28443:1	O
utrition	AFINITOR.xml:S1:28448:8	O
d	AFINITOR.xml:S1:28460:1	O
isorders	AFINITOR.xml:S1:28465:8	O

Anorexia	AFINITOR.xml:S1:28486:8	B-AdverseReaction
25	AFINITOR.xml:S1:28497:2	O
1	AFINITOR.xml:S1:28514:1	O
0	AFINITOR.xml:S1:28531:1	O
14	AFINITOR.xml:S1:28548:2	O
1	AFINITOR.xml:S1:28566:1	O
0	AFINITOR.xml:S1:28582:1	O

Nervous	AFINITOR.xml:S1:28604:7	O
s	AFINITOR.xml:S1:28615:1	O
ystem	AFINITOR.xml:S1:28620:5	O
d	AFINITOR.xml:S1:28629:1	O
isorders	AFINITOR.xml:S1:28634:8	O

Headache	AFINITOR.xml:S1:28655:8	B-AdverseReaction
19	AFINITOR.xml:S1:28666:2	O
1	AFINITOR.xml:S1:28684:1	O
1	AFINITOR.xml:S1:28701:1	O
9	AFINITOR.xml:S1:28717:1	O
1	AFINITOR.xml:S1:28735:1	O
0	AFINITOR.xml:S1:28751:1	O

Dysgeusia	AFINITOR.xml:S1:28777:9	B-AdverseReaction
10	AFINITOR.xml:S1:28788:2	O
0	AFINITOR.xml:S1:28805:1	O
0	AFINITOR.xml:S1:28822:1	O
2	AFINITOR.xml:S1:28839:1	O
0	AFINITOR.xml:S1:28856:1	O
0	AFINITOR.xml:S1:28873:1	O

Musculoskeletal	AFINITOR.xml:S1:28895:15	O
and	AFINITOR.xml:S1:28911:3	O
c	AFINITOR.xml:S1:28918:1	O
onnective	AFINITOR.xml:S1:28923:9	O
t	AFINITOR.xml:S1:28936:1	O
issue	AFINITOR.xml:S1:28941:5	O
d	AFINITOR.xml:S1:28950:1	O
isorders	AFINITOR.xml:S1:28955:8	O

Pain	AFINITOR.xml:S1:28976:4	B-AdverseReaction
in	AFINITOR.xml:S1:28981:2	I-AdverseReaction
extremity	AFINITOR.xml:S1:28984:9	I-AdverseReaction
10	AFINITOR.xml:S1:28995:2	O
1	AFINITOR.xml:S1:29012:1	O
0	AFINITOR.xml:S1:29029:1	O
7	AFINITOR.xml:S1:29046:1	O
0	AFINITOR.xml:S1:29063:1	O
0	AFINITOR.xml:S1:29080:1	O

Medi	AFINITOR.xml:S1:29102:4	O
an	AFINITOR.xml:S1:29110:2	O
d	AFINITOR.xml:S1:29116:1	O
uration	AFINITOR.xml:S1:29121:7	O
of	AFINITOR.xml:S1:29129:2	O
t	AFINITOR.xml:S1:29135:1	O
reatment	AFINITOR.xml:S1:29140:8	O
(	AFINITOR.xml:S1:29149:1	O
d	AFINITOR.xml:S1:29150:1	O
)	AFINITOR.xml:S1:29151:1	O
141	AFINITOR.xml:S1:29158:3	O
60	AFINITOR.xml:S1:29175:2	O

Other	AFINITOR.xml:S1:29205:5	O
notable	AFINITOR.xml:S1:29211:7	O
adverse	AFINITOR.xml:S1:29219:7	O
reactions	AFINITOR.xml:S1:29227:9	O
occurring	AFINITOR.xml:S1:29237:9	O
more	AFINITOR.xml:S1:29247:4	O
frequently	AFINITOR.xml:S1:29252:10	O
with	AFINITOR.xml:S1:29263:4	O
AFINITOR	AFINITOR.xml:S1:29268:8	O
than	AFINITOR.xml:S1:29277:4	O
with	AFINITOR.xml:S1:29282:4	O
placebo	AFINITOR.xml:S1:29287:7	O
,	AFINITOR.xml:S1:29294:1	O
but	AFINITOR.xml:S1:29296:3	O
with	AFINITOR.xml:S1:29300:4	O
an	AFINITOR.xml:S1:29305:2	O
incidence	AFINITOR.xml:S1:29308:9	O
of	AFINITOR.xml:S1:29318:2	O
10%	AFINITOR.xml:S1:29323:3	O
include	AFINITOR.xml:S1:29327:7	O
:	AFINITOR.xml:S1:29334:1	O

Gastrointestinal	AFINITOR.xml:S1:29346:16	O

disorders	AFINITOR.xml:S1:29363:9	O
:	AFINITOR.xml:S1:29372:1	O
Abdominal	AFINITOR.xml:S1:29374:9	B-AdverseReaction
pain	AFINITOR.xml:S1:29384:4	I-AdverseReaction
(	AFINITOR.xml:S1:29389:1	O
9%	AFINITOR.xml:S1:29390:2	O
)	AFINITOR.xml:S1:29392:1	O
,	AFINITOR.xml:S1:29393:1	O
dry	AFINITOR.xml:S1:29395:3	B-AdverseReaction
mouth	AFINITOR.xml:S1:29399:5	I-AdverseReaction
(	AFINITOR.xml:S1:29405:1	O
8%	AFINITOR.xml:S1:29406:2	O
)	AFINITOR.xml:S1:29408:1	O
,	AFINITOR.xml:S1:29409:1	O
hemorrhoids	AFINITOR.xml:S1:29411:11	B-AdverseReaction
(	AFINITOR.xml:S1:29423:1	O
5%	AFINITOR.xml:S1:29424:2	O
)	AFINITOR.xml:S1:29426:1	O
,	AFINITOR.xml:S1:29427:1	O
dysphagia	AFINITOR.xml:S1:29429:9	B-AdverseReaction
(	AFINITOR.xml:S1:29439:1	O
4%	AFINITOR.xml:S1:29440:2	O
)	AFINITOR.xml:S1:29442:1	O

General	AFINITOR.xml:S1:29454:7	O
disorders	AFINITOR.xml:S1:29462:9	O
and	AFINITOR.xml:S1:29472:3	O
administration	AFINITOR.xml:S1:29476:14	O
site	AFINITOR.xml:S1:29491:4	O
conditions	AFINITOR.xml:S1:29496:10	O
:	AFINITOR.xml:S1:29506:1	O
Weight	AFINITOR.xml:S1:29508:6	B-AdverseReaction
decreased	AFINITOR.xml:S1:29515:9	I-AdverseReaction
(	AFINITOR.xml:S1:29525:1	O
9%	AFINITOR.xml:S1:29526:2	O
)	AFINITOR.xml:S1:29528:1	O
,	AFINITOR.xml:S1:29529:1	O
chest	AFINITOR.xml:S1:29531:5	B-AdverseReaction
pain	AFINITOR.xml:S1:29537:4	I-AdverseReaction
(	AFINITOR.xml:S1:29542:1	O
5%	AFINITOR.xml:S1:29543:2	O
)	AFINITOR.xml:S1:29545:1	O
,	AFINITOR.xml:S1:29546:1	O
chills	AFINITOR.xml:S1:29548:6	B-AdverseReaction
(	AFINITOR.xml:S1:29555:1	O
4%	AFINITOR.xml:S1:29556:2	O
)	AFINITOR.xml:S1:29558:1	O
,	AFINITOR.xml:S1:29559:1	O
impaired	AFINITOR.xml:S1:29561:8	B-AdverseReaction
wound	AFINITOR.xml:S1:29570:5	I-AdverseReaction
healing	AFINITOR.xml:S1:29576:7	I-AdverseReaction
(	AFINITOR.xml:S1:29584:1	O
1%	AFINITOR.xml:S1:29587:2	O
)	AFINITOR.xml:S1:29589:1	O

Respiratory	AFINITOR.xml:S1:29601:11	O
,	AFINITOR.xml:S1:29612:1	O
thoracic	AFINITOR.xml:S1:29614:8	O
and	AFINITOR.xml:S1:29623:3	O
mediastinal	AFINITOR.xml:S1:29627:11	O
disorders	AFINITOR.xml:S1:29639:9	O
:	AFINITOR.xml:S1:29648:1	O
Pleural	AFINITOR.xml:S1:29650:7	B-AdverseReaction
effusion	AFINITOR.xml:S1:29658:8	I-AdverseReaction
(	AFINITOR.xml:S1:29667:1	O
7%	AFINITOR.xml:S1:29668:2	O
)	AFINITOR.xml:S1:29670:1	O
,	AFINITOR.xml:S1:29671:1	O
pharyngolaryngeal	AFINITOR.xml:S1:29673:17	B-AdverseReaction
pain	AFINITOR.xml:S1:29691:4	I-AdverseReaction
(	AFINITOR.xml:S1:29696:1	O
4%	AFINITOR.xml:S1:29697:2	O
)	AFINITOR.xml:S1:29699:1	O
,	AFINITOR.xml:S1:29700:1	O
rhinorrhea	AFINITOR.xml:S1:29702:10	B-AdverseReaction
(	AFINITOR.xml:S1:29713:1	O
3%	AFINITOR.xml:S1:29714:2	O
)	AFINITOR.xml:S1:29716:1	O

Skin	AFINITOR.xml:S1:29728:4	O
and	AFINITOR.xml:S1:29733:3	O
subcutaneous	AFINITOR.xml:S1:29737:12	O
tissue	AFINITOR.xml:S1:29750:6	O
disorders	AFINITOR.xml:S1:29757:9	O
:	AFINITOR.xml:S1:29766:1	O
Hand	AFINITOR.xml:S1:29768:4	B-AdverseReaction
-	AFINITOR.xml:S1:29772:1	I-AdverseReaction
foot	AFINITOR.xml:S1:29773:4	I-AdverseReaction
syndrome	AFINITOR.xml:S1:29778:8	I-AdverseReaction
(	AFINITOR.xml:S1:29787:1	O
reported	AFINITOR.xml:S1:29788:8	O
as	AFINITOR.xml:S1:29797:2	O
palmar	AFINITOR.xml:S1:29800:6	B-AdverseReaction
-	AFINITOR.xml:S1:29806:1	I-AdverseReaction
plantar	AFINITOR.xml:S1:29807:7	I-AdverseReaction
erythrodysesthesia	AFINITOR.xml:S1:29815:18	I-AdverseReaction
syndrome	AFINITOR.xml:S1:29834:8	I-AdverseReaction
)	AFINITOR.xml:S1:29842:1	O
(	AFINITOR.xml:S1:29844:1	O
5%	AFINITOR.xml:S1:29845:2	O
)	AFINITOR.xml:S1:29847:1	O
,	AFINITOR.xml:S1:29848:1	O
nail	AFINITOR.xml:S1:29850:4	B-AdverseReaction
disorder	AFINITOR.xml:S1:29855:8	I-AdverseReaction
(	AFINITOR.xml:S1:29864:1	O
5%	AFINITOR.xml:S1:29865:2	O
)	AFINITOR.xml:S1:29867:1	O
,	AFINITOR.xml:S1:29868:1	O
erythema	AFINITOR.xml:S1:29870:8	B-AdverseReaction
(	AFINITOR.xml:S1:29879:1	O
4%	AFINITOR.xml:S1:29880:2	O
)	AFINITOR.xml:S1:29882:1	O
,	AFINITOR.xml:S1:29883:1	O
onychoclasis	AFINITOR.xml:S1:29885:12	B-AdverseReaction
(	AFINITOR.xml:S1:29898:1	O
4%	AFINITOR.xml:S1:29899:2	O
)	AFINITOR.xml:S1:29901:1	O
,	AFINITOR.xml:S1:29902:1	O
skin	AFINITOR.xml:S1:29904:4	B-AdverseReaction
lesion	AFINITOR.xml:S1:29909:6	I-AdverseReaction
(	AFINITOR.xml:S1:29916:1	O
4%	AFINITOR.xml:S1:29917:2	O
)	AFINITOR.xml:S1:29919:1	O
,	AFINITOR.xml:S1:29920:1	O
acneiform	AFINITOR.xml:S1:29922:9	B-AdverseReaction
dermatitis	AFINITOR.xml:S1:29932:10	I-AdverseReaction
(	AFINITOR.xml:S1:29943:1	O
3%	AFINITOR.xml:S1:29944:2	O
)	AFINITOR.xml:S1:29946:1	O
,	AFINITOR.xml:S1:29947:1	O
angioedema	AFINITOR.xml:S1:29949:10	B-AdverseReaction
(	AFINITOR.xml:S1:29960:1	O
1%	AFINITOR.xml:S1:29962:2	O
)	AFINITOR.xml:S1:29964:1	O

Metabolism	AFINITOR.xml:S1:29976:10	O
and	AFINITOR.xml:S1:29987:3	O
nutrition	AFINITOR.xml:S1:29991:9	O
disorders	AFINITOR.xml:S1:30001:9	O
:	AFINITOR.xml:S1:30010:1	O
Exacerbation	AFINITOR.xml:S1:30012:12	B-AdverseReaction
of	AFINITOR.xml:S1:30025:2	O
pre	AFINITOR.xml:S1:30028:3	O
-	AFINITOR.xml:S1:30031:1	O
existing	AFINITOR.xml:S1:30032:8	O
diabetes	AFINITOR.xml:S1:30041:8	I-AdverseReaction
mellitus	AFINITOR.xml:S1:30050:8	I-AdverseReaction
(	AFINITOR.xml:S1:30059:1	O
2%	AFINITOR.xml:S1:30060:2	O
)	AFINITOR.xml:S1:30062:1	O
,	AFINITOR.xml:S1:30063:1	O
new	AFINITOR.xml:S1:30065:3	B-AdverseReaction
onset	AFINITOR.xml:S1:30069:5	I-AdverseReaction
of	AFINITOR.xml:S1:30075:2	I-AdverseReaction
diabetes	AFINITOR.xml:S1:30078:8	I-AdverseReaction
mellitus	AFINITOR.xml:S1:30087:8	I-AdverseReaction
(	AFINITOR.xml:S1:30096:1	O
1%	AFINITOR.xml:S1:30099:2	O
)	AFINITOR.xml:S1:30101:1	O

Psychiatric	AFINITOR.xml:S1:30113:11	O
disorders	AFINITOR.xml:S1:30125:9	O
:	AFINITOR.xml:S1:30134:1	O
Insomnia	AFINITOR.xml:S1:30136:8	B-AdverseReaction
(	AFINITOR.xml:S1:30145:1	O
9%	AFINITOR.xml:S1:30146:2	O
)	AFINITOR.xml:S1:30148:1	O

Nervous	AFINITOR.xml:S1:30160:7	O
system	AFINITOR.xml:S1:30168:6	O
disorders	AFINITOR.xml:S1:30175:9	O
:	AFINITOR.xml:S1:30184:1	O
Dizziness	AFINITOR.xml:S1:30186:9	B-AdverseReaction
(	AFINITOR.xml:S1:30196:1	O
7%	AFINITOR.xml:S1:30197:2	O
)	AFINITOR.xml:S1:30199:1	O
,	AFINITOR.xml:S1:30200:1	O
paresthesia	AFINITOR.xml:S1:30202:11	B-AdverseReaction
(	AFINITOR.xml:S1:30214:1	O
5%	AFINITOR.xml:S1:30215:2	O
)	AFINITOR.xml:S1:30217:1	O

Eye	AFINITOR.xml:S1:30229:3	O
disorders	AFINITOR.xml:S1:30233:9	O
:	AFINITOR.xml:S1:30242:1	O
Eyelid	AFINITOR.xml:S1:30244:6	B-AdverseReaction
edema	AFINITOR.xml:S1:30251:5	I-AdverseReaction
(	AFINITOR.xml:S1:30257:1	O
4%	AFINITOR.xml:S1:30258:2	O
)	AFINITOR.xml:S1:30260:1	O
,	AFINITOR.xml:S1:30261:1	O
conjunctivitis	AFINITOR.xml:S1:30263:14	B-AdverseReaction
(	AFINITOR.xml:S1:30278:1	O
2%	AFINITOR.xml:S1:30279:2	O
)	AFINITOR.xml:S1:30281:1	O

Vascular	AFINITOR.xml:S1:30293:8	O
disorders	AFINITOR.xml:S1:30302:9	O
:	AFINITOR.xml:S1:30311:1	O
Hypertension	AFINITOR.xml:S1:30313:12	B-AdverseReaction
(	AFINITOR.xml:S1:30326:1	O
4%	AFINITOR.xml:S1:30327:2	O
)	AFINITOR.xml:S1:30329:1	O
,	AFINITOR.xml:S1:30330:1	O
deep	AFINITOR.xml:S1:30332:4	B-AdverseReaction
vein	AFINITOR.xml:S1:30337:4	I-AdverseReaction
thrombosis	AFINITOR.xml:S1:30342:10	I-AdverseReaction
(	AFINITOR.xml:S1:30353:1	O
1%	AFINITOR.xml:S1:30356:2	O
)	AFINITOR.xml:S1:30358:1	O

Renal	AFINITOR.xml:S1:30370:5	O
and	AFINITOR.xml:S1:30376:3	O
urinary	AFINITOR.xml:S1:30380:7	O
disorders	AFINITOR.xml:S1:30388:9	O
:	AFINITOR.xml:S1:30397:1	O
Renal	AFINITOR.xml:S1:30399:5	B-AdverseReaction
failure	AFINITOR.xml:S1:30405:7	I-AdverseReaction
(	AFINITOR.xml:S1:30413:1	O
3%	AFINITOR.xml:S1:30414:2	O
)	AFINITOR.xml:S1:30416:1	O

Cardiac	AFINITOR.xml:S1:30428:7	O
disorders	AFINITOR.xml:S1:30436:9	O
:	AFINITOR.xml:S1:30445:1	O
Tachycardia	AFINITOR.xml:S1:30447:11	B-AdverseReaction
(	AFINITOR.xml:S1:30459:1	O
3%	AFINITOR.xml:S1:30460:2	O
)	AFINITOR.xml:S1:30462:1	O
,	AFINITOR.xml:S1:30463:1	O
congestive	AFINITOR.xml:S1:30465:10	B-AdverseReaction
cardiac	AFINITOR.xml:S1:30476:7	I-AdverseReaction
failure	AFINITOR.xml:S1:30484:7	I-AdverseReaction
(	AFINITOR.xml:S1:30492:1	O
1%	AFINITOR.xml:S1:30493:2	O
)	AFINITOR.xml:S1:30495:1	O

Musculoskeletal	AFINITOR.xml:S1:30507:15	O
and	AFINITOR.xml:S1:30523:3	O
connective	AFINITOR.xml:S1:30527:10	O
tissue	AFINITOR.xml:S1:30538:6	O
disorders	AFINITOR.xml:S1:30545:9	O
:	AFINITOR.xml:S1:30554:1	O
Jaw	AFINITOR.xml:S1:30556:3	B-AdverseReaction
pain	AFINITOR.xml:S1:30560:4	I-AdverseReaction
(	AFINITOR.xml:S1:30565:1	O
3%	AFINITOR.xml:S1:30566:2	O
)	AFINITOR.xml:S1:30568:1	O

Hematologic	AFINITOR.xml:S1:30580:11	O
disorders	AFINITOR.xml:S1:30592:9	O
:	AFINITOR.xml:S1:30601:1	O
Hemorrhage	AFINITOR.xml:S1:30603:10	B-AdverseReaction
(	AFINITOR.xml:S1:30614:1	O
3%	AFINITOR.xml:S1:30615:2	O
)	AFINITOR.xml:S1:30617:1	O

Key	AFINITOR.xml:S1:30623:3	O
laboratory	AFINITOR.xml:S1:30627:10	O
abnormalities	AFINITOR.xml:S1:30638:13	O
are	AFINITOR.xml:S1:30652:3	O
presented	AFINITOR.xml:S1:30656:9	O
in	AFINITOR.xml:S1:30666:2	O
Table	AFINITOR.xml:S1:30669:5	O
7	AFINITOR.xml:S1:30675:1	O
.	AFINITOR.xml:S1:30676:1	O

Table	AFINITOR.xml:S1:30682:5	O
7	AFINITOR.xml:S1:30688:1	O
:	AFINITOR.xml:S1:30689:1	O
Key	AFINITOR.xml:S1:30691:3	O
Laboratory	AFINITOR.xml:S1:30695:10	O
Abnormalities	AFINITOR.xml:S1:30706:13	O
Reported	AFINITOR.xml:S1:30720:8	O
in	AFINITOR.xml:S1:30729:2	O
Patients	AFINITOR.xml:S1:30732:8	O
with	AFINITOR.xml:S1:30741:4	O
RCC	AFINITOR.xml:S1:30746:3	O
at	AFINITOR.xml:S1:30750:2	O
a	AFINITOR.xml:S1:30753:1	O
Higher	AFINITOR.xml:S1:30755:6	O
Rate	AFINITOR.xml:S1:30762:4	O
in	AFINITOR.xml:S1:30767:2	O
the	AFINITOR.xml:S1:30770:3	O
AFINITOR	AFINITOR.xml:S1:30774:8	O
Arm	AFINITOR.xml:S1:30783:3	O
than	AFINITOR.xml:S1:30787:4	O
the	AFINITOR.xml:S1:30792:3	O
Placebo	AFINITOR.xml:S1:30796:7	O
Arm	AFINITOR.xml:S1:30804:3	O

Grading	AFINITOR.xml:S1:30810:7	O
according	AFINITOR.xml:S1:30818:9	O
to	AFINITOR.xml:S1:30828:2	O
CTCAE	AFINITOR.xml:S1:30831:5	O
Version	AFINITOR.xml:S1:30837:7	O
3.0	AFINITOR.xml:S1:30845:3	O
a	AFINITOR.xml:S1:30850:1	O
Reflects	AFINITOR.xml:S1:30853:8	O
corresponding	AFINITOR.xml:S1:30862:13	O
adverse	AFINITOR.xml:S1:30876:7	O
drug	AFINITOR.xml:S1:30884:4	O
reaction	AFINITOR.xml:S1:30889:8	O
reports	AFINITOR.xml:S1:30898:7	O
of	AFINITOR.xml:S1:30906:2	O
anemia	AFINITOR.xml:S1:30909:6	B-AdverseReaction
,	AFINITOR.xml:S1:30915:1	O
leukopenia	AFINITOR.xml:S1:30917:10	B-AdverseReaction
,	AFINITOR.xml:S1:30927:1	O
lymphopenia	AFINITOR.xml:S1:30929:11	B-AdverseReaction
,	AFINITOR.xml:S1:30940:1	O
neutropenia	AFINITOR.xml:S1:30942:11	B-AdverseReaction
,	AFINITOR.xml:S1:30953:1	O
and	AFINITOR.xml:S1:30955:3	O
thrombocytopenia	AFINITOR.xml:S1:30959:16	B-AdverseReaction
(	AFINITOR.xml:S1:30976:1	O
collectively	AFINITOR.xml:S1:30977:12	O
pancytopenia	AFINITOR.xml:S1:30990:12	B-AdverseReaction
)	AFINITOR.xml:S1:31002:1	O
,	AFINITOR.xml:S1:31003:1	O
which	AFINITOR.xml:S1:31005:5	O
occurred	AFINITOR.xml:S1:31011:8	O
at	AFINITOR.xml:S1:31020:2	O
lower	AFINITOR.xml:S1:31023:5	O
frequency	AFINITOR.xml:S1:31029:9	O
.	AFINITOR.xml:S1:31038:1	O

Laboratory	AFINITOR.xml:S1:31049:10	O

p	AFINITOR.xml:S1:31063:1	O
arameter	AFINITOR.xml:S1:31068:8	O
AFINITOR	AFINITOR.xml:S1:31082:8	O
10	AFINITOR.xml:S1:31094:2	O
mg	AFINITOR.xml:S1:31097:2	O
day	AFINITOR.xml:S1:31100:3	O
N	AFINITOR.xml:S1:31107:1	O
274	AFINITOR.xml:S1:31109:3	O
Placebo	AFINITOR.xml:S1:31118:7	O
N	AFINITOR.xml:S1:31129:1	O
137	AFINITOR.xml:S1:31131:3	O

All	AFINITOR.xml:S1:31160:3	O
grades	AFINITOR.xml:S1:31164:6	O
Grade	AFINITOR.xml:S1:31177:5	O
3	AFINITOR.xml:S1:31183:1	O
Grade	AFINITOR.xml:S1:31194:5	O
4	AFINITOR.xml:S1:31200:1	O
All	AFINITOR.xml:S1:31211:3	O
grades	AFINITOR.xml:S1:31215:6	O
Grade	AFINITOR.xml:S1:31228:5	O
3	AFINITOR.xml:S1:31234:1	O
Grade	AFINITOR.xml:S1:31245:5	O
4	AFINITOR.xml:S1:31251:1	O

Hematology	AFINITOR.xml:S1:31387:10	O

a	AFINITOR.xml:S1:31403:1	O

Hemoglobin	AFINITOR.xml:S1:31521:10	B-AdverseReaction
decreased	AFINITOR.xml:S1:31532:9	I-AdverseReaction
92	AFINITOR.xml:S1:31543:2	O
12	AFINITOR.xml:S1:31560:2	O
1	AFINITOR.xml:S1:31577:1	O
79	AFINITOR.xml:S1:31594:2	O
5	AFINITOR.xml:S1:31611:1	O
1	AFINITOR.xml:S1:31629:1	O

Lymphocytes	AFINITOR.xml:S1:31654:11	B-AdverseReaction
decreased	AFINITOR.xml:S1:31666:9	I-AdverseReaction
51	AFINITOR.xml:S1:31677:2	O
16	AFINITOR.xml:S1:31694:2	O
2	AFINITOR.xml:S1:31711:1	O
28	AFINITOR.xml:S1:31728:2	O
5	AFINITOR.xml:S1:31745:1	O
0	AFINITOR.xml:S1:31762:1	O

Platelets	AFINITOR.xml:S1:31788:9	B-AdverseReaction
decreased	AFINITOR.xml:S1:31798:9	I-AdverseReaction
23	AFINITOR.xml:S1:31809:2	O
1	AFINITOR.xml:S1:31826:1	O
0	AFINITOR.xml:S1:31843:1	O
2	AFINITOR.xml:S1:31860:1	O
0	AFINITOR.xml:S1:31877:1	O
1	AFINITOR.xml:S1:31895:1	O

Neutrophils	AFINITOR.xml:S1:31920:11	B-AdverseReaction
decreased	AFINITOR.xml:S1:31932:9	I-AdverseReaction
14	AFINITOR.xml:S1:31943:2	O
0	AFINITOR.xml:S1:31960:1	O
1	AFINITOR.xml:S1:31978:1	O
4	AFINITOR.xml:S1:31994:1	O
0	AFINITOR.xml:S1:32011:1	O
0	AFINITOR.xml:S1:32028:1	O

Clinical	AFINITOR.xml:S1:32050:8	O
c	AFINITOR.xml:S1:32062:1	O
hemistry	AFINITOR.xml:S1:32067:8	O

Cholesterol	AFINITOR.xml:S1:32190:11	B-AdverseReaction
increased	AFINITOR.xml:S1:32202:9	I-AdverseReaction
77	AFINITOR.xml:S1:32213:2	O
4	AFINITOR.xml:S1:32230:1	O
0	AFINITOR.xml:S1:32247:1	O
35	AFINITOR.xml:S1:32264:2	O
0	AFINITOR.xml:S1:32281:1	O
0	AFINITOR.xml:S1:32298:1	O

Triglycerides	AFINITOR.xml:S1:32324:13	B-AdverseReaction
increased	AFINITOR.xml:S1:32338:9	I-AdverseReaction
73	AFINITOR.xml:S1:32349:2	O
1	AFINITOR.xml:S1:32367:1	O
0	AFINITOR.xml:S1:32383:1	O
34	AFINITOR.xml:S1:32400:2	O
0	AFINITOR.xml:S1:32417:1	O
0	AFINITOR.xml:S1:32434:1	O

Glucose	AFINITOR.xml:S1:32460:7	B-AdverseReaction
increased	AFINITOR.xml:S1:32468:9	I-AdverseReaction
57	AFINITOR.xml:S1:32479:2	O
15	AFINITOR.xml:S1:32496:2	O
1	AFINITOR.xml:S1:32514:1	O
25	AFINITOR.xml:S1:32530:2	O
1	AFINITOR.xml:S1:32547:1	O
0	AFINITOR.xml:S1:32564:1	O

Creatinine	AFINITOR.xml:S1:32590:10	B-AdverseReaction
increased	AFINITOR.xml:S1:32601:9	I-AdverseReaction
50	AFINITOR.xml:S1:32612:2	O
1	AFINITOR.xml:S1:32629:1	O
0	AFINITOR.xml:S1:32646:1	O
34	AFINITOR.xml:S1:32663:2	O
0	AFINITOR.xml:S1:32680:1	O
0	AFINITOR.xml:S1:32697:1	O

Phosphate	AFINITOR.xml:S1:32723:9	B-AdverseReaction
decreased	AFINITOR.xml:S1:32733:9	I-AdverseReaction
37	AFINITOR.xml:S1:32744:2	O
6	AFINITOR.xml:S1:32761:1	O
0	AFINITOR.xml:S1:32778:1	O
8	AFINITOR.xml:S1:32795:1	O
0	AFINITOR.xml:S1:32812:1	O
0	AFINITOR.xml:S1:32829:1	O

Aspartate	AFINITOR.xml:S1:32855:9	B-AdverseReaction
transaminase	AFINITOR.xml:S1:32865:12	I-AdverseReaction
(	AFINITOR.xml:S1:32878:1	O
AST	AFINITOR.xml:S1:32879:3	B-AdverseReaction
)	AFINITOR.xml:S1:32882:1	O
increased	AFINITOR.xml:S1:32884:9	I-AdverseReaction
25	AFINITOR.xml:S1:32895:2	O
1	AFINITOR.xml:S1:32913:1	O
1	AFINITOR.xml:S1:32930:1	O
7	AFINITOR.xml:S1:32946:1	O
0	AFINITOR.xml:S1:32963:1	O
0	AFINITOR.xml:S1:32980:1	O

Alanine	AFINITOR.xml:S1:33006:7	B-AdverseReaction
transaminase	AFINITOR.xml:S1:33014:12	I-AdverseReaction
(	AFINITOR.xml:S1:33027:1	O
ALT	AFINITOR.xml:S1:33028:3	B-AdverseReaction
)	AFINITOR.xml:S1:33031:1	O
increased	AFINITOR.xml:S1:33033:9	I-AdverseReaction
21	AFINITOR.xml:S1:33044:2	O
1	AFINITOR.xml:S1:33061:1	O
0	AFINITOR.xml:S1:33078:1	O
4	AFINITOR.xml:S1:33095:1	O
0	AFINITOR.xml:S1:33112:1	O
0	AFINITOR.xml:S1:33129:1	O

Bilirubin	AFINITOR.xml:S1:33155:9	B-AdverseReaction
increased	AFINITOR.xml:S1:33165:9	I-AdverseReaction
3	AFINITOR.xml:S1:33176:1	O
1	AFINITOR.xml:S1:33194:1	O
1	AFINITOR.xml:S1:33211:1	O
2	AFINITOR.xml:S1:33227:1	O
0	AFINITOR.xml:S1:33244:1	O
0	AFINITOR.xml:S1:33261:1	O

6.4	AFINITOR.xml:S1:33295:3	O
Clinical	AFINITOR.xml:S1:33303:8	O
Study	AFINITOR.xml:S1:33312:5	O
Experience	AFINITOR.xml:S1:33318:10	O
in	AFINITOR.xml:S1:33329:2	O
Renal	AFINITOR.xml:S1:33332:5	O
Angiomyolipoma	AFINITOR.xml:S1:33338:14	O
with	AFINITOR.xml:S1:33353:4	O
Tuberous	AFINITOR.xml:S1:33358:8	O
Sclerosis	AFINITOR.xml:S1:33367:9	O
Complex	AFINITOR.xml:S1:33377:7	O

The	AFINITOR.xml:S1:33388:3	O
data	AFINITOR.xml:S1:33392:4	O
described	AFINITOR.xml:S1:33397:9	O
below	AFINITOR.xml:S1:33407:5	O
are	AFINITOR.xml:S1:33413:3	O
based	AFINITOR.xml:S1:33417:5	O
on	AFINITOR.xml:S1:33423:2	O
a	AFINITOR.xml:S1:33426:1	O
randomized	AFINITOR.xml:S1:33428:10	O
(	AFINITOR.xml:S1:33439:1	O
2	AFINITOR.xml:S1:33440:1	O
:	AFINITOR.xml:S1:33441:1	O
1	AFINITOR.xml:S1:33442:1	O
)	AFINITOR.xml:S1:33443:1	O
,	AFINITOR.xml:S1:33444:1	O
double	AFINITOR.xml:S1:33446:6	O
-	AFINITOR.xml:S1:33452:1	O
blind	AFINITOR.xml:S1:33453:5	O
,	AFINITOR.xml:S1:33458:1	O
placebo	AFINITOR.xml:S1:33460:7	O
-	AFINITOR.xml:S1:33467:1	O
controlled	AFINITOR.xml:S1:33468:10	O
trial	AFINITOR.xml:S1:33479:5	O
of	AFINITOR.xml:S1:33485:2	O
AFINITOR	AFINITOR.xml:S1:33488:8	O
in	AFINITOR.xml:S1:33497:2	O
118	AFINITOR.xml:S1:33500:3	O
patients	AFINITOR.xml:S1:33504:8	O
with	AFINITOR.xml:S1:33513:4	O
renal	AFINITOR.xml:S1:33518:5	O
angiomyolipoma	AFINITOR.xml:S1:33524:14	O
as	AFINITOR.xml:S1:33539:2	O
a	AFINITOR.xml:S1:33542:1	O
feature	AFINITOR.xml:S1:33544:7	O
of	AFINITOR.xml:S1:33552:2	O
TSC	AFINITOR.xml:S1:33555:3	O
(	AFINITOR.xml:S1:33559:1	O
n	AFINITOR.xml:S1:33560:1	O
113	AFINITOR.xml:S1:33562:3	O
)	AFINITOR.xml:S1:33565:1	O
or	AFINITOR.xml:S1:33567:2	O
sporadic	AFINITOR.xml:S1:33570:8	O
lymphangioleiomyomatosis	AFINITOR.xml:S1:33579:24	O
(	AFINITOR.xml:S1:33604:1	O
n	AFINITOR.xml:S1:33605:1	O
5	AFINITOR.xml:S1:33607:1	O
)	AFINITOR.xml:S1:33608:1	O
.	AFINITOR.xml:S1:33609:1	O

The	AFINITOR.xml:S1:33611:3	O
median	AFINITOR.xml:S1:33615:6	O
age	AFINITOR.xml:S1:33622:3	O
of	AFINITOR.xml:S1:33626:2	O
patients	AFINITOR.xml:S1:33629:8	O
was	AFINITOR.xml:S1:33638:3	O
31	AFINITOR.xml:S1:33642:2	O
years	AFINITOR.xml:S1:33645:5	O
(	AFINITOR.xml:S1:33651:1	O
range	AFINITOR.xml:S1:33652:5	O
18	AFINITOR.xml:S1:33658:2	O
to	AFINITOR.xml:S1:33661:2	O
61	AFINITOR.xml:S1:33664:2	O
years	AFINITOR.xml:S1:33667:5	O
)	AFINITOR.xml:S1:33672:1	O
,	AFINITOR.xml:S1:33673:1	O
89%	AFINITOR.xml:S1:33675:3	O
were	AFINITOR.xml:S1:33679:4	O
Caucasian	AFINITOR.xml:S1:33684:9	O
,	AFINITOR.xml:S1:33693:1	O
and	AFINITOR.xml:S1:33695:3	O
34%	AFINITOR.xml:S1:33699:3	O
were	AFINITOR.xml:S1:33703:4	O
male	AFINITOR.xml:S1:33708:4	O
.	AFINITOR.xml:S1:33712:1	O

The	AFINITOR.xml:S1:33714:3	O
median	AFINITOR.xml:S1:33718:6	O
duration	AFINITOR.xml:S1:33725:8	O
of	AFINITOR.xml:S1:33734:2	O
blinded	AFINITOR.xml:S1:33737:7	O
study	AFINITOR.xml:S1:33745:5	O
treatment	AFINITOR.xml:S1:33751:9	O
was	AFINITOR.xml:S1:33761:3	O
48	AFINITOR.xml:S1:33765:2	O
weeks	AFINITOR.xml:S1:33768:5	O
(	AFINITOR.xml:S1:33774:1	O
range	AFINITOR.xml:S1:33775:5	O
2	AFINITOR.xml:S1:33781:1	O
to	AFINITOR.xml:S1:33783:2	O
115	AFINITOR.xml:S1:33786:3	O
weeks	AFINITOR.xml:S1:33790:5	O
)	AFINITOR.xml:S1:33795:1	O
for	AFINITOR.xml:S1:33797:3	O
patients	AFINITOR.xml:S1:33801:8	O
receiving	AFINITOR.xml:S1:33810:9	O
AFINITOR	AFINITOR.xml:S1:33820:8	O
and	AFINITOR.xml:S1:33829:3	O
45	AFINITOR.xml:S1:33833:2	O
weeks	AFINITOR.xml:S1:33836:5	O
(	AFINITOR.xml:S1:33842:1	O
range	AFINITOR.xml:S1:33843:5	O
9	AFINITOR.xml:S1:33849:1	O
to	AFINITOR.xml:S1:33851:2	O
115	AFINITOR.xml:S1:33854:3	O
weeks	AFINITOR.xml:S1:33858:5	O
)	AFINITOR.xml:S1:33863:1	O
for	AFINITOR.xml:S1:33865:3	O
those	AFINITOR.xml:S1:33869:5	O
receiving	AFINITOR.xml:S1:33875:9	O
placebo	AFINITOR.xml:S1:33885:7	O
.	AFINITOR.xml:S1:33892:1	O

The	AFINITOR.xml:S1:33898:3	O
most	AFINITOR.xml:S1:33902:4	O
common	AFINITOR.xml:S1:33907:6	O
adverse	AFINITOR.xml:S1:33914:7	O
reaction	AFINITOR.xml:S1:33922:8	O
reported	AFINITOR.xml:S1:33931:8	O
for	AFINITOR.xml:S1:33940:3	O
AFINITOR	AFINITOR.xml:S1:33944:8	O
(	AFINITOR.xml:S1:33953:1	O
incidence	AFINITOR.xml:S1:33954:9	O
30%	AFINITOR.xml:S1:33967:3	O
)	AFINITOR.xml:S1:33970:1	O
was	AFINITOR.xml:S1:33972:3	O
stomatitis	AFINITOR.xml:S1:33976:10	B-AdverseReaction
.	AFINITOR.xml:S1:33986:1	O

The	AFINITOR.xml:S1:33988:3	O
most	AFINITOR.xml:S1:33992:4	O
common	AFINITOR.xml:S1:33997:6	O
Grade	AFINITOR.xml:S1:34004:5	O
3	AFINITOR.xml:S1:34010:1	O
-	AFINITOR.xml:S1:34011:1	O
4	AFINITOR.xml:S1:34012:1	O
adverse	AFINITOR.xml:S1:34014:7	O
reactions	AFINITOR.xml:S1:34022:9	O
(	AFINITOR.xml:S1:34032:1	O
incidence	AFINITOR.xml:S1:34033:9	O
2%	AFINITOR.xml:S1:34046:2	O
)	AFINITOR.xml:S1:34048:1	O
were	AFINITOR.xml:S1:34050:4	O
stomatitis	AFINITOR.xml:S1:34055:10	B-AdverseReaction
and	AFINITOR.xml:S1:34066:3	O
amenorrhea	AFINITOR.xml:S1:34070:10	B-AdverseReaction
.	AFINITOR.xml:S1:34080:1	O

The	AFINITOR.xml:S1:34082:3	O
most	AFINITOR.xml:S1:34086:4	O
common	AFINITOR.xml:S1:34091:6	O
laboratory	AFINITOR.xml:S1:34098:10	O
abnormalities	AFINITOR.xml:S1:34109:13	O
(	AFINITOR.xml:S1:34123:1	O
incidence	AFINITOR.xml:S1:34124:9	O
50%	AFINITOR.xml:S1:34137:3	O
)	AFINITOR.xml:S1:34140:1	O
were	AFINITOR.xml:S1:34142:4	O
hypercholesterolemia	AFINITOR.xml:S1:34147:20	B-AdverseReaction
,	AFINITOR.xml:S1:34167:1	O
hypertriglyceridemia	AFINITOR.xml:S1:34169:20	B-AdverseReaction
,	AFINITOR.xml:S1:34189:1	O
and	AFINITOR.xml:S1:34191:3	O
anemia	AFINITOR.xml:S1:34195:6	B-AdverseReaction
.	AFINITOR.xml:S1:34201:1	O

The	AFINITOR.xml:S1:34203:3	O
most	AFINITOR.xml:S1:34207:4	O
common	AFINITOR.xml:S1:34212:6	O
Grade	AFINITOR.xml:S1:34219:5	O
3	AFINITOR.xml:S1:34225:1	O
-	AFINITOR.xml:S1:34226:1	O
4	AFINITOR.xml:S1:34227:1	O
laboratory	AFINITOR.xml:S1:34229:10	O
abnormality	AFINITOR.xml:S1:34240:11	O
(	AFINITOR.xml:S1:34252:1	O
incidence	AFINITOR.xml:S1:34253:9	O
3%	AFINITOR.xml:S1:34266:2	O
)	AFINITOR.xml:S1:34268:1	O
was	AFINITOR.xml:S1:34270:3	O
hypophosphatemia	AFINITOR.xml:S1:34274:16	B-AdverseReaction
.	AFINITOR.xml:S1:34290:1	O

The	AFINITOR.xml:S1:34296:3	O
rate	AFINITOR.xml:S1:34300:4	O
of	AFINITOR.xml:S1:34305:2	O
adverse	AFINITOR.xml:S1:34308:7	O
reactions	AFINITOR.xml:S1:34316:9	O
resulting	AFINITOR.xml:S1:34326:9	O
in	AFINITOR.xml:S1:34336:2	O
permanent	AFINITOR.xml:S1:34339:9	O
discontinuation	AFINITOR.xml:S1:34349:15	O
was	AFINITOR.xml:S1:34365:3	O
3.8%	AFINITOR.xml:S1:34369:4	O
in	AFINITOR.xml:S1:34374:2	O
the	AFINITOR.xml:S1:34377:3	O
AFINITOR	AFINITOR.xml:S1:34381:8	O
-	AFINITOR.xml:S1:34389:1	O
treated	AFINITOR.xml:S1:34390:7	O
patients	AFINITOR.xml:S1:34398:8	O
.	AFINITOR.xml:S1:34406:1	O

Adverse	AFINITOR.xml:S1:34408:7	O
reactions	AFINITOR.xml:S1:34416:9	O
leading	AFINITOR.xml:S1:34426:7	O
to	AFINITOR.xml:S1:34434:2	O
permanent	AFINITOR.xml:S1:34437:9	O
discontinuation	AFINITOR.xml:S1:34447:15	O
in	AFINITOR.xml:S1:34463:2	O
the	AFINITOR.xml:S1:34466:3	O
AFINITOR	AFINITOR.xml:S1:34470:8	O
arm	AFINITOR.xml:S1:34479:3	O
were	AFINITOR.xml:S1:34483:4	O
hypersensitivity	AFINITOR.xml:S1:34488:16	B-AdverseReaction
angioedema	AFINITOR.xml:S1:34505:10	B-AdverseReaction
bronchospasm	AFINITOR.xml:S1:34516:12	B-AdverseReaction
,	AFINITOR.xml:S1:34528:1	O
convulsion	AFINITOR.xml:S1:34530:10	B-AdverseReaction
,	AFINITOR.xml:S1:34540:1	O
and	AFINITOR.xml:S1:34542:3	O
hypophosphatemia	AFINITOR.xml:S1:34546:16	B-AdverseReaction
.	AFINITOR.xml:S1:34562:1	O

Dose	AFINITOR.xml:S1:34564:4	O
adjustments	AFINITOR.xml:S1:34569:11	O
(	AFINITOR.xml:S1:34581:1	O
interruptions	AFINITOR.xml:S1:34582:13	O
or	AFINITOR.xml:S1:34596:2	O
reductions	AFINITOR.xml:S1:34599:10	O
)	AFINITOR.xml:S1:34609:1	O
due	AFINITOR.xml:S1:34611:3	O
to	AFINITOR.xml:S1:34615:2	O
adverse	AFINITOR.xml:S1:34618:7	O
reactions	AFINITOR.xml:S1:34626:9	O
occurred	AFINITOR.xml:S1:34636:8	O
in	AFINITOR.xml:S1:34645:2	O
52%	AFINITOR.xml:S1:34648:3	O
of	AFINITOR.xml:S1:34652:2	O
AFINITOR	AFINITOR.xml:S1:34655:8	O
-	AFINITOR.xml:S1:34663:1	O
treated	AFINITOR.xml:S1:34664:7	O
patients	AFINITOR.xml:S1:34672:8	O
.	AFINITOR.xml:S1:34680:1	O

The	AFINITOR.xml:S1:34682:3	O
most	AFINITOR.xml:S1:34686:4	O
common	AFINITOR.xml:S1:34691:6	O
adverse	AFINITOR.xml:S1:34698:7	O
reaction	AFINITOR.xml:S1:34706:8	O
leading	AFINITOR.xml:S1:34715:7	O
to	AFINITOR.xml:S1:34723:2	O
AFINITOR	AFINITOR.xml:S1:34726:8	O
dose	AFINITOR.xml:S1:34735:4	O
adjustment	AFINITOR.xml:S1:34740:10	O
was	AFINITOR.xml:S1:34751:3	O
stomatitis	AFINITOR.xml:S1:34755:10	B-AdverseReaction
.	AFINITOR.xml:S1:34765:1	O

Table	AFINITOR.xml:S1:34771:5	O
8	AFINITOR.xml:S1:34777:1	O
compares	AFINITOR.xml:S1:34779:8	O
the	AFINITOR.xml:S1:34788:3	O
incidence	AFINITOR.xml:S1:34792:9	O
of	AFINITOR.xml:S1:34802:2	O
adverse	AFINITOR.xml:S1:34805:7	O
reactions	AFINITOR.xml:S1:34813:9	O
reported	AFINITOR.xml:S1:34823:8	O
with	AFINITOR.xml:S1:34832:4	O
an	AFINITOR.xml:S1:34837:2	O
incidence	AFINITOR.xml:S1:34840:9	O
of	AFINITOR.xml:S1:34850:2	O
10%	AFINITOR.xml:S1:34856:3	O
for	AFINITOR.xml:S1:34860:3	O
patients	AFINITOR.xml:S1:34864:8	O
receiving	AFINITOR.xml:S1:34873:9	O
AFINITOR	AFINITOR.xml:S1:34883:8	O
and	AFINITOR.xml:S1:34892:3	O
occurring	AFINITOR.xml:S1:34896:9	O
more	AFINITOR.xml:S1:34906:4	O
frequently	AFINITOR.xml:S1:34911:10	O
with	AFINITOR.xml:S1:34922:4	O
AFINITOR	AFINITOR.xml:S1:34927:8	O
than	AFINITOR.xml:S1:34936:4	O
with	AFINITOR.xml:S1:34941:4	O
placebo	AFINITOR.xml:S1:34946:7	O
.	AFINITOR.xml:S1:34953:1	O

Laboratory	AFINITOR.xml:S1:34955:10	O
abnormalities	AFINITOR.xml:S1:34966:13	O
are	AFINITOR.xml:S1:34980:3	O
described	AFINITOR.xml:S1:34984:9	O
separately	AFINITOR.xml:S1:34994:10	O
in	AFINITOR.xml:S1:35005:2	O
Table	AFINITOR.xml:S1:35008:5	O
9	AFINITOR.xml:S1:35014:1	O
.	AFINITOR.xml:S1:35015:1	O

Table	AFINITOR.xml:S1:35021:5	O
8	AFINITOR.xml:S1:35027:1	O
:	AFINITOR.xml:S1:35028:1	O
Adverse	AFINITOR.xml:S1:35030:7	O
Reactions	AFINITOR.xml:S1:35038:9	O
Reported	AFINITOR.xml:S1:35048:8	O
in	AFINITOR.xml:S1:35057:2	O
10%	AFINITOR.xml:S1:35063:3	O
of	AFINITOR.xml:S1:35067:2	O
AFINITOR	AFINITOR.xml:S1:35070:8	O
-	AFINITOR.xml:S1:35078:1	O
treated	AFINITOR.xml:S1:35079:7	O
Patients	AFINITOR.xml:S1:35087:8	O
with	AFINITOR.xml:S1:35096:4	O
Renal	AFINITOR.xml:S1:35101:5	O
Angiomyolipoma	AFINITOR.xml:S1:35107:14	O

Grading	AFINITOR.xml:S1:35124:7	O
according	AFINITOR.xml:S1:35132:9	O
to	AFINITOR.xml:S1:35142:2	O
CTCAE	AFINITOR.xml:S1:35145:5	O
Version	AFINITOR.xml:S1:35151:7	O
3.0	AFINITOR.xml:S1:35159:3	O
a	AFINITOR.xml:S1:35164:1	O
Includes	AFINITOR.xml:S1:35167:8	O
stomatitis	AFINITOR.xml:S1:35176:10	B-AdverseReaction
,	AFINITOR.xml:S1:35186:1	O
aphthous	AFINITOR.xml:S1:35188:8	B-AdverseReaction
stomatitis	AFINITOR.xml:S1:35197:10	I-AdverseReaction
,	AFINITOR.xml:S1:35207:1	O
mouth	AFINITOR.xml:S1:35209:5	B-AdverseReaction
ulceration	AFINITOR.xml:S1:35215:10	I-AdverseReaction
,	AFINITOR.xml:S1:35225:1	O
gingival	AFINITOR.xml:S1:35227:8	B-AdverseReaction
pain	AFINITOR.xml:S1:35236:4	I-AdverseReaction
,	AFINITOR.xml:S1:35240:1	O
glossitis	AFINITOR.xml:S1:35242:9	B-AdverseReaction
,	AFINITOR.xml:S1:35251:1	O
and	AFINITOR.xml:S1:35253:3	O
glossodynia	AFINITOR.xml:S1:35257:11	B-AdverseReaction
.	AFINITOR.xml:S1:35268:1	O

AFINITOR	AFINITOR.xml:S1:35296:8	O

N	AFINITOR.xml:S1:35313:1	O
79	AFINITOR.xml:S1:35315:2	O
Placebo	AFINITOR.xml:S1:35323:7	O
N	AFINITOR.xml:S1:35339:1	O
39	AFINITOR.xml:S1:35341:2	O

All	AFINITOR.xml:S1:35369:3	O
grades	AFINITOR.xml:S1:35373:6	O
Grade	AFINITOR.xml:S1:35390:5	O
3	AFINITOR.xml:S1:35396:1	O
Grade	AFINITOR.xml:S1:35408:5	O
4	AFINITOR.xml:S1:35414:1	O
All	AFINITOR.xml:S1:35426:3	O
grades	AFINITOR.xml:S1:35430:6	O
Grade	AFINITOR.xml:S1:35447:5	O
3	AFINITOR.xml:S1:35453:1	O
Grade	AFINITOR.xml:S1:35465:5	O
4	AFINITOR.xml:S1:35471:1	O

Any	AFINITOR.xml:S1:35486:3	O
adverse	AFINITOR.xml:S1:35490:7	O
reaction	AFINITOR.xml:S1:35498:8	O
100	AFINITOR.xml:S1:35512:3	O
25	AFINITOR.xml:S1:35529:2	O
5	AFINITOR.xml:S1:35546:1	O
97	AFINITOR.xml:S1:35563:2	O
8	AFINITOR.xml:S1:35580:1	O
5	AFINITOR.xml:S1:35597:1	O

Gastrointestinal	AFINITOR.xml:S1:35617:16	O
disorders	AFINITOR.xml:S1:35634:9	O

Stomatitis	AFINITOR.xml:S1:35758:10	B-AdverseReaction
a	AFINITOR.xml:S1:35770:1	O
78	AFINITOR.xml:S1:35775:2	O
6	AFINITOR.xml:S1:35792:1	O
0	AFINITOR.xml:S1:35809:1	O
23	AFINITOR.xml:S1:35826:2	O
0	AFINITOR.xml:S1:35843:1	O
0	AFINITOR.xml:S1:35860:1	O

Vomiting	AFINITOR.xml:S1:35886:8	B-AdverseReaction
15	AFINITOR.xml:S1:35897:2	O
0	AFINITOR.xml:S1:35914:1	O
0	AFINITOR.xml:S1:35931:1	O
5	AFINITOR.xml:S1:35948:1	O
0	AFINITOR.xml:S1:35965:1	O
0	AFINITOR.xml:S1:35982:1	O

Diarrhea	AFINITOR.xml:S1:36008:8	B-AdverseReaction
14	AFINITOR.xml:S1:36019:2	O
0	AFINITOR.xml:S1:36036:1	O
0	AFINITOR.xml:S1:36053:1	O
5	AFINITOR.xml:S1:36070:1	O
0	AFINITOR.xml:S1:36087:1	O
0	AFINITOR.xml:S1:36104:1	O

General	AFINITOR.xml:S1:36126:7	O
disorders	AFINITOR.xml:S1:36134:9	O
and	AFINITOR.xml:S1:36144:3	O
administration	AFINITOR.xml:S1:36148:14	O
site	AFINITOR.xml:S1:36163:4	O
conditions	AFINITOR.xml:S1:36168:10	O

Peripheral	AFINITOR.xml:S1:36293:10	B-AdverseReaction
edema	AFINITOR.xml:S1:36304:5	I-AdverseReaction
13	AFINITOR.xml:S1:36311:2	O
0	AFINITOR.xml:S1:36328:1	O
0	AFINITOR.xml:S1:36345:1	O
8	AFINITOR.xml:S1:36362:1	O
0	AFINITOR.xml:S1:36379:1	O
0	AFINITOR.xml:S1:36396:1	O

Infections	AFINITOR.xml:S1:36418:10	O
and	AFINITOR.xml:S1:36429:3	O
infestations	AFINITOR.xml:S1:36433:12	O

Upper	AFINITOR.xml:S1:36560:5	B-AdverseReaction
respiratory	AFINITOR.xml:S1:36566:11	I-AdverseReaction
tract	AFINITOR.xml:S1:36578:5	I-AdverseReaction
infection	AFINITOR.xml:S1:36584:9	I-AdverseReaction
11	AFINITOR.xml:S1:36595:2	O
0	AFINITOR.xml:S1:36612:1	O
0	AFINITOR.xml:S1:36629:1	O
5	AFINITOR.xml:S1:36646:1	O
0	AFINITOR.xml:S1:36663:1	O
0	AFINITOR.xml:S1:36680:1	O

Musculoskeletal	AFINITOR.xml:S1:36702:15	O
and	AFINITOR.xml:S1:36718:3	O
connective	AFINITOR.xml:S1:36722:10	O
tissue	AFINITOR.xml:S1:36733:6	O
disorders	AFINITOR.xml:S1:36740:9	O

Arthralgia	AFINITOR.xml:S1:36864:10	B-AdverseReaction
13	AFINITOR.xml:S1:36876:2	O
0	AFINITOR.xml:S1:36893:1	O
0	AFINITOR.xml:S1:36910:1	O
5	AFINITOR.xml:S1:36927:1	O
0	AFINITOR.xml:S1:36944:1	O
0	AFINITOR.xml:S1:36961:1	O

Respiratory	AFINITOR.xml:S1:36983:11	O
,	AFINITOR.xml:S1:36994:1	O
thoracic	AFINITOR.xml:S1:36996:8	O
and	AFINITOR.xml:S1:37005:3	O
mediastinal	AFINITOR.xml:S1:37009:11	O
disorders	AFINITOR.xml:S1:37021:9	O

Cough	AFINITOR.xml:S1:37145:5	B-AdverseReaction
20	AFINITOR.xml:S1:37156:2	O
0	AFINITOR.xml:S1:37173:1	O
0	AFINITOR.xml:S1:37190:1	O
13	AFINITOR.xml:S1:37207:2	O
0	AFINITOR.xml:S1:37224:1	O
0	AFINITOR.xml:S1:37241:1	O

Skin	AFINITOR.xml:S1:37263:4	O
and	AFINITOR.xml:S1:37268:3	O
subcutaneous	AFINITOR.xml:S1:37272:12	O
tissue	AFINITOR.xml:S1:37285:6	O
disorders	AFINITOR.xml:S1:37292:9	O

Acne	AFINITOR.xml:S1:37416:4	B-AdverseReaction
22	AFINITOR.xml:S1:37427:2	O
0	AFINITOR.xml:S1:37444:1	O
0	AFINITOR.xml:S1:37461:1	O
5	AFINITOR.xml:S1:37478:1	O
0	AFINITOR.xml:S1:37495:1	O
0	AFINITOR.xml:S1:37512:1	O

Amenorrhea	AFINITOR.xml:S1:37544:10	B-AdverseReaction
occurred	AFINITOR.xml:S1:37555:8	O
in	AFINITOR.xml:S1:37564:2	O
15%	AFINITOR.xml:S1:37567:3	O
of	AFINITOR.xml:S1:37571:2	O
AFINITOR	AFINITOR.xml:S1:37574:8	O
-	AFINITOR.xml:S1:37582:1	O
treated	AFINITOR.xml:S1:37583:7	O
females	AFINITOR.xml:S1:37591:7	O
(	AFINITOR.xml:S1:37599:1	O
8	AFINITOR.xml:S1:37600:1	O
of	AFINITOR.xml:S1:37602:2	O
52	AFINITOR.xml:S1:37605:2	O
)	AFINITOR.xml:S1:37607:1	O
and	AFINITOR.xml:S1:37609:3	O
4%	AFINITOR.xml:S1:37613:2	O
(	AFINITOR.xml:S1:37616:1	O
1	AFINITOR.xml:S1:37617:1	O
of	AFINITOR.xml:S1:37619:2	O
26	AFINITOR.xml:S1:37622:2	O
)	AFINITOR.xml:S1:37624:1	O
of	AFINITOR.xml:S1:37626:2	O
females	AFINITOR.xml:S1:37629:7	O
in	AFINITOR.xml:S1:37637:2	O
the	AFINITOR.xml:S1:37640:3	O
placebo	AFINITOR.xml:S1:37644:7	O
group	AFINITOR.xml:S1:37652:5	O
.	AFINITOR.xml:S1:37657:1	O

Other	AFINITOR.xml:S1:37659:5	O
adverse	AFINITOR.xml:S1:37665:7	O
reactions	AFINITOR.xml:S1:37673:9	O
involving	AFINITOR.xml:S1:37683:9	O
the	AFINITOR.xml:S1:37693:3	O
female	AFINITOR.xml:S1:37697:6	O
reproductive	AFINITOR.xml:S1:37704:12	O
system	AFINITOR.xml:S1:37717:6	O
were	AFINITOR.xml:S1:37724:4	O
menorrhagia	AFINITOR.xml:S1:37729:11	B-AdverseReaction
(	AFINITOR.xml:S1:37741:1	O
10%	AFINITOR.xml:S1:37742:3	O
)	AFINITOR.xml:S1:37745:1	O
,	AFINITOR.xml:S1:37746:1	O
menstrual	AFINITOR.xml:S1:37748:9	B-AdverseReaction
irregularities	AFINITOR.xml:S1:37758:14	I-AdverseReaction
(	AFINITOR.xml:S1:37773:1	O
10%	AFINITOR.xml:S1:37774:3	O
)	AFINITOR.xml:S1:37777:1	O
,	AFINITOR.xml:S1:37778:1	O
and	AFINITOR.xml:S1:37780:3	O
vaginal	AFINITOR.xml:S1:37784:7	B-AdverseReaction
hemorrhage	AFINITOR.xml:S1:37792:10	I-AdverseReaction
(	AFINITOR.xml:S1:37803:1	O
8%	AFINITOR.xml:S1:37804:2	O
)	AFINITOR.xml:S1:37806:1	O
.	AFINITOR.xml:S1:37807:1	O

The	AFINITOR.xml:S1:37813:3	O

following	AFINITOR.xml:S1:37817:9	O
additional	AFINITOR.xml:S1:37827:10	O
adverse	AFINITOR.xml:S1:37838:7	O
reactions	AFINITOR.xml:S1:37846:9	O
occurred	AFINITOR.xml:S1:37856:8	O
in	AFINITOR.xml:S1:37865:2	O
less	AFINITOR.xml:S1:37868:4	O
than	AFINITOR.xml:S1:37873:4	O
10%	AFINITOR.xml:S1:37878:3	O
of	AFINITOR.xml:S1:37882:2	O
AFINITOR	AFINITOR.xml:S1:37885:8	O
-	AFINITOR.xml:S1:37894:1	O
treated	AFINITOR.xml:S1:37895:7	O
patients	AFINITOR.xml:S1:37903:8	O
:	AFINITOR.xml:S1:37911:1	O
epistaxis	AFINITOR.xml:S1:37913:9	B-AdverseReaction
(	AFINITOR.xml:S1:37923:1	O
9%	AFINITOR.xml:S1:37924:2	O
)	AFINITOR.xml:S1:37926:1	O
,	AFINITOR.xml:S1:37927:1	O
decreased	AFINITOR.xml:S1:37929:9	B-AdverseReaction
appetite	AFINITOR.xml:S1:37939:8	I-AdverseReaction
(	AFINITOR.xml:S1:37948:1	O
6%	AFINITOR.xml:S1:37949:2	O
)	AFINITOR.xml:S1:37951:1	O
,	AFINITOR.xml:S1:37952:1	O
otitis	AFINITOR.xml:S1:37954:6	B-AdverseReaction
media	AFINITOR.xml:S1:37961:5	I-AdverseReaction
(	AFINITOR.xml:S1:37967:1	O
6%	AFINITOR.xml:S1:37968:2	O
)	AFINITOR.xml:S1:37970:1	O
,	AFINITOR.xml:S1:37971:1	O
depression	AFINITOR.xml:S1:37973:10	B-AdverseReaction
(	AFINITOR.xml:S1:37984:1	O
5%	AFINITOR.xml:S1:37985:2	O
)	AFINITOR.xml:S1:37987:1	O
,	AFINITOR.xml:S1:37988:1	O
abnormal	AFINITOR.xml:S1:37990:8	B-AdverseReaction
taste	AFINITOR.xml:S1:37999:5	I-AdverseReaction
(	AFINITOR.xml:S1:38005:1	O
5%	AFINITOR.xml:S1:38006:2	O
)	AFINITOR.xml:S1:38008:1	O
,	AFINITOR.xml:S1:38009:1	O
increased	AFINITOR.xml:S1:38011:9	B-AdverseReaction
blood	AFINITOR.xml:S1:38021:5	I-AdverseReaction
luteinizing	AFINITOR.xml:S1:38027:11	I-AdverseReaction
hormone	AFINITOR.xml:S1:38039:7	I-AdverseReaction
(	AFINITOR.xml:S1:38047:1	O
LH	AFINITOR.xml:S1:38048:2	I-AdverseReaction
)	AFINITOR.xml:S1:38050:1	O
levels	AFINITOR.xml:S1:38052:6	I-AdverseReaction
(	AFINITOR.xml:S1:38059:1	O
4%	AFINITOR.xml:S1:38060:2	O
)	AFINITOR.xml:S1:38062:1	O
,	AFINITOR.xml:S1:38063:1	O
increased	AFINITOR.xml:S1:38065:9	B-AdverseReaction
blood	AFINITOR.xml:S1:38075:5	I-AdverseReaction
follicle	AFINITOR.xml:S1:38081:8	I-AdverseReaction
stimulating	AFINITOR.xml:S1:38090:11	I-AdverseReaction
hormone	AFINITOR.xml:S1:38102:7	I-AdverseReaction
(	AFINITOR.xml:S1:38110:1	O
FSH	AFINITOR.xml:S1:38111:3	I-AdverseReaction
)	AFINITOR.xml:S1:38114:1	O
levels	AFINITOR.xml:S1:38116:6	I-AdverseReaction
(	AFINITOR.xml:S1:38123:1	O
3%	AFINITOR.xml:S1:38124:2	O
)	AFINITOR.xml:S1:38126:1	O
,	AFINITOR.xml:S1:38127:1	O
hypersensitivity	AFINITOR.xml:S1:38129:16	B-AdverseReaction
(	AFINITOR.xml:S1:38146:1	O
3%	AFINITOR.xml:S1:38147:2	O
)	AFINITOR.xml:S1:38149:1	O
,	AFINITOR.xml:S1:38150:1	O
ovarian	AFINITOR.xml:S1:38152:7	B-AdverseReaction
cyst	AFINITOR.xml:S1:38160:4	I-AdverseReaction
(	AFINITOR.xml:S1:38165:1	O
3%	AFINITOR.xml:S1:38166:2	O
)	AFINITOR.xml:S1:38168:1	O
,	AFINITOR.xml:S1:38169:1	O
pneumonitis	AFINITOR.xml:S1:38171:11	B-AdverseReaction
(	AFINITOR.xml:S1:38183:1	O
1%	AFINITOR.xml:S1:38184:2	O
)	AFINITOR.xml:S1:38186:1	O
,	AFINITOR.xml:S1:38187:1	O
and	AFINITOR.xml:S1:38189:3	O
angioedema	AFINITOR.xml:S1:38193:10	B-AdverseReaction
(	AFINITOR.xml:S1:38204:1	O
1%	AFINITOR.xml:S1:38205:2	O
)	AFINITOR.xml:S1:38207:1	O
.	AFINITOR.xml:S1:38208:1	O

Table	AFINITOR.xml:S1:38214:5	O
9	AFINITOR.xml:S1:38220:1	O
:	AFINITOR.xml:S1:38221:1	O
Key	AFINITOR.xml:S1:38223:3	O
Laboratory	AFINITOR.xml:S1:38227:10	O
Abnormalities	AFINITOR.xml:S1:38238:13	O
Reported	AFINITOR.xml:S1:38252:8	O
in	AFINITOR.xml:S1:38261:2	O
AFINITOR	AFINITOR.xml:S1:38264:8	O
-	AFINITOR.xml:S1:38272:1	O
treated	AFINITOR.xml:S1:38273:7	O
Patients	AFINITOR.xml:S1:38281:8	O
with	AFINITOR.xml:S1:38290:4	O
Renal	AFINITOR.xml:S1:38295:5	O
Angiomyolipoma	AFINITOR.xml:S1:38301:14	O

Grading	AFINITOR.xml:S1:38318:7	O
according	AFINITOR.xml:S1:38326:9	O
to	AFINITOR.xml:S1:38336:2	O
CTCAE	AFINITOR.xml:S1:38339:5	O
Version	AFINITOR.xml:S1:38345:7	O
3.0	AFINITOR.xml:S1:38353:3	O

AFINITOR	AFINITOR.xml:S1:38383:8	O

N	AFINITOR.xml:S1:38400:1	O
79	AFINITOR.xml:S1:38402:2	O
Placebo	AFINITOR.xml:S1:38410:7	O
N	AFINITOR.xml:S1:38426:1	O
39	AFINITOR.xml:S1:38428:2	O

All	AFINITOR.xml:S1:38456:3	O
grades	AFINITOR.xml:S1:38460:6	O
Grade	AFINITOR.xml:S1:38477:5	O
3	AFINITOR.xml:S1:38483:1	O
Grade	AFINITOR.xml:S1:38495:5	O
4	AFINITOR.xml:S1:38501:1	O
All	AFINITOR.xml:S1:38513:3	O
grades	AFINITOR.xml:S1:38517:6	O
Grade	AFINITOR.xml:S1:38534:5	O
3	AFINITOR.xml:S1:38540:1	O
Grade	AFINITOR.xml:S1:38552:5	O
4	AFINITOR.xml:S1:38558:1	O

Hematology	AFINITOR.xml:S1:38573:10	O

Anemia	AFINITOR.xml:S1:38699:6	O
61	AFINITOR.xml:S1:38710:2	O
0	AFINITOR.xml:S1:38727:1	O
0	AFINITOR.xml:S1:38744:1	O
49	AFINITOR.xml:S1:38761:2	O
0	AFINITOR.xml:S1:38778:1	O
0	AFINITOR.xml:S1:38795:1	O

Leucopenia	AFINITOR.xml:S1:38821:10	B-AdverseReaction
37	AFINITOR.xml:S1:38833:2	O
0	AFINITOR.xml:S1:38850:1	O
0	AFINITOR.xml:S1:38867:1	O
21	AFINITOR.xml:S1:38884:2	O
0	AFINITOR.xml:S1:38901:1	O
0	AFINITOR.xml:S1:38918:1	O

Neutropenia	AFINITOR.xml:S1:38944:11	B-AdverseReaction
25	AFINITOR.xml:S1:38957:2	O
0	AFINITOR.xml:S1:38974:1	O
1	AFINITOR.xml:S1:38991:1	O
26	AFINITOR.xml:S1:39008:2	O
0	AFINITOR.xml:S1:39025:1	O
0	AFINITOR.xml:S1:39042:1	O

Lymphopenia	AFINITOR.xml:S1:39068:11	B-AdverseReaction
20	AFINITOR.xml:S1:39081:2	O
1	AFINITOR.xml:S1:39098:1	O
0	AFINITOR.xml:S1:39115:1	O
8	AFINITOR.xml:S1:39132:1	O
0	AFINITOR.xml:S1:39149:1	O
0	AFINITOR.xml:S1:39166:1	O

Thrombocytopenia	AFINITOR.xml:S1:39192:16	B-AdverseReaction
19	AFINITOR.xml:S1:39210:2	O
0	AFINITOR.xml:S1:39227:1	O
0	AFINITOR.xml:S1:39244:1	O
3	AFINITOR.xml:S1:39261:1	O
0	AFINITOR.xml:S1:39278:1	O
0	AFINITOR.xml:S1:39295:1	O

Clinical	AFINITOR.xml:S1:39439:8	O

chemistry	AFINITOR.xml:S1:39448:9	O

Hypercholesterolemia	AFINITOR.xml:S1:39572:20	B-AdverseReaction
85	AFINITOR.xml:S1:39594:2	O
1	AFINITOR.xml:S1:39611:1	O
0	AFINITOR.xml:S1:39628:1	O
46	AFINITOR.xml:S1:39645:2	O
0	AFINITOR.xml:S1:39662:1	O
0	AFINITOR.xml:S1:39679:1	O

Hypertriglyceridemia	AFINITOR.xml:S1:39705:20	B-AdverseReaction
52	AFINITOR.xml:S1:39727:2	O
0	AFINITOR.xml:S1:39744:1	O
0	AFINITOR.xml:S1:39761:1	O
10	AFINITOR.xml:S1:39778:2	O
0	AFINITOR.xml:S1:39795:1	O
0	AFINITOR.xml:S1:39812:1	O

Hypophosphatemia	AFINITOR.xml:S1:39838:16	B-AdverseReaction
49	AFINITOR.xml:S1:39856:2	O
5	AFINITOR.xml:S1:39873:1	O
0	AFINITOR.xml:S1:39890:1	O
15	AFINITOR.xml:S1:39907:2	O
0	AFINITOR.xml:S1:39924:1	O
0	AFINITOR.xml:S1:39941:1	O

Alkaline	AFINITOR.xml:S1:39967:8	B-AdverseReaction
phosphatase	AFINITOR.xml:S1:39976:11	I-AdverseReaction
increased	AFINITOR.xml:S1:39988:9	I-AdverseReaction
32	AFINITOR.xml:S1:39999:2	O
1	AFINITOR.xml:S1:40016:1	O
0	AFINITOR.xml:S1:40033:1	O
10	AFINITOR.xml:S1:40050:2	O
0	AFINITOR.xml:S1:40067:1	O
0	AFINITOR.xml:S1:40084:1	O

Elevated	AFINITOR.xml:S1:40110:8	B-AdverseReaction
aspartate	AFINITOR.xml:S1:40119:9	I-AdverseReaction
transaminase	AFINITOR.xml:S1:40129:12	I-AdverseReaction
(	AFINITOR.xml:S1:40142:1	O
AST	AFINITOR.xml:S1:40143:3	I-AdverseReaction
)	AFINITOR.xml:S1:40146:1	O
23	AFINITOR.xml:S1:40149:2	O
1	AFINITOR.xml:S1:40166:1	O
0	AFINITOR.xml:S1:40183:1	O
8	AFINITOR.xml:S1:40200:1	O
0	AFINITOR.xml:S1:40217:1	O
0	AFINITOR.xml:S1:40234:1	O

Elevated	AFINITOR.xml:S1:40260:8	B-AdverseReaction
alanine	AFINITOR.xml:S1:40269:7	I-AdverseReaction
transaminase	AFINITOR.xml:S1:40277:12	I-AdverseReaction
(	AFINITOR.xml:S1:40290:1	O
ALT	AFINITOR.xml:S1:40291:3	I-AdverseReaction
)	AFINITOR.xml:S1:40294:1	O
20	AFINITOR.xml:S1:40297:2	O
1	AFINITOR.xml:S1:40314:1	O
0	AFINITOR.xml:S1:40331:1	O
15	AFINITOR.xml:S1:40348:2	O
0	AFINITOR.xml:S1:40365:1	O
0	AFINITOR.xml:S1:40382:1	O

Fasting	AFINITOR.xml:S1:40408:7	B-AdverseReaction
hyperglycemia	AFINITOR.xml:S1:40416:13	I-AdverseReaction
14	AFINITOR.xml:S1:40431:2	O
0	AFINITOR.xml:S1:40448:1	O
0	AFINITOR.xml:S1:40465:1	O
8	AFINITOR.xml:S1:40482:1	O
0	AFINITOR.xml:S1:40499:1	O
0	AFINITOR.xml:S1:40516:1	O

6.5	AFINITOR.xml:S1:40550:3	O
Clinical	AFINITOR.xml:S1:40558:8	O
Study	AFINITOR.xml:S1:40567:5	O
Experience	AFINITOR.xml:S1:40573:10	O
in	AFINITOR.xml:S1:40584:2	O
Subependymal	AFINITOR.xml:S1:40587:12	O
Giant	AFINITOR.xml:S1:40600:5	O
Cell	AFINITOR.xml:S1:40606:4	O
Astrocytoma	AFINITOR.xml:S1:40611:11	O
with	AFINITOR.xml:S1:40623:4	O
Tuberous	AFINITOR.xml:S1:40628:8	O
Sclerosis	AFINITOR.xml:S1:40637:9	O
Complex	AFINITOR.xml:S1:40647:7	O

The	AFINITOR.xml:S1:40658:3	O
data	AFINITOR.xml:S1:40662:4	O
described	AFINITOR.xml:S1:40667:9	O
below	AFINITOR.xml:S1:40677:5	O
are	AFINITOR.xml:S1:40683:3	O
based	AFINITOR.xml:S1:40687:5	O
on	AFINITOR.xml:S1:40693:2	O
a	AFINITOR.xml:S1:40696:1	O
randomized	AFINITOR.xml:S1:40698:10	O
(	AFINITOR.xml:S1:40709:1	O
2	AFINITOR.xml:S1:40710:1	O
:	AFINITOR.xml:S1:40711:1	O
1	AFINITOR.xml:S1:40712:1	O
)	AFINITOR.xml:S1:40713:1	O
,	AFINITOR.xml:S1:40714:1	O
double	AFINITOR.xml:S1:40716:6	O
-	AFINITOR.xml:S1:40722:1	O
blind	AFINITOR.xml:S1:40723:5	O
,	AFINITOR.xml:S1:40728:1	O
placebo	AFINITOR.xml:S1:40730:7	O
-	AFINITOR.xml:S1:40737:1	O
controlled	AFINITOR.xml:S1:40738:10	O
trial	AFINITOR.xml:S1:40749:5	O
(	AFINITOR.xml:S1:40755:1	O
Study	AFINITOR.xml:S1:40756:5	O
1	AFINITOR.xml:S1:40762:1	O
)	AFINITOR.xml:S1:40763:1	O
of	AFINITOR.xml:S1:40765:2	O
AFINITOR	AFINITOR.xml:S1:40768:8	O
in	AFINITOR.xml:S1:40777:2	O
117	AFINITOR.xml:S1:40780:3	O
patients	AFINITOR.xml:S1:40784:8	O
with	AFINITOR.xml:S1:40793:4	O
subependymal	AFINITOR.xml:S1:40798:12	O
giant	AFINITOR.xml:S1:40811:5	O
cell	AFINITOR.xml:S1:40817:4	O
astrocytoma	AFINITOR.xml:S1:40822:11	O
(	AFINITOR.xml:S1:40834:1	O
SEGA	AFINITOR.xml:S1:40835:4	O
)	AFINITOR.xml:S1:40839:1	O
and	AFINITOR.xml:S1:40841:3	O
tuberous	AFINITOR.xml:S1:40845:8	O
sclerosis	AFINITOR.xml:S1:40854:9	O
complex	AFINITOR.xml:S1:40864:7	O
(	AFINITOR.xml:S1:40872:1	O
TSC	AFINITOR.xml:S1:40873:3	O
)	AFINITOR.xml:S1:40876:1	O
.	AFINITOR.xml:S1:40877:1	O

The	AFINITOR.xml:S1:40879:3	O
median	AFINITOR.xml:S1:40883:6	O
age	AFINITOR.xml:S1:40890:3	O
of	AFINITOR.xml:S1:40894:2	O
patients	AFINITOR.xml:S1:40897:8	O
was	AFINITOR.xml:S1:40906:3	O
9.5	AFINITOR.xml:S1:40910:3	O
years	AFINITOR.xml:S1:40914:5	O
(	AFINITOR.xml:S1:40920:1	O
range	AFINITOR.xml:S1:40921:5	O
0.8	AFINITOR.xml:S1:40927:3	O
to	AFINITOR.xml:S1:40931:2	O
26	AFINITOR.xml:S1:40934:2	O
years	AFINITOR.xml:S1:40937:5	O
)	AFINITOR.xml:S1:40942:1	O
,	AFINITOR.xml:S1:40943:1	O
93%	AFINITOR.xml:S1:40945:3	O
were	AFINITOR.xml:S1:40949:4	O
Caucasian	AFINITOR.xml:S1:40954:9	O
,	AFINITOR.xml:S1:40963:1	O
and	AFINITOR.xml:S1:40965:3	O
57%	AFINITOR.xml:S1:40969:3	O
were	AFINITOR.xml:S1:40973:4	O
male	AFINITOR.xml:S1:40978:4	O
.	AFINITOR.xml:S1:40982:1	O

The	AFINITOR.xml:S1:40984:3	O
median	AFINITOR.xml:S1:40988:6	O
duration	AFINITOR.xml:S1:40995:8	O
of	AFINITOR.xml:S1:41004:2	O
blinded	AFINITOR.xml:S1:41007:7	O
study	AFINITOR.xml:S1:41015:5	O
treatment	AFINITOR.xml:S1:41021:9	O
was	AFINITOR.xml:S1:41031:3	O
52	AFINITOR.xml:S1:41035:2	O
weeks	AFINITOR.xml:S1:41038:5	O
(	AFINITOR.xml:S1:41044:1	O
range	AFINITOR.xml:S1:41045:5	O
24	AFINITOR.xml:S1:41051:2	O
to	AFINITOR.xml:S1:41054:2	O
89	AFINITOR.xml:S1:41057:2	O
weeks	AFINITOR.xml:S1:41060:5	O
)	AFINITOR.xml:S1:41065:1	O
for	AFINITOR.xml:S1:41067:3	O
patients	AFINITOR.xml:S1:41071:8	O
receiving	AFINITOR.xml:S1:41080:9	O
AFINITOR	AFINITOR.xml:S1:41090:8	O
and	AFINITOR.xml:S1:41099:3	O
47	AFINITOR.xml:S1:41103:2	O
weeks	AFINITOR.xml:S1:41106:5	O
(	AFINITOR.xml:S1:41112:1	O
range	AFINITOR.xml:S1:41113:5	O
14	AFINITOR.xml:S1:41119:2	O
to	AFINITOR.xml:S1:41122:2	O
88	AFINITOR.xml:S1:41125:2	O
weeks	AFINITOR.xml:S1:41128:5	O
)	AFINITOR.xml:S1:41133:1	O
for	AFINITOR.xml:S1:41135:3	O
those	AFINITOR.xml:S1:41139:5	O
receiving	AFINITOR.xml:S1:41145:9	O
placebo	AFINITOR.xml:S1:41155:7	O
.	AFINITOR.xml:S1:41162:1	O

The	AFINITOR.xml:S1:41168:3	O
most	AFINITOR.xml:S1:41172:4	O
common	AFINITOR.xml:S1:41177:6	O
adverse	AFINITOR.xml:S1:41184:7	O
reactions	AFINITOR.xml:S1:41192:9	O
reported	AFINITOR.xml:S1:41202:8	O
for	AFINITOR.xml:S1:41211:3	O
AFINITOR	AFINITOR.xml:S1:41215:8	O
(	AFINITOR.xml:S1:41224:1	O
incidence	AFINITOR.xml:S1:41225:9	O
30%	AFINITOR.xml:S1:41238:3	O
)	AFINITOR.xml:S1:41241:1	O
were	AFINITOR.xml:S1:41243:4	O
stomatitis	AFINITOR.xml:S1:41248:10	B-AdverseReaction
and	AFINITOR.xml:S1:41259:3	O
respiratory	AFINITOR.xml:S1:41263:11	B-AdverseReaction
tract	AFINITOR.xml:S1:41275:5	I-AdverseReaction
infection	AFINITOR.xml:S1:41281:9	I-AdverseReaction
.	AFINITOR.xml:S1:41290:1	O

The	AFINITOR.xml:S1:41292:3	O
most	AFINITOR.xml:S1:41296:4	O
common	AFINITOR.xml:S1:41301:6	O
Grade	AFINITOR.xml:S1:41308:5	B-Severity
3	AFINITOR.xml:S1:41314:1	I-Severity
-	AFINITOR.xml:S1:41315:1	I-Severity
4	AFINITOR.xml:S1:41316:1	I-Severity
adverse	AFINITOR.xml:S1:41318:7	O
reactions	AFINITOR.xml:S1:41326:9	O
(	AFINITOR.xml:S1:41336:1	O
incidence	AFINITOR.xml:S1:41337:9	O
2%	AFINITOR.xml:S1:41350:2	O
)	AFINITOR.xml:S1:41352:1	O
were	AFINITOR.xml:S1:41354:4	O
stomatitis	AFINITOR.xml:S1:41359:10	B-AdverseReaction
,	AFINITOR.xml:S1:41369:1	O
pyrexia	AFINITOR.xml:S1:41371:7	B-AdverseReaction
,	AFINITOR.xml:S1:41378:1	O
pneumonia	AFINITOR.xml:S1:41380:9	B-AdverseReaction
,	AFINITOR.xml:S1:41389:1	O
gastroenteritis	AFINITOR.xml:S1:41391:15	B-AdverseReaction
,	AFINITOR.xml:S1:41406:1	O
aggression	AFINITOR.xml:S1:41408:10	B-AdverseReaction
,	AFINITOR.xml:S1:41418:1	O
agitation	AFINITOR.xml:S1:41420:9	B-AdverseReaction
,	AFINITOR.xml:S1:41429:1	O
and	AFINITOR.xml:S1:41431:3	O
amenorrhea	AFINITOR.xml:S1:41435:10	B-AdverseReaction
.	AFINITOR.xml:S1:41445:1	O

The	AFINITOR.xml:S1:41447:3	O
most	AFINITOR.xml:S1:41451:4	O
common	AFINITOR.xml:S1:41456:6	O
key	AFINITOR.xml:S1:41463:3	O
laboratory	AFINITOR.xml:S1:41467:10	O
abnormalities	AFINITOR.xml:S1:41478:13	O
(	AFINITOR.xml:S1:41492:1	O
incidence	AFINITOR.xml:S1:41493:9	O
50%	AFINITOR.xml:S1:41506:3	O
)	AFINITOR.xml:S1:41509:1	O
were	AFINITOR.xml:S1:41511:4	O
hypercholesterolemia	AFINITOR.xml:S1:41516:20	B-AdverseReaction
and	AFINITOR.xml:S1:41537:3	O
elevated	AFINITOR.xml:S1:41541:8	B-AdverseReaction
partial	AFINITOR.xml:S1:41550:7	I-AdverseReaction
thromboplastin	AFINITOR.xml:S1:41558:14	I-AdverseReaction
time	AFINITOR.xml:S1:41573:4	I-AdverseReaction
.	AFINITOR.xml:S1:41577:1	O

The	AFINITOR.xml:S1:41579:3	O
most	AFINITOR.xml:S1:41583:4	O
common	AFINITOR.xml:S1:41588:6	O
Grade	AFINITOR.xml:S1:41595:5	B-Severity
3	AFINITOR.xml:S1:41601:1	I-Severity
-	AFINITOR.xml:S1:41602:1	I-Severity
4	AFINITOR.xml:S1:41603:1	I-Severity
laboratory	AFINITOR.xml:S1:41605:10	O
abnormality	AFINITOR.xml:S1:41616:11	O
(	AFINITOR.xml:S1:41628:1	O
incidence	AFINITOR.xml:S1:41629:9	O
3%	AFINITOR.xml:S1:41642:2	O
)	AFINITOR.xml:S1:41644:1	O
was	AFINITOR.xml:S1:41646:3	O
neutropenia	AFINITOR.xml:S1:41650:11	B-AdverseReaction
.	AFINITOR.xml:S1:41661:1	O

There	AFINITOR.xml:S1:41667:5	O
were	AFINITOR.xml:S1:41673:4	O
no	AFINITOR.xml:S1:41678:2	O
adverse	AFINITOR.xml:S1:41681:7	O
reactions	AFINITOR.xml:S1:41689:9	O
resulting	AFINITOR.xml:S1:41699:9	O
in	AFINITOR.xml:S1:41709:2	O
permanent	AFINITOR.xml:S1:41712:9	O
discontinuation	AFINITOR.xml:S1:41722:15	O
.	AFINITOR.xml:S1:41737:1	O

Dose	AFINITOR.xml:S1:41739:4	O
adjustments	AFINITOR.xml:S1:41744:11	O
(	AFINITOR.xml:S1:41756:1	O
interruptions	AFINITOR.xml:S1:41757:13	O
or	AFINITOR.xml:S1:41771:2	O
reductions	AFINITOR.xml:S1:41774:10	O
)	AFINITOR.xml:S1:41784:1	O
due	AFINITOR.xml:S1:41786:3	O
to	AFINITOR.xml:S1:41790:2	O
adverse	AFINITOR.xml:S1:41793:7	O
reactions	AFINITOR.xml:S1:41801:9	O
occurred	AFINITOR.xml:S1:41811:8	O
in	AFINITOR.xml:S1:41820:2	O
55%	AFINITOR.xml:S1:41823:3	O
of	AFINITOR.xml:S1:41827:2	O
AFINITOR	AFINITOR.xml:S1:41830:8	O
-	AFINITOR.xml:S1:41838:1	O
treated	AFINITOR.xml:S1:41839:7	O
patients	AFINITOR.xml:S1:41847:8	O
.	AFINITOR.xml:S1:41855:1	O

The	AFINITOR.xml:S1:41857:3	O
most	AFINITOR.xml:S1:41861:4	O
common	AFINITOR.xml:S1:41866:6	O
adverse	AFINITOR.xml:S1:41873:7	O
reaction	AFINITOR.xml:S1:41881:8	O
leading	AFINITOR.xml:S1:41890:7	O
to	AFINITOR.xml:S1:41898:2	O
AFINITOR	AFINITOR.xml:S1:41901:8	O
dose	AFINITOR.xml:S1:41910:4	O
adjustment	AFINITOR.xml:S1:41915:10	O
was	AFINITOR.xml:S1:41926:3	O
stomatitis	AFINITOR.xml:S1:41930:10	B-AdverseReaction
.	AFINITOR.xml:S1:41940:1	O

Table	AFINITOR.xml:S1:41946:5	O
10	AFINITOR.xml:S1:41952:2	O
compares	AFINITOR.xml:S1:41955:8	O
the	AFINITOR.xml:S1:41964:3	O
incidence	AFINITOR.xml:S1:41968:9	O
of	AFINITOR.xml:S1:41978:2	O
adverse	AFINITOR.xml:S1:41981:7	O
reactions	AFINITOR.xml:S1:41989:9	O
reported	AFINITOR.xml:S1:41999:8	O
with	AFINITOR.xml:S1:42008:4	O
an	AFINITOR.xml:S1:42013:2	O
incidence	AFINITOR.xml:S1:42016:9	O
of	AFINITOR.xml:S1:42026:2	O
10%	AFINITOR.xml:S1:42032:3	O
for	AFINITOR.xml:S1:42036:3	O
patients	AFINITOR.xml:S1:42040:8	O
receiving	AFINITOR.xml:S1:42049:9	O
AFINITOR	AFINITOR.xml:S1:42059:8	O
and	AFINITOR.xml:S1:42068:3	O
occurring	AFINITOR.xml:S1:42072:9	O
more	AFINITOR.xml:S1:42082:4	O
frequently	AFINITOR.xml:S1:42087:10	O
with	AFINITOR.xml:S1:42098:4	O
AFINITOR	AFINITOR.xml:S1:42103:8	O
than	AFINITOR.xml:S1:42112:4	O
with	AFINITOR.xml:S1:42117:4	O
placebo	AFINITOR.xml:S1:42122:7	O
.	AFINITOR.xml:S1:42129:1	O

Laboratory	AFINITOR.xml:S1:42131:10	O
abnormalities	AFINITOR.xml:S1:42142:13	O
are	AFINITOR.xml:S1:42156:3	O
described	AFINITOR.xml:S1:42160:9	O
separately	AFINITOR.xml:S1:42170:10	O
in	AFINITOR.xml:S1:42181:2	O
Table	AFINITOR.xml:S1:42184:5	O
11	AFINITOR.xml:S1:42190:2	O
.	AFINITOR.xml:S1:42192:1	O

Table	AFINITOR.xml:S1:42198:5	O
10	AFINITOR.xml:S1:42204:2	O
:	AFINITOR.xml:S1:42206:1	O
Adverse	AFINITOR.xml:S1:42208:7	O
Reactions	AFINITOR.xml:S1:42216:9	O
Reported	AFINITOR.xml:S1:42226:8	O
in	AFINITOR.xml:S1:42235:2	O
10%	AFINITOR.xml:S1:42240:3	O
of	AFINITOR.xml:S1:42244:2	O
AFINITOR	AFINITOR.xml:S1:42247:8	O
-	AFINITOR.xml:S1:42255:1	O
treated	AFINITOR.xml:S1:42256:7	O
Patients	AFINITOR.xml:S1:42264:8	O
with	AFINITOR.xml:S1:42273:4	O
SEGA	AFINITOR.xml:S1:42278:4	O
in	AFINITOR.xml:S1:42283:2	O
Study	AFINITOR.xml:S1:42286:5	O
1	AFINITOR.xml:S1:42292:1	O

Grading	AFINITOR.xml:S1:42296:7	O
according	AFINITOR.xml:S1:42304:9	O
to	AFINITOR.xml:S1:42314:2	O
CTCAE	AFINITOR.xml:S1:42317:5	O
Version	AFINITOR.xml:S1:42323:7	O
3.0	AFINITOR.xml:S1:42331:3	O
a	AFINITOR.xml:S1:42336:1	O
Includes	AFINITOR.xml:S1:42339:8	O
mouth	AFINITOR.xml:S1:42348:5	B-AdverseReaction
ulceration	AFINITOR.xml:S1:42354:10	I-AdverseReaction
,	AFINITOR.xml:S1:42364:1	O
stomatitis	AFINITOR.xml:S1:42366:10	B-AdverseReaction
,	AFINITOR.xml:S1:42376:1	O
and	AFINITOR.xml:S1:42378:3	O
lip	AFINITOR.xml:S1:42382:3	B-AdverseReaction
ulceration	AFINITOR.xml:S1:42386:10	I-AdverseReaction
b	AFINITOR.xml:S1:42398:1	O
Includes	AFINITOR.xml:S1:42401:8	O
respiratory	AFINITOR.xml:S1:42410:11	B-AdverseReaction
tract	AFINITOR.xml:S1:42422:5	I-AdverseReaction
infection	AFINITOR.xml:S1:42428:9	I-AdverseReaction
,	AFINITOR.xml:S1:42437:1	O
upper	AFINITOR.xml:S1:42439:5	B-AdverseReaction
respiratory	AFINITOR.xml:S1:42445:11	I-AdverseReaction
tract	AFINITOR.xml:S1:42457:5	I-AdverseReaction
infection	AFINITOR.xml:S1:42463:9	I-AdverseReaction
,	AFINITOR.xml:S1:42472:1	O
and	AFINITOR.xml:S1:42474:3	O
respiratory	AFINITOR.xml:S1:42478:11	B-AdverseReaction
tract	AFINITOR.xml:S1:42490:5	I-AdverseReaction
infection	AFINITOR.xml:S1:42496:9	I-AdverseReaction
viral	AFINITOR.xml:S1:42506:5	I-AdverseReaction
c	AFINITOR.xml:S1:42513:1	O
Includes	AFINITOR.xml:S1:42516:8	O
gastroenteritis	AFINITOR.xml:S1:42525:15	B-AdverseReaction
,	AFINITOR.xml:S1:42540:1	O
gastroenteritis	AFINITOR.xml:S1:42542:15	B-AdverseReaction
viral	AFINITOR.xml:S1:42558:5	I-AdverseReaction
,	AFINITOR.xml:S1:42563:1	O
and	AFINITOR.xml:S1:42565:3	O
gastrointestinal	AFINITOR.xml:S1:42569:16	B-AdverseReaction
infection	AFINITOR.xml:S1:42586:9	I-AdverseReaction
d	AFINITOR.xml:S1:42597:1	O
Includes	AFINITOR.xml:S1:42600:8	O
agitation	AFINITOR.xml:S1:42609:9	B-AdverseReaction
,	AFINITOR.xml:S1:42618:1	O
anxiety	AFINITOR.xml:S1:42620:7	B-AdverseReaction
,	AFINITOR.xml:S1:42627:1	O
panic	AFINITOR.xml:S1:42629:5	B-AdverseReaction
attack	AFINITOR.xml:S1:42635:6	I-AdverseReaction
,	AFINITOR.xml:S1:42641:1	O
aggression	AFINITOR.xml:S1:42643:10	B-AdverseReaction
,	AFINITOR.xml:S1:42653:1	O
abnormal	AFINITOR.xml:S1:42655:8	B-AdverseReaction
behavior	AFINITOR.xml:S1:42664:8	I-AdverseReaction
,	AFINITOR.xml:S1:42672:1	O
and	AFINITOR.xml:S1:42674:3	O
obsessive	AFINITOR.xml:S1:42678:9	B-AdverseReaction
compulsive	AFINITOR.xml:S1:42688:10	I-AdverseReaction
disorder	AFINITOR.xml:S1:42699:8	I-AdverseReaction
e	AFINITOR.xml:S1:42709:1	O
Includes	AFINITOR.xml:S1:42712:8	O
rash	AFINITOR.xml:S1:42721:4	B-AdverseReaction
,	AFINITOR.xml:S1:42725:1	O
rash	AFINITOR.xml:S1:42727:4	B-AdverseReaction
generalized	AFINITOR.xml:S1:42732:11	I-AdverseReaction
,	AFINITOR.xml:S1:42743:1	O
rash	AFINITOR.xml:S1:42745:4	B-AdverseReaction
macular	AFINITOR.xml:S1:42750:7	I-AdverseReaction
,	AFINITOR.xml:S1:42757:1	O
rash	AFINITOR.xml:S1:42759:4	B-AdverseReaction
maculo	AFINITOR.xml:S1:42764:6	I-AdverseReaction
-	AFINITOR.xml:S1:42770:1	I-AdverseReaction
papular	AFINITOR.xml:S1:42771:7	I-AdverseReaction
,	AFINITOR.xml:S1:42778:1	O
rash	AFINITOR.xml:S1:42780:4	B-AdverseReaction
papular	AFINITOR.xml:S1:42785:7	I-AdverseReaction
,	AFINITOR.xml:S1:42792:1	O
dermatitis	AFINITOR.xml:S1:42794:10	B-AdverseReaction
allergic	AFINITOR.xml:S1:42805:8	I-AdverseReaction
,	AFINITOR.xml:S1:42813:1	O
and	AFINITOR.xml:S1:42815:3	O
urticaria	AFINITOR.xml:S1:42819:9	B-AdverseReaction

AFINITOR	AFINITOR.xml:S1:42855:8	O

N	AFINITOR.xml:S1:42867:1	O
78	AFINITOR.xml:S1:42869:2	O
Placebo	AFINITOR.xml:S1:42877:7	O
N	AFINITOR.xml:S1:42888:1	O
39	AFINITOR.xml:S1:42890:2	O

All	AFINITOR.xml:S1:42918:3	O
grades	AFINITOR.xml:S1:42922:6	O
Grade	AFINITOR.xml:S1:42939:5	O
3	AFINITOR.xml:S1:42945:1	O
Grade	AFINITOR.xml:S1:42957:5	O
4	AFINITOR.xml:S1:42963:1	O
All	AFINITOR.xml:S1:42975:3	O
grades	AFINITOR.xml:S1:42979:6	O
Grade	AFINITOR.xml:S1:42996:5	O
3	AFINITOR.xml:S1:43002:1	O
Grade	AFINITOR.xml:S1:43014:5	O
4	AFINITOR.xml:S1:43020:1	O

Any	AFINITOR.xml:S1:43035:3	O
adverse	AFINITOR.xml:S1:43039:7	O
reaction	AFINITOR.xml:S1:43047:8	O
97	AFINITOR.xml:S1:43061:2	O
36	AFINITOR.xml:S1:43078:2	O
3	AFINITOR.xml:S1:43095:1	O
92	AFINITOR.xml:S1:43112:2	O
23	AFINITOR.xml:S1:43129:2	O
3	AFINITOR.xml:S1:43146:1	O

Gastrointestinal	AFINITOR.xml:S1:43166:16	O
disorders	AFINITOR.xml:S1:43183:9	O

Stomatitis	AFINITOR.xml:S1:43307:10	B-AdverseReaction
a	AFINITOR.xml:S1:43319:1	O
62	AFINITOR.xml:S1:43324:2	O
9	AFINITOR.xml:S1:43341:1	O
0	AFINITOR.xml:S1:43358:1	O
26	AFINITOR.xml:S1:43375:2	O
3	AFINITOR.xml:S1:43392:1	O
0	AFINITOR.xml:S1:43409:1	O

Vomiting	AFINITOR.xml:S1:43435:8	B-AdverseReaction
22	AFINITOR.xml:S1:43446:2	O
1	AFINITOR.xml:S1:43463:1	O
0	AFINITOR.xml:S1:43480:1	O
13	AFINITOR.xml:S1:43497:2	O
0	AFINITOR.xml:S1:43514:1	O
0	AFINITOR.xml:S1:43531:1	O

Diarrhea	AFINITOR.xml:S1:43557:8	B-AdverseReaction
17	AFINITOR.xml:S1:43568:2	O
0	AFINITOR.xml:S1:43585:1	O
0	AFINITOR.xml:S1:43602:1	O
5	AFINITOR.xml:S1:43619:1	O
0	AFINITOR.xml:S1:43636:1	O
0	AFINITOR.xml:S1:43653:1	O

Constipation	AFINITOR.xml:S1:43679:12	B-AdverseReaction
10	AFINITOR.xml:S1:43693:2	O
0	AFINITOR.xml:S1:43710:1	O
0	AFINITOR.xml:S1:43727:1	O
3	AFINITOR.xml:S1:43744:1	O
0	AFINITOR.xml:S1:43761:1	O
0	AFINITOR.xml:S1:43778:1	O

Infections	AFINITOR.xml:S1:43800:10	O
and	AFINITOR.xml:S1:43811:3	O
infestations	AFINITOR.xml:S1:43815:12	O

Respiratory	AFINITOR.xml:S1:43942:11	B-AdverseReaction
tract	AFINITOR.xml:S1:43954:5	I-AdverseReaction
infection	AFINITOR.xml:S1:43960:9	I-AdverseReaction
b	AFINITOR.xml:S1:43971:1	O
31	AFINITOR.xml:S1:43976:2	O
1	AFINITOR.xml:S1:43993:1	O
1	AFINITOR.xml:S1:44010:1	O
23	AFINITOR.xml:S1:44027:2	O
0	AFINITOR.xml:S1:44044:1	O
0	AFINITOR.xml:S1:44061:1	O

Gastroenteritis	AFINITOR.xml:S1:44087:15	B-AdverseReaction
c	AFINITOR.xml:S1:44104:1	O
10	AFINITOR.xml:S1:44109:2	O
4	AFINITOR.xml:S1:44126:1	O
1	AFINITOR.xml:S1:44143:1	O
3	AFINITOR.xml:S1:44160:1	O
0	AFINITOR.xml:S1:44177:1	O
0	AFINITOR.xml:S1:44194:1	O

Pharyngitis	AFINITOR.xml:S1:44220:11	O
streptococcal	AFINITOR.xml:S1:44232:13	O
10	AFINITOR.xml:S1:44247:2	O
0	AFINITOR.xml:S1:44264:1	O
0	AFINITOR.xml:S1:44281:1	O
3	AFINITOR.xml:S1:44298:1	O
0	AFINITOR.xml:S1:44315:1	O
0	AFINITOR.xml:S1:44332:1	O

General	AFINITOR.xml:S1:44354:7	O
disorders	AFINITOR.xml:S1:44362:9	O
and	AFINITOR.xml:S1:44372:3	O
administration	AFINITOR.xml:S1:44376:14	O
site	AFINITOR.xml:S1:44391:4	O
conditions	AFINITOR.xml:S1:44396:10	O

Pyrexia	AFINITOR.xml:S1:44521:7	B-AdverseReaction
23	AFINITOR.xml:S1:44532:2	O
6	AFINITOR.xml:S1:44549:1	O
0	AFINITOR.xml:S1:44566:1	O
18	AFINITOR.xml:S1:44583:2	O
3	AFINITOR.xml:S1:44600:1	O
0	AFINITOR.xml:S1:44617:1	O

Fatigue	AFINITOR.xml:S1:44643:7	B-AdverseReaction
14	AFINITOR.xml:S1:44654:2	O
0	AFINITOR.xml:S1:44671:1	O
0	AFINITOR.xml:S1:44688:1	O
3	AFINITOR.xml:S1:44705:1	O
0	AFINITOR.xml:S1:44722:1	O
0	AFINITOR.xml:S1:44739:1	O

Psychiatric	AFINITOR.xml:S1:44761:11	O
disorders	AFINITOR.xml:S1:44773:9	O

Anxiety	AFINITOR.xml:S1:44897:7	B-AdverseReaction
,	AFINITOR.xml:S1:44904:1	O
aggression	AFINITOR.xml:S1:44906:10	B-AdverseReaction
or	AFINITOR.xml:S1:44917:2	O
other	AFINITOR.xml:S1:44920:5	O
behavioral	AFINITOR.xml:S1:44926:10	B-AdverseReaction
disturbance	AFINITOR.xml:S1:44937:11	I-AdverseReaction
d	AFINITOR.xml:S1:44950:1	O
21	AFINITOR.xml:S1:44955:2	O
5	AFINITOR.xml:S1:44972:1	O
0	AFINITOR.xml:S1:44989:1	O
3	AFINITOR.xml:S1:45006:1	O
0	AFINITOR.xml:S1:45023:1	O
0	AFINITOR.xml:S1:45040:1	O

Skin	AFINITOR.xml:S1:45062:4	O
and	AFINITOR.xml:S1:45067:3	O
subcutaneous	AFINITOR.xml:S1:45071:12	O
tissue	AFINITOR.xml:S1:45084:6	O
disorders	AFINITOR.xml:S1:45091:9	O

Rash	AFINITOR.xml:S1:45215:4	B-AdverseReaction
e	AFINITOR.xml:S1:45221:1	O
21	AFINITOR.xml:S1:45226:2	O
0	AFINITOR.xml:S1:45243:1	O
0	AFINITOR.xml:S1:45260:1	O
8	AFINITOR.xml:S1:45277:1	O
0	AFINITOR.xml:S1:45294:1	O
0	AFINITOR.xml:S1:45311:1	O

Acne	AFINITOR.xml:S1:45337:4	B-AdverseReaction
10	AFINITOR.xml:S1:45348:2	O
0	AFINITOR.xml:S1:45365:1	O
0	AFINITOR.xml:S1:45382:1	O
5	AFINITOR.xml:S1:45399:1	O
0	AFINITOR.xml:S1:45416:1	O
0	AFINITOR.xml:S1:45433:1	O

Amenorrhea	AFINITOR.xml:S1:45465:10	B-AdverseReaction
occurred	AFINITOR.xml:S1:45476:8	O
in	AFINITOR.xml:S1:45485:2	O
17%	AFINITOR.xml:S1:45488:3	O
of	AFINITOR.xml:S1:45492:2	O
AFINITOR	AFINITOR.xml:S1:45495:8	O
-	AFINITOR.xml:S1:45503:1	O
treated	AFINITOR.xml:S1:45504:7	O
females	AFINITOR.xml:S1:45512:7	O
aged	AFINITOR.xml:S1:45520:4	O
10	AFINITOR.xml:S1:45525:2	O
to	AFINITOR.xml:S1:45528:2	O
55	AFINITOR.xml:S1:45531:2	O
years	AFINITOR.xml:S1:45534:5	O
(	AFINITOR.xml:S1:45540:1	O
3	AFINITOR.xml:S1:45541:1	O
of	AFINITOR.xml:S1:45543:2	O
18	AFINITOR.xml:S1:45546:2	O
)	AFINITOR.xml:S1:45548:1	O
and	AFINITOR.xml:S1:45550:3	O
none	AFINITOR.xml:S1:45554:4	O
of	AFINITOR.xml:S1:45559:2	O
the	AFINITOR.xml:S1:45562:3	O
females	AFINITOR.xml:S1:45566:7	O
in	AFINITOR.xml:S1:45574:2	O
the	AFINITOR.xml:S1:45577:3	O
placebo	AFINITOR.xml:S1:45581:7	O
group	AFINITOR.xml:S1:45589:5	O
.	AFINITOR.xml:S1:45594:1	O

For	AFINITOR.xml:S1:45596:3	O
this	AFINITOR.xml:S1:45600:4	O
same	AFINITOR.xml:S1:45605:4	O
group	AFINITOR.xml:S1:45610:5	O
of	AFINITOR.xml:S1:45616:2	O
AFINITOR	AFINITOR.xml:S1:45619:8	O
-	AFINITOR.xml:S1:45627:1	O
treated	AFINITOR.xml:S1:45628:7	O
females	AFINITOR.xml:S1:45636:7	O
,	AFINITOR.xml:S1:45643:1	O
the	AFINITOR.xml:S1:45645:3	O
following	AFINITOR.xml:S1:45649:9	O
menstrual	AFINITOR.xml:S1:45659:9	B-AdverseReaction
abnormalities	AFINITOR.xml:S1:45669:13	I-AdverseReaction
were	AFINITOR.xml:S1:45683:4	O
reported	AFINITOR.xml:S1:45688:8	O
:	AFINITOR.xml:S1:45696:1	O
dysmenorrhea	AFINITOR.xml:S1:45698:12	B-AdverseReaction
(	AFINITOR.xml:S1:45711:1	O
6%	AFINITOR.xml:S1:45712:2	O
)	AFINITOR.xml:S1:45714:1	O
,	AFINITOR.xml:S1:45715:1	O
menorrhagia	AFINITOR.xml:S1:45717:11	B-AdverseReaction
(	AFINITOR.xml:S1:45729:1	O
6%	AFINITOR.xml:S1:45730:2	O
)	AFINITOR.xml:S1:45732:1	O
,	AFINITOR.xml:S1:45733:1	O
metrorrhagia	AFINITOR.xml:S1:45735:12	B-AdverseReaction
(	AFINITOR.xml:S1:45748:1	O
6%	AFINITOR.xml:S1:45749:2	O
)	AFINITOR.xml:S1:45751:1	O
,	AFINITOR.xml:S1:45752:1	O
and	AFINITOR.xml:S1:45754:3	O
unspecified	AFINITOR.xml:S1:45758:11	B-AdverseReaction
menstrual	AFINITOR.xml:S1:45770:9	I-AdverseReaction
irregularity	AFINITOR.xml:S1:45780:12	I-AdverseReaction
(	AFINITOR.xml:S1:45793:1	O
6%	AFINITOR.xml:S1:45794:2	O
)	AFINITOR.xml:S1:45796:1	O
.	AFINITOR.xml:S1:45797:1	O

The	AFINITOR.xml:S1:45803:3	O

following	AFINITOR.xml:S1:45807:9	O
additional	AFINITOR.xml:S1:45817:10	O
adverse	AFINITOR.xml:S1:45828:7	O
reactions	AFINITOR.xml:S1:45836:9	O
occurred	AFINITOR.xml:S1:45846:8	O
in	AFINITOR.xml:S1:45855:2	O
less	AFINITOR.xml:S1:45858:4	O
than	AFINITOR.xml:S1:45863:4	O
10%	AFINITOR.xml:S1:45868:3	O
of	AFINITOR.xml:S1:45872:2	O
AFINITOR	AFINITOR.xml:S1:45875:8	O
-	AFINITOR.xml:S1:45883:1	O
treated	AFINITOR.xml:S1:45884:7	O
patients	AFINITOR.xml:S1:45892:8	O
:	AFINITOR.xml:S1:45900:1	O
nausea	AFINITOR.xml:S1:45902:6	B-AdverseReaction
(	AFINITOR.xml:S1:45909:1	O
8%	AFINITOR.xml:S1:45910:2	O
)	AFINITOR.xml:S1:45912:1	O
,	AFINITOR.xml:S1:45913:1	O
pain	AFINITOR.xml:S1:45915:4	B-AdverseReaction
in	AFINITOR.xml:S1:45920:2	I-AdverseReaction
extremity	AFINITOR.xml:S1:45923:9	I-AdverseReaction
(	AFINITOR.xml:S1:45933:1	O
8%	AFINITOR.xml:S1:45934:2	O
)	AFINITOR.xml:S1:45936:1	O
,	AFINITOR.xml:S1:45937:1	O
insomnia	AFINITOR.xml:S1:45939:8	B-AdverseReaction
(	AFINITOR.xml:S1:45948:1	O
6%	AFINITOR.xml:S1:45949:2	O
)	AFINITOR.xml:S1:45951:1	O
,	AFINITOR.xml:S1:45952:1	O
pneumonia	AFINITOR.xml:S1:45954:9	B-AdverseReaction
(	AFINITOR.xml:S1:45964:1	O
6%	AFINITOR.xml:S1:45965:2	O
)	AFINITOR.xml:S1:45967:1	O
,	AFINITOR.xml:S1:45968:1	O
epistaxis	AFINITOR.xml:S1:45970:9	B-AdverseReaction
(	AFINITOR.xml:S1:45980:1	O
5%	AFINITOR.xml:S1:45981:2	O
)	AFINITOR.xml:S1:45983:1	O
,	AFINITOR.xml:S1:45984:1	O
hypersensitivity	AFINITOR.xml:S1:45986:16	B-AdverseReaction
(	AFINITOR.xml:S1:46003:1	O
3%	AFINITOR.xml:S1:46004:2	O
)	AFINITOR.xml:S1:46006:1	O
,	AFINITOR.xml:S1:46007:1	O
increased	AFINITOR.xml:S1:46009:9	B-AdverseReaction
blood	AFINITOR.xml:S1:46019:5	I-AdverseReaction
luteinizing	AFINITOR.xml:S1:46025:11	I-AdverseReaction
hormone	AFINITOR.xml:S1:46037:7	I-AdverseReaction
(	AFINITOR.xml:S1:46045:1	O
LH	AFINITOR.xml:S1:46046:2	I-AdverseReaction
)	AFINITOR.xml:S1:46048:1	O
levels	AFINITOR.xml:S1:46050:6	I-AdverseReaction
(	AFINITOR.xml:S1:46057:1	O
1%	AFINITOR.xml:S1:46058:2	O
)	AFINITOR.xml:S1:46060:1	O
and	AFINITOR.xml:S1:46062:3	O
pneumonitis	AFINITOR.xml:S1:46066:11	B-AdverseReaction
(	AFINITOR.xml:S1:46078:1	O
1%	AFINITOR.xml:S1:46079:2	O
)	AFINITOR.xml:S1:46081:1	O
.	AFINITOR.xml:S1:46082:1	O

Table	AFINITOR.xml:S1:46088:5	O
11	AFINITOR.xml:S1:46094:2	O
:	AFINITOR.xml:S1:46096:1	O
Key	AFINITOR.xml:S1:46098:3	O
Laboratory	AFINITOR.xml:S1:46102:10	O
Abnormalities	AFINITOR.xml:S1:46113:13	O
Reported	AFINITOR.xml:S1:46127:8	O
in	AFINITOR.xml:S1:46136:2	O
AFINITOR	AFINITOR.xml:S1:46139:8	O
-	AFINITOR.xml:S1:46147:1	O
treated	AFINITOR.xml:S1:46148:7	O
Patients	AFINITOR.xml:S1:46156:8	O
with	AFINITOR.xml:S1:46165:4	O
SEGA	AFINITOR.xml:S1:46170:4	O
in	AFINITOR.xml:S1:46175:2	O
Study	AFINITOR.xml:S1:46178:5	O
1	AFINITOR.xml:S1:46184:1	O

Grading	AFINITOR.xml:S1:46188:7	O
according	AFINITOR.xml:S1:46196:9	O
to	AFINITOR.xml:S1:46206:2	O
CTCAE	AFINITOR.xml:S1:46209:5	O
Version	AFINITOR.xml:S1:46215:7	O
3.0	AFINITOR.xml:S1:46223:3	O

AFINITOR	AFINITOR.xml:S1:46253:8	O

N	AFINITOR.xml:S1:46265:1	O
78	AFINITOR.xml:S1:46267:2	O
Placebo	AFINITOR.xml:S1:46275:7	O
N	AFINITOR.xml:S1:46286:1	O
39	AFINITOR.xml:S1:46288:2	O

All	AFINITOR.xml:S1:46316:3	O
grades	AFINITOR.xml:S1:46320:6	O
Grade	AFINITOR.xml:S1:46337:5	O
3	AFINITOR.xml:S1:46343:1	O
Grade	AFINITOR.xml:S1:46355:5	O
4	AFINITOR.xml:S1:46361:1	O
All	AFINITOR.xml:S1:46373:3	O
grades	AFINITOR.xml:S1:46377:6	O
Grade	AFINITOR.xml:S1:46394:5	O
3	AFINITOR.xml:S1:46400:1	O
Grade	AFINITOR.xml:S1:46412:5	O
4	AFINITOR.xml:S1:46418:1	O

Hematology	AFINITOR.xml:S1:46433:10	O

Elevated	AFINITOR.xml:S1:46559:8	B-AdverseReaction
partial	AFINITOR.xml:S1:46568:7	I-AdverseReaction
thromboplastin	AFINITOR.xml:S1:46576:14	I-AdverseReaction
time	AFINITOR.xml:S1:46591:4	I-AdverseReaction
72	AFINITOR.xml:S1:46597:2	O
3	AFINITOR.xml:S1:46614:1	O
0	AFINITOR.xml:S1:46631:1	O
44	AFINITOR.xml:S1:46648:2	O
5	AFINITOR.xml:S1:46665:1	O
0	AFINITOR.xml:S1:46682:1	O

Neutropenia	AFINITOR.xml:S1:46708:11	B-AdverseReaction
46	AFINITOR.xml:S1:46721:2	O
9	AFINITOR.xml:S1:46738:1	O
0	AFINITOR.xml:S1:46755:1	O
41	AFINITOR.xml:S1:46772:2	O
3	AFINITOR.xml:S1:46789:1	O
0	AFINITOR.xml:S1:46806:1	O

Anemia	AFINITOR.xml:S1:46832:6	B-AdverseReaction
41	AFINITOR.xml:S1:46843:2	O
0	AFINITOR.xml:S1:46860:1	O
0	AFINITOR.xml:S1:46877:1	O
21	AFINITOR.xml:S1:46894:2	O
0	AFINITOR.xml:S1:46911:1	O
0	AFINITOR.xml:S1:46928:1	O

Clinical	AFINITOR.xml:S1:46950:8	O
chemistry	AFINITOR.xml:S1:46959:9	O

Hypercholesterolemia	AFINITOR.xml:S1:47083:20	B-AdverseReaction
81	AFINITOR.xml:S1:47105:2	O
0	AFINITOR.xml:S1:47122:1	O
0	AFINITOR.xml:S1:47139:1	O
39	AFINITOR.xml:S1:47156:2	O
0	AFINITOR.xml:S1:47173:1	O
0	AFINITOR.xml:S1:47190:1	O

Elevated	AFINITOR.xml:S1:47216:8	B-AdverseReaction
aspartate	AFINITOR.xml:S1:47225:9	I-AdverseReaction
transaminase	AFINITOR.xml:S1:47235:12	I-AdverseReaction
(	AFINITOR.xml:S1:47248:1	O
AST	AFINITOR.xml:S1:47249:3	I-AdverseReaction
)	AFINITOR.xml:S1:47252:1	O
33	AFINITOR.xml:S1:47255:2	O
0	AFINITOR.xml:S1:47272:1	O
0	AFINITOR.xml:S1:47289:1	O
0	AFINITOR.xml:S1:47306:1	O
0	AFINITOR.xml:S1:47323:1	O
0	AFINITOR.xml:S1:47340:1	O

Hypertriglyceridemia	AFINITOR.xml:S1:47366:20	B-AdverseReaction
27	AFINITOR.xml:S1:47388:2	O
0	AFINITOR.xml:S1:47405:1	O
0	AFINITOR.xml:S1:47422:1	O
15	AFINITOR.xml:S1:47439:2	O
0	AFINITOR.xml:S1:47456:1	O
0	AFINITOR.xml:S1:47473:1	O

Elevated	AFINITOR.xml:S1:47499:8	B-AdverseReaction
alanine	AFINITOR.xml:S1:47508:7	I-AdverseReaction
transaminase	AFINITOR.xml:S1:47516:12	I-AdverseReaction
(	AFINITOR.xml:S1:47529:1	O
ALT	AFINITOR.xml:S1:47530:3	I-AdverseReaction
)	AFINITOR.xml:S1:47533:1	O
18	AFINITOR.xml:S1:47536:2	O
0	AFINITOR.xml:S1:47553:1	O
0	AFINITOR.xml:S1:47570:1	O
3	AFINITOR.xml:S1:47587:1	O
0	AFINITOR.xml:S1:47604:1	O
0	AFINITOR.xml:S1:47621:1	O

Hypophosphatemia	AFINITOR.xml:S1:47647:16	B-AdverseReaction
9	AFINITOR.xml:S1:47665:1	O
1	AFINITOR.xml:S1:47682:1	O
0	AFINITOR.xml:S1:47699:1	O
3	AFINITOR.xml:S1:47716:1	O
0	AFINITOR.xml:S1:47733:1	O
0	AFINITOR.xml:S1:47750:1	O

Longer	AFINITOR.xml:S1:47782:6	O
-	AFINITOR.xml:S1:47788:1	O
term	AFINITOR.xml:S1:47789:4	O
follow	AFINITOR.xml:S1:47794:6	O
-	AFINITOR.xml:S1:47800:1	O
up	AFINITOR.xml:S1:47801:2	O
of	AFINITOR.xml:S1:47804:2	O
34.2	AFINITOR.xml:S1:47807:4	O
months	AFINITOR.xml:S1:47812:6	O
(	AFINITOR.xml:S1:47819:1	O
range	AFINITOR.xml:S1:47820:5	O
4.7	AFINITOR.xml:S1:47826:3	O
to	AFINITOR.xml:S1:47830:2	O
47.1	AFINITOR.xml:S1:47833:4	O
months	AFINITOR.xml:S1:47838:6	O
)	AFINITOR.xml:S1:47844:1	O
from	AFINITOR.xml:S1:47846:4	O
a	AFINITOR.xml:S1:47851:1	O
non	AFINITOR.xml:S1:47853:3	O
-	AFINITOR.xml:S1:47856:1	O
randomized	AFINITOR.xml:S1:47857:10	O
,	AFINITOR.xml:S1:47867:1	O
open	AFINITOR.xml:S1:47869:4	O
-	AFINITOR.xml:S1:47873:1	O
label	AFINITOR.xml:S1:47874:5	O
,	AFINITOR.xml:S1:47879:1	O
28	AFINITOR.xml:S1:47881:2	O
-	AFINITOR.xml:S1:47883:1	O
patient	AFINITOR.xml:S1:47884:7	O
trial	AFINITOR.xml:S1:47892:5	O
resulted	AFINITOR.xml:S1:47898:8	O
in	AFINITOR.xml:S1:47907:2	O
the	AFINITOR.xml:S1:47910:3	O
following	AFINITOR.xml:S1:47914:9	O
additional	AFINITOR.xml:S1:47924:10	O
notable	AFINITOR.xml:S1:47935:7	O
adverse	AFINITOR.xml:S1:47943:7	O
reactions	AFINITOR.xml:S1:47951:9	O
and	AFINITOR.xml:S1:47961:3	O
key	AFINITOR.xml:S1:47965:3	O
laboratory	AFINITOR.xml:S1:47969:10	O
abnormalities	AFINITOR.xml:S1:47980:13	O
:	AFINITOR.xml:S1:47993:1	O
cellulitis	AFINITOR.xml:S1:47995:10	B-AdverseReaction
(	AFINITOR.xml:S1:48006:1	O
29%	AFINITOR.xml:S1:48007:3	O
)	AFINITOR.xml:S1:48010:1	O
,	AFINITOR.xml:S1:48011:1	O
hyperglycemia	AFINITOR.xml:S1:48013:13	B-AdverseReaction
(	AFINITOR.xml:S1:48027:1	O
25%	AFINITOR.xml:S1:48028:3	O
)	AFINITOR.xml:S1:48031:1	O
,	AFINITOR.xml:S1:48032:1	O
and	AFINITOR.xml:S1:48034:3	O
elevated	AFINITOR.xml:S1:48038:8	B-AdverseReaction
creatinine	AFINITOR.xml:S1:48047:10	I-AdverseReaction
(	AFINITOR.xml:S1:48058:1	O
14%	AFINITOR.xml:S1:48059:3	O
)	AFINITOR.xml:S1:48062:1	O
.	AFINITOR.xml:S1:48063:1	O

6.6	AFINITOR.xml:S1:48071:3	O

Postmarketing	AFINITOR.xml:S1:48079:13	O
Experience	AFINITOR.xml:S1:48093:10	O

The	AFINITOR.xml:S1:48107:3	O
following	AFINITOR.xml:S1:48111:9	O
adverse	AFINITOR.xml:S1:48121:7	O
reactions	AFINITOR.xml:S1:48129:9	O
have	AFINITOR.xml:S1:48139:4	O
been	AFINITOR.xml:S1:48144:4	O
identified	AFINITOR.xml:S1:48149:10	O
during	AFINITOR.xml:S1:48160:6	O
post	AFINITOR.xml:S1:48167:4	O
approval	AFINITOR.xml:S1:48172:8	O
use	AFINITOR.xml:S1:48181:3	O
of	AFINITOR.xml:S1:48185:2	O
AFINITOR	AFINITOR.xml:S1:48188:8	O
.	AFINITOR.xml:S1:48196:1	O

Because	AFINITOR.xml:S1:48198:7	O
these	AFINITOR.xml:S1:48206:5	O
reactions	AFINITOR.xml:S1:48212:9	O
are	AFINITOR.xml:S1:48222:3	O
reported	AFINITOR.xml:S1:48226:8	O
voluntarily	AFINITOR.xml:S1:48235:11	O
from	AFINITOR.xml:S1:48247:4	O
a	AFINITOR.xml:S1:48252:1	O
population	AFINITOR.xml:S1:48254:10	O
of	AFINITOR.xml:S1:48265:2	O
uncertain	AFINITOR.xml:S1:48268:9	O
size	AFINITOR.xml:S1:48278:4	O
,	AFINITOR.xml:S1:48282:1	O
it	AFINITOR.xml:S1:48284:2	O
is	AFINITOR.xml:S1:48287:2	O
not	AFINITOR.xml:S1:48290:3	O
always	AFINITOR.xml:S1:48294:6	O
possible	AFINITOR.xml:S1:48301:8	O
to	AFINITOR.xml:S1:48310:2	O
reliably	AFINITOR.xml:S1:48313:8	O
estimate	AFINITOR.xml:S1:48322:8	O
frequency	AFINITOR.xml:S1:48331:9	O
or	AFINITOR.xml:S1:48341:2	O
establish	AFINITOR.xml:S1:48344:9	O
a	AFINITOR.xml:S1:48354:1	O
causal	AFINITOR.xml:S1:48356:6	O
relationship	AFINITOR.xml:S1:48363:12	O
to	AFINITOR.xml:S1:48376:2	O
drug	AFINITOR.xml:S1:48379:4	O
exposure	AFINITOR.xml:S1:48384:8	O
:	AFINITOR.xml:S1:48392:1	O
acute	AFINITOR.xml:S1:48394:5	B-AdverseReaction
pancreatitis	AFINITOR.xml:S1:48400:12	I-AdverseReaction
,	AFINITOR.xml:S1:48412:1	O
cholecystitis	AFINITOR.xml:S1:48414:13	B-AdverseReaction
,	AFINITOR.xml:S1:48427:1	O
cholelithiasis	AFINITOR.xml:S1:48429:14	B-AdverseReaction
,	AFINITOR.xml:S1:48443:1	O
arterial	AFINITOR.xml:S1:48445:8	B-AdverseReaction
thrombotic	AFINITOR.xml:S1:48454:10	I-AdverseReaction
events	AFINITOR.xml:S1:48465:6	I-AdverseReaction
and	AFINITOR.xml:S1:48472:3	O
reflex	AFINITOR.xml:S1:48476:6	B-AdverseReaction
sympathetic	AFINITOR.xml:S1:48483:11	I-AdverseReaction
dystrophy	AFINITOR.xml:S1:48495:9	I-AdverseReaction
.	AFINITOR.xml:S1:48504:1	O
5	AFINITOR.xml:S2:4:1	O
WARNINGS	AFINITOR.xml:S2:10:8	O
AND	AFINITOR.xml:S2:19:3	O
PRECAUTIONS	AFINITOR.xml:S2:23:11	O

EXCERPT	AFINITOR.xml:S2:41:7	O
:	AFINITOR.xml:S2:48:1	O
Non	AFINITOR.xml:S2:56:3	B-AdverseReaction
-	AFINITOR.xml:S2:59:1	I-AdverseReaction
infectious	AFINITOR.xml:S2:60:10	I-AdverseReaction
pneumonitis	AFINITOR.xml:S2:71:11	I-AdverseReaction
:	AFINITOR.xml:S2:82:1	O
Monitor	AFINITOR.xml:S2:84:7	O
for	AFINITOR.xml:S2:92:3	O
clinical	AFINITOR.xml:S2:96:8	O
symptoms	AFINITOR.xml:S2:105:8	O
or	AFINITOR.xml:S2:114:2	O
radiological	AFINITOR.xml:S2:117:12	O
changes	AFINITOR.xml:S2:130:7	O
;	AFINITOR.xml:S2:137:1	O
fatal	AFINITOR.xml:S2:139:5	B-AdverseReaction
cases	AFINITOR.xml:S2:145:5	O
have	AFINITOR.xml:S2:151:4	O
occurred	AFINITOR.xml:S2:156:8	O
.	AFINITOR.xml:S2:164:1	O

Manage	AFINITOR.xml:S2:166:6	O
by	AFINITOR.xml:S2:173:2	O
dose	AFINITOR.xml:S2:176:4	O
reduction	AFINITOR.xml:S2:181:9	O
or	AFINITOR.xml:S2:191:2	O
discontinuation	AFINITOR.xml:S2:194:15	O
until	AFINITOR.xml:S2:210:5	O
symptoms	AFINITOR.xml:S2:216:8	O
resolve	AFINITOR.xml:S2:225:7	O
,	AFINITOR.xml:S2:232:1	O
and	AFINITOR.xml:S2:234:3	O
consider	AFINITOR.xml:S2:238:8	O
use	AFINITOR.xml:S2:247:3	O
of	AFINITOR.xml:S2:251:2	O
corticosteroids	AFINITOR.xml:S2:254:15	O
.	AFINITOR.xml:S2:269:1	O

(	AFINITOR.xml:S2:271:1	O
5.1	AFINITOR.xml:S2:274:3	O
)	AFINITOR.xml:S2:279:1	O

Infections	AFINITOR.xml:S2:286:10	B-AdverseReaction
:	AFINITOR.xml:S2:296:1	O
Increased	AFINITOR.xml:S2:298:9	O
risk	AFINITOR.xml:S2:308:4	B-Factor
of	AFINITOR.xml:S2:313:2	O
infections	AFINITOR.xml:S2:316:10	B-AdverseReaction
,	AFINITOR.xml:S2:326:1	O
some	AFINITOR.xml:S2:328:4	O
fatal	AFINITOR.xml:S2:333:5	B-AdverseReaction
.	AFINITOR.xml:S2:338:1	O

Monitor	AFINITOR.xml:S2:340:7	O
for	AFINITOR.xml:S2:348:3	O
signs	AFINITOR.xml:S2:352:5	O
and	AFINITOR.xml:S2:358:3	O
symptoms	AFINITOR.xml:S2:362:8	O
,	AFINITOR.xml:S2:370:1	O
and	AFINITOR.xml:S2:372:3	O
treat	AFINITOR.xml:S2:376:5	O
promptly	AFINITOR.xml:S2:382:8	O
.	AFINITOR.xml:S2:390:1	O

(	AFINITOR.xml:S2:392:1	O
5.2	AFINITOR.xml:S2:395:3	O
)	AFINITOR.xml:S2:400:1	O

Angioedema	AFINITOR.xml:S2:407:10	B-AdverseReaction
:	AFINITOR.xml:S2:417:1	O
Patients	AFINITOR.xml:S2:419:8	O
taking	AFINITOR.xml:S2:428:6	O
concomitant	AFINITOR.xml:S2:435:11	O
ACE	AFINITOR.xml:S2:447:3	O
inhibitor	AFINITOR.xml:S2:451:9	O
therapy	AFINITOR.xml:S2:461:7	O
may	AFINITOR.xml:S2:469:3	O
be	AFINITOR.xml:S2:473:2	O
at	AFINITOR.xml:S2:476:2	O
increased	AFINITOR.xml:S2:479:9	O
risk	AFINITOR.xml:S2:489:4	O
for	AFINITOR.xml:S2:494:3	O
angioedema	AFINITOR.xml:S2:498:10	O
.	AFINITOR.xml:S2:508:1	O

(	AFINITOR.xml:S2:510:1	O
5.3	AFINITOR.xml:S2:513:3	O
)	AFINITOR.xml:S2:518:1	O

Oral	AFINITOR.xml:S2:525:4	B-AdverseReaction
ulceration	AFINITOR.xml:S2:530:10	I-AdverseReaction
:	AFINITOR.xml:S2:540:1	O
Mouth	AFINITOR.xml:S2:542:5	B-AdverseReaction
ulcers	AFINITOR.xml:S2:548:6	I-AdverseReaction
,	AFINITOR.xml:S2:554:1	O
stomatitis	AFINITOR.xml:S2:556:10	B-AdverseReaction
,	AFINITOR.xml:S2:566:1	O
and	AFINITOR.xml:S2:568:3	O
oral	AFINITOR.xml:S2:572:4	B-AdverseReaction
mucositis	AFINITOR.xml:S2:577:9	I-AdverseReaction
are	AFINITOR.xml:S2:587:3	O
common	AFINITOR.xml:S2:591:6	O
.	AFINITOR.xml:S2:597:1	O

Management	AFINITOR.xml:S2:599:10	O
includes	AFINITOR.xml:S2:610:8	O
mouthwashes	AFINITOR.xml:S2:619:11	O
and	AFINITOR.xml:S2:631:3	O
topical	AFINITOR.xml:S2:635:7	O
treatments	AFINITOR.xml:S2:643:10	O
.	AFINITOR.xml:S2:653:1	O

(	AFINITOR.xml:S2:655:1	O
5.4	AFINITOR.xml:S2:658:3	O
)	AFINITOR.xml:S2:663:1	O

Renal	AFINITOR.xml:S2:670:5	B-AdverseReaction
failure	AFINITOR.xml:S2:676:7	I-AdverseReaction
:	AFINITOR.xml:S2:683:1	O
Cases	AFINITOR.xml:S2:685:5	O
of	AFINITOR.xml:S2:691:2	O
renal	AFINITOR.xml:S2:694:5	B-AdverseReaction
failure	AFINITOR.xml:S2:700:7	I-AdverseReaction
(	AFINITOR.xml:S2:708:1	O
including	AFINITOR.xml:S2:709:9	O
acute	AFINITOR.xml:S2:719:5	B-AdverseReaction
renal	AFINITOR.xml:S2:725:5	I-AdverseReaction
failure	AFINITOR.xml:S2:731:7	I-AdverseReaction
)	AFINITOR.xml:S2:738:1	O
,	AFINITOR.xml:S2:739:1	O
some	AFINITOR.xml:S2:741:4	O
with	AFINITOR.xml:S2:746:4	O
a	AFINITOR.xml:S2:751:1	O
fatal	AFINITOR.xml:S2:753:5	B-AdverseReaction
outcome	AFINITOR.xml:S2:759:7	O
,	AFINITOR.xml:S2:766:1	O
have	AFINITOR.xml:S2:768:4	O
been	AFINITOR.xml:S2:773:4	O
observed	AFINITOR.xml:S2:778:8	O
.	AFINITOR.xml:S2:786:1	O

(	AFINITOR.xml:S2:788:1	O
5.5	AFINITOR.xml:S2:791:3	O
)	AFINITOR.xml:S2:796:1	O

Impaired	AFINITOR.xml:S2:803:8	B-AdverseReaction
wound	AFINITOR.xml:S2:812:5	I-AdverseReaction
healing	AFINITOR.xml:S2:818:7	I-AdverseReaction
:	AFINITOR.xml:S2:825:1	O
Increased	AFINITOR.xml:S2:827:9	O
risk	AFINITOR.xml:S2:837:4	B-Factor
of	AFINITOR.xml:S2:842:2	O
wound	AFINITOR.xml:S2:845:5	B-AdverseReaction
-	AFINITOR.xml:S2:850:1	I-AdverseReaction
related	AFINITOR.xml:S2:851:7	I-AdverseReaction
complications	AFINITOR.xml:S2:859:13	I-AdverseReaction
.	AFINITOR.xml:S2:872:1	O

Monitor	AFINITOR.xml:S2:874:7	O
signs	AFINITOR.xml:S2:882:5	O
and	AFINITOR.xml:S2:888:3	O
symptoms	AFINITOR.xml:S2:892:8	O
.	AFINITOR.xml:S2:900:1	O

Exercise	AFINITOR.xml:S2:902:8	O
caution	AFINITOR.xml:S2:911:7	O
in	AFINITOR.xml:S2:919:2	O
the	AFINITOR.xml:S2:922:3	O
peri	AFINITOR.xml:S2:926:4	O
-	AFINITOR.xml:S2:930:1	O
surgical	AFINITOR.xml:S2:931:8	O
period	AFINITOR.xml:S2:940:6	O
.	AFINITOR.xml:S2:946:1	O

(	AFINITOR.xml:S2:948:1	O
5.6	AFINITOR.xml:S2:951:3	O
)	AFINITOR.xml:S2:956:1	O

Laboratory	AFINITOR.xml:S2:963:10	O
test	AFINITOR.xml:S2:974:4	O
alterations	AFINITOR.xml:S2:979:11	O
:	AFINITOR.xml:S2:990:1	O
Elevations	AFINITOR.xml:S2:992:10	B-AdverseReaction
of	AFINITOR.xml:S2:1003:2	I-AdverseReaction
serum	AFINITOR.xml:S2:1006:5	I-AdverseReaction
creatinine	AFINITOR.xml:S2:1012:10	I-AdverseReaction
,	AFINITOR.xml:S2:1022:1	O
urinary	AFINITOR.xml:S2:1024:7	I-AdverseReaction
protein	AFINITOR.xml:S2:1032:7	I-AdverseReaction
,	AFINITOR.xml:S2:1039:1	O
blood	AFINITOR.xml:S2:1041:5	I-AdverseReaction
glucose	AFINITOR.xml:S2:1047:7	I-AdverseReaction
,	AFINITOR.xml:S2:1054:1	O
and	AFINITOR.xml:S2:1056:3	O
lipids	AFINITOR.xml:S2:1060:6	I-AdverseReaction
may	AFINITOR.xml:S2:1067:3	O
occur	AFINITOR.xml:S2:1071:5	O
.	AFINITOR.xml:S2:1076:1	O

Decreases	AFINITOR.xml:S2:1078:9	B-AdverseReaction
in	AFINITOR.xml:S2:1088:2	I-AdverseReaction
hemoglobin	AFINITOR.xml:S2:1091:10	I-AdverseReaction
,	AFINITOR.xml:S2:1101:1	O
neutrophils	AFINITOR.xml:S2:1103:11	I-AdverseReaction
,	AFINITOR.xml:S2:1114:1	O
and	AFINITOR.xml:S2:1116:3	O
platelets	AFINITOR.xml:S2:1120:9	I-AdverseReaction
may	AFINITOR.xml:S2:1130:3	B-Factor
also	AFINITOR.xml:S2:1134:4	O
occur	AFINITOR.xml:S2:1139:5	O
.	AFINITOR.xml:S2:1144:1	O

Monitor	AFINITOR.xml:S2:1146:7	O
renal	AFINITOR.xml:S2:1154:5	O
function	AFINITOR.xml:S2:1160:8	O
,	AFINITOR.xml:S2:1168:1	O
blood	AFINITOR.xml:S2:1170:5	O
glucose	AFINITOR.xml:S2:1176:7	O
,	AFINITOR.xml:S2:1183:1	O
lipids	AFINITOR.xml:S2:1185:6	O
,	AFINITOR.xml:S2:1191:1	O
and	AFINITOR.xml:S2:1193:3	O
hematologic	AFINITOR.xml:S2:1197:11	O
parameters	AFINITOR.xml:S2:1209:10	O
prior	AFINITOR.xml:S2:1220:5	O
to	AFINITOR.xml:S2:1226:2	O
treatment	AFINITOR.xml:S2:1229:9	O
and	AFINITOR.xml:S2:1239:3	O
periodically	AFINITOR.xml:S2:1243:12	O
thereafter	AFINITOR.xml:S2:1256:10	O
.	AFINITOR.xml:S2:1266:1	O

(	AFINITOR.xml:S2:1268:1	O
5.8	AFINITOR.xml:S2:1271:3	O
)	AFINITOR.xml:S2:1276:1	O

Vaccinations	AFINITOR.xml:S2:1283:12	O
:	AFINITOR.xml:S2:1295:1	O
Avoid	AFINITOR.xml:S2:1297:5	O
live	AFINITOR.xml:S2:1303:4	O
vaccines	AFINITOR.xml:S2:1308:8	O
and	AFINITOR.xml:S2:1317:3	O
close	AFINITOR.xml:S2:1321:5	O
contact	AFINITOR.xml:S2:1327:7	O
with	AFINITOR.xml:S2:1335:4	O
those	AFINITOR.xml:S2:1340:5	O
who	AFINITOR.xml:S2:1346:3	O
have	AFINITOR.xml:S2:1350:4	O
received	AFINITOR.xml:S2:1355:8	O
live	AFINITOR.xml:S2:1364:4	O
vaccines	AFINITOR.xml:S2:1369:8	O
.	AFINITOR.xml:S2:1377:1	O

(	AFINITOR.xml:S2:1379:1	O
5.11	AFINITOR.xml:S2:1382:4	O
)	AFINITOR.xml:S2:1388:1	O

Embryo	AFINITOR.xml:S2:1395:6	B-AdverseReaction
-	AFINITOR.xml:S2:1401:1	I-AdverseReaction
fetal	AFINITOR.xml:S2:1402:5	I-AdverseReaction
toxicity	AFINITOR.xml:S2:1408:8	I-AdverseReaction
:	AFINITOR.xml:S2:1416:1	O
Fetal	AFINITOR.xml:S2:1418:5	B-AdverseReaction
harm	AFINITOR.xml:S2:1424:4	I-AdverseReaction
can	AFINITOR.xml:S2:1429:3	B-Factor
occur	AFINITOR.xml:S2:1433:5	O
when	AFINITOR.xml:S2:1439:4	O
administered	AFINITOR.xml:S2:1444:12	O
to	AFINITOR.xml:S2:1457:2	O
a	AFINITOR.xml:S2:1460:1	O
pregnant	AFINITOR.xml:S2:1462:8	O
woman	AFINITOR.xml:S2:1471:5	O
.	AFINITOR.xml:S2:1476:1	O

Apprise	AFINITOR.xml:S2:1478:7	O
women	AFINITOR.xml:S2:1486:5	O
of	AFINITOR.xml:S2:1492:2	O
potential	AFINITOR.xml:S2:1495:9	O
harm	AFINITOR.xml:S2:1505:4	O
to	AFINITOR.xml:S2:1510:2	O
the	AFINITOR.xml:S2:1513:3	O
fetus	AFINITOR.xml:S2:1517:5	O
.	AFINITOR.xml:S2:1522:1	O

(	AFINITOR.xml:S2:1524:1	O
5.12	AFINITOR.xml:S2:1527:4	O
,	AFINITOR.xml:S2:1533:1	O
8.1	AFINITOR.xml:S2:1536:3	O
)	AFINITOR.xml:S2:1541:1	O

5.1	AFINITOR.xml:S2:1555:3	O

Non	AFINITOR.xml:S2:1563:3	O

-	AFINITOR.xml:S2:1566:1	O
infectious	AFINITOR.xml:S2:1567:10	O
Pneumonitis	AFINITOR.xml:S2:1578:11	O

Non	AFINITOR.xml:S2:1595:3	B-AdverseReaction
-	AFINITOR.xml:S2:1598:1	I-AdverseReaction
infectious	AFINITOR.xml:S2:1599:10	I-AdverseReaction
pneumonitis	AFINITOR.xml:S2:1610:11	I-AdverseReaction
is	AFINITOR.xml:S2:1622:2	O
a	AFINITOR.xml:S2:1625:1	O
class	AFINITOR.xml:S2:1627:5	O
effect	AFINITOR.xml:S2:1633:6	O
of	AFINITOR.xml:S2:1640:2	O
rapamycin	AFINITOR.xml:S2:1643:9	O
derivatives	AFINITOR.xml:S2:1653:11	O
,	AFINITOR.xml:S2:1664:1	O
including	AFINITOR.xml:S2:1666:9	O
AFINITOR	AFINITOR.xml:S2:1676:8	O
.	AFINITOR.xml:S2:1684:1	O

Non	AFINITOR.xml:S2:1686:3	B-AdverseReaction
-	AFINITOR.xml:S2:1689:1	I-AdverseReaction
infectious	AFINITOR.xml:S2:1690:10	I-AdverseReaction
pneumonitis	AFINITOR.xml:S2:1701:11	I-AdverseReaction
was	AFINITOR.xml:S2:1713:3	O
reported	AFINITOR.xml:S2:1717:8	O
in	AFINITOR.xml:S2:1726:2	O
up	AFINITOR.xml:S2:1729:2	O
to	AFINITOR.xml:S2:1732:2	O
19%	AFINITOR.xml:S2:1735:3	O
of	AFINITOR.xml:S2:1739:2	O
patients	AFINITOR.xml:S2:1742:8	O
treated	AFINITOR.xml:S2:1751:7	O
with	AFINITOR.xml:S2:1759:4	O
AFINITOR	AFINITOR.xml:S2:1764:8	O
in	AFINITOR.xml:S2:1773:2	O
clinical	AFINITOR.xml:S2:1776:8	O
trials	AFINITOR.xml:S2:1785:6	O
.	AFINITOR.xml:S2:1791:1	O

The	AFINITOR.xml:S2:1793:3	O
incidence	AFINITOR.xml:S2:1797:9	O
of	AFINITOR.xml:S2:1807:2	O
Common	AFINITOR.xml:S2:1810:6	O
Terminology	AFINITOR.xml:S2:1817:11	O
Criteria	AFINITOR.xml:S2:1829:8	O
(	AFINITOR.xml:S2:1838:1	O
CTC	AFINITOR.xml:S2:1839:3	O
)	AFINITOR.xml:S2:1842:1	O
Grade	AFINITOR.xml:S2:1844:5	B-Severity
3	AFINITOR.xml:S2:1850:1	I-Severity
and	AFINITOR.xml:S2:1852:3	O
4	AFINITOR.xml:S2:1856:1	I-Severity
non	AFINITOR.xml:S2:1858:3	B-AdverseReaction
-	AFINITOR.xml:S2:1861:1	I-AdverseReaction
infectious	AFINITOR.xml:S2:1862:10	I-AdverseReaction
pneumonitis	AFINITOR.xml:S2:1873:11	I-AdverseReaction
was	AFINITOR.xml:S2:1885:3	O
up	AFINITOR.xml:S2:1889:2	O
to	AFINITOR.xml:S2:1892:2	O
4.0%	AFINITOR.xml:S2:1895:4	O
and	AFINITOR.xml:S2:1900:3	O
up	AFINITOR.xml:S2:1904:2	O
to	AFINITOR.xml:S2:1907:2	O
0.2%	AFINITOR.xml:S2:1910:4	O
,	AFINITOR.xml:S2:1914:1	O
respectively	AFINITOR.xml:S2:1916:12	O
[	AFINITOR.xml:S2:1930:1	O
see	AFINITOR.xml:S2:1931:3	O
Adverse	AFINITOR.xml:S2:1935:7	O
Reactions	AFINITOR.xml:S2:1943:9	O
(	AFINITOR.xml:S2:1953:1	O
6.1	AFINITOR.xml:S2:1954:3	O
,	AFINITOR.xml:S2:1957:1	O
6.2	AFINITOR.xml:S2:1959:3	O
,	AFINITOR.xml:S2:1962:1	O
6.3	AFINITOR.xml:S2:1964:3	O
,	AFINITOR.xml:S2:1967:1	O
6.4	AFINITOR.xml:S2:1969:3	O
,	AFINITOR.xml:S2:1972:1	O
6.5	AFINITOR.xml:S2:1974:3	O
)]	AFINITOR.xml:S2:1977:2	O
.	AFINITOR.xml:S2:1981:1	O

Fatal	AFINITOR.xml:S2:1983:5	B-AdverseReaction
outcomes	AFINITOR.xml:S2:1989:8	O
have	AFINITOR.xml:S2:1998:4	O
been	AFINITOR.xml:S2:2003:4	O
observed	AFINITOR.xml:S2:2008:8	O
.	AFINITOR.xml:S2:2016:1	O

Consider	AFINITOR.xml:S2:2022:8	B-Factor
a	AFINITOR.xml:S2:2031:1	O
diagnosis	AFINITOR.xml:S2:2033:9	O
of	AFINITOR.xml:S2:2043:2	O
non	AFINITOR.xml:S2:2046:3	O
-	AFINITOR.xml:S2:2049:1	O
infectious	AFINITOR.xml:S2:2050:10	O
pneumonitis	AFINITOR.xml:S2:2061:11	O
in	AFINITOR.xml:S2:2073:2	O
patients	AFINITOR.xml:S2:2076:8	O
presenting	AFINITOR.xml:S2:2085:10	O
with	AFINITOR.xml:S2:2096:4	O
non	AFINITOR.xml:S2:2101:3	O
-	AFINITOR.xml:S2:2104:1	O
specific	AFINITOR.xml:S2:2105:8	O
respiratory	AFINITOR.xml:S2:2114:11	O
signs	AFINITOR.xml:S2:2126:5	O
and	AFINITOR.xml:S2:2132:3	O
symptoms	AFINITOR.xml:S2:2136:8	O
such	AFINITOR.xml:S2:2145:4	O
as	AFINITOR.xml:S2:2150:2	O
hypoxia	AFINITOR.xml:S2:2153:7	O
,	AFINITOR.xml:S2:2160:1	O
pleural	AFINITOR.xml:S2:2162:7	O
effusion	AFINITOR.xml:S2:2170:8	O
,	AFINITOR.xml:S2:2178:1	O
cough	AFINITOR.xml:S2:2180:5	O
,	AFINITOR.xml:S2:2185:1	O
or	AFINITOR.xml:S2:2187:2	O
dyspnea	AFINITOR.xml:S2:2190:7	O
,	AFINITOR.xml:S2:2197:1	O
and	AFINITOR.xml:S2:2199:3	O
in	AFINITOR.xml:S2:2203:2	O
whom	AFINITOR.xml:S2:2206:4	O
infectious	AFINITOR.xml:S2:2211:10	O
,	AFINITOR.xml:S2:2221:1	O
neoplastic	AFINITOR.xml:S2:2223:10	O
,	AFINITOR.xml:S2:2233:1	O
and	AFINITOR.xml:S2:2235:3	O
other	AFINITOR.xml:S2:2239:5	O
causes	AFINITOR.xml:S2:2245:6	O
have	AFINITOR.xml:S2:2252:4	O
been	AFINITOR.xml:S2:2257:4	O
excluded	AFINITOR.xml:S2:2262:8	O
by	AFINITOR.xml:S2:2271:2	O
means	AFINITOR.xml:S2:2274:5	O
of	AFINITOR.xml:S2:2280:2	O
appropriate	AFINITOR.xml:S2:2283:11	O
investigations	AFINITOR.xml:S2:2295:14	O
.	AFINITOR.xml:S2:2309:1	O

Opportunistic	AFINITOR.xml:S2:2311:13	O
infections	AFINITOR.xml:S2:2325:10	O
such	AFINITOR.xml:S2:2336:4	O
as	AFINITOR.xml:S2:2341:2	O
pneumocystis	AFINITOR.xml:S2:2344:12	O
jiroveci	AFINITOR.xml:S2:2357:8	O
pneumonia	AFINITOR.xml:S2:2366:9	O
(	AFINITOR.xml:S2:2376:1	O
PJP	AFINITOR.xml:S2:2377:3	O
)	AFINITOR.xml:S2:2380:1	O
should	AFINITOR.xml:S2:2382:6	O
be	AFINITOR.xml:S2:2389:2	O
considered	AFINITOR.xml:S2:2392:10	O
in	AFINITOR.xml:S2:2403:2	O
the	AFINITOR.xml:S2:2406:3	O
differential	AFINITOR.xml:S2:2410:12	O
diagnosis	AFINITOR.xml:S2:2423:9	O
.	AFINITOR.xml:S2:2432:1	O

Advise	AFINITOR.xml:S2:2434:6	O
patients	AFINITOR.xml:S2:2441:8	O
to	AFINITOR.xml:S2:2450:2	O
report	AFINITOR.xml:S2:2453:6	O
promptly	AFINITOR.xml:S2:2460:8	O
any	AFINITOR.xml:S2:2469:3	O
new	AFINITOR.xml:S2:2473:3	O
or	AFINITOR.xml:S2:2477:2	O
worsening	AFINITOR.xml:S2:2480:9	O
respiratory	AFINITOR.xml:S2:2490:11	O
symptoms	AFINITOR.xml:S2:2502:8	O
.	AFINITOR.xml:S2:2510:1	O

Patients	AFINITOR.xml:S2:2516:8	O
who	AFINITOR.xml:S2:2525:3	O
develop	AFINITOR.xml:S2:2529:7	O
radiological	AFINITOR.xml:S2:2537:12	O
changes	AFINITOR.xml:S2:2550:7	O
suggestive	AFINITOR.xml:S2:2558:10	O
of	AFINITOR.xml:S2:2569:2	O
non	AFINITOR.xml:S2:2572:3	O
-	AFINITOR.xml:S2:2575:1	O
infectious	AFINITOR.xml:S2:2576:10	O
pneumonitis	AFINITOR.xml:S2:2587:11	O
and	AFINITOR.xml:S2:2599:3	O
have	AFINITOR.xml:S2:2603:4	O
few	AFINITOR.xml:S2:2608:3	O
or	AFINITOR.xml:S2:2612:2	O
no	AFINITOR.xml:S2:2615:2	O
symptoms	AFINITOR.xml:S2:2618:8	O
may	AFINITOR.xml:S2:2627:3	O
continue	AFINITOR.xml:S2:2631:8	O
AFINITOR	AFINITOR.xml:S2:2640:8	O
therapy	AFINITOR.xml:S2:2649:7	O
without	AFINITOR.xml:S2:2657:7	O
dose	AFINITOR.xml:S2:2665:4	O
alteration	AFINITOR.xml:S2:2670:10	O
.	AFINITOR.xml:S2:2680:1	O

Imaging	AFINITOR.xml:S2:2682:7	O
appears	AFINITOR.xml:S2:2690:7	O
to	AFINITOR.xml:S2:2698:2	O
overestimate	AFINITOR.xml:S2:2701:12	O
the	AFINITOR.xml:S2:2714:3	O
incidence	AFINITOR.xml:S2:2718:9	O
of	AFINITOR.xml:S2:2728:2	O
clinical	AFINITOR.xml:S2:2731:8	O
pneumonitis	AFINITOR.xml:S2:2740:11	O
.	AFINITOR.xml:S2:2751:1	O

If	AFINITOR.xml:S2:2757:2	O
symptoms	AFINITOR.xml:S2:2760:8	O
are	AFINITOR.xml:S2:2769:3	O
moderate	AFINITOR.xml:S2:2773:8	O
,	AFINITOR.xml:S2:2781:1	O
consider	AFINITOR.xml:S2:2783:8	O
interrupting	AFINITOR.xml:S2:2792:12	O
therapy	AFINITOR.xml:S2:2805:7	O
until	AFINITOR.xml:S2:2813:5	O
symptoms	AFINITOR.xml:S2:2819:8	O
improve	AFINITOR.xml:S2:2828:7	O
.	AFINITOR.xml:S2:2835:1	O

The	AFINITOR.xml:S2:2837:3	O
use	AFINITOR.xml:S2:2841:3	O
of	AFINITOR.xml:S2:2845:2	O
corticosteroids	AFINITOR.xml:S2:2848:15	O
may	AFINITOR.xml:S2:2864:3	O
be	AFINITOR.xml:S2:2868:2	O
indicated	AFINITOR.xml:S2:2871:9	B-Factor
.	AFINITOR.xml:S2:2880:1	O

AFINITOR	AFINITOR.xml:S2:2882:8	O
may	AFINITOR.xml:S2:2891:3	O
be	AFINITOR.xml:S2:2895:2	O
reintroduced	AFINITOR.xml:S2:2898:12	O
at	AFINITOR.xml:S2:2911:2	O
a	AFINITOR.xml:S2:2914:1	O
daily	AFINITOR.xml:S2:2916:5	O
dose	AFINITOR.xml:S2:2922:4	O
approximately	AFINITOR.xml:S2:2927:13	O
50%	AFINITOR.xml:S2:2941:3	O
lower	AFINITOR.xml:S2:2945:5	O
than	AFINITOR.xml:S2:2951:4	O
the	AFINITOR.xml:S2:2956:3	O
dose	AFINITOR.xml:S2:2960:4	O
previously	AFINITOR.xml:S2:2965:10	O
administered	AFINITOR.xml:S2:2976:12	O
[	AFINITOR.xml:S2:2989:1	O
see	AFINITOR.xml:S2:2990:3	O
Table	AFINITOR.xml:S2:2994:5	O
1	AFINITOR.xml:S2:3000:1	O
in	AFINITOR.xml:S2:3002:2	O
Dosage	AFINITOR.xml:S2:3005:6	O
and	AFINITOR.xml:S2:3012:3	O
Administration	AFINITOR.xml:S2:3016:14	O
(	AFINITOR.xml:S2:3031:1	O
2.2	AFINITOR.xml:S2:3032:3	O
)]	AFINITOR.xml:S2:3035:2	O
.	AFINITOR.xml:S2:3039:1	O

For	AFINITOR.xml:S2:3045:3	O
cases	AFINITOR.xml:S2:3049:5	O
of	AFINITOR.xml:S2:3055:2	O
Grade	AFINITOR.xml:S2:3058:5	O
3	AFINITOR.xml:S2:3064:1	O
non	AFINITOR.xml:S2:3066:3	O
-	AFINITOR.xml:S2:3069:1	O
infectious	AFINITOR.xml:S2:3070:10	O
pneumonitis	AFINITOR.xml:S2:3081:11	O
interrupt	AFINITOR.xml:S2:3093:9	O
AFINITOR	AFINITOR.xml:S2:3103:8	O
until	AFINITOR.xml:S2:3112:5	O
resolution	AFINITOR.xml:S2:3118:10	O
to	AFINITOR.xml:S2:3129:2	O
less	AFINITOR.xml:S2:3132:4	O
than	AFINITOR.xml:S2:3137:4	O
or	AFINITOR.xml:S2:3142:2	O
equal	AFINITOR.xml:S2:3145:5	O
to	AFINITOR.xml:S2:3151:2	O
Grade	AFINITOR.xml:S2:3154:5	O
1	AFINITOR.xml:S2:3160:1	O
.	AFINITOR.xml:S2:3161:1	O

AFINITOR	AFINITOR.xml:S2:3163:8	O
may	AFINITOR.xml:S2:3172:3	O
be	AFINITOR.xml:S2:3176:2	O
re	AFINITOR.xml:S2:3179:2	O
-	AFINITOR.xml:S2:3181:1	O
introduced	AFINITOR.xml:S2:3182:10	O
at	AFINITOR.xml:S2:3193:2	O
a	AFINITOR.xml:S2:3196:1	O
daily	AFINITOR.xml:S2:3198:5	O
dose	AFINITOR.xml:S2:3204:4	O
approximately	AFINITOR.xml:S2:3209:13	O
50%	AFINITOR.xml:S2:3223:3	O
lower	AFINITOR.xml:S2:3227:5	O
than	AFINITOR.xml:S2:3233:4	O
the	AFINITOR.xml:S2:3238:3	O
dose	AFINITOR.xml:S2:3242:4	O
previously	AFINITOR.xml:S2:3247:10	O
administered	AFINITOR.xml:S2:3258:12	O
depending	AFINITOR.xml:S2:3271:9	O
on	AFINITOR.xml:S2:3281:2	O
the	AFINITOR.xml:S2:3284:3	O
individual	AFINITOR.xml:S2:3288:10	O
clinical	AFINITOR.xml:S2:3299:8	O
circumstances	AFINITOR.xml:S2:3308:13	O
[	AFINITOR.xml:S2:3322:1	O
see	AFINITOR.xml:S2:3323:3	O
Dosage	AFINITOR.xml:S2:3327:6	O
and	AFINITOR.xml:S2:3334:3	O
Administration	AFINITOR.xml:S2:3338:14	O
(	AFINITOR.xml:S2:3353:1	O
2.2	AFINITOR.xml:S2:3354:3	O
)]	AFINITOR.xml:S2:3357:2	O
.	AFINITOR.xml:S2:3361:1	O

If	AFINITOR.xml:S2:3363:2	O
toxicity	AFINITOR.xml:S2:3366:8	O
recurs	AFINITOR.xml:S2:3375:6	O
at	AFINITOR.xml:S2:3382:2	O
Grade	AFINITOR.xml:S2:3385:5	O
3	AFINITOR.xml:S2:3391:1	O
,	AFINITOR.xml:S2:3392:1	O
consider	AFINITOR.xml:S2:3394:8	O
discontinuation	AFINITOR.xml:S2:3403:15	O
of	AFINITOR.xml:S2:3419:2	O
AFINITOR	AFINITOR.xml:S2:3422:8	O
.	AFINITOR.xml:S2:3430:1	O

For	AFINITOR.xml:S2:3432:3	O
cases	AFINITOR.xml:S2:3436:5	O
of	AFINITOR.xml:S2:3442:2	O
Grade	AFINITOR.xml:S2:3445:5	O
4	AFINITOR.xml:S2:3451:1	O
non	AFINITOR.xml:S2:3453:3	O
-	AFINITOR.xml:S2:3456:1	O
infectious	AFINITOR.xml:S2:3457:10	O
pneumonitis	AFINITOR.xml:S2:3468:11	O
,	AFINITOR.xml:S2:3479:1	O
discontinue	AFINITOR.xml:S2:3481:11	O
AFINITOR	AFINITOR.xml:S2:3493:8	O
.	AFINITOR.xml:S2:3501:1	O

Corticosteroids	AFINITOR.xml:S2:3503:15	O
may	AFINITOR.xml:S2:3519:3	O
be	AFINITOR.xml:S2:3523:2	O
indicated	AFINITOR.xml:S2:3526:9	O
until	AFINITOR.xml:S2:3536:5	O
clinical	AFINITOR.xml:S2:3542:8	O
symptoms	AFINITOR.xml:S2:3551:8	O
resolve	AFINITOR.xml:S2:3560:7	O
.	AFINITOR.xml:S2:3567:1	O

For	AFINITOR.xml:S2:3569:3	O
patients	AFINITOR.xml:S2:3573:8	O
who	AFINITOR.xml:S2:3582:3	O
require	AFINITOR.xml:S2:3586:7	O
use	AFINITOR.xml:S2:3594:3	O
of	AFINITOR.xml:S2:3598:2	O
corticosteroids	AFINITOR.xml:S2:3601:15	O
for	AFINITOR.xml:S2:3617:3	O
treatment	AFINITOR.xml:S2:3621:9	O
of	AFINITOR.xml:S2:3631:2	O
non	AFINITOR.xml:S2:3634:3	O
-	AFINITOR.xml:S2:3637:1	O
infectious	AFINITOR.xml:S2:3638:10	O
pneumonitis	AFINITOR.xml:S2:3649:11	O
,	AFINITOR.xml:S2:3660:1	O
prophylaxis	AFINITOR.xml:S2:3662:11	O
for	AFINITOR.xml:S2:3674:3	O
PJP	AFINITOR.xml:S2:3678:3	O
may	AFINITOR.xml:S2:3682:3	O
be	AFINITOR.xml:S2:3686:2	O
considered	AFINITOR.xml:S2:3689:10	O
.	AFINITOR.xml:S2:3699:1	O

The	AFINITOR.xml:S2:3701:3	O
development	AFINITOR.xml:S2:3705:11	O
of	AFINITOR.xml:S2:3717:2	O
pneumonitis	AFINITOR.xml:S2:3720:11	B-AdverseReaction
has	AFINITOR.xml:S2:3732:3	O
been	AFINITOR.xml:S2:3736:4	O
reported	AFINITOR.xml:S2:3741:8	O
even	AFINITOR.xml:S2:3750:4	O
at	AFINITOR.xml:S2:3755:2	O
a	AFINITOR.xml:S2:3758:1	O
reduced	AFINITOR.xml:S2:3760:7	O
dose	AFINITOR.xml:S2:3768:4	O
.	AFINITOR.xml:S2:3772:1	O

5.2	AFINITOR.xml:S2:3781:3	O
Infections	AFINITOR.xml:S2:3789:10	O

AFINITOR	AFINITOR.xml:S2:3805:8	O
has	AFINITOR.xml:S2:3814:3	O
immunosuppressive	AFINITOR.xml:S2:3818:17	O
properties	AFINITOR.xml:S2:3836:10	O
and	AFINITOR.xml:S2:3847:3	O
may	AFINITOR.xml:S2:3851:3	B-Factor
predispose	AFINITOR.xml:S2:3855:10	O
patients	AFINITOR.xml:S2:3866:8	O
to	AFINITOR.xml:S2:3875:2	O
bacterial	AFINITOR.xml:S2:3878:9	B-AdverseReaction
,	AFINITOR.xml:S2:3887:1	O
fungal	AFINITOR.xml:S2:3889:6	B-AdverseReaction
,	AFINITOR.xml:S2:3895:1	O
viral	AFINITOR.xml:S2:3897:5	B-AdverseReaction
,	AFINITOR.xml:S2:3902:1	O
or	AFINITOR.xml:S2:3904:2	O
protozoal	AFINITOR.xml:S2:3907:9	B-AdverseReaction
infections	AFINITOR.xml:S2:3917:10	I-AdverseReaction
,	AFINITOR.xml:S2:3927:1	O
including	AFINITOR.xml:S2:3929:9	O
infections	AFINITOR.xml:S2:3939:10	B-AdverseReaction
with	AFINITOR.xml:S2:3950:4	I-AdverseReaction
opportunistic	AFINITOR.xml:S2:3955:13	I-AdverseReaction
pathogens	AFINITOR.xml:S2:3969:9	I-AdverseReaction
[	AFINITOR.xml:S2:3979:1	O
see	AFINITOR.xml:S2:3980:3	O
Adverse	AFINITOR.xml:S2:3984:7	O
Reactions	AFINITOR.xml:S2:3992:9	O
(	AFINITOR.xml:S2:4002:1	O
6.1	AFINITOR.xml:S2:4003:3	O
,	AFINITOR.xml:S2:4006:1	O
6.2	AFINITOR.xml:S2:4008:3	O
,	AFINITOR.xml:S2:4011:1	O
6.3	AFINITOR.xml:S2:4013:3	O
,	AFINITOR.xml:S2:4016:1	O
6.4	AFINITOR.xml:S2:4018:3	O
,	AFINITOR.xml:S2:4021:1	O
6.5	AFINITOR.xml:S2:4023:3	O
)]	AFINITOR.xml:S2:4026:2	O
.	AFINITOR.xml:S2:4030:1	O

Localized	AFINITOR.xml:S2:4032:9	O
and	AFINITOR.xml:S2:4042:3	O
systemic	AFINITOR.xml:S2:4046:8	O
infections	AFINITOR.xml:S2:4055:10	O
,	AFINITOR.xml:S2:4065:1	O
including	AFINITOR.xml:S2:4067:9	O
pneumonia	AFINITOR.xml:S2:4077:9	B-AdverseReaction
,	AFINITOR.xml:S2:4086:1	O
mycobacterial	AFINITOR.xml:S2:4088:13	B-AdverseReaction
infections	AFINITOR.xml:S2:4102:10	I-AdverseReaction
,	AFINITOR.xml:S2:4112:1	O
other	AFINITOR.xml:S2:4114:5	O
bacterial	AFINITOR.xml:S2:4120:9	B-AdverseReaction
infections	AFINITOR.xml:S2:4130:10	I-AdverseReaction
,	AFINITOR.xml:S2:4140:1	O
invasive	AFINITOR.xml:S2:4142:8	B-AdverseReaction
fungal	AFINITOR.xml:S2:4151:6	I-AdverseReaction
infections	AFINITOR.xml:S2:4158:10	I-AdverseReaction
,	AFINITOR.xml:S2:4168:1	O
such	AFINITOR.xml:S2:4170:4	O
as	AFINITOR.xml:S2:4175:2	O
aspergillosis	AFINITOR.xml:S2:4178:13	B-AdverseReaction
,	AFINITOR.xml:S2:4191:1	O
candidiasis	AFINITOR.xml:S2:4193:11	B-AdverseReaction
,	AFINITOR.xml:S2:4204:1	O
or	AFINITOR.xml:S2:4206:2	O
pneumocystis	AFINITOR.xml:S2:4209:12	B-AdverseReaction
jiroveci	AFINITOR.xml:S2:4222:8	I-AdverseReaction
pneumonia	AFINITOR.xml:S2:4231:9	I-AdverseReaction
(	AFINITOR.xml:S2:4241:1	O
PJP	AFINITOR.xml:S2:4242:3	B-AdverseReaction
)	AFINITOR.xml:S2:4245:1	O
and	AFINITOR.xml:S2:4247:3	O
viral	AFINITOR.xml:S2:4251:5	B-AdverseReaction
infections	AFINITOR.xml:S2:4257:10	I-AdverseReaction
including	AFINITOR.xml:S2:4268:9	O
reactivation	AFINITOR.xml:S2:4278:12	B-AdverseReaction
of	AFINITOR.xml:S2:4291:2	I-AdverseReaction
hepatitis	AFINITOR.xml:S2:4294:9	I-AdverseReaction
B	AFINITOR.xml:S2:4304:1	I-AdverseReaction
virus	AFINITOR.xml:S2:4306:5	I-AdverseReaction
have	AFINITOR.xml:S2:4312:4	O
occurred	AFINITOR.xml:S2:4317:8	O
in	AFINITOR.xml:S2:4326:2	O
patients	AFINITOR.xml:S2:4329:8	O
taking	AFINITOR.xml:S2:4338:6	O
AFINITOR	AFINITOR.xml:S2:4345:8	O
.	AFINITOR.xml:S2:4353:1	O

Some	AFINITOR.xml:S2:4355:4	O
of	AFINITOR.xml:S2:4360:2	O
these	AFINITOR.xml:S2:4363:5	O
infections	AFINITOR.xml:S2:4369:10	B-AdverseReaction
have	AFINITOR.xml:S2:4380:4	O
been	AFINITOR.xml:S2:4385:4	O
severe	AFINITOR.xml:S2:4390:6	B-Severity
(	AFINITOR.xml:S2:4397:1	O
e	AFINITOR.xml:S2:4398:1	O
.	AFINITOR.xml:S2:4399:1	O
g	AFINITOR.xml:S2:4400:1	O
.	AFINITOR.xml:S2:4401:1	O
,	AFINITOR.xml:S2:4402:1	O
leading	AFINITOR.xml:S2:4404:7	O
to	AFINITOR.xml:S2:4412:2	O
sepsis	AFINITOR.xml:S2:4415:6	B-AdverseReaction
,	AFINITOR.xml:S2:4421:1	O
respiratory	AFINITOR.xml:S2:4423:11	B-AdverseReaction
or	AFINITOR.xml:S2:4435:2	O
hepatic	AFINITOR.xml:S2:4438:7	B-AdverseReaction
failure	AFINITOR.xml:S2:4446:7	I-AdverseReaction
)	AFINITOR.xml:S2:4453:1	O
or	AFINITOR.xml:S2:4455:2	O
fatal	AFINITOR.xml:S2:4458:5	B-AdverseReaction
.	AFINITOR.xml:S2:4463:1	O

Physicians	AFINITOR.xml:S2:4465:10	O
and	AFINITOR.xml:S2:4476:3	O
patients	AFINITOR.xml:S2:4480:8	O
should	AFINITOR.xml:S2:4489:6	O
be	AFINITOR.xml:S2:4496:2	O
aware	AFINITOR.xml:S2:4499:5	O
of	AFINITOR.xml:S2:4505:2	O
the	AFINITOR.xml:S2:4508:3	O
increased	AFINITOR.xml:S2:4512:9	O
risk	AFINITOR.xml:S2:4522:4	O
of	AFINITOR.xml:S2:4527:2	O
infection	AFINITOR.xml:S2:4530:9	O
with	AFINITOR.xml:S2:4540:4	O
AFINITOR	AFINITOR.xml:S2:4545:8	O
.	AFINITOR.xml:S2:4553:1	O

Complete	AFINITOR.xml:S2:4555:8	O
treatment	AFINITOR.xml:S2:4564:9	O
of	AFINITOR.xml:S2:4574:2	O
pre	AFINITOR.xml:S2:4577:3	O
-	AFINITOR.xml:S2:4580:1	O
existing	AFINITOR.xml:S2:4581:8	O
invasive	AFINITOR.xml:S2:4590:8	O
fungal	AFINITOR.xml:S2:4599:6	O
infections	AFINITOR.xml:S2:4606:10	O
prior	AFINITOR.xml:S2:4617:5	O
to	AFINITOR.xml:S2:4623:2	O
starting	AFINITOR.xml:S2:4626:8	O
treatment	AFINITOR.xml:S2:4635:9	O
with	AFINITOR.xml:S2:4645:4	O
AFINITOR	AFINITOR.xml:S2:4650:8	O
.	AFINITOR.xml:S2:4658:1	O

While	AFINITOR.xml:S2:4660:5	O
taking	AFINITOR.xml:S2:4666:6	O
AFINITOR	AFINITOR.xml:S2:4673:8	O
,	AFINITOR.xml:S2:4681:1	O
be	AFINITOR.xml:S2:4683:2	O
vigilant	AFINITOR.xml:S2:4686:8	O
for	AFINITOR.xml:S2:4695:3	O
signs	AFINITOR.xml:S2:4699:5	O
and	AFINITOR.xml:S2:4705:3	O
symptoms	AFINITOR.xml:S2:4709:8	O
of	AFINITOR.xml:S2:4718:2	O
infection	AFINITOR.xml:S2:4721:9	O
;	AFINITOR.xml:S2:4730:1	O
if	AFINITOR.xml:S2:4732:2	O
a	AFINITOR.xml:S2:4735:1	O
diagnosis	AFINITOR.xml:S2:4737:9	O
of	AFINITOR.xml:S2:4747:2	O
an	AFINITOR.xml:S2:4750:2	O
infection	AFINITOR.xml:S2:4753:9	O
is	AFINITOR.xml:S2:4763:2	O
made	AFINITOR.xml:S2:4766:4	O
,	AFINITOR.xml:S2:4770:1	O
institute	AFINITOR.xml:S2:4772:9	O
appropriate	AFINITOR.xml:S2:4782:11	O
treatment	AFINITOR.xml:S2:4794:9	O
promptly	AFINITOR.xml:S2:4804:8	O
and	AFINITOR.xml:S2:4813:3	O
consider	AFINITOR.xml:S2:4817:8	O
interruption	AFINITOR.xml:S2:4826:12	O
or	AFINITOR.xml:S2:4839:2	O
discontinuation	AFINITOR.xml:S2:4842:15	O
of	AFINITOR.xml:S2:4858:2	O
AFINITOR	AFINITOR.xml:S2:4861:8	O
.	AFINITOR.xml:S2:4869:1	O

If	AFINITOR.xml:S2:4871:2	O
a	AFINITOR.xml:S2:4874:1	O
diagnosis	AFINITOR.xml:S2:4876:9	O
of	AFINITOR.xml:S2:4886:2	O
invasive	AFINITOR.xml:S2:4889:8	O
systemic	AFINITOR.xml:S2:4898:8	O
fungal	AFINITOR.xml:S2:4907:6	O
infection	AFINITOR.xml:S2:4914:9	O
is	AFINITOR.xml:S2:4924:2	O
made	AFINITOR.xml:S2:4927:4	O
,	AFINITOR.xml:S2:4931:1	O
discontinue	AFINITOR.xml:S2:4933:11	O
AFINITOR	AFINITOR.xml:S2:4945:8	O
and	AFINITOR.xml:S2:4954:3	O
treat	AFINITOR.xml:S2:4958:5	O
with	AFINITOR.xml:S2:4964:4	O
appropriate	AFINITOR.xml:S2:4969:11	O
antifungal	AFINITOR.xml:S2:4981:10	O
therapy	AFINITOR.xml:S2:4992:7	O
.	AFINITOR.xml:S2:4999:1	O

Pneumocystis	AFINITOR.xml:S2:5005:12	B-AdverseReaction
jiroveci	AFINITOR.xml:S2:5018:8	I-AdverseReaction
pneumonia	AFINITOR.xml:S2:5027:9	I-AdverseReaction
,	AFINITOR.xml:S2:5036:1	O
some	AFINITOR.xml:S2:5038:4	O
with	AFINITOR.xml:S2:5043:4	O
a	AFINITOR.xml:S2:5048:1	O
fatal	AFINITOR.xml:S2:5050:5	B-AdverseReaction
outcome	AFINITOR.xml:S2:5056:7	O
,	AFINITOR.xml:S2:5063:1	O
has	AFINITOR.xml:S2:5065:3	O
been	AFINITOR.xml:S2:5069:4	O
reported	AFINITOR.xml:S2:5074:8	O
in	AFINITOR.xml:S2:5083:2	O
patients	AFINITOR.xml:S2:5086:8	O
who	AFINITOR.xml:S2:5095:3	O
received	AFINITOR.xml:S2:5099:8	O
everolimus	AFINITOR.xml:S2:5108:10	O
.	AFINITOR.xml:S2:5118:1	O

This	AFINITOR.xml:S2:5120:4	O
may	AFINITOR.xml:S2:5125:3	O
be	AFINITOR.xml:S2:5129:2	O
associated	AFINITOR.xml:S2:5132:10	O
with	AFINITOR.xml:S2:5143:4	O
concomitant	AFINITOR.xml:S2:5148:11	O
use	AFINITOR.xml:S2:5160:3	O
of	AFINITOR.xml:S2:5164:2	O
corticosteroids	AFINITOR.xml:S2:5167:15	O
or	AFINITOR.xml:S2:5183:2	O
other	AFINITOR.xml:S2:5186:5	O
immunosuppressive	AFINITOR.xml:S2:5192:17	O
agents	AFINITOR.xml:S2:5210:6	O
.	AFINITOR.xml:S2:5216:1	O

Prophylaxis	AFINITOR.xml:S2:5218:11	O
for	AFINITOR.xml:S2:5230:3	O
PJP	AFINITOR.xml:S2:5234:3	O
should	AFINITOR.xml:S2:5238:6	O
be	AFINITOR.xml:S2:5245:2	O
considered	AFINITOR.xml:S2:5248:10	O
when	AFINITOR.xml:S2:5259:4	O
concomitant	AFINITOR.xml:S2:5264:11	O
use	AFINITOR.xml:S2:5276:3	O
of	AFINITOR.xml:S2:5280:2	O
corticosteroids	AFINITOR.xml:S2:5283:15	O
or	AFINITOR.xml:S2:5299:2	O
other	AFINITOR.xml:S2:5302:5	O
immunosuppressive	AFINITOR.xml:S2:5308:17	O
agents	AFINITOR.xml:S2:5326:6	O
are	AFINITOR.xml:S2:5333:3	O
required	AFINITOR.xml:S2:5337:8	O
.	AFINITOR.xml:S2:5345:1	O

5.3	AFINITOR.xml:S2:5354:3	O
Angioedema	AFINITOR.xml:S2:5362:10	O
with	AFINITOR.xml:S2:5373:4	O
Concomitant	AFINITOR.xml:S2:5378:11	O
Use	AFINITOR.xml:S2:5390:3	O
of	AFINITOR.xml:S2:5394:2	O
Angiotensin	AFINITOR.xml:S2:5397:11	O
-	AFINITOR.xml:S2:5408:1	O
Converting	AFINITOR.xml:S2:5409:10	O
Enzyme	AFINITOR.xml:S2:5420:6	O
(	AFINITOR.xml:S2:5427:1	O
ACE	AFINITOR.xml:S2:5428:3	O
)	AFINITOR.xml:S2:5431:1	O
Inhibitors	AFINITOR.xml:S2:5433:10	O

Patients	AFINITOR.xml:S2:5450:8	O
taking	AFINITOR.xml:S2:5459:6	O
concomitant	AFINITOR.xml:S2:5466:11	O
ACE	AFINITOR.xml:S2:5478:3	O
inhibitor	AFINITOR.xml:S2:5482:9	O
therapy	AFINITOR.xml:S2:5492:7	O
may	AFINITOR.xml:S2:5500:3	O
be	AFINITOR.xml:S2:5504:2	O
at	AFINITOR.xml:S2:5507:2	O
increased	AFINITOR.xml:S2:5510:9	O
risk	AFINITOR.xml:S2:5520:4	B-Factor
for	AFINITOR.xml:S2:5525:3	O
angioedema	AFINITOR.xml:S2:5529:10	B-AdverseReaction
(	AFINITOR.xml:S2:5540:1	O
e	AFINITOR.xml:S2:5541:1	O
.	AFINITOR.xml:S2:5542:1	O
g	AFINITOR.xml:S2:5543:1	O
.	AFINITOR.xml:S2:5544:1	O
,	AFINITOR.xml:S2:5545:1	O
swelling	AFINITOR.xml:S2:5547:8	B-AdverseReaction
of	AFINITOR.xml:S2:5556:2	I-AdverseReaction
the	AFINITOR.xml:S2:5559:3	I-AdverseReaction
airways	AFINITOR.xml:S2:5563:7	I-AdverseReaction
or	AFINITOR.xml:S2:5571:2	O
tongue	AFINITOR.xml:S2:5574:6	I-AdverseReaction
,	AFINITOR.xml:S2:5580:1	O
with	AFINITOR.xml:S2:5582:4	O
or	AFINITOR.xml:S2:5587:2	O
without	AFINITOR.xml:S2:5590:7	O
respiratory	AFINITOR.xml:S2:5598:11	B-AdverseReaction
impairment	AFINITOR.xml:S2:5610:10	I-AdverseReaction
)	AFINITOR.xml:S2:5620:1	O
.	AFINITOR.xml:S2:5621:1	O

In	AFINITOR.xml:S2:5623:2	O
a	AFINITOR.xml:S2:5626:1	O
pooled	AFINITOR.xml:S2:5628:6	O
analysis	AFINITOR.xml:S2:5635:8	O
of	AFINITOR.xml:S2:5644:2	O
randomized	AFINITOR.xml:S2:5647:10	O
double	AFINITOR.xml:S2:5658:6	O
-	AFINITOR.xml:S2:5664:1	O
blind	AFINITOR.xml:S2:5665:5	O
oncology	AFINITOR.xml:S2:5671:8	O
clinical	AFINITOR.xml:S2:5680:8	O
trials	AFINITOR.xml:S2:5689:6	O
,	AFINITOR.xml:S2:5695:1	O
the	AFINITOR.xml:S2:5697:3	O
incidence	AFINITOR.xml:S2:5701:9	O
of	AFINITOR.xml:S2:5711:2	O
angioedema	AFINITOR.xml:S2:5714:10	B-AdverseReaction
in	AFINITOR.xml:S2:5725:2	O
patients	AFINITOR.xml:S2:5728:8	O
taking	AFINITOR.xml:S2:5737:6	O
everolimus	AFINITOR.xml:S2:5744:10	O
with	AFINITOR.xml:S2:5755:4	O
an	AFINITOR.xml:S2:5760:2	O
ACE	AFINITOR.xml:S2:5763:3	O
inhibitor	AFINITOR.xml:S2:5767:9	O
was	AFINITOR.xml:S2:5777:3	O
6.8%	AFINITOR.xml:S2:5781:4	O
compared	AFINITOR.xml:S2:5786:8	O
to	AFINITOR.xml:S2:5795:2	O
1.3%	AFINITOR.xml:S2:5798:4	O
in	AFINITOR.xml:S2:5803:2	O
the	AFINITOR.xml:S2:5806:3	O
control	AFINITOR.xml:S2:5810:7	O
arm	AFINITOR.xml:S2:5818:3	O
with	AFINITOR.xml:S2:5822:4	O
an	AFINITOR.xml:S2:5827:2	O
ACE	AFINITOR.xml:S2:5830:3	O
inhibitor	AFINITOR.xml:S2:5834:9	O
.	AFINITOR.xml:S2:5843:1	O

5.4	AFINITOR.xml:S2:5854:3	O
Oral	AFINITOR.xml:S2:5862:4	O
Ulceration	AFINITOR.xml:S2:5867:10	O

Mouth	AFINITOR.xml:S2:5883:5	B-AdverseReaction
ulcers	AFINITOR.xml:S2:5889:6	I-AdverseReaction
,	AFINITOR.xml:S2:5895:1	O
stomatitis	AFINITOR.xml:S2:5897:10	B-AdverseReaction
,	AFINITOR.xml:S2:5907:1	O
and	AFINITOR.xml:S2:5909:3	O
oral	AFINITOR.xml:S2:5913:4	B-AdverseReaction
mucositis	AFINITOR.xml:S2:5918:9	I-AdverseReaction
have	AFINITOR.xml:S2:5928:4	O
occurred	AFINITOR.xml:S2:5933:8	O
in	AFINITOR.xml:S2:5942:2	O
patients	AFINITOR.xml:S2:5945:8	O
treated	AFINITOR.xml:S2:5954:7	O
with	AFINITOR.xml:S2:5962:4	O
AFINITOR	AFINITOR.xml:S2:5967:8	O
at	AFINITOR.xml:S2:5976:2	O
an	AFINITOR.xml:S2:5979:2	O
incidence	AFINITOR.xml:S2:5982:9	O
ranging	AFINITOR.xml:S2:5992:7	O
from	AFINITOR.xml:S2:6000:4	O
44%	AFINITOR.xml:S2:6005:3	O
-	AFINITOR.xml:S2:6008:1	O
78%	AFINITOR.xml:S2:6009:3	O
across	AFINITOR.xml:S2:6013:6	O
the	AFINITOR.xml:S2:6020:3	O
clinical	AFINITOR.xml:S2:6024:8	O
trial	AFINITOR.xml:S2:6033:5	O
experience	AFINITOR.xml:S2:6039:10	O
.	AFINITOR.xml:S2:6049:1	O

Grade	AFINITOR.xml:S2:6051:5	B-Severity
3	AFINITOR.xml:S2:6057:1	I-Severity
or	AFINITOR.xml:S2:6059:2	O
4	AFINITOR.xml:S2:6062:1	I-Severity
stomatitis	AFINITOR.xml:S2:6064:10	B-AdverseReaction
was	AFINITOR.xml:S2:6075:3	O
reported	AFINITOR.xml:S2:6079:8	O
in	AFINITOR.xml:S2:6088:2	O
4%	AFINITOR.xml:S2:6091:2	O
-	AFINITOR.xml:S2:6093:1	O
9%	AFINITOR.xml:S2:6094:2	O
of	AFINITOR.xml:S2:6097:2	O
patients	AFINITOR.xml:S2:6100:8	O
[	AFINITOR.xml:S2:6109:1	O
see	AFINITOR.xml:S2:6110:3	O
Adverse	AFINITOR.xml:S2:6114:7	O
Reactions	AFINITOR.xml:S2:6122:9	O
(	AFINITOR.xml:S2:6132:1	O
6.1	AFINITOR.xml:S2:6133:3	O
,	AFINITOR.xml:S2:6136:1	O
6.2	AFINITOR.xml:S2:6138:3	O
,	AFINITOR.xml:S2:6141:1	O
6.3	AFINITOR.xml:S2:6143:3	O
,	AFINITOR.xml:S2:6146:1	O
6.4	AFINITOR.xml:S2:6148:3	O
,	AFINITOR.xml:S2:6151:1	O
6.5	AFINITOR.xml:S2:6153:3	O
)]	AFINITOR.xml:S2:6156:2	O
.	AFINITOR.xml:S2:6160:1	O

In	AFINITOR.xml:S2:6162:2	O
such	AFINITOR.xml:S2:6165:4	O
cases	AFINITOR.xml:S2:6170:5	O
,	AFINITOR.xml:S2:6175:1	O
topical	AFINITOR.xml:S2:6177:7	O
treatments	AFINITOR.xml:S2:6185:10	O
are	AFINITOR.xml:S2:6196:3	O
recommended	AFINITOR.xml:S2:6200:11	O
,	AFINITOR.xml:S2:6211:1	O
but	AFINITOR.xml:S2:6213:3	O
alcohol	AFINITOR.xml:S2:6217:7	O
-	AFINITOR.xml:S2:6224:1	O
,	AFINITOR.xml:S2:6225:1	O
hydrogen	AFINITOR.xml:S2:6227:8	O
peroxide	AFINITOR.xml:S2:6236:8	O
-	AFINITOR.xml:S2:6244:1	O
,	AFINITOR.xml:S2:6245:1	O
iodine	AFINITOR.xml:S2:6247:6	O
-	AFINITOR.xml:S2:6253:1	O
,	AFINITOR.xml:S2:6254:1	O
or	AFINITOR.xml:S2:6256:2	O
thyme	AFINITOR.xml:S2:6259:5	O
-	AFINITOR.xml:S2:6264:1	O
containing	AFINITOR.xml:S2:6266:10	O
mouthwashes	AFINITOR.xml:S2:6277:11	O
should	AFINITOR.xml:S2:6289:6	O
be	AFINITOR.xml:S2:6296:2	O
avoided	AFINITOR.xml:S2:6299:7	O
as	AFINITOR.xml:S2:6307:2	O
they	AFINITOR.xml:S2:6310:4	O
may	AFINITOR.xml:S2:6315:3	O
exacerbate	AFINITOR.xml:S2:6319:10	O
the	AFINITOR.xml:S2:6330:3	O
condition	AFINITOR.xml:S2:6334:9	O
.	AFINITOR.xml:S2:6343:1	O

Antifungal	AFINITOR.xml:S2:6345:10	O
agents	AFINITOR.xml:S2:6356:6	O
should	AFINITOR.xml:S2:6363:6	O
not	AFINITOR.xml:S2:6370:3	O
be	AFINITOR.xml:S2:6374:2	O
used	AFINITOR.xml:S2:6377:4	O
unless	AFINITOR.xml:S2:6382:6	O
fungal	AFINITOR.xml:S2:6389:6	O
infection	AFINITOR.xml:S2:6396:9	O
has	AFINITOR.xml:S2:6406:3	O
been	AFINITOR.xml:S2:6410:4	O
diagnosed	AFINITOR.xml:S2:6415:9	O
[	AFINITOR.xml:S2:6425:1	O
see	AFINITOR.xml:S2:6426:3	O
Drug	AFINITOR.xml:S2:6430:4	O
Interactions	AFINITOR.xml:S2:6435:12	O
(	AFINITOR.xml:S2:6448:1	O
7.1	AFINITOR.xml:S2:6449:3	O
)]	AFINITOR.xml:S2:6452:2	O
.	AFINITOR.xml:S2:6456:1	O

5.5	AFINITOR.xml:S2:6465:3	O
Renal	AFINITOR.xml:S2:6473:5	O
Failure	AFINITOR.xml:S2:6479:7	O

Cases	AFINITOR.xml:S2:6492:5	O
of	AFINITOR.xml:S2:6498:2	O
renal	AFINITOR.xml:S2:6501:5	B-AdverseReaction
failure	AFINITOR.xml:S2:6507:7	I-AdverseReaction
(	AFINITOR.xml:S2:6515:1	O
including	AFINITOR.xml:S2:6516:9	O
acute	AFINITOR.xml:S2:6526:5	B-AdverseReaction
renal	AFINITOR.xml:S2:6532:5	I-AdverseReaction
failure	AFINITOR.xml:S2:6538:7	I-AdverseReaction
)	AFINITOR.xml:S2:6545:1	O
,	AFINITOR.xml:S2:6546:1	O
some	AFINITOR.xml:S2:6548:4	O
with	AFINITOR.xml:S2:6553:4	O
a	AFINITOR.xml:S2:6558:1	O
fatal	AFINITOR.xml:S2:6560:5	B-AdverseReaction
outcome	AFINITOR.xml:S2:6566:7	O
,	AFINITOR.xml:S2:6573:1	O
have	AFINITOR.xml:S2:6575:4	O
been	AFINITOR.xml:S2:6580:4	O
observed	AFINITOR.xml:S2:6585:8	O
in	AFINITOR.xml:S2:6594:2	O
patients	AFINITOR.xml:S2:6597:8	O
treated	AFINITOR.xml:S2:6606:7	O
with	AFINITOR.xml:S2:6614:4	O
AFINITOR	AFINITOR.xml:S2:6619:8	O
[	AFINITOR.xml:S2:6628:1	O
see	AFINITOR.xml:S2:6629:3	O
Laboratory	AFINITOR.xml:S2:6633:10	O
Tests	AFINITOR.xml:S2:6644:5	O
and	AFINITOR.xml:S2:6650:3	O
Monitoring	AFINITOR.xml:S2:6654:10	O
(	AFINITOR.xml:S2:6665:1	O
5.8	AFINITOR.xml:S2:6666:3	O
)]	AFINITOR.xml:S2:6669:2	O
.	AFINITOR.xml:S2:6673:1	O

5.6	AFINITOR.xml:S2:6682:3	O
Impaired	AFINITOR.xml:S2:6690:8	O
Wound	AFINITOR.xml:S2:6699:5	O
Healing	AFINITOR.xml:S2:6705:7	O

Everolimus	AFINITOR.xml:S2:6718:10	O
delays	AFINITOR.xml:S2:6729:6	B-AdverseReaction
wound	AFINITOR.xml:S2:6736:5	I-AdverseReaction
healing	AFINITOR.xml:S2:6742:7	I-AdverseReaction
and	AFINITOR.xml:S2:6750:3	O
increases	AFINITOR.xml:S2:6754:9	O
the	AFINITOR.xml:S2:6764:3	O
occurrence	AFINITOR.xml:S2:6768:10	O
of	AFINITOR.xml:S2:6779:2	O
wound	AFINITOR.xml:S2:6782:5	B-AdverseReaction
-	AFINITOR.xml:S2:6787:1	I-AdverseReaction
related	AFINITOR.xml:S2:6788:7	I-AdverseReaction
complications	AFINITOR.xml:S2:6796:13	I-AdverseReaction
like	AFINITOR.xml:S2:6810:4	O
wound	AFINITOR.xml:S2:6815:5	B-AdverseReaction
dehiscence	AFINITOR.xml:S2:6821:10	I-AdverseReaction
,	AFINITOR.xml:S2:6831:1	O
wound	AFINITOR.xml:S2:6833:5	B-AdverseReaction
infection	AFINITOR.xml:S2:6839:9	I-AdverseReaction
,	AFINITOR.xml:S2:6848:1	O
incisional	AFINITOR.xml:S2:6850:10	B-AdverseReaction
hernia	AFINITOR.xml:S2:6861:6	I-AdverseReaction
,	AFINITOR.xml:S2:6867:1	O
lymphocele	AFINITOR.xml:S2:6869:10	B-AdverseReaction
,	AFINITOR.xml:S2:6879:1	O
and	AFINITOR.xml:S2:6881:3	O
seroma	AFINITOR.xml:S2:6885:6	B-AdverseReaction
.	AFINITOR.xml:S2:6891:1	O

These	AFINITOR.xml:S2:6893:5	O
wound	AFINITOR.xml:S2:6899:5	O
-	AFINITOR.xml:S2:6904:1	O
related	AFINITOR.xml:S2:6905:7	O
complications	AFINITOR.xml:S2:6913:13	O
may	AFINITOR.xml:S2:6927:3	O
require	AFINITOR.xml:S2:6931:7	O
surgical	AFINITOR.xml:S2:6939:8	O
intervention	AFINITOR.xml:S2:6948:12	O
.	AFINITOR.xml:S2:6960:1	O

Exercise	AFINITOR.xml:S2:6962:8	O
caution	AFINITOR.xml:S2:6971:7	O
with	AFINITOR.xml:S2:6979:4	O
the	AFINITOR.xml:S2:6984:3	O
use	AFINITOR.xml:S2:6988:3	O
of	AFINITOR.xml:S2:6992:2	O
AFINITOR	AFINITOR.xml:S2:6995:8	O
in	AFINITOR.xml:S2:7004:2	O
the	AFINITOR.xml:S2:7007:3	O
peri	AFINITOR.xml:S2:7011:4	O
-	AFINITOR.xml:S2:7015:1	O
surgical	AFINITOR.xml:S2:7016:8	O
period	AFINITOR.xml:S2:7025:6	O
.	AFINITOR.xml:S2:7031:1	O

5.7	AFINITOR.xml:S2:7040:3	O
Geriatric	AFINITOR.xml:S2:7048:9	O
Patients	AFINITOR.xml:S2:7058:8	O

In	AFINITOR.xml:S2:7072:2	O
the	AFINITOR.xml:S2:7075:3	O
randomized	AFINITOR.xml:S2:7079:10	O
advanced	AFINITOR.xml:S2:7090:8	O
hormone	AFINITOR.xml:S2:7099:7	O
receptor	AFINITOR.xml:S2:7107:8	O
-	AFINITOR.xml:S2:7115:1	O
positive	AFINITOR.xml:S2:7116:8	O
,	AFINITOR.xml:S2:7124:1	O
HER2	AFINITOR.xml:S2:7126:4	O
-	AFINITOR.xml:S2:7130:1	O
negative	AFINITOR.xml:S2:7131:8	O
breast	AFINITOR.xml:S2:7140:6	O
cancer	AFINITOR.xml:S2:7147:6	O
study	AFINITOR.xml:S2:7154:5	O
,	AFINITOR.xml:S2:7159:1	O
the	AFINITOR.xml:S2:7161:3	O
incidence	AFINITOR.xml:S2:7165:9	O
of	AFINITOR.xml:S2:7175:2	O
deaths	AFINITOR.xml:S2:7178:6	B-AdverseReaction
due	AFINITOR.xml:S2:7185:3	O
to	AFINITOR.xml:S2:7189:2	O
any	AFINITOR.xml:S2:7192:3	O
cause	AFINITOR.xml:S2:7196:5	O
within	AFINITOR.xml:S2:7202:6	O
28	AFINITOR.xml:S2:7209:2	O
days	AFINITOR.xml:S2:7212:4	O
of	AFINITOR.xml:S2:7217:2	O
the	AFINITOR.xml:S2:7220:3	O
last	AFINITOR.xml:S2:7224:4	O
AFINITOR	AFINITOR.xml:S2:7229:8	O
dose	AFINITOR.xml:S2:7238:4	O
was	AFINITOR.xml:S2:7243:3	O
6%	AFINITOR.xml:S2:7247:2	O
in	AFINITOR.xml:S2:7250:2	O
patients	AFINITOR.xml:S2:7253:8	O
65	AFINITOR.xml:S2:7265:2	O
years	AFINITOR.xml:S2:7268:5	O
of	AFINITOR.xml:S2:7274:2	O
age	AFINITOR.xml:S2:7277:3	O
compared	AFINITOR.xml:S2:7281:8	O
to	AFINITOR.xml:S2:7290:2	O
2%	AFINITOR.xml:S2:7293:2	O
in	AFINITOR.xml:S2:7296:2	O
patients	AFINITOR.xml:S2:7299:8	O
65	AFINITOR.xml:S2:7310:2	O
years	AFINITOR.xml:S2:7313:5	O
of	AFINITOR.xml:S2:7319:2	O
age	AFINITOR.xml:S2:7322:3	O
.	AFINITOR.xml:S2:7325:1	O

Adverse	AFINITOR.xml:S2:7327:7	O
reactions	AFINITOR.xml:S2:7335:9	O
leading	AFINITOR.xml:S2:7345:7	O
to	AFINITOR.xml:S2:7353:2	O
permanent	AFINITOR.xml:S2:7356:9	O
treatment	AFINITOR.xml:S2:7366:9	O
discontinuation	AFINITOR.xml:S2:7376:15	O
occurred	AFINITOR.xml:S2:7392:8	O
in	AFINITOR.xml:S2:7401:2	O
33%	AFINITOR.xml:S2:7404:3	O
of	AFINITOR.xml:S2:7408:2	O
patients	AFINITOR.xml:S2:7411:8	O
65	AFINITOR.xml:S2:7423:2	O
years	AFINITOR.xml:S2:7426:5	O
of	AFINITOR.xml:S2:7432:2	O
age	AFINITOR.xml:S2:7435:3	O
compared	AFINITOR.xml:S2:7439:8	O
to	AFINITOR.xml:S2:7448:2	O
17%	AFINITOR.xml:S2:7451:3	O
in	AFINITOR.xml:S2:7455:2	O
patients	AFINITOR.xml:S2:7458:8	O
65	AFINITOR.xml:S2:7469:2	O
years	AFINITOR.xml:S2:7472:5	O
of	AFINITOR.xml:S2:7478:2	O
age	AFINITOR.xml:S2:7481:3	O
.	AFINITOR.xml:S2:7484:1	O

Careful	AFINITOR.xml:S2:7486:7	O
monitoring	AFINITOR.xml:S2:7494:10	O
and	AFINITOR.xml:S2:7505:3	O
appropriate	AFINITOR.xml:S2:7509:11	O
dose	AFINITOR.xml:S2:7521:4	O
adjustments	AFINITOR.xml:S2:7526:11	O
for	AFINITOR.xml:S2:7538:3	O
adverse	AFINITOR.xml:S2:7542:7	O
reactions	AFINITOR.xml:S2:7550:9	O
are	AFINITOR.xml:S2:7560:3	O
recommended	AFINITOR.xml:S2:7564:11	O
[	AFINITOR.xml:S2:7576:1	O
see	AFINITOR.xml:S2:7577:3	O
Dosage	AFINITOR.xml:S2:7581:6	O
and	AFINITOR.xml:S2:7588:3	O
Administration	AFINITOR.xml:S2:7592:14	O
(	AFINITOR.xml:S2:7607:1	O
2.2	AFINITOR.xml:S2:7608:3	O
)	AFINITOR.xml:S2:7611:1	O
,	AFINITOR.xml:S2:7612:1	O
Use	AFINITOR.xml:S2:7614:3	O
in	AFINITOR.xml:S2:7618:2	O
Specific	AFINITOR.xml:S2:7621:8	O
Populations	AFINITOR.xml:S2:7630:11	O
(	AFINITOR.xml:S2:7642:1	O
8.5	AFINITOR.xml:S2:7643:3	O
)]	AFINITOR.xml:S2:7646:2	O
.	AFINITOR.xml:S2:7650:1	O

5.8	AFINITOR.xml:S2:7659:3	O
Laboratory	AFINITOR.xml:S2:7667:10	O
Tests	AFINITOR.xml:S2:7678:5	O
and	AFINITOR.xml:S2:7684:3	O
Monitoring	AFINITOR.xml:S2:7688:10	O

Renal	AFINITOR.xml:S2:7705:5	O
Function	AFINITOR.xml:S2:7711:8	O

Elevations	AFINITOR.xml:S2:7726:10	B-AdverseReaction
of	AFINITOR.xml:S2:7737:2	I-AdverseReaction
serum	AFINITOR.xml:S2:7740:5	I-AdverseReaction
creatinine	AFINITOR.xml:S2:7746:10	I-AdverseReaction
and	AFINITOR.xml:S2:7757:3	O
proteinuria	AFINITOR.xml:S2:7761:11	B-AdverseReaction
have	AFINITOR.xml:S2:7773:4	O
been	AFINITOR.xml:S2:7778:4	O
reported	AFINITOR.xml:S2:7783:8	O
in	AFINITOR.xml:S2:7792:2	O
patients	AFINITOR.xml:S2:7795:8	O
taking	AFINITOR.xml:S2:7804:6	O
AFINITOR	AFINITOR.xml:S2:7811:8	O
[	AFINITOR.xml:S2:7820:1	O
see	AFINITOR.xml:S2:7821:3	O
Adverse	AFINITOR.xml:S2:7825:7	O
Reactions	AFINITOR.xml:S2:7833:9	O
(	AFINITOR.xml:S2:7843:1	O
6.1	AFINITOR.xml:S2:7844:3	O
,	AFINITOR.xml:S2:7847:1	O
6.2	AFINITOR.xml:S2:7849:3	O
,	AFINITOR.xml:S2:7852:1	O
6.3	AFINITOR.xml:S2:7854:3	O
,	AFINITOR.xml:S2:7857:1	O
6.4	AFINITOR.xml:S2:7859:3	O
,	AFINITOR.xml:S2:7862:1	O
6.5	AFINITOR.xml:S2:7864:3	O
)]	AFINITOR.xml:S2:7867:2	O
.	AFINITOR.xml:S2:7871:1	O

Monitoring	AFINITOR.xml:S2:7873:10	O
of	AFINITOR.xml:S2:7884:2	O
renal	AFINITOR.xml:S2:7887:5	O
function	AFINITOR.xml:S2:7893:8	O
,	AFINITOR.xml:S2:7901:1	O
including	AFINITOR.xml:S2:7903:9	O
measurement	AFINITOR.xml:S2:7913:11	O
of	AFINITOR.xml:S2:7925:2	O
blood	AFINITOR.xml:S2:7928:5	O
urea	AFINITOR.xml:S2:7934:4	O
nitrogen	AFINITOR.xml:S2:7939:8	O
(	AFINITOR.xml:S2:7948:1	O
BUN	AFINITOR.xml:S2:7949:3	O
)	AFINITOR.xml:S2:7952:1	O
,	AFINITOR.xml:S2:7953:1	O
urinary	AFINITOR.xml:S2:7955:7	O
protein	AFINITOR.xml:S2:7963:7	O
,	AFINITOR.xml:S2:7970:1	O
or	AFINITOR.xml:S2:7972:2	O
serum	AFINITOR.xml:S2:7975:5	O
creatinine	AFINITOR.xml:S2:7981:10	O
,	AFINITOR.xml:S2:7991:1	O
is	AFINITOR.xml:S2:7993:2	O
recommended	AFINITOR.xml:S2:7996:11	O
prior	AFINITOR.xml:S2:8008:5	O
to	AFINITOR.xml:S2:8014:2	O
the	AFINITOR.xml:S2:8017:3	O
start	AFINITOR.xml:S2:8021:5	O
of	AFINITOR.xml:S2:8027:2	O
AFINITOR	AFINITOR.xml:S2:8030:8	O
therapy	AFINITOR.xml:S2:8039:7	O
and	AFINITOR.xml:S2:8047:3	O
periodically	AFINITOR.xml:S2:8051:12	O
thereafter	AFINITOR.xml:S2:8064:10	O
.	AFINITOR.xml:S2:8074:1	O

Renal	AFINITOR.xml:S2:8076:5	O
function	AFINITOR.xml:S2:8082:8	O
of	AFINITOR.xml:S2:8091:2	O
patients	AFINITOR.xml:S2:8094:8	O
should	AFINITOR.xml:S2:8103:6	O
be	AFINITOR.xml:S2:8110:2	O
monitored	AFINITOR.xml:S2:8113:9	O
particularly	AFINITOR.xml:S2:8123:12	O
where	AFINITOR.xml:S2:8136:5	O
patients	AFINITOR.xml:S2:8142:8	O
have	AFINITOR.xml:S2:8151:4	O
additional	AFINITOR.xml:S2:8156:10	O
risk	AFINITOR.xml:S2:8167:4	O
factors	AFINITOR.xml:S2:8172:7	O
that	AFINITOR.xml:S2:8180:4	O
may	AFINITOR.xml:S2:8185:3	O
further	AFINITOR.xml:S2:8189:7	O
impair	AFINITOR.xml:S2:8197:6	O
renal	AFINITOR.xml:S2:8204:5	O
function	AFINITOR.xml:S2:8210:8	O
.	AFINITOR.xml:S2:8218:1	O

Blood	AFINITOR.xml:S2:8225:5	O
Glucose	AFINITOR.xml:S2:8231:7	O
and	AFINITOR.xml:S2:8239:3	O
Lipids	AFINITOR.xml:S2:8243:6	O

Hyperglycemia	AFINITOR.xml:S2:8256:13	B-AdverseReaction
,	AFINITOR.xml:S2:8269:1	O
hyperlipidemia	AFINITOR.xml:S2:8271:14	B-AdverseReaction
,	AFINITOR.xml:S2:8285:1	O
and	AFINITOR.xml:S2:8287:3	O
hypertriglyceridemia	AFINITOR.xml:S2:8291:20	B-AdverseReaction
have	AFINITOR.xml:S2:8312:4	O
been	AFINITOR.xml:S2:8317:4	O
reported	AFINITOR.xml:S2:8322:8	O
in	AFINITOR.xml:S2:8331:2	O
patients	AFINITOR.xml:S2:8334:8	O
taking	AFINITOR.xml:S2:8343:6	O
AFINITOR	AFINITOR.xml:S2:8350:8	O
[	AFINITOR.xml:S2:8359:1	O
see	AFINITOR.xml:S2:8360:3	O
Adverse	AFINITOR.xml:S2:8364:7	O
Reactions	AFINITOR.xml:S2:8372:9	O
(	AFINITOR.xml:S2:8382:1	O
6.1	AFINITOR.xml:S2:8383:3	O
,	AFINITOR.xml:S2:8386:1	O
6.2	AFINITOR.xml:S2:8388:3	O
,	AFINITOR.xml:S2:8391:1	O
6.3	AFINITOR.xml:S2:8393:3	O
,	AFINITOR.xml:S2:8396:1	O
6.4	AFINITOR.xml:S2:8398:3	O
,	AFINITOR.xml:S2:8401:1	O
6.5	AFINITOR.xml:S2:8403:3	O
)]	AFINITOR.xml:S2:8406:2	O
.	AFINITOR.xml:S2:8410:1	O

Monitoring	AFINITOR.xml:S2:8412:10	O
of	AFINITOR.xml:S2:8423:2	O
fasting	AFINITOR.xml:S2:8426:7	O
serum	AFINITOR.xml:S2:8434:5	O
glucose	AFINITOR.xml:S2:8440:7	O
and	AFINITOR.xml:S2:8448:3	O
lipid	AFINITOR.xml:S2:8452:5	O
profile	AFINITOR.xml:S2:8458:7	O
is	AFINITOR.xml:S2:8466:2	O
recommended	AFINITOR.xml:S2:8469:11	O
prior	AFINITOR.xml:S2:8481:5	O
to	AFINITOR.xml:S2:8487:2	O
the	AFINITOR.xml:S2:8490:3	O
start	AFINITOR.xml:S2:8494:5	O
of	AFINITOR.xml:S2:8500:2	O
AFINITOR	AFINITOR.xml:S2:8503:8	O
therapy	AFINITOR.xml:S2:8512:7	O
and	AFINITOR.xml:S2:8520:3	O
periodically	AFINITOR.xml:S2:8524:12	O
thereafter	AFINITOR.xml:S2:8537:10	O
as	AFINITOR.xml:S2:8548:2	O
well	AFINITOR.xml:S2:8551:4	O
as	AFINITOR.xml:S2:8556:2	O
management	AFINITOR.xml:S2:8559:10	O
with	AFINITOR.xml:S2:8570:4	O
appropriate	AFINITOR.xml:S2:8575:11	O
medical	AFINITOR.xml:S2:8587:7	O
therapy	AFINITOR.xml:S2:8595:7	O
.	AFINITOR.xml:S2:8602:1	O

More	AFINITOR.xml:S2:8604:4	O
frequent	AFINITOR.xml:S2:8609:8	O
monitoring	AFINITOR.xml:S2:8618:10	O
is	AFINITOR.xml:S2:8629:2	O
recommended	AFINITOR.xml:S2:8632:11	O
when	AFINITOR.xml:S2:8644:4	O
AFINITOR	AFINITOR.xml:S2:8649:8	O
is	AFINITOR.xml:S2:8658:2	O
co	AFINITOR.xml:S2:8661:2	O
-	AFINITOR.xml:S2:8663:1	O
administered	AFINITOR.xml:S2:8664:12	O
with	AFINITOR.xml:S2:8677:4	O
other	AFINITOR.xml:S2:8682:5	O
drugs	AFINITOR.xml:S2:8688:5	O
that	AFINITOR.xml:S2:8694:4	O
may	AFINITOR.xml:S2:8699:3	O
induce	AFINITOR.xml:S2:8703:6	O
hyperglycemia	AFINITOR.xml:S2:8710:13	O
.	AFINITOR.xml:S2:8723:1	O

When	AFINITOR.xml:S2:8725:4	O
possible	AFINITOR.xml:S2:8730:8	O
,	AFINITOR.xml:S2:8738:1	O
optimal	AFINITOR.xml:S2:8740:7	O
glucose	AFINITOR.xml:S2:8748:7	O
and	AFINITOR.xml:S2:8756:3	O
lipid	AFINITOR.xml:S2:8760:5	O
control	AFINITOR.xml:S2:8766:7	O
should	AFINITOR.xml:S2:8774:6	O
be	AFINITOR.xml:S2:8781:2	O
achieved	AFINITOR.xml:S2:8784:8	O
before	AFINITOR.xml:S2:8793:6	O
starting	AFINITOR.xml:S2:8800:8	O
a	AFINITOR.xml:S2:8809:1	O
patient	AFINITOR.xml:S2:8811:7	O
on	AFINITOR.xml:S2:8819:2	O
AFINITOR	AFINITOR.xml:S2:8822:8	O
.	AFINITOR.xml:S2:8830:1	O

Hematologic	AFINITOR.xml:S2:8837:11	O
Parameters	AFINITOR.xml:S2:8849:10	O

Decreased	AFINITOR.xml:S2:8866:9	B-AdverseReaction
hemoglobin	AFINITOR.xml:S2:8876:10	I-AdverseReaction
,	AFINITOR.xml:S2:8886:1	O
lymphocytes	AFINITOR.xml:S2:8888:11	I-AdverseReaction
,	AFINITOR.xml:S2:8899:1	O
neutrophils	AFINITOR.xml:S2:8901:11	I-AdverseReaction
,	AFINITOR.xml:S2:8912:1	O
and	AFINITOR.xml:S2:8914:3	O
platelets	AFINITOR.xml:S2:8918:9	I-AdverseReaction
have	AFINITOR.xml:S2:8928:4	O
been	AFINITOR.xml:S2:8933:4	O
reported	AFINITOR.xml:S2:8938:8	O
in	AFINITOR.xml:S2:8947:2	O
patients	AFINITOR.xml:S2:8950:8	O
taking	AFINITOR.xml:S2:8959:6	O
AFINITOR	AFINITOR.xml:S2:8966:8	O
[	AFINITOR.xml:S2:8975:1	O
see	AFINITOR.xml:S2:8976:3	O
Adverse	AFINITOR.xml:S2:8980:7	O
Reactions	AFINITOR.xml:S2:8988:9	O
(	AFINITOR.xml:S2:8998:1	O
6.1	AFINITOR.xml:S2:8999:3	O
,	AFINITOR.xml:S2:9002:1	O
6.2	AFINITOR.xml:S2:9004:3	O
,	AFINITOR.xml:S2:9007:1	O
6.3	AFINITOR.xml:S2:9009:3	O
,	AFINITOR.xml:S2:9012:1	O
6.4	AFINITOR.xml:S2:9014:3	O
,	AFINITOR.xml:S2:9017:1	O
6.5	AFINITOR.xml:S2:9019:3	O
)]	AFINITOR.xml:S2:9022:2	O
.	AFINITOR.xml:S2:9026:1	O

Monitoring	AFINITOR.xml:S2:9028:10	O
of	AFINITOR.xml:S2:9039:2	O
complete	AFINITOR.xml:S2:9042:8	O
blood	AFINITOR.xml:S2:9051:5	O
count	AFINITOR.xml:S2:9057:5	O
is	AFINITOR.xml:S2:9063:2	O
recommended	AFINITOR.xml:S2:9066:11	O
prior	AFINITOR.xml:S2:9078:5	O
to	AFINITOR.xml:S2:9084:2	O
the	AFINITOR.xml:S2:9087:3	O
start	AFINITOR.xml:S2:9091:5	O
of	AFINITOR.xml:S2:9097:2	O
AFINITOR	AFINITOR.xml:S2:9100:8	O
therapy	AFINITOR.xml:S2:9109:7	O
and	AFINITOR.xml:S2:9117:3	O
periodically	AFINITOR.xml:S2:9121:12	O
thereafter	AFINITOR.xml:S2:9134:10	O
.	AFINITOR.xml:S2:9144:1	O

5.9	AFINITOR.xml:S2:9153:3	O
Drug	AFINITOR.xml:S2:9161:4	O
-	AFINITOR.xml:S2:9165:1	O
drug	AFINITOR.xml:S2:9166:4	O
Interactions	AFINITOR.xml:S2:9171:12	O

Due	AFINITOR.xml:S2:9189:3	O
to	AFINITOR.xml:S2:9193:2	O
significant	AFINITOR.xml:S2:9196:11	O
increases	AFINITOR.xml:S2:9208:9	O
in	AFINITOR.xml:S2:9218:2	O
exposure	AFINITOR.xml:S2:9221:8	O
of	AFINITOR.xml:S2:9230:2	O
everolimus	AFINITOR.xml:S2:9233:10	O
,	AFINITOR.xml:S2:9243:1	O
co	AFINITOR.xml:S2:9245:2	O
-	AFINITOR.xml:S2:9247:1	O
administration	AFINITOR.xml:S2:9248:14	O
with	AFINITOR.xml:S2:9263:4	O
strong	AFINITOR.xml:S2:9268:6	O
CYP3A4	AFINITOR.xml:S2:9275:6	O
PgP	AFINITOR.xml:S2:9282:3	O
inhibitors	AFINITOR.xml:S2:9286:10	O
should	AFINITOR.xml:S2:9297:6	O
be	AFINITOR.xml:S2:9304:2	O
avoided	AFINITOR.xml:S2:9307:7	O
[	AFINITOR.xml:S2:9316:1	O
see	AFINITOR.xml:S2:9317:3	O
Dosage	AFINITOR.xml:S2:9321:6	O
and	AFINITOR.xml:S2:9328:3	O
Administration	AFINITOR.xml:S2:9332:14	O
(	AFINITOR.xml:S2:9347:1	O
2.2	AFINITOR.xml:S2:9348:3	O
,	AFINITOR.xml:S2:9351:1	O
2.5	AFINITOR.xml:S2:9353:3	O
)	AFINITOR.xml:S2:9356:1	O
and	AFINITOR.xml:S2:9358:3	O
Drug	AFINITOR.xml:S2:9362:4	O
Interactions	AFINITOR.xml:S2:9367:12	O
(	AFINITOR.xml:S2:9380:1	O
7.1	AFINITOR.xml:S2:9381:3	O
)]	AFINITOR.xml:S2:9384:2	O
.	AFINITOR.xml:S2:9388:1	O

A	AFINITOR.xml:S2:9394:1	O
reduction	AFINITOR.xml:S2:9396:9	O
of	AFINITOR.xml:S2:9406:2	O
the	AFINITOR.xml:S2:9409:3	O
AFINITOR	AFINITOR.xml:S2:9413:8	O
dose	AFINITOR.xml:S2:9422:4	O
is	AFINITOR.xml:S2:9427:2	O
recommended	AFINITOR.xml:S2:9430:11	O
when	AFINITOR.xml:S2:9442:4	O
co	AFINITOR.xml:S2:9447:2	O
-	AFINITOR.xml:S2:9449:1	O
administered	AFINITOR.xml:S2:9450:12	O
with	AFINITOR.xml:S2:9463:4	O
a	AFINITOR.xml:S2:9468:1	O
moderate	AFINITOR.xml:S2:9470:8	O
CYP3A4	AFINITOR.xml:S2:9479:6	O
PgP	AFINITOR.xml:S2:9486:3	O
inhibitor	AFINITOR.xml:S2:9490:9	O
[	AFINITOR.xml:S2:9500:1	O
see	AFINITOR.xml:S2:9501:3	O
Dosage	AFINITOR.xml:S2:9505:6	O
and	AFINITOR.xml:S2:9512:3	O
Administration	AFINITOR.xml:S2:9516:14	O
(	AFINITOR.xml:S2:9531:1	O
2.2	AFINITOR.xml:S2:9532:3	O
,	AFINITOR.xml:S2:9535:1	O
2.5	AFINITOR.xml:S2:9537:3	O
)	AFINITOR.xml:S2:9540:1	O
and	AFINITOR.xml:S2:9542:3	O
Drug	AFINITOR.xml:S2:9546:4	O
Interactions	AFINITOR.xml:S2:9551:12	O
(	AFINITOR.xml:S2:9564:1	O
7.1	AFINITOR.xml:S2:9565:3	O
)]	AFINITOR.xml:S2:9568:2	O
.	AFINITOR.xml:S2:9572:1	O

An	AFINITOR.xml:S2:9578:2	O
increase	AFINITOR.xml:S2:9581:8	O
in	AFINITOR.xml:S2:9590:2	O
the	AFINITOR.xml:S2:9593:3	O
AFINITOR	AFINITOR.xml:S2:9597:8	O
dose	AFINITOR.xml:S2:9606:4	O
is	AFINITOR.xml:S2:9611:2	O
recommended	AFINITOR.xml:S2:9614:11	O
when	AFINITOR.xml:S2:9626:4	O
co	AFINITOR.xml:S2:9631:2	O
-	AFINITOR.xml:S2:9633:1	O
administered	AFINITOR.xml:S2:9634:12	O
with	AFINITOR.xml:S2:9647:4	O
a	AFINITOR.xml:S2:9652:1	O
strong	AFINITOR.xml:S2:9654:6	O
CYP3A4	AFINITOR.xml:S2:9661:6	O
PgP	AFINITOR.xml:S2:9668:3	O
inducer	AFINITOR.xml:S2:9672:7	O
[	AFINITOR.xml:S2:9680:1	O
see	AFINITOR.xml:S2:9681:3	O
Dosage	AFINITOR.xml:S2:9685:6	O
and	AFINITOR.xml:S2:9692:3	O
Administration	AFINITOR.xml:S2:9696:14	O
(	AFINITOR.xml:S2:9711:1	O
2.2	AFINITOR.xml:S2:9712:3	O
,	AFINITOR.xml:S2:9715:1	O
2.5	AFINITOR.xml:S2:9717:3	O
)	AFINITOR.xml:S2:9720:1	O
and	AFINITOR.xml:S2:9722:3	O
Drug	AFINITOR.xml:S2:9726:4	O
Interactions	AFINITOR.xml:S2:9731:12	O
(	AFINITOR.xml:S2:9744:1	O
7.2	AFINITOR.xml:S2:9745:3	O
)]	AFINITOR.xml:S2:9748:2	O
.	AFINITOR.xml:S2:9752:1	O

5.10	AFINITOR.xml:S2:9761:4	O
Hepatic	AFINITOR.xml:S2:9770:7	O
Impairment	AFINITOR.xml:S2:9778:10	O

Exposure	AFINITOR.xml:S2:9794:8	O
to	AFINITOR.xml:S2:9803:2	O
everolimus	AFINITOR.xml:S2:9806:10	O
was	AFINITOR.xml:S2:9817:3	O
increased	AFINITOR.xml:S2:9821:9	O
in	AFINITOR.xml:S2:9831:2	O
patients	AFINITOR.xml:S2:9834:8	O
with	AFINITOR.xml:S2:9843:4	O
hepatic	AFINITOR.xml:S2:9848:7	B-AdverseReaction
impairment	AFINITOR.xml:S2:9856:10	I-AdverseReaction
[	AFINITOR.xml:S2:9868:1	O
see	AFINITOR.xml:S2:9869:3	O
Clinical	AFINITOR.xml:S2:9873:8	O
Pharmacology	AFINITOR.xml:S2:9882:12	O
(	AFINITOR.xml:S2:9895:1	O
12.3	AFINITOR.xml:S2:9896:4	O
)]	AFINITOR.xml:S2:9900:2	O
.	AFINITOR.xml:S2:9904:1	O

For	AFINITOR.xml:S2:9910:3	O
advanced	AFINITOR.xml:S2:9914:8	O
HR	AFINITOR.xml:S2:9923:2	O
BC	AFINITOR.xml:S2:9927:2	O
,	AFINITOR.xml:S2:9929:1	O
advanced	AFINITOR.xml:S2:9931:8	O
PNET	AFINITOR.xml:S2:9940:4	O
,	AFINITOR.xml:S2:9944:1	O
advanced	AFINITOR.xml:S2:9946:8	O
RCC	AFINITOR.xml:S2:9955:3	O
,	AFINITOR.xml:S2:9958:1	O
and	AFINITOR.xml:S2:9960:3	O
renal	AFINITOR.xml:S2:9964:5	O
angiomyolipoma	AFINITOR.xml:S2:9970:14	O
with	AFINITOR.xml:S2:9985:4	O
TSC	AFINITOR.xml:S2:9990:3	O
patients	AFINITOR.xml:S2:9994:8	O
with	AFINITOR.xml:S2:10003:4	O
severe	AFINITOR.xml:S2:10008:6	B-Severity
hepatic	AFINITOR.xml:S2:10015:7	B-AdverseReaction
impairment	AFINITOR.xml:S2:10023:10	I-AdverseReaction
(	AFINITOR.xml:S2:10034:1	O
Child	AFINITOR.xml:S2:10035:5	O
-	AFINITOR.xml:S2:10040:1	O
Pugh	AFINITOR.xml:S2:10041:4	O
class	AFINITOR.xml:S2:10046:5	O
C	AFINITOR.xml:S2:10052:1	O
)	AFINITOR.xml:S2:10053:1	O
,	AFINITOR.xml:S2:10054:1	O
AFINITOR	AFINITOR.xml:S2:10056:8	O
may	AFINITOR.xml:S2:10065:3	O
be	AFINITOR.xml:S2:10069:2	O
used	AFINITOR.xml:S2:10072:4	O
at	AFINITOR.xml:S2:10077:2	O
a	AFINITOR.xml:S2:10080:1	O
reduced	AFINITOR.xml:S2:10082:7	O
dose	AFINITOR.xml:S2:10090:4	O
if	AFINITOR.xml:S2:10095:2	O
the	AFINITOR.xml:S2:10098:3	O
desired	AFINITOR.xml:S2:10102:7	O
benefit	AFINITOR.xml:S2:10110:7	O
outweighs	AFINITOR.xml:S2:10118:9	O
the	AFINITOR.xml:S2:10128:3	O
risk	AFINITOR.xml:S2:10132:4	O
.	AFINITOR.xml:S2:10136:1	O

For	AFINITOR.xml:S2:10138:3	O
patients	AFINITOR.xml:S2:10142:8	O
with	AFINITOR.xml:S2:10151:4	O
mild	AFINITOR.xml:S2:10156:4	O
(	AFINITOR.xml:S2:10161:1	O
Child	AFINITOR.xml:S2:10162:5	O
-	AFINITOR.xml:S2:10167:1	O
Pugh	AFINITOR.xml:S2:10168:4	O
class	AFINITOR.xml:S2:10173:5	O
A	AFINITOR.xml:S2:10179:1	O
)	AFINITOR.xml:S2:10180:1	O
or	AFINITOR.xml:S2:10182:2	O
moderate	AFINITOR.xml:S2:10185:8	O
(	AFINITOR.xml:S2:10194:1	O
Child	AFINITOR.xml:S2:10195:5	O
-	AFINITOR.xml:S2:10200:1	O
Pugh	AFINITOR.xml:S2:10201:4	O
class	AFINITOR.xml:S2:10206:5	O
B	AFINITOR.xml:S2:10212:1	O
)	AFINITOR.xml:S2:10213:1	O
hepatic	AFINITOR.xml:S2:10215:7	O
impairment	AFINITOR.xml:S2:10223:10	O
,	AFINITOR.xml:S2:10233:1	O
a	AFINITOR.xml:S2:10235:1	O
dose	AFINITOR.xml:S2:10237:4	O
reduction	AFINITOR.xml:S2:10242:9	O
is	AFINITOR.xml:S2:10252:2	O
recommended	AFINITOR.xml:S2:10255:11	O
[	AFINITOR.xml:S2:10267:1	O
see	AFINITOR.xml:S2:10268:3	O
Dosage	AFINITOR.xml:S2:10272:6	O
and	AFINITOR.xml:S2:10279:3	O
Administration	AFINITOR.xml:S2:10283:14	O
(	AFINITOR.xml:S2:10298:1	O
2.2	AFINITOR.xml:S2:10299:3	O
)	AFINITOR.xml:S2:10302:1	O
and	AFINITOR.xml:S2:10304:3	O
Clinical	AFINITOR.xml:S2:10308:8	O
Pharmacology	AFINITOR.xml:S2:10317:12	O
(	AFINITOR.xml:S2:10330:1	O
12.3	AFINITOR.xml:S2:10331:4	O
)]	AFINITOR.xml:S2:10335:2	O
.	AFINITOR.xml:S2:10339:1	O

For	AFINITOR.xml:S2:10345:3	O
patients	AFINITOR.xml:S2:10349:8	O
with	AFINITOR.xml:S2:10358:4	O
SEGA	AFINITOR.xml:S2:10363:4	O
and	AFINITOR.xml:S2:10368:3	O
mild	AFINITOR.xml:S2:10372:4	O
or	AFINITOR.xml:S2:10377:2	O
moderate	AFINITOR.xml:S2:10380:8	O
hepatic	AFINITOR.xml:S2:10389:7	O
impairment	AFINITOR.xml:S2:10397:10	O
,	AFINITOR.xml:S2:10407:1	O
adjust	AFINITOR.xml:S2:10409:6	O
the	AFINITOR.xml:S2:10416:3	O
dose	AFINITOR.xml:S2:10420:4	O
of	AFINITOR.xml:S2:10425:2	O
AFINITOR	AFINITOR.xml:S2:10428:8	O
Tablets	AFINITOR.xml:S2:10437:7	O
or	AFINITOR.xml:S2:10445:2	O
AFINITOR	AFINITOR.xml:S2:10448:8	O
DISPERZ	AFINITOR.xml:S2:10457:7	O
based	AFINITOR.xml:S2:10465:5	O
on	AFINITOR.xml:S2:10471:2	O
therapeutic	AFINITOR.xml:S2:10474:11	O
drug	AFINITOR.xml:S2:10486:4	O
monitoring	AFINITOR.xml:S2:10491:10	O
.	AFINITOR.xml:S2:10501:1	O

For	AFINITOR.xml:S2:10503:3	O
patients	AFINITOR.xml:S2:10507:8	O
with	AFINITOR.xml:S2:10516:4	O
SEGA	AFINITOR.xml:S2:10521:4	O
and	AFINITOR.xml:S2:10526:3	O
severe	AFINITOR.xml:S2:10530:6	O
hepatic	AFINITOR.xml:S2:10537:7	O
impairment	AFINITOR.xml:S2:10545:10	O
,	AFINITOR.xml:S2:10555:1	O
reduce	AFINITOR.xml:S2:10557:6	O
the	AFINITOR.xml:S2:10564:3	O
starting	AFINITOR.xml:S2:10568:8	O
dose	AFINITOR.xml:S2:10577:4	O
of	AFINITOR.xml:S2:10582:2	O
AFINITOR	AFINITOR.xml:S2:10585:8	O
Tablets	AFINITOR.xml:S2:10594:7	O
or	AFINITOR.xml:S2:10602:2	O
AFINITOR	AFINITOR.xml:S2:10605:8	O
DISPERZ	AFINITOR.xml:S2:10614:7	O
by	AFINITOR.xml:S2:10622:2	O
approximately	AFINITOR.xml:S2:10625:13	O
50%	AFINITOR.xml:S2:10639:3	O
and	AFINITOR.xml:S2:10643:3	O
adjust	AFINITOR.xml:S2:10647:6	O
subsequent	AFINITOR.xml:S2:10654:10	O
doses	AFINITOR.xml:S2:10665:5	O
based	AFINITOR.xml:S2:10671:5	O
on	AFINITOR.xml:S2:10677:2	O
therapeutic	AFINITOR.xml:S2:10680:11	O
drug	AFINITOR.xml:S2:10692:4	O
monitoring	AFINITOR.xml:S2:10697:10	O
[	AFINITOR.xml:S2:10708:1	O
see	AFINITOR.xml:S2:10709:3	O
Dosage	AFINITOR.xml:S2:10713:6	O
and	AFINITOR.xml:S2:10720:3	O
Administration	AFINITOR.xml:S2:10724:14	O
(	AFINITOR.xml:S2:10739:1	O
2.4	AFINITOR.xml:S2:10740:3	O
,	AFINITOR.xml:S2:10743:1	O
2.5	AFINITOR.xml:S2:10745:3	O
)]	AFINITOR.xml:S2:10748:2	O
.	AFINITOR.xml:S2:10752:1	O

5.11	AFINITOR.xml:S2:10761:4	O
Vaccinations	AFINITOR.xml:S2:10770:12	O

During	AFINITOR.xml:S2:10788:6	O
AFINITOR	AFINITOR.xml:S2:10795:8	O
treatment	AFINITOR.xml:S2:10804:9	O
,	AFINITOR.xml:S2:10813:1	O
avoid	AFINITOR.xml:S2:10815:5	O
the	AFINITOR.xml:S2:10821:3	O
use	AFINITOR.xml:S2:10825:3	O
of	AFINITOR.xml:S2:10829:2	O
live	AFINITOR.xml:S2:10832:4	O
vaccines	AFINITOR.xml:S2:10837:8	O
and	AFINITOR.xml:S2:10846:3	O
avoid	AFINITOR.xml:S2:10850:5	O
close	AFINITOR.xml:S2:10856:5	O
contact	AFINITOR.xml:S2:10862:7	O
with	AFINITOR.xml:S2:10870:4	O
individuals	AFINITOR.xml:S2:10875:11	O
who	AFINITOR.xml:S2:10887:3	O
have	AFINITOR.xml:S2:10891:4	O
received	AFINITOR.xml:S2:10896:8	O
live	AFINITOR.xml:S2:10905:4	O
vaccines	AFINITOR.xml:S2:10910:8	O
(	AFINITOR.xml:S2:10919:1	O
e	AFINITOR.xml:S2:10920:1	O
.	AFINITOR.xml:S2:10921:1	O
g	AFINITOR.xml:S2:10922:1	O
.	AFINITOR.xml:S2:10923:1	O
,	AFINITOR.xml:S2:10924:1	O
intranasal	AFINITOR.xml:S2:10926:10	O
influenza	AFINITOR.xml:S2:10937:9	O
,	AFINITOR.xml:S2:10946:1	O
measles	AFINITOR.xml:S2:10948:7	O
,	AFINITOR.xml:S2:10955:1	O
mumps	AFINITOR.xml:S2:10957:5	O
,	AFINITOR.xml:S2:10962:1	O
rubella	AFINITOR.xml:S2:10964:7	O
,	AFINITOR.xml:S2:10971:1	O
oral	AFINITOR.xml:S2:10973:4	O
polio	AFINITOR.xml:S2:10978:5	O
,	AFINITOR.xml:S2:10983:1	O
BCG	AFINITOR.xml:S2:10985:3	O
,	AFINITOR.xml:S2:10988:1	O
yellow	AFINITOR.xml:S2:10990:6	O
fever	AFINITOR.xml:S2:10997:5	O
,	AFINITOR.xml:S2:11002:1	O
varicella	AFINITOR.xml:S2:11004:9	O
,	AFINITOR.xml:S2:11013:1	O
and	AFINITOR.xml:S2:11015:3	O
TY21a	AFINITOR.xml:S2:11019:5	O
typhoid	AFINITOR.xml:S2:11025:7	O
vaccines	AFINITOR.xml:S2:11033:8	O
)	AFINITOR.xml:S2:11041:1	O
.	AFINITOR.xml:S2:11042:1	O

For	AFINITOR.xml:S2:11048:3	O
pediatric	AFINITOR.xml:S2:11052:9	O
patients	AFINITOR.xml:S2:11062:8	O
with	AFINITOR.xml:S2:11071:4	O
SEGA	AFINITOR.xml:S2:11076:4	O
that	AFINITOR.xml:S2:11081:4	O
do	AFINITOR.xml:S2:11086:2	O
not	AFINITOR.xml:S2:11089:3	O
require	AFINITOR.xml:S2:11093:7	O
immediate	AFINITOR.xml:S2:11101:9	O
treatment	AFINITOR.xml:S2:11111:9	O
,	AFINITOR.xml:S2:11120:1	O
complete	AFINITOR.xml:S2:11122:8	O
the	AFINITOR.xml:S2:11131:3	O
recommended	AFINITOR.xml:S2:11135:11	O
childhood	AFINITOR.xml:S2:11147:9	O
series	AFINITOR.xml:S2:11157:6	O
of	AFINITOR.xml:S2:11164:2	O
live	AFINITOR.xml:S2:11167:4	O
virus	AFINITOR.xml:S2:11172:5	O
vaccinations	AFINITOR.xml:S2:11178:12	O
according	AFINITOR.xml:S2:11191:9	O
to	AFINITOR.xml:S2:11201:2	O
American	AFINITOR.xml:S2:11204:8	O
Council	AFINITOR.xml:S2:11213:7	O
on	AFINITOR.xml:S2:11221:2	O
Immunization	AFINITOR.xml:S2:11224:12	O
Practices	AFINITOR.xml:S2:11237:9	O
(	AFINITOR.xml:S2:11247:1	O
ACIP	AFINITOR.xml:S2:11248:4	O
)	AFINITOR.xml:S2:11252:1	O
guidelines	AFINITOR.xml:S2:11254:10	O
prior	AFINITOR.xml:S2:11265:5	O
to	AFINITOR.xml:S2:11271:2	O
the	AFINITOR.xml:S2:11274:3	O
start	AFINITOR.xml:S2:11278:5	O
of	AFINITOR.xml:S2:11284:2	O
therapy	AFINITOR.xml:S2:11287:7	O
.	AFINITOR.xml:S2:11294:1	O

An	AFINITOR.xml:S2:11296:2	O
accelerated	AFINITOR.xml:S2:11299:11	O
vaccination	AFINITOR.xml:S2:11311:11	O
schedule	AFINITOR.xml:S2:11323:8	O
may	AFINITOR.xml:S2:11332:3	O
be	AFINITOR.xml:S2:11336:2	O
appropriate	AFINITOR.xml:S2:11339:11	O
.	AFINITOR.xml:S2:11350:1	O

5.12	AFINITOR.xml:S2:11359:4	O
Embryo	AFINITOR.xml:S2:11368:6	O
-	AFINITOR.xml:S2:11374:1	O
fetal	AFINITOR.xml:S2:11375:5	O
Toxicity	AFINITOR.xml:S2:11381:8	O

Based	AFINITOR.xml:S2:11395:5	O
on	AFINITOR.xml:S2:11401:2	O
the	AFINITOR.xml:S2:11404:3	O
mechanism	AFINITOR.xml:S2:11408:9	O
of	AFINITOR.xml:S2:11418:2	O
action	AFINITOR.xml:S2:11421:6	O
,	AFINITOR.xml:S2:11427:1	O
AFINITOR	AFINITOR.xml:S2:11429:8	O
can	AFINITOR.xml:S2:11438:3	B-Factor
cause	AFINITOR.xml:S2:11442:5	O
fetal	AFINITOR.xml:S2:11448:5	B-AdverseReaction
harm	AFINITOR.xml:S2:11454:4	I-AdverseReaction
.	AFINITOR.xml:S2:11458:1	O

Everolimus	AFINITOR.xml:S2:11460:10	O
caused	AFINITOR.xml:S2:11471:6	O
embryo	AFINITOR.xml:S2:11478:6	B-AdverseReaction
-	AFINITOR.xml:S2:11484:1	I-AdverseReaction
fetal	AFINITOR.xml:S2:11485:5	I-AdverseReaction
toxicities	AFINITOR.xml:S2:11491:10	I-AdverseReaction
in	AFINITOR.xml:S2:11502:2	O
animals	AFINITOR.xml:S2:11505:7	B-Animal
at	AFINITOR.xml:S2:11513:2	O
maternal	AFINITOR.xml:S2:11516:8	O
exposures	AFINITOR.xml:S2:11525:9	O
that	AFINITOR.xml:S2:11535:4	O
were	AFINITOR.xml:S2:11540:4	O
lower	AFINITOR.xml:S2:11545:5	O
than	AFINITOR.xml:S2:11551:4	O
human	AFINITOR.xml:S2:11556:5	O
exposures	AFINITOR.xml:S2:11562:9	O
.	AFINITOR.xml:S2:11571:1	O

If	AFINITOR.xml:S2:11573:2	O
this	AFINITOR.xml:S2:11576:4	O
drug	AFINITOR.xml:S2:11581:4	O
is	AFINITOR.xml:S2:11586:2	O
used	AFINITOR.xml:S2:11589:4	O
during	AFINITOR.xml:S2:11594:6	O
pregnancy	AFINITOR.xml:S2:11601:9	O
or	AFINITOR.xml:S2:11611:2	O
if	AFINITOR.xml:S2:11614:2	O
the	AFINITOR.xml:S2:11617:3	O
patient	AFINITOR.xml:S2:11621:7	O
becomes	AFINITOR.xml:S2:11629:7	O
pregnant	AFINITOR.xml:S2:11637:8	O
while	AFINITOR.xml:S2:11646:5	O
taking	AFINITOR.xml:S2:11652:6	O
this	AFINITOR.xml:S2:11659:4	O
drug	AFINITOR.xml:S2:11664:4	O
,	AFINITOR.xml:S2:11668:1	O
the	AFINITOR.xml:S2:11670:3	O
patient	AFINITOR.xml:S2:11674:7	O
should	AFINITOR.xml:S2:11682:6	O
be	AFINITOR.xml:S2:11689:2	O
apprised	AFINITOR.xml:S2:11692:8	O
of	AFINITOR.xml:S2:11701:2	O
the	AFINITOR.xml:S2:11704:3	O
potential	AFINITOR.xml:S2:11708:9	O
hazard	AFINITOR.xml:S2:11718:6	O
to	AFINITOR.xml:S2:11725:2	O
a	AFINITOR.xml:S2:11728:1	O
fetus	AFINITOR.xml:S2:11730:5	O
[	AFINITOR.xml:S2:11736:1	O
see	AFINITOR.xml:S2:11737:3	O
Use	AFINITOR.xml:S2:11741:3	O
in	AFINITOR.xml:S2:11745:2	O
Specific	AFINITOR.xml:S2:11748:8	O
Populations	AFINITOR.xml:S2:11757:11	O
(	AFINITOR.xml:S2:11769:1	O
8.1	AFINITOR.xml:S2:11770:3	O
)]	AFINITOR.xml:S2:11773:2	O
.	AFINITOR.xml:S2:11777:1	O

Advise	AFINITOR.xml:S2:11783:6	O
female	AFINITOR.xml:S2:11790:6	O
patients	AFINITOR.xml:S2:11797:8	O
of	AFINITOR.xml:S2:11806:2	O
reproductive	AFINITOR.xml:S2:11809:12	O
potential	AFINITOR.xml:S2:11822:9	O
to	AFINITOR.xml:S2:11832:2	O
avoid	AFINITOR.xml:S2:11835:5	O
becoming	AFINITOR.xml:S2:11841:8	O
pregnant	AFINITOR.xml:S2:11850:8	O
and	AFINITOR.xml:S2:11859:3	O
to	AFINITOR.xml:S2:11863:2	O
use	AFINITOR.xml:S2:11866:3	O
highly	AFINITOR.xml:S2:11870:6	O
effective	AFINITOR.xml:S2:11877:9	O
contraception	AFINITOR.xml:S2:11887:13	O
while	AFINITOR.xml:S2:11901:5	O
using	AFINITOR.xml:S2:11907:5	O
AFINITOR	AFINITOR.xml:S2:11913:8	O
and	AFINITOR.xml:S2:11922:3	O
for	AFINITOR.xml:S2:11926:3	O
up	AFINITOR.xml:S2:11930:2	O
to	AFINITOR.xml:S2:11933:2	O
8	AFINITOR.xml:S2:11936:1	O
weeks	AFINITOR.xml:S2:11938:5	O
after	AFINITOR.xml:S2:11944:5	O
ending	AFINITOR.xml:S2:11950:6	O
treatment	AFINITOR.xml:S2:11957:9	O
[	AFINITOR.xml:S2:11967:1	O
see	AFINITOR.xml:S2:11968:3	O
Use	AFINITOR.xml:S2:11972:3	O
in	AFINITOR.xml:S2:11976:2	O
Specific	AFINITOR.xml:S2:11979:8	O
Populations	AFINITOR.xml:S2:11988:11	O
(	AFINITOR.xml:S2:12000:1	O
8.6	AFINITOR.xml:S2:12001:3	O
)]	AFINITOR.xml:S2:12004:2	O
.	AFINITOR.xml:S2:12008:1	O
